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Abstract 
Background and Aim 
Lateral Elbow Tendinopathy (LET) is a common, painful condition, predominantly 
affecting working age people. Although numerous studies have been conducted 
assessing a multitude of therapeutic interventions, fundamental information 
regarding outcome measure choice, treatment delivery techniques, and trial 
feasibility have not been explored. This thesis aims to optimise the investigation of 
interventional therapies in lateral elbow tendinopathy by furthering the foundational 
knowledge from which future researchers can inform their study design.   
Methods 
A portfolio of studies was undertaken to explore three main themes: the choice of 
patient-centred outcome measure, the rationale for injection therapy technique and 
the feasibility and acceptability of a randomised controlled study methodology in 
Platelet-Rich Plasma (PRP) injection therapy. Seven studies addressing these 
themes were undertaken: a three-phase systematic review and standardised 
evaluation of patient-centred clinical rating systems in elbow pathology, a 
validation study of outcome measures in a UK population of lateral elbow 
tendinopathy patients, a cadaveric assessment of elbow injection distribution, a 
Delphi consensus study of PRP injection use and a feasibility randomised 
controlled trial of PRP versus surgery for chronic LET.      
Results 
The systematic review identified 72 clinical rating systems used in elbow 
pathology, 15 of which had a history of validation in lateral elbow tendinopathy 
patients. Standardised comparative assessment found that only four reached the 
minimum threshold for recommendation (QDASH, DASH, OES and PRTEE). The 
correlation between the frequency of clinical rating systems use and their 
performance was r = 0.35. Cross-culturally specific validity of these rating systems 
in a UK population was limited to 20 patients embedded in mixed pathology 
cohorts. Evaluation of the psychometric properties of the highest performing 
clinical rating systems was performed in 50 tendinopathy patients recruited across 
general practice, physiotherapy and secondary care settings, with all instruments 
achieving adequate internal consistency (Cronbach's alpha >0.87), reliability 
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(intraclass correlation coefficient >0.85) and responsiveness (effect sizes >0.46). 
The cadaveric evaluation found no statistical difference between the 
intratendinous distribution of lateral elbow injections between 1ml and 3ml or 
between single shot or fenestrated injection techniques. The Delphi consensus 
study on the application of platelet-rich plasma injections found poor levels of 
agreement amongst experts on the technical preparation and application of this 
treatment. The feasibility randomised control trial found that a randomised 
controlled trial is technically feasible (86% recruitment rate, 8% drop-out and 8% 
cross-over). Qualitative interviews with these patients identified very high levels of 
procedural injection pain.    
Conclusion 
This research improves upon the knowledge base from which future evaluations of 
interventional treatment in lateral elbow tendinopathy can be constructed. It is the 
first one to identify the wide choice and disparate utility of patient-centred outcome 
measures in elbow pathology. It can recommend the QDASH, DASH, OES or 
PRTEE for use in the English language and provides evidence of the validity and 
reliability of these instruments in the UK. Injection methodology should be 
rationalised to low volume single-shot injections, and research priorities should be 
allied to areas identified as lacking expert consensus. Though feasible and 
acceptable, future parallel group studies should quantify and report procedural 
pain.    
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Thesis components at a glance 
Study Question Methods Results Conclusion 
I What clinical rating 
systems are used to 
assess patient-
focused outcomes in 
elbow pathology? 
A systematic review 
identifying all rating 
systems used in elbow 
disorders, categorised by 
pathology, time period of 
use and geographical 
distribution.  
980 studies were identified that 
used 72 separate rating systems. 
41% of studies used two or more 
separate measures. Overall 54% 
of studies used the Mayo Elbow 
Performance Score (MEPS). 
A vast number of instruments exist, 
although recently developed 
PROMs are increasingly used, 
historic instruments continue to be 
reported. The use of multiple rating 
systems is common, increasing 
participant burden. Lack of 
conformity is likely to hinder 
evidence synthesis.   
II In Lateral Elbow 
Tendinopathy (LET), 
what is the evidence 
that the available 
clinical rating systems 
meet acceptable 
psychometric 
standards?  
Systematic review and 
standardised evaluation 
of all rating systems with 
a history of development, 
metric property 
assessment or use in LET.  
229 articles report the 
development and/or application 
of 15 separate rating systems. 
Standardised evaluation using the 
EMPRO tool identified the 
QDASH, DASH, OES and PRTEE as 
meeting minimum criteria for 
recommendation.  
Though numerous rating systems 
exist, only four meet minimum 
criteria for recommendation in LET.  
III Are LET rating 
systems used in the 
UK cross-culturally 
valid and is it possible 
to conform to 
outcome measure 
reporting guidelines?  
Focused review of data on 
the use and validity of 
rating systems in the UK. 
Assessment of  
accordance with cross-
cultural & COSMIN-PRO 
guidelines. 
16 articles reporting the use of 
seven rating systems. No RCT 
complied with COSMIN-PRO 
guidelines. Comprehensive 
assessment of metric properties 
of the seven rating systems has 
only been undertaken on 20 
individual UK participants.   
No rating systems have been 
adequately cross-culturally 
validated in UK individuals. 
Consequently, COSMIN-PRO 
guidelines cannot be adhered to.  
IV Are Patient-Reported 
Outcome Measures 
(PROM) valid, reliable 
and responsive for 
LET patients in the 
UK? 
Comparison of the three 
best performing PROMs 
identified from study II 
and new PROMIS short 
forms. Assessment of 
validity, reliability and 
responsiveness in LET 
participants.  
738 invitations yielded 81 recruits 
and 50 participants who 
completed all questionnaires. 
Internal consistency, reliability, 
construct validity were all found 
to be adequate. Effect sizes were 
found to be greatest in pain sub-
scales. 
This study expands the evidence 
base for PROM validity in UK 
populations, allowing future 
authors to adhere to COSMIN-PRO 
guidelines. Poor recruitment and 
retention hinders this study from 
making clearer recommendations 
on specific PROM superiority.  
V When an 
intratendinous 
injection is 
undertaken for LET, 
where does the 
injectate distribute 
and is there an 
optimal technique?  
Cadaveric assessment of 
Common Extensor 
Tendon (CET) injection 
volumes and techniques. 
Distribution assessed 
through arthroscopy, 
dissection and cross-
sectional image analysis 
of microtome sections.  
No statistical difference between 
1 and 3ml injection distribution or 
single shot or fenestrated 
injection protocols. 
Distribution fraction of over 97% 
of the cross-sectional area of the 
tendon.  Joint contamination 
occurred in all cases.  
Commonly used injection volumes 
and techniques distribute injectate 
widely through the CET with no 
evidence of superiority in higher 
volumes or fenestration. Joint 
contamination may be inevitable. 
VI Can an expert 
consensus be 
reached to guide 
patient selection, 
delivery and follow-
up of Platelet-Rich 
Plasma (PRP) in LET.  
Assessment of consensus 
between international 
group of PRP users and 
researchers using the 
Delphi consensus 
methodology. 
28 individuals completed three 
rounds of consensus statement 
scoring. Overall agreement was 
reached for 17/40 statements. 
Only 2/6 statements on PRP 
formulation reached consensus.    
Amongst an international group of 
expert researchers and users, only 
limited consensus on the 
application of PRP can be achieved. 
The area identified as not reaching 
consensus should be utilised as 
research priorities.  
VII Is it feasible to 
undertake a 
randomised 
controlled trial of PRP 
vs surgery in chronic 
LET?  
Feasibility assessment of 
12 participants recruited 
to receive PRP injection or 
surgery. Recruitment, 
retention and adherence 
to study design and 
qualitative assessment of 
the patient experience.  
The target sample was achieved 
in 10 months. Recruitment rate 
was 86%. One participant 
dropped out and one crossed-
over from PRP to surgery. 
Qualitative interviews revealed 
very high levels of patient 
discomfort on injection delivery.  
It is technically feasible to 
undertake a study assessing PRP to 
surgery. Reporting guideline 
adherence was achieved, and 
qualitative assessment deemed the 
methodology acceptable.  Future 
studies must assess and report 
procedural pain.   
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1 Introduction  
1.1 Overview 
“There is probably nothing which brings the surgical profession into greater 
discredit at the present time than the inability to cure “tennis elbow”. The condition 
is extremely common, and so helpless have we been in treatment that most 
sufferers now never consider consulting a medical man at all”.  
(G.Percival Mills, 1928) 
“Tennis elbow does not threaten quantity of life, but is a major impediment to 
quality of life.” 
(R. Nirschl 2015) 
Lateral Elbow Tendinopathy (LET) is a condition characterised by pain on the 
outside of the elbow. The pain is associated with gripping and manipulation of the 
hand. The level of discomfort can range from mild and self-limiting, to severe and 
debilitating. In some cases, the pain, and consequent functional impairment cause 
the patient significant daily intrusion and disruption to general health and 
wellbeing.  
In this thesis, the approach to investigating treatments for LET will be explored. 
This will proceed with a review of the aetiology, burden and impact of the disease, 
and will be followed by an appraisal of the current levels of evidence supporting 
the most popular interventions. These elements will then be aligned with an 
evaluation of the methods currently applied to assess the therapeutic effect of 
interventional treatment. A summary of knowledge gaps, justification and scope of 
the thesis will   precede the presentation of seven studies which aim to identify, 
inform and assist in the optimisation of future research into LET. An overarching 
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synthesis of this evidence, the potential impact of its findings and the author’s 
perspective on the future of LET research will then conclude this thesis.     
1.2 History 
The first description of Lateral Elbow Tendinopathy (LET) is regularly attributed to 
the German physician Dr F. Runge [1], who in 1873 published his paper entitled 
“On the causes and management of writer’s cramp”. The little known Dr Runge is 
also believed to have been a pioneer of sclerosing therapy, whereby he cauterised 
the skin at the outer aspect of the elbow, under the belief that the resultant 
scarring provided sustained pain relief and return to function, with good results 
reported at a year following the procedure [2].  The condition’s most colloquial term 
of reference is “Tennis Elbow”, a derivation from the description reported by 
esteemed surgeon Sir Henry Morris who introduced the term “Lawn tennis arm”. 
Sir Henry surmised that the use of a frequent backstroke with forceful pronation 
led to a sprain of the pronator teres muscle. This original description, therefore, 
contains some confusion, being that Sir Henry may have been describing what we 
now term “Golfer’s elbow”, a condition that presents with pain on the inside of the 
elbow.  
Following Sir Henry’s publication, a multitude of correspondence from interested 
parties ensued in the British Medical Journal. In a review of the early history of 
Tennis Elbow, Thurston [3] describes the impassioned communication whereby Dr 
H.P. Major, speaking of his own affliction, felt the condition emanated from the 
annular ligament, Dr Winkworth felt an entrapment of the posterior interosseous 
nerve was far more likely, and Dr O’Sullivan who felt the radial nerve was 
implicated and a treatment of “continuous current of electricity” would be 
beneficial. Therein we see the beginning of aetiological and therapeutic arguments 
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that continue to this day. At the turn of the century the volume of literature was 
disproportionately high, particularly for a condition many believed too trivial to 
merit discussion, and though the condition was recognised in numerous 
recreations and occupations, for some reason, the term “Tennis Elbow” persisted. 
This was much to the disdain of the German literature who tended to call it 
“Sogenannten Tennisellenbogen” (“so-called tennis elbow”) [3].  
Lack of consensus surrounding an exact term of reference for LET continued 
through the 19th century. In fact, the persistence of the colloquialism “Tennis 
Elbow” may be related to the medical community’s reticence to commit to common 
terminology. Cyriax (1936) [4] in his correspondence to the British Medical Journal, 
cautions on a change of name to that proposed by Mr McKee, “traumatic periostitis 
at the origin of the extensor carpi radialis brevis” as it is “premature to label tennis 
elbow with a name that precludes a difference of opinion on pathology”. In his 
communication he collates the succession of terms applied in the literature 
including Remak (1894) and Bernhardt (1896) who apply the term “periosteal tear 
of the extensor muscles”, Couderc (1896) “ruptured epicondylar tendon”, Fere 
(1897) epicondylalgia and Franke (1910) epicondylitis. Though Cyriax concedes 
that “tennis elbow” will have to remain, this “does not imply the acceptance of any 
particular theory or pathology”.  
Though 80 years have passed from Cyriax’s perceptive commentary, numerous 
authors have continued in earnest to define the terms of reference. Most recently, 
veracious commentary provided by two authors within a year of one another 
proposed very different terms, Waugh (2005) [5] championed the term 
“epicondylalgia” and Stasinopoulos (2006) [6] “lateral elbow tendinopathy”. 
Interestingly both cite the lack of consensus on pathophysiology as reasons 
behind the adoption of their respective generic term.  It is without surprise that 
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varied terminology continues, which beyond those already mentioned includes 
“lateral humeral epicondylitis” [7], “peritendinitis of the elbow” [8] and “enthesopathy 
of the extensor carpi radialis brevis” [9].  
It, therefore, becomes a challenge for an author to choose a term that is 
acceptable to a collective readership. Though nearly all studies qualify their 
chosen term with the statement “also known as tennis elbow”, it seems rather 
improper to include a term for which many authors postscript their term with 
versions of the statement “a condition that is far from exclusively experienced by 
tennis players”. Indeed this colloquialism upsets many sufferers, and in many 
respects is felt to trivialise a painful and functionally limiting condition. Therefore, 
the term “lateral elbow tendinopathy” seems appropriate at this juncture, where 
simple reference to the anatomical site, the tissue of reference and the suffix 
derived from the Greek “pathos” denoting “suffering”, without allusion to the 
pathology of a condition that is still a source of debate.     
1.3 Epidemiology 
Historically, estimations on the prevalence of LET were nominally reported as 
between 1-3%; these figures were based on the assessment of small cohorts of 
patients [10, 11] and are felt to be ungeneralisable [12].  Of the larger epidemiological 
studies, Walker-Bone et al [13]  estimated the point prevalence to be 0.8% in males 
and 0.7% in females in a cross-sectional assessment of 6038 participants from 
two UK general practices. Shiri et al [14] performed a cluster analysis of Finnish 
population-based survey respondents, of 4,783 individuals who were interviewed. 
They reported a prevalence of LET of 1.3% (95% CI 1.0-1.7). Roquelaure et al [15] 
in an analysis of 3,710 French workers participating in a surveillance programme 
of musculoskeletal disorders, where the disorders were diagnosed by occupational 
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physicians, reported a prevalence of LET of 2.7% (95% CI 1.8-3.1) in men and 
2.7% (95% CI 1.9-3.5) in women. Salaffi et al [16] as part of a large study assessing 
the prevalence of musculoskeletal conditions in an Italian population of 3,664 
individuals estimated the prevalence of LET at 0.74% (95% CI 0.47-1.33).   
The incidence of LET has been reported in three large epidemiological studies, 
Titchener et al [12], deriving data from the UK health improvement network 
database (THIN) whose records are estimated to cover the primary care health 
records of 5.7% of the UK population, assessed general practitioner-reported 
cases of LET over the period 1987-2006. They reported an overall incidence of 
2.45 (95% CI 2.43-2.46) per 1000 person-years, significantly higher in males at 
2.63 (95% CI 2.60-2.65) than females 2.55 (95% CI 2.53-2.58) (P<0.001). Sanders 
et al [17], reported on the population-based incidence of LET in a sample of 
144,260 residents of Olmsted County, Minnesota. They reported an overall 
incidence of 3.4 (95% CI 3.3-3.5) per 1000 person-years, lower in males at 3.3 
(95% CI 3.2-3.5) than females 3.5 (95% CI 3.4-3.7). Bot et al [18] in their analysis of 
the second Dutch national survey of general practice assessed over 1.5 million 
primary care contacts over a 12 month period. They reported an incidence of 5.1 
(95%CI 4.8-5.3) per 1000 person-years with no difference between male and 
females.  
Studies conducted in specific populations demonstrate wide variations in the 
epidemiology of LET, dependent predominantly on occupational exposure. 
Hopkins et al [19] in their systematic review reported an average prevalence  of 
8.9% in those with occupational exposure, with a notably high prevalence reported 
in spinal surgeons [20] (18%) and coal miners [21] (41%). Limited data are available 
on those in sedentary work, but the findings of Kryger et al [22] are notable for 
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reporting a prevalence of 5.8% in a population of 1369 computer-based workers 
presenting with neck and/or arm pain.  
A common aspect reported in almost all of the epidemiological studies on LET is 
the age-dependent spread of LET. The condition has been reported as uncommon 
in those under 18 years, with a rise in incidence which peaks between 40-55 years 
to as high as 10.2 per 1000 person-years [17], followed by a decrease towards the 
eighth decade when it becomes very rare [12, 14, 17, 23]. Of note, this age-related 
distribution of LET parallels that of cumulative incidence of neck and upper 
extremity musculoskeletal disorders [18]. Both the patient age of highest prevalence 
of LET being at a time of occupational activity, and many analogous descriptors 
from occupation-specific prevalence studies, correspond to occupational exposure 
as a potential risk-factor for LET. Walker-bone et al [23] report LET to be associated 
with manual work (Odds ratio (OR) = 4.0, 95% CI 1.9-8.4) and both Walker-Bone 
et al [23] and Shiri et al [14] report an association between repetitive and forceful 
movements of the arm resulting in repeated bending/straightening at the elbow 
and wrist to be an independent risk factor (OR = 2.5, 95% CI 1.2-5.5 and OR 5.6, 
95% CI 1.9-16.5 respectively). One may surmise that these findings correspond 
with an association with hand dominance. Although studies do report a higher 
prevalence of LET symptoms in the right side, 63% right vs 25% left reported by 
Sanders et al [17], few have studied or recorded hand dominance. Shiri et al [24] in 
their Finnish population study of 6,254 adults do however report that LET was 
significantly more prevalent in the dominant elbow (p=0.03 in men and p=0.05 in 
women). Interestingly, LET was more common in left dominant individuals (2.5% 
prevalence) than right dominant individuals (0.7%); however, this only reached 
statistical significance in men (p=0.001). This tallies with studies such as Sanders 
et al [17] who report a higher than the expected proportion of left-handed patients 
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when the population distribution is approximately 10% [25]. These hand dominance 
findings are, however, not repeated in the study by Walker-Bone [23] of 6,038 
participants.   
Epidemiological analysis of LET has identified that it represents a disease of 
middle age. Though the population prevalence is often quoted as between 1-3%, 
larger epidemiological studies would suggest this may be an overestimation. What 
is more relevant, however, is the risk of development of the disease in the fourth 
decade of life and in the context of occupational exposure.  
1.4 Anatomy 
The site of the lesion in LET is most commonly ascribed to the proximal extensor 
radialis brevis (ECRB) tendon (Figure 1.1) [26-29]. The ECRB is a component of a 
conjoint tendon, which also includes the tendons of the extensor digitorum 
communis (EDC) and extensor carpi ulnaris (ECU) that have their origin at the 
anterior aspect of the lateral epicondyle and lateral supracondylar ridge [30]. This is 
also the site of attachment for the extensor digiti minimi (EDM) and supinator 
which merge with the ECRB, EDC and ECU to form the common extensor tendon 
(CET). The ECRB is a wrist extensor that inserts at the base of the 3rd metacarpal, 
it is innervated by the deep branch of the radial nerve and has an arterial supply 
from branches of the radial artery. Its mode of action on muscle contraction is to 
extend and abduct the hand at the wrist joint [31]. In the action of grasping and 
pinching at the hand, a flexion moment is caused at the wrist joint, to counteract 
this moment an equilibrium of moments is initiated by the  
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Figure 1.1: Anatomical drawing of the lateral aspect of the elbow. Position of ECRB highlighted in red. 
Reproduced and modified from The Body Almanac. © American Academy of Orthopaedic Surgeons, 
2003. 
 
contraction of the extensor musculature [32]. The bony origin of the ECRB can be 
reliably identified beneath the distal-most aspect of the supracondylar ridge, with a 
mean dimension of 13 ± 2mm in length by 7 ± 2mm in width [33]. This origin is 
particularly small in comparison to the surrounding tendons of the CET [34]. This 
origin is also purely tendinous, in contrast to the EDC, EDM and ECU which 
originate as a mixture of tendon and muscle, it has been postulated this may 
correspond to a reduction in vascularity in comparison to the surrounding extensor 
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origins [35]. The undersurface of the ECRB has a close relationship with the joint 
capsule that varies across the origin, on the anterior side it appears delicate and 
thin, posteriorlodistally there is a stronger, thicker origin attachment as the ECRB 
merges with the supinator [35]. This anterior edge has been proposed as a factor 
causing the initiation of the pathology of LET [35], this is particularly pertinent when 
combined with dynamic assessments of the tendon position, whereas when the 
elbow is extended the undersurface of the ECRB has been shown to rub against 
the lateral edge of the capitellum, whilst overlying ECRL compresses brevis 
against underlying bone [36].  
It is worth noting that although there is an anatomical basis for ECRB being the 
predominant site of LET, some authors have questioned whether one can ascribe 
this so specifically. Greenbaum et al [37] report that the relative difficulty in isolating 
the origin of the ECRB from the surrounding tendons of the CET and state that the 
pathology would appear to be coming from the whole common extensor. In a 
pathological study of the common extensor tendons, it has also been noted that 
one-third of patients have involvement of the EDC [38, 39].  
1.5 Pathology, aetiology and pathogenesis   
Lateral elbow tendinopathy is considered to be an overload injury [40], where 
minimal cumulative trauma to the elbow extensor muscles initiates a cascade of 
pathological changes to the tendon, where the resultant effect is the 
symptomatology already discussed. Though this aetiological mechanism is 
relatively well accepted, consensus on the associated pathological alterations to 
the tendon itself has not been reached. This is in keeping with the overarching 
theories on the pathophysiology of tendinopathy that have been described by 
Millar et al [41] as varied, probably not mutually exclusive and largely unproven.  
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In keeping with the nomenclature of LET, prior to the 1990s the pain associated 
with LET was referred to as a ‘tendinitis’ and the associated pathology was 
thought to be inflammatory in origin, consequently treatments were directed at 
resolving this, relying predominantly on non-steroidal anti-inflammatory 
medications [42]. Though the view of an inflammatory component was deeply 
ingrained in the medical literature [43], the work of Nirschl [44] and Regan [38] began 
to cast doubt on this assertion. Microscopic and histological analysis of 
pathological tendons identified four key changes, collectively termed 
“angiofibroblastic hyperplasia”: 1) increased cell numbers and ground substance, 
2) vascular hyperplasia or neovascularisation, 3) increased concentration of 
neurochemicals and 4) disorganised and mature collagen [38, 44]. However, it was 
the consistent absence of inflammatory cells which led to the development of the 
term “degenerative” tendinopathy [38, 44]. This finding, analogous with 
tendinopathies at other sites led to a move away from the term “tendinitis”, this 
was summed up in an editorial in the British Medical Journal by Khan et al [43] 
urging their readership to “accept the irrefutable evidence that the term tendinitis 
must be abandoned”.  
The non-inflammatory or degenerative theories of tendinopathy were the principal 
thinking of the first decade of the 21st century, leading Rees et al [42] to term this 
period “Degeneration without inflammation: the paradigm of the 2000s”. This led to 
the development of models of thinking as to why tendons fail and why they are 
unable to repair themselves. Furthermore, models that integrate the interrelated 
components of: 1) local tendon pathology, 2) changes in pain systems and 3) 
motor system impairments, have been particularly popular in the pursuit of 
targeted or individualised treatments in LET [45]. Pathophysiologically guided 
treatment algorithms have maintained momentum, even in the scenario of 
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underdeveloped understanding of true tissue changes, Bhabra et al [46] have 
proposed a four-stage treatment algorithm based on four histologically defined 
grades of tendon tendinopathy: 1) collagen fibre pattern becomes increasingly 
wavy. Although cellular and vascular changes are minimal, there is an increase in 
the proportion of type 3 collagen, 2) tendinosis and angiofibroblastic hyperplasia 
as described by Nirschl [44], 3) programmed cell death leading to the depletion of 
functional tendon cells and breakdown of collagen and extracellular matrix and 4) 
gross structural and mechanical failure. They propose a spectrum of therapeutic 
interventions targeted at each stage of the disease, from conservative measures 
to surgery for stage 4 disease. However, this is clearly limited by the need to gain 
a tissue biopsy for grading and the current lack of evidence base for many 
treatments in LET. Miller et al [41] also note that the absence of pain and functional 
limitation make the diagnosis of early tendinopathy difficult, consequently one of 
the major limitations of human studies on tendinopathy is that tendon biopsy 
samples are usually only obtained when patients are sufficiently symptomatic. 
Therefore the tissue is likely to represent chronic rather than early stage disease.   
The various models proposed to explain the pathological process of tendinopathy 
have suggested a primarily degenerative process, with some clearly stating that 
the process of tendon overuse is non-inflammatory in nature [42]. However, the 
limitations of this view have begun to be highlighted with a particular focus on the 
role of, thus far, underappreciated inflammation and neuronal regulation. Though 
not yet specific to the pathology of LET, systematic analysis of studies assessing 
inflammation using modern techniques have identified a plethora of inflammatory 
mediators [47, 48]. Indeed, a proportion of the more historic studies refuting the role 
of inflammation had only attempted to identify neutrophils [48]. Modern research 
tools have confirmed the presence of inflammatory cells including macrophages 
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and lymphocytes in chronic tendinopathy [41, 42]. Also, inflammatory mediators 
including numerous inflammatory cytokines, substance P, MMPs, VEGF and COX 
have all been identified and associated with a role in chronic inflammation [41]. The 
neuronal component has become a source of interest for two key reasons, firstly 
that there is often a mismatch between the tendons’ histological appearance and 
the patients’ level of pain, and secondly that there is growing recognition that there 
is an increased expression of glutaminergic pathways at tendinopathic sites. 
Patients with histologically matched tendinopathy but differences in pain 
symptomatology have been found to differ in their levels of glutamate receptor 
expression [49] in the rotator cuff. Though these findings are yet to be translated to 
LET, there remains a level of equipoise over the pathology of tendinopathy that is 
likely to hamper or confuse directed treatments until these issues are resolved. 
Even at its simplest terms, as recognised by Rees et al [42], even if inflammation is 
not seen at a particular point in time, this does not in itself imply that inflammation 
has not played a role in the initiation of tendinopathic change.  
With a condition whose basic pathoaetiology remains a source of significant 
scientific exploration, and an expert consensus that has shifted almost 180 
degrees on at least two occasions, it is unsurprising that the choice of 
pathologically linked treatments has taken a parallel course. It is vital however, 
that the treating clinician also heeds the fact that the patient presenting with LET 
may have pathological changes that reside on a spectrum. Whereby the above 
discussed tissue alterations may not be exclusively right or wrong, but rather occur 
a different stages of the disease. Analogous to many musculoskeletal disease, this 
continuum of pathology is likely influence the efficacy of interventions directed 
toward the treatment of a particular pathological element. This aspect of the 
disease is particularly relevant in the conduct of trials of interventions, whereby the 
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selection of participants with the same overarching diagnosis may be in different 
stages of the disease and thereby respond in differing ways, introducing and 
unappreciated bias. As yet no pathology specific trial guided treatments has been 
conducted in LET, which in many ways mirror the overarching infancy of 
tendinopathic pathology. 
This is of no conciliation to the vast number of people suffering from LET and their 
clinicians who strive to provide evidence-based treatment. Fundamentally, a better 
understanding of the pathogenesis of the condition is necessary to develop long-
term treatment strategies but this, in turn, must then be allied to valid clinical 
outcome recording methods, a thorough understanding of treatment delivery 
methods and the exploration and development of consensus amongst clinicians. 
1.6 Clinical features 
As with many other tendinopathies, LET characteristically presents with gradual 
activity-related pain, decreased function and sometimes localised swelling [41]. It 
has been commented that the combination of pain on the outer aspect of the 
elbow that is exacerbated by lifting objects is almost invariably related to LET [9] 
and that the clinical presentation is reasonably straightforward [50], yet the same 
authors also caution that there is distinct heterogeneity in the intensity and 
frequency of these symptoms, both between individuals and over the time course 
of the disorder [9, 50]. 
The pain is most commonly localised to the lateral epicondyle but has also been 
reported to spread up and down the upper limb [51]. Nirschl and Sobel [52] have 
described a “phases of pain” classification for LET; this seven phase system 
describes the levels of patient affliction from mild pain to an unremitting discomfort 
affecting times of activity and rest:  
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 Phase 0: No pain or soreness 
 Phase 1: Stiffness or mild soreness after exercise activity. Pain is usually 
gone in 24 hours. 
 Phase 2: Mild stiffness and soreness before activity which disappears with 
warm up. No pain during activity, but mild soreness after activity that 
disappears within 24 hours. 
 Phase 3: Same as above with mild pain during activity which does not alter 
activity, disappearing in 24-48 hours.  
 Phase 4: Mild to moderate pain before, during, and after exercise which 
alters the exercise or activity. ADLs are affected. Phase 4 is indicative of 
some level of tendon damage. 
 Phase 5: Moderate or greater pain before, during, and after exercise or 
activity, forcing the patient to discontinue the exercise. Pain is experienced 
with ADLs. Usually reflects permanent tendon damage 
 Phase 6: Phase 5 pain that persists with complete rest. Pain disrupts ADLs, 
many activities have to be eliminated.  
 Phase 7: Phase 6 pain with disruption of sleep on a consistent basis. Pain 
is aching in nature and intensifies with activity. 
It is highly relevant to note that in the context of a chronic pain state, patients with 
LET experience changes in both the peripheral and central nervous system, 
Coombes et al [50] has termed this complex issue as “pain system changes”. 
Patients with LET have demonstrated states of hyperalgesia with reductions in 
pain pressure thresholds by 45-54% compared to the contralateral side [53-56] and 
control participants [57]. Selective improvement in cold hyperalgesia in chronic LET 
patients who had undergone guanethidine regional block (a principle often 
employed in those afflicted with chronic regional pain syndrome), point to a 
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potential sympathetic driver to the chronic pain. It is clear that the complex pain 
picture associated with LET should not be underestimated; once this hyperalgesic 
state ensues, correlations to catastrophic thinking, kinesiophobia or low self-
esteem have been reported within the secondary analysis of a randomised trial of 
steroid vs placebo injection [58]. 
Although there is interplay between pain and function, specific motor impairments 
have been noted in LET. Pain-free grip force is reduced by an average of 43-64% 
when compared to the contralateral side in LET patients [54, 55, 59-61]. Though the 
cut-off in this regard relates to the onset of pain, rather than a true limitation in 
functional strength, the onset of pain can be seen as limiting functional ability, 
particularly in the context of occupational demand. Testing of maximal strength 
has revealed varied results, be it unilateral weakness [57], bilateral weakness [62] or 
no deficit [59], the confounder of pain clearly makes collection of these data 
challenging, particularly in reference to the interplay with hyperalesic 
symptomatology. 
Reduced activity of the ECRB has been demonstrated in LET patients during 
isometric extension exercise [63] and gripping tasks [64] which may imply an 
endurance deficit [50]. Optimal wrist position for maximal grip strength is in slight 
extension [65, 66] and LET patients have been shown to demonstrate a more flexed 
position (11° less extension) [59], in accordance with the length-tension relationship 
model [67]; this may also account for a component of grip strength deficit noted by 
LET patients [50]. Furthermore, LET patients also demonstrate reduced forearm 
reaction time and speed of movement with reaching tasks [59, 68]. A synthesis of 
this information, in light of the occupation associations highlighted above, 
underlines the potential impact of this condition on the ability to work if manual 
tasks are required, or if the wrist position is in an extended position such as it is 
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when typing at a keyboard. This has been explored by Haahr and Andersen [69]; in 
267 new cases of LET in Denmark against a population reference, they reported 
increased odds of LET in non-neutral posture of the hands (OR 7.4 95% CI 2.9 – 
18.7), or high physical strain index established on posture, repetition and force  
(OR 4.4 95% CI 1.6 – 4.6).  
1.7 Diagnosis  
Diagnosis of LET is typically made on clinical grounds [70], where a suggestive 
history of pain around the lateral humeral condyle is supplemented with 
confirmatory examination findings. As an adjunct to the supposed ‘classical 
history’ and diagnosis, which is reliant on the clinical acumen of the attending 
clinician, attempts have been made to supplement the identification of LET with 
specific diagnostic criteria, clinical tests and imaging studies.  
The first set of diagnostic criteria for LET emerged as a set of consensus 
definitions for the surveillance of work-related upper limb pathologies using an 
iterative Delphi methodology [71].  The resultant criteria for LET were;  
o Lateral epicondylar pain  
AND  
o Lateral epicondylar tenderness on palpation  
AND  
o Pain on resisted extension of the wrist with the elbow extended.   
It was subsequently reported that the relaxing of these criteria to include one of the 
two clinical examination signs led to a sensitivity of 73% and a specificity of 97%. 
The one further attempt to produce diagnostic criteria was produced by Sluiter et 
al [72], again for occupational health research, who derived a set of symptom and 
sign criteria through literature review. 
Symptom criteria:  
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1. At least intermittent, activity-dependent pain directly located around the 
lateral epicondyle 
AND 
2. Symptoms present now or on at least 4 days during the last 7 days 
OR 
3. Symptoms present on at least 4 days during at least 1 week in the last 12 
months 
Symptom and sign criteria: 
4. Symptoms present now or on at least 4 days during the last 7 days 
AND 
5. At least intermittent, activity-dependent pain directly located around the 
lateral epicondyle 
AND 
6. Local pain on resisted wrist extension     
The authors also suggest the application of the International Statistical 
Classification of Diseases and Related Health Problems (10th Revision) (ICD-10) 
code M77.0.  
A plethora of examination ‘special tests’ have been proposed to assist in the 
diagnosis of LET. These include active examination where pain is provoked at the 
lateral epicondyle by Cozen’s test [73], where wrist extension is resisted, the 
holding a book test [74], the ‘chair test’ [75] elicits pain when the patient lifts a chair 
with a pronated hand, the Maudsley’s test where dorsal extension of the middle 
finger is tested against resistance and the Mill’s test which is performed by 
passively bringing the elbow from a flexed to extended position whilst the wrist is 
fully pronated and flexed [76]. None of these tests has had their diagnostic accuracy 
assessed [76]. Only the grip strength reduction test has been formally assessed [77], 
where a 5% deficit in power has an 83% Sensitivity and 80% Specificity, 8% deficit 
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has an 80% Sensitivity and 85% Specificity, and 10% deficit has a 78% Sensitivity 
and 90% Specificity.  
Imaging modalities have been employed in the investigation of LET. Plain 
radiographs are not felt to be additive in the assessment of LET, other than when 
an alternative diagnosis is a possibility or the patient also presents with symptoms 
of crepitus, restricted motion or loose body symptoms that may be suggestive of 
arthritis [9]. There has been far more interest in the role of ultrasound and magnetic 
resonance imagery (MRI). Ultrasound scanning of symptomatic patients has 
reported common findings of hypoechogenecity, calcifications and tendon tears [78-
81], similarly MRI has demonstrated deficits in the enthesis and high signal in the 
tendon substance [82, 83]. However, it is unclear how these findings relate to the 
prognosis [9] and high levels of abnormalities have also been identified in 
asymptomatic individuals [84, 85]. A single study has positively correlated the 
pathological grade of LET to a validated outcome measure, Qi et al [86] reported a 
positive correlation (r= 0.920 p<0.01) between their modified three-stage grading 
system based on tendon signal change and the Patient-Rated Tennis Elbow 
Evaluation (PRTEE) in 96 LET patients. There has been greater interest in the 
assessment of neovascularity in the common extensor tendons, the absence of 
which is highly predictive of LET not being the diagnosis [80], however, no 
correlation with symptoms has been identified.  
The prevalence of LET is such that in patients between 35-65 years with 
suggestive symptoms, LET is almost certainly the diagnosis [9], however two 
possble differential diagnoses are worth mentioning; arthritis in those with 
restrictions of range of motion, and radial tunnel syndrome, a compressive 
neuropathy of the Posterior Interosseous Nerve (PIN) at the radial tunnel in those 
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not responding to LET treatments. The latter being very difficult to prove owing to 
the fact that MRI and electrodiagnostic studies are often inconclusive [87].  
1.8 Patient-level and societal impact of lateral elbow tendinopathy 
Lateral Elbow Tendinopathy is often referred to as a self-limiting condition [26]. One 
supposes that this terminology implies that, without specific treatment, LET 
resolves.  However, it is vital that the patient and societal impact of this “self–
limiting” condition are quantified and appreciated, therein to what duration do we 
denote boundaries of self-limitation, and to what level of personal symptoms or 
societal burden is deemed acceptable to offer “watchful waiting” as a treatment 
choice.  Information on the natural history of LET is extremely limited, however, 
the best available evidence would suggest that of the population of LET sufferers 
who have had symptoms for at least four weeks, between 80 - 90% report 
improvement at 1 year [88-90], of note the authors classify resolution as a self-report 
of “completely resolved” and “much improved”, beyond this time point the data are 
even more uncertain, Hudak et al [91] report evidence from a systematic review of 
moderate quality studies reporting symptoms beyond two years but the 
proportional representation within this cohort is not provided. Bot et al [18] in their 
analysis of elbow complaints, of which LET was the most common, in contrast, 
report very low rates of improvement within the first 12 months, with only 34% of 
patients reporting a full recovery. Recurrence rates within two years of initial onset 
have been reported as 8.5%, a figure that remained constant between 2000 and 
2012 [17]. It has been estimated that between 5-10% of patients with symptoms 
longer than six months will eventually undergo surgical intervention [92].  
Though it has been estimated that 25% of LET sufferers report difficulty dressing, 
carrying objects [62], driving and sleeping and that up to 5% of LET patients have 
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claimed sickness absence with a median duration of 29 days per year [23]. No 
estimation of personal burden, be it economic costs associated with work absence 
or treatments has been made. Furthermore, though it is recognised that LET 
sufferers experience significant levels of depression and anxiety [62], societal costs 
associated with caregiving, societal integration or individual well-being have also 
not been quantified.   
Though it may be surprising that for a condition so prevalent in the general 
population, information on the individual natural history and burden of the 
condition, on which a clinician can base their advice to patients, remains limited. It 
may be more surprising that information on the global socio-economic impact of 
LET, a disease of the working age, is even more restricted. Hopkins et al [19] in a 
global assessment of the burden of tendinopathy, performed the only estimate of 
socio-economic burden utilising figures on work absenteeism derived from the 
work of Walker-Bone et al [23] and applying 2012 population statistics and a United 
Kingdom derived median wage, that LET in the UK alone is estimated to cost £27 
million. Due to a paucity of data this evaluation was limited to the UK only.  
The relative paucity of data may be one of the reasons that upper limb 
tendinopathy draws a relatively low profile compared to its relative high 
prevalence. The available data are in stark contrast to other musculoskeletal 
ailments of the working age population, with the prime example being back pain [93-
96]. As a foundational aspect it has been proposed that the difficulty gaining this 
information may be related to the coding structures and documentation of this 
condition. Though it has been mentioned that the nomenclature has changed on 
numerous occasions, it is notable that the International Classification of Diseases 
(ICD-10) [97] continues to apply the term ‘lateral epicondylitis’, and does not 
recognise the terms ‘tendinopathy’ or ‘tendinopathy at the elbow’. Furthermore, the 
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International Classification of Functioning, Disability and Health (ICF) [98] that aims 
to classify health and health-related domains does not recognise tendon as a body 
structure, unlike muscle and ligament which are registered. Without this 
recognition within such well-utilised coding structures, adequate epidemiological 
study will remain limited.  
1.9 Treatments  
There are no UK guidelines for the optimal management of LET [99] and though 
there is a wealth of interventional study data, there is also a perceived lack of 
expert consensus [9]. Treatment options discussed and recommended to a patient 
population who often desperately seek a cure, tend to be based on clinician level 
experience and expertise, availability and acceptability. Broadly, the 
armamentarium of treatments available fall into the categories of non-
interventional (conservative) and interventional (injections or surgery). It is also 
important to recognise that there are numerous “over the counter” or alternative 
remedies that fall outside of the empirically represented treatments. The utilisation 
and effectiveness of these treatments are unknown, however as a proxy, the 
ubiquitousness of products in chemists and websites purporting a new miracle 
cure should be considered.  
The place that most patients will start their treatment is the self-administration of 
analgesia. Bisset et al [45] are the only authors to synthesise the available evidence 
on oral and topical analgesia. They report very low-quality evidence from two 
RCTs that oral NSAIDs may be more effective at improving pain than placebo in 
the short term but no assessment of global or functional improvement can be 
made. For topical NSAIDs, they report moderate quality evidence from three RCTs 
that they seem more effective at improving pain than a placebo. However, they 
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may be no more effective than placebo at improving function. The effect of other 
simple analgesics or compound analgesia has not been assessed in a systematic 
review.  
Beyond simple analgesia, many patients use counter-force braces. These braces, 
when correctly applied have been found to alter forearm muscle activity and 
angular joint acceleration in tennis players [100]. However, there have never been 
studies against a sham orthosis or no treatment.  Low-quality evidence from four 
RCTs found counter-force bracing to be less effective at reducing pain than 
physiotherapy alone and corticosteroid injection [45].  
The most extensive review of conservative therapies was conducted by Long et al 
[101]. Their overview of 29 systematic reviews and 36 randomised controlled trials 
reported the clinical and cost-effectiveness of therapies in LET. Of the therapies 
assessed, it was concluded that there was insufficient evidence to demonstrate 
either benefit or lack of effect of extracorporeal shockwave therapy (ESWT), laser 
therapy and exercise therapy. They report moderate quality and consistency of 
results for pain relief using therapeutic ultrasound in the short and medium term. 
Their cost-effectiveness assessment was based on the assessment of only two 
studies and reported that physiotherapy might be more cost-effective than 
glucocorticoid injection in the longer term, however, estimates of effectiveness 
relied on the accompanying trials which were deemed to be too small to overcome 
uncertainty about the size of the effect. This evidence has been more recently 
expanded following the work of Coombes et al [99] who in an assessment of 
randomised control data on 165 LET patients report a superiority and improved 
cost-effectiveness of physiotherapy over glucocorticoid injection, where the 
probability of being more cost-effective than placebo at values above the quality-
adjusted life year (QALY) threshold of £28,000 was 81% for physiotherapy and 
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53% for corticosteroid injection. Phsyiotherapy as an intervention does, of course, 
include a great variety of modalities and therapies. Most commonly patients will 
undertake a structured exercise programme to primarily address motor 
impairments. Coombes et al [102], in the above study utilise three main exercise 
groups: 1) sensoy retaining of grip and and forearm movements, 2) progressive 
resistance exercise utilising both concentric and eccentric execises and 3) 
exercises directed at general arm strengthening. This intensive protocol was 
delivereed during eight 30minute specialist physiotherapy sessions delivered over 
eight weeks. Although commonalities exist within exercises for LET, the level of 
supervision varies within each healthcare structure and hence generalisability of 
the findings of such protocols should be contrasted with the intended delivery 
system.   
The review conducted by Long et al [101] concludes that for all of the non-
interventional studies, the analysis is significantly limited by the lack of well-
conducted randomised controlled trials, of adequate follow-up and inclusion of 
validated outcome measurement. Their report is particularly concerning regarding 
our most commonly deployed intervention of physiotherapy and exercise, where 
synthesis of results has been particularly hampered by poor quality methodology, 
use of unvalidated outcome measures and short follow-up periods. Of particular 
interest throughout this review are the 28 randomised controlled trials that are 
excluded for outcome measure or study design reasons, rendering their potential 
contribution to the evidence base minimal at best.  
The use of injection therapy in LET has become a common second-line treatment 
following the failure of conservative treatments [103]. Corticosteroid injections have 
been a mainstay of treatment over the last 60 years [104] but numerous other 
injectates have been applied, these include blood product injections such as 
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Platelet Rich Plasma (PRP), sodium hyaluronate, sclerosant solutions, 
glycosaminoglycan polysulphate and botulinum toxin. Of the less common 
injection therapies, Long et al [101] report low-level evidence for short, medium and 
long-term pain relief from sodium hyaluronate injection, a finding supported by two 
further, more recent, network meta-analyses [105, 106]. There is moderate level 
evidence showing no benefit from sclerosant therapy or glycosaminoglycan. 
Botulinum toxin has demonstrated large benefits in short-term pain relief. 
However, this should be assessed in the context of a high complication rate of 
temporary paresis of finger extension [105].  The use of prolotherapy, an injection of 
dextrose +/- a local anaesthetic is supported by low-level evidence of a large 
reduction in pain, but this assessment is hampered by a limited number of studies 
[101, 106].  
One of the most interesting conclusions of the recent reviews on LET treatment is 
their consensus on the use of corticosteroid injections. These injections, 
administered commonly in primary care [107], secondary care and physiotherapy 
clinics [103, 108] have been shown to have a short-term pain relieving effect, with no 
benefit for the intermediate and long-term [45, 101]. Though repeat systematic review 
may be required [101], recent RCT evidence also suggests that long-term outcomes 
may be worse with corticosteroid injection [109] and that the use of a corticosteroid 
is associated with inferior outcomes from surgery in refractory cases [110]. Kachooei 
et al [111] identify that of the 13 RCTs conducted since 1954, that have compared 
corticosteroids with placebo, it was deemed to have favourable outcomes in three 
of the five early studies, but in these studies they did not blind their patients or 
clinicians; among the eight double-blind studies, two found an early benefit (one 
with a later detriment) and six found no benefit.  
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The use of Platelet-Rich Plasma (PRP) injection as a treatment for LET has 
received particular focus in systematic reviews of injection therapies. PRP is a 
term used to describe a concentrate of platelets prepared using autologous blood 
[112]. The principle of its application is the potential to enhance tendon healing and 
tissue regeneration by delivering various growth factors and cytokines, thereby 
affecting cell proliferation, chemotaxis, cell differentiation and angiogenesis [113]. 
The theory is that by injecting PRP intratendinously, repair mechanisms will be 
upregulated and tissue healing will be promoted.  
As an autologous formulation, PRP production, dosing and safety has not been 
scrutinised as a medication. In the UK the medical device must hold a CE mark, 
whereby it meets the European Union’s safety, health and environmental 
requirements, but the blood product itself is not assessed, and no statement or 
application of clinical evidence is required. The modest regulatory barriers and the 
patients’ desire for new treatments have, unsurprisingly, been accompanied by a 
rise in the use of this treatment [114]. The PRP international market has been 
valued at $160 million in 2015, and over 40 different PRP systems are available on 
the market [115]. However, the evidence for its use is not commensurate with this 
rapid adoption. The discussed review by Long et al [101] does not comment 
specifically on the clinical effectiveness of PRP and evidence for its cost-
effectiveness is derived from a single abstract and therefore not recommended for 
interpretation, however they do call for further systematic review as no high-quality 
and limited RCT evidence was available. Pooled analysis of PRP use in 
tendinopathy of all pathologies (e.g. LET, Achilles tendinopathy, rotator cuff 
tendinopathy) [79, 116, 117] have been conducted but the disease specificity of these 
findings is challenging to elucidate. For reviews on LET specifically, the findings 
are incredibly challenging to untangle. Four key reviews, with a focus on PRP in 
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LET have been published. Ahmad et al [118] found eight studies that met inclusion 
criteria, de Vos et al [119], using a more rigorous inclusion criteria based on the 
Physiotherapy Evidence Database score (PEDro), identified six studies, Dong et al 
[106] selected five and Arirachakaran et al [120] selected seven. There is significant 
crossover between the studies selected with the exception of Arirachakaran et al 
[120] who included three more recent studies. Interestingly their headline 
conclusions are somewhat different. Ahmad et al [118] cautiously state that their 
assessment adds strength to the case for clinical benefit of PRP, as does 
Arirachakaran et al [120], yet de Vos et al [119] conclude that their review provides 
strong evidence against PRP for LET and Dong et al cautiously state that PRP 
may be a treatment candidate but current evidence is inconclusive. It is worth 
noting the de Vos et al and Ahmad et al reviews have received a critical response 
[121] both for their identification criteria and data synthesis, however beneath their 
primary conclusions, all four reviews clearly state what may be the key issue: that 
the quality of evidence within the literature is not yet strong enough to provide a 
clear insight into PRP’s efficacy. The key methodological limitations within the 
present literature include the lack of a proper control group, the variation in PRP 
preparations and outcome scoring methods.  
The concerns regarding the interpretation of PRP research has been elegantly 
highlighted by Murray et al [122]. Utilising an iterative Delphi methodology they have 
proposed a study checklist named the Minimum Information for Studies Evaluating 
Biologics in Orthopaedics (MIBO). The authors are very clear that the current 
confusion regarding the efficacy of PRP can only be resolved following the clear 
reporting of the study methodology and outcomes. However, no level of 
consensus on study methodology standards or outcome measure choice is 
currently available. 
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Surgery is deemed to be reserved for patients who have failed conservative and 
injection therapy. Surgery can be conducted using an open, arthroscopic or 
percutaneous technique [123]. The predominant technique was described by Nirschl 
and Pettrone in 1979 [27], whereby the diseased tendon is excised. However,13 
other techniques have been defined with over 300 modifications reported [123]. The 
outcome of surgery is often quoted as yielding good to excellent long-term results 
with improvement rates of up to 97% at 10 years [124] with no difference in 
outcomes reported between differing techniques [123]. However, systematic review 
evidence of the available RCTs have been less favourable. Buchbinder et al [40] 
and Bisset et al [45] both state that due to a small number of studies, large 
heterogeneity of interventions, small sample sizes and poor outcome reporting, 
there is insufficient evidence to support or refute surgery as a treatment. 
Buchbinder et al [40]  performed the largest review of four RCTs comparing surgical 
techniques and one comparing surgery to a therapy (extracorporal shock wave 
therapy), they were unable to find any studies comparing surgery versus no 
treatment, or surgery versus the more commonly applied treatments (e.g. 
corticosteroid, physiotherapy or PRP). Recent reports of pilot trial evidence of a 
placebo-controlled trial of surgery did not demonstrate any evidence of superiority 
over surgery [125], but this requires further corroboration in larger studies. A 
randomised, double-blind sham-controlled trial of arthroscopic release is currently 
being conducted [126].  
It is of interest to compare the trends in use of the common treatments to the 
evidence presented. The use of corticosteroids as a treatment of LET by 1000 
Australian general practitioners was assessed over a 15 year period (2000-2015) 
[107]. Despite the growing body of evidence questioning its long-term efficacy, the 
authors report that the rate of corticosteroid injection did not change over this 
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period.  In a population cohort study of approximately 144,000 people, assessed 
between 2000 and 2012, the proportion of surgically treated cases of LET tripled 
over time, despite a lack of compelling level one evidence of its effectiveness [92]. 
The apparent mismatch between the evidence base and treatments offered to 
patients is in many respects unsurprising. The lack of compelling evidence for any 
particular treatment method will, of course, prompt the clinician to offer the 
suffering patient what their experience leads them to believe will work. In a 2017 
UK survey of 142 physiotherapists and 123 surgeons, physiotherapy or exercise-
based treatments were the first-line treatment for 81% of respondents and 
corticosteroid injection was the most popular second-line treatment, recommended 
by 27%. Surgery and PRP injection were both recommended as a preferred 
second-line treatment, both by 9.82%. Of the surgeons, 59% would consider 
surgery only following symptoms of at least 12 months’ duration. There is no doubt 
that treatments are being prescribed, which carry an associated healthcare cost, 
complication rate and in some cases inferior outcome. Drake et al [9] state that 
those “who endorse the current best evidence acknowledge that no treatments 
have been proven to alter the natural history of LET… because patients often feel 
vulnerable and seek a cure, conveying this expert advice whilst maintaining this is 
a delicate endeavour”. This dour summation of current best evidence is a stark 
representation of our current time, and as interesting as it is to reflect on our 
progress from 1928 when Percival Mills said “…and so helpless have we been in 
treatment…” , it is not to say that research into the condition should be halted and 
we should be resigned to failure, rather that it is a call to arms to ensure that future 
research is undertaken with great attention to methodological and reporting 
details, that inferior treatments are not employed by the practising clinician and 
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that treatments which offer hope are tirelessly evaluated and translated into clinical 
practice according to best practice guidelines.   
 
1.10 Outcome evaluation 
"Each patient who entered the operating room was provided with a 5-inch by 8-
inch card on which the operating surgeon filled out the details of the case before 
and after surgery. This card was brought up 1 year later, the patient was 
examined, and the previous year’s treatment was then evaluated based on the 
patient's condition. This system enabled the hospital and the public to evaluate the 
results of treatments and to provide comparisons among individual surgeons and 
different hospitals.” 
(Ernest Codman 1910) [127] 
 
“The biggest problem in health care isn’t with insurance or politics. It’s that we’re 
measuring the wrong things the wrong way.”  
(Robert S. Kaplan and Michael E. Porter 2011) [128] 
 
It is over 100 years ago that the orthopaedic surgeon Ernest Amory Codman, MD, 
established the principle of “end results based care”, whereby the patients’ 
outcome of surgery is systematically assessed and placed at the centre of the 
healthcare system. This principle, and his further promotion that this information 
should be within the public domain, was surprisingly dissident at the time and had 
the unfortunate result of him being professionally segregated. His forethought is 
now considered as pioneering, and his actions regarded as paving the way for 
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outcome measurement. One would surmise, therefore, that even within a system 
known to be slow to adapt to change, a healthcare focus on patient outcomes 
would now be established. It is hence surprising that a shift from focusing on the 
volume of services delivered to an emphasis on “value” created for patients [129], is 
conceptually rather modern. In musculoskeletal health, where an exemplary model 
of a common burdensome condition is LET, patient improvement is the purpose of 
all intervention, ergo the realisation of any effective interventional treatment in LET 
is dependent upon the measurement of its impact on patients. “Value” in 
healthcare has been defined with simplistic elegance as 𝑉𝑎𝑙𝑢𝑒 =
𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑠 
𝐶𝑜𝑠𝑡𝑠
 [130]. The 
calculation of ‘cost’ may be dependent upon the system structure, but as a 
financial summation of resources it is broadly simple to derive. The calculation of 
‘outcome’ is far more challenging to quantify as it is a less tangible construct. In 
interventional treatments, historically it was the easily defined binary outcomes 
such as: 30 day readmission, infection or death. However, these factors do not 
quantify the patient experience of a treatment. In the scenario of low-risk, high-
volume intervention, such as injection for LET, these binary outcomes may be so 
infrequent and therefore of little relevance to patients as to not provide any 
indicator of “value”. For these reasons musculoskeletal conditions, amongst many 
other chronic conditions, where the outcome is inherently condition-specific and 
multidimensional [130], have seen a shift to try and quantify Health Related Quality 
of Life (HRQoL). This is achieved by focusing assessments on domains such as 
pain and physical function and psychosocial health. Though instruments aiming to 
place a score on these dimensions were traditionally reported by clinicians, there 
has also been a move to collect Patient Reported Outcomes (PROs) utilising 
instruments collectively known as Patient Reported Outcome Measures (PROMs). 
These instruments are standardised and are designed to measure specific 
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phenomena or constructs of the health status in defined patient populations [131]. 
They can be generic quality of life measures, or specific to particular diseases, 
organs, body regions or body functions [132].  This fundamental shift in focus has 
seen the use of PROMs in interventional trials being much more common, 
furthermore they are now either recommended, or seen as a mandatory 
requirement, by national regulatory bodies and research funders [131, 133].  
The ability to measure something, be it blood pressure, range of motion or patient-
reported pain, is first dependent upon the availability of an instrument that is 
designed to undertake this task. Whereas a sphygmomanometer or goniometer 
have been commonplace in the physician’s office over the last century, the use of 
questionnaires that report patient outcomes has only emerged since the late 
1970s [134]. Though the field of clinical and educational psychology applied 
standards for the assessment of subjective variables decades ago [135], these 
principles have only recently crossed over to questionnaire validation in clinical 
medicine. The reason for  the relatively slow uptake of PROMs may, therefore, be 
that there were no instruments available, or that the instruments were not of an 
appropriate standard, or due to a deeper reticence to embrace this form of 
measurement by paternalistic clinicians [136], or simply a combination of all of these 
factors. Of course, we may never know the true reasons behind the relatively 
recent emergence of PROMs in healthcare and its exponential rise in utilisation. 
More pertinent is the fact that they are now accepted as part of our outcome 
assessment, are supported and recommended by high-level organisations, and 
crucially, can now be designed with and critiqued against an agreed set of 
psychometric standards.  
Psychometrics is the field of mathematics concerned with the statistical description 
of instrumental data and the relationships between variables [137]. A mature field in 
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psychology, its principles are now commonly applied to the design and 
assessment of PROMs in healthcare. Commensurate with an instrument that aims 
to quantify something of such importance as quality of life, each instrument should 
comply with a set of methodological standards to ensure sufficient accuracy, while 
also being feasible regarding cost and complexity [138]. Therefore, a PROM is far 
more than a mechanism for gathering an opinion, it should be designed to 
measure and quantify a specific concept in a standardised way; to that end there 
is a great deal of science involved in producing good quality PROMs and the 
process requires careful consideration of several key issues [139]. The construct is 
the aspect the PROM is designed to assess, the content of the PROM itself should 
be a reasonable representation of a patient’s experience (content validity), and it 
should measure what it purports to measure  (construct validity), the level of 
measurement error should be acceptable (reliability), it should not change when 
no change has occurred (repeatable) and should be sensitive to measure real 
change in the construct (responsive), the resultant score, and the change related 
to it after an intervention should mean something to the clinician researcher and 
patient (interpretability) [135]. Each of these metric properties should be evidenced 
through the use of statistical tests or qualitative assessment. Each instrument 
should finally be rigorously tested in the population of interest [135, 140].  
In the absence of gold standard treatments, lateral elbow tendinopathy research 
continues to assess the effectiveness of novel interventions. In this endeavour, it is 
clear that the researcher should aspire to include PROMs if the assessment of 
patient impact is to be understood. The researcher and clinician bear the 
responsibility for selecting an instrument and ensuring that it meets the previously 
discussed standards. The choice of a poor PROM can have significant 
implications on the quality of the study, resulting in potentially biased or unreliable 
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effect estimates, which can mislead decision makers as well as harm patients and 
waste resources [141]. To be able to inform the choice of outcome measure, it is 
essential that four key pieces of information are explored and understood: 
1. What patient-centred outcome instruments are available? 
2. Of these instruments, how frequently are they being used? 
3. For the specific condition of interest, which instrument/s perform best?  
4. In the particular population of interest, have the best-performing instruments 
been used and validated?  
Though points three and four are commonly cited as key aspects in the process of 
choosing a PROM, essentially as a confirmation of validity [140, 142-144], much of the 
criticism of outcome measure choice is related to the lack of conformity within the 
research literature. Multiple systematic reviews in LET have discussed the 
heterogeneity of outcome measure choice as the major stumbling block in the 
comparison of study results, rendering attempts at meta-analysis or meta-
synthesis impossible [40, 45, 101, 118]. Therefore for any progress to be made, it is 
essential that points one and two are explored, to assess not least the levels of 
choice facing the researcher, but also any level of disparity between the validity 
and the proportional application. Only then can any barriers to conformity be 
explored, for example, is it that some of the best designed and validated PROMs 
are burdensome on both patient and researcher, and therefore not chosen [140], are 
some of the heritage outcome measures reported due to a ‘follow the leader’ 
approach to PROM choice [141], and do some researchers simply apply an 
unjustified battery of PROMs [143], often exploring the same constructs, in an effort 
to optimise the impact of their work.   
56 
 
1.11 Context of the presented research  
It is the author’s opinion that this exploration of background research in LET 
highlights why there is an absence of clear treatment pathways. The inability for 
clinicians to practise evidenced-based medicine, for a condition so prevalent is 
somewhat surprising. It is also apparent that the only way in which patients will 
realise the benefit of new treatments for LET, will be through diligent dedication to 
methodologically robust research. The author believes that for LET this can only 
be achieved with new foundational study, which uses a critical eye to question the 
basis of the contemporary research approach. As has been explored, thus far 
interventional treatments for LET have failed to show a significant benefit beyond 
placebo. There are two possible explanations, firstly that no treatment ever tested 
is superior to the body’s healing mechanisms, or secondly, that the methodologies 
applied have failed to reveal the true efficacy of treatment. However, owing to the 
consistent criticisms directed at the intervention techniques, outcome choices and 
parallel comparator groups, it remains almost impossible to elucidate which of 
these explanations is true.  
Short of giving up in the pursuit of interventions for a condition which clearly 
imparts significant levels of morbidity, it is the research community’s responsibility 
to ensure that the investigational approach for LET is optimised, all previous 
methodologies and outcomes approaches should rightly be questioned, and a 
robust strategy is required to justify future research protocols.  This approach is in 
accordance with guidance on the early stages of intervention development by the 
Medical Research Councils [145], whereby the development-evaluation-
implementation axis should lie as the check rein for the production of a trial 
methodology, with all elements being important, and caution given to neglecting 
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the adequate feasibility work or practical consideration of implementation issues, 
lest it result in weaker conclusions.    
This background evidence review has revealed three significant themes related to 
future LET research. Firstly, that the outcome evaluation of interventional research 
is becoming dominated by efforts ensuring that the instruments used are patient-
centred, however, there is no guidance available on instrument choice in LET. 
Secondly, there is a particular emergence of injection-based therapies for LET, 
with PRP being the most popular. However, there is a paucity of basic research 
into injection techniques and limited discussion on both the technical aspects and 
patient experience associated with injection treatments. Finally, the feasibility of 
performing randomised trials aiming to investigate Platelet-Rich Plasma in LET 
should be assessed with a particular focus on compliance with outcome measure 
reporting standards, injection technique reporting and qualitative assessment of 
acceptability to patients. This work will therefore endeavour to: inform the selection 
of valid outcome measures, rationalise the methodology behind the delivery of 
injection-based interventions, and assess the feasibility of a trial directed at an 
intervention in clinical equipoise in LET.  
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Figure 1.2: Venn diagram outlining the three main research themes and their association with the 
primary aim of optimising the research methodology 
 
1.12 Aim, research themes and objectives 
This thesis will use multiple methodologies in an effort to realise this aim: 
To optimise the investigation of interventional treatments in lateral elbow 
tendinopathy 
The overarching aim is informed by investigation of three strategic themes (Figure 
1.2), which are in turn informed through the individual studies. Each study is 
designed to collate information relating to these themes by addressing specific 
questions (Figure 1.3). 
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Figure 1.3: Visual representation of the linking information from individual chapters to inform the three main themes of the thesis 
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Themes and Objectives  
1. To inform outcome measure choice 
o To explore and uncover the breadth of patient-centred outcomes 
available for elbow pathology and specifically elbow tendinopathy.  
o To assess for particular trends in outcome use over time and 
geographic location 
o To systematically assess the evidence for LET outcome measures 
using a standardised methodology 
o To assess whether the best performing outcome measures are 
the ones in use in interventional trials  
o To assess the UK-based validity of outcome measures in LET 
o If required, to undertake validation of the best performing LET 
outcome measures in a UK population   
o To assess the feasibility of using the outcome measures in an 
interventional trial 
o To gain patient and public involvement feedback on the delivery 
and use of outcome measures in LET 
2. To rationalise the delivery of injection-based interventions 
o To evaluate the accuracy and distribution of commonly applied 
volumes and techniques of injectate using a cadaveric model 
o To develop levels of expert consensus in the use and application 
of injections in LET using Platelet-Rich Plasma as the model novel 
intervention  
3. To assess the feasibility of PRP trials in LET  
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o To undertake a feasibility trial of a novel intervention (PRP) 
against an established UK-based gold standard therapy for 
chronic LET 
o To collect and compare quantitative and qualitative feedback from 
patients to assess trial feasibility  
o To compare qualitative feedback of PRP in LET with literature 
reports of safety and adverse events 
1.13 Research methods and clarification of the researchers’ role 
To achieve the research aims the multiple methodologies were undertaken. The 
methods employed to undertake the PROMs systematic review were 
undertaken in a stepwise manner. The methods employed to inform injection 
technique and trial feasibility occurred in parallel.   
An initial systematic review was conducted assessing patient-centred outcomes 
in elbow pathology. This was then followed by a focused systematic review and 
standardised evaluation of outcome instruments in LET. This highlighted the 
requirement for an in-depth assessment of outcome instruments in UK studies 
which was undertaken through a further iteration of the systematic review. The 
collation of information from these reviews informed the requirement for a UK-
based validation study of outcome instruments in LET patients.  
• The systematic review search strategy was constructed by the thesis 
author with assistance from Professor J Valderas and Dr J Gangannagaripalli 
(Health Services and Policy Research Group, University of Exeter).  
• The manuscript screening was conducted by the thesis author with co-
review at all stages by Dr I Porter and Dr J Gangannagaripalli (Health Services 
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and Policy Research Group, University of Exeter), Mr C Smith and Miss N Fine 
(Department of Orthopaedics, Royal Devon and Exeter Hospital) 
• The standardised evaluation (EMPRO) was conducted by the thesis 
author with co-review of all instruments by Dr I Porter, Dr J Gangannagaripalli, 
Dr C Bramwell and Mrs A Davey (Health Services and Policy Research Group, 
University of Exeter), all of whom received training from Professor J Valderas.  
• The validation study was devised by the thesis author under guidance 
from Professor J Valderas. Ethical approval was sought by the lead author and 
granted following proportionate review by the NHS East of Scotland Research 
Ethics Service (REC reference 17/ES/0017). Assistance in the administration of 
the study was provided by the NIHR CRN South West Peninsula (following 
NIHR portfolio adoption ID 33853). Statistical analysis was undertaken by the 
lead author following in-house training in psychometrics and completion of the 
International Society for Quality of Life Research (ISOQOL) quality of life and 
patient reported outcomes theory, measurement and application research 
course. The study was funded following successful application by the lead 
author and independent scientific review by the British Elbow and Shoulder 
Society (funding reference Ltr014PPG) and Royal Devon and Exeter Research 
and Development Directorate (funding reference JV/11/11/16).  
o Assessment of the delivery of injection-based interventions was 
conducted through two parallel studies; a cadaveric study and Delphi 
study.  
• The cadaveric study was devised by the thesis author with assistance 
from Mr C Smith. Proportional NHS ethical approval was sought by the thesis 
author and granted by the NHS North West Preston Research Ethics Service 
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(REC reference 17/NW/0065). The study was funded following successful 
application by the thesis author and independent scientific review by the British 
Elbow and Shoulder Society (funding reference Ltr014PPG) and industry 
sponsorship from Stryker UK.   
• The cadaveric study was undertaken by the thesis author with the 
assistance of Dr Rahul Anaspure (Consultant musculoskeletal radiologist, Royal 
Devon and Exeter Hospital) who administered the injections and Mr C Smith 
and Mr W Thomas (Consultant orthopaedic shoulder and elbow surgeons) who 
dissected the specimens following injection delivery.  
• The cadaveric study’s image processing methodology was devised and 
conducted by the thesis author with assistance and processing by Dr J Metz 
(Head of imaging analysis, Wellcome Trust Biomedical Informatics Hub).  
• The cadaveric study’s statistical analysis was conducted by the thesis 
author with assistance from Dr Fiona Warren (Senior Lecturer in Medical 
Statistics, University of Exeter Medical School).  
• The Delphi study was conceived by Professor R Taylor (Health Services 
Research, University of Exeter) and Professor Valderas (Health Services Policy 
Research Group, University of Exeter) and devised by the thesis author with 
assistance from Associate Professor V Goodwin (Associate Professor of Ageing 
and Rehabilitation, National Institute for Health Research (NIHR) Collaboration 
for Leadership in Applied Health Research and Care (CLAHRC) South West 
Peninsula). Institutional ethical approval was sought by the thesis author and 
granted following review approval by the University of Exeter Medical School 
Research Ethics Committee (Nov16/B/105).  
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• The Delphi study was run by the thesis author with overview from a 
committee of Southwest England orthopaedic consultants: Professor A Watts 
(Consultant hand and upper limb surgeon, Wrightington, Wigan and Leigh NHS 
Foundation Trust) and Professor N Maffulli (Consultant orthopaedic surgeon 
and director of the centre for sport and exercise medicine, Barts and the London 
school of medicine and dentistry). 
o The feasibility randomised controlled study was conducted in parallel to 
the above studies.  
• The feasibility study was devised by the thesis author with assistance 
from Mr C Smith. Ethical approval was sought by the thesis author and granted 
following review by the NHS Devon and Torbay Research Ethics Committee 
(REC) (16/SW/0007). The study was funded following successful application by 
the lead author and independent scientific review by the Royal Devon and 
Exeter Research and Development Directorate (funding reference 1510155).  
• The trial was run by the thesis author with assistance from Mrs Sian 
Gallacher (Upper limb research nurse, Royal Devon and Exeter Hospital) and 
Dr Rahul Anaspure (Consultant musculoskeletal radiologist, Royal Devon and 
Exeter Hospital) who delivered the injections.  
• The qualitative data collection and analysis was conducted by the thesis 
author with assistance in the semi-structured interview design and thematic 
analysis from Mrs Antoinette Davey and Dr Ian Porter (Health Services and 
Policy Research Group, University of Exeter).  
• Patient and public involvement group meetings were designed and run 
by the thesis author with assistance from Dr Emma Cockcroft and Mrs Kate 
Boddy (Patient and Public Involvement Team, National Institute for Health 
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Research (NIHR) Collaboration for Leadership in Applied Health Research and 
Care (CLAHRC) South West Peninsula).  
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2 Chapter 2 – Clinical Rating Systems in Elbow Research – 
A Systematic Review Exploring Trends and Distributions 
of Use 
2.1 Abstract 
Background 
Clinical rating systems are used as outcome measures in clinical trials and 
attempt to gauge the patient’s views of their own health. The choice of clinical 
rating system should be supported by its performance against established 
quality standards.  
Methods 
A search strategy was developed to identify all studies reporting the use of 
clinical rating systems in the elbow literature. The strategy was run from 
inception in Medline Embase and CINHAL. Data extraction identified the date of 
publication, country of data collection, pathology assessed and outcome 
measure used. 
Results 
980 studies were identified that reported clinical rating system use. 72 separate 
rating systems were identified. 41% of studies used two or more separate 
measures. Overall 54% of studies used the Mayo Elbow Performance Score 
(MEPS). For Arthroplasty 82% used MEPS, 17% used Disabilities of Arm, 
Shoulder and Hand (DASH), 7% used quickDASH. For Trauma 66.7% used 
MEPS, 32% used DASH, 23% used the Morrey Score. For Tendinopathy, 31% 
used DASH, 23% used Patient-Rated Tennis Elbow Evaluation (PRTEE), 13% 
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used MEPS. Over time there is increased proportional use of the MEPS, DASH, 
QDASH, PRTEE and Oxford Elbow Score (OES).  
Conclusions 
This study has identified the wide choice and usage of clinical rating systems in 
the elbow literature. Numerous studies report measures without a history of 
either pathology-specific or cross-cultural validation. Interpretability and 
comparison of outcomes is dependent on the unification of outcome measure 
choice. This is not currently demonstrated.
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2.2 Overview 
The previous chapter has identified the paucity of information on clinical rating 
systems in elbow pathology.  
The following three chapters document a three-stage systematic review that 
ultimately aims to provide a comprehensive assessment of clinical rating system 
validity in LET. Specific methodologies are utilised in order collate and refine 
information, starting from a broad international perspective and honing down on 
to UK-specific application, a conceptualisation for this decision making process 
is shown in Figure 2.1. 
 
Figure 2.1: Systematic review decision chart utilised in the following chapters. 
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Though the application of instruments that aim to quantify patient-centred 
impact in interventional trials is believed to be becoming more frequent, the 
level and patterns of use has not been assessed. This chapter attempts to 
address this gap in the knowledge by quantifying the number of instruments 
available and assessing patterns in their use.    
2.3 Background 
The ultimate measure of success in healthcare is whether it helps patients as 
they see it [146]. In an effort to capture the effect of health interventions on 
patients, there has been a considerable investment of resources by academics 
and clinicians to develop systematic, robust and valid ways of collecting health 
data from patients [147].  It is now an agreed standard that treatment evaluations 
include clinical rating systems as an outcome metric [133].  
Currently, clinical rating systems in elbow research utilise both physician and 
patient completed measures. They aggregate various attributes of interest such 
as elbow pain, range of motion and ability to perform specific tasks [148]. Though 
there was a historical focus on physician-administered tools, recent emphasis 
has been on the patient-rated outcome measurement (PROM), whereby 
information is gathered pertaining to the patients’ perception of their elbow 
function [149]. 
The rise in the use of clinical rating systems has accompanied a fundamental 
shift in how we measure health. Traditional measurements of treatment effect, 
such as length of hospital stay, radiographic markers or range of motion, are 
increasingly accompanied by, or indeed replaced by rating systems, with a 
particular emphasis on PROMs [147]. In the United States, the Food and Drug 
Administration (FDA) recommends the use of PROMs in clinical trials [150]. 
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Within the UK, the National Institute for Health and Care Excellence (NICE) 
advocates the necessity of PROMs in assessing the effectiveness and cost-
effectiveness of healthcare technologies [133].  
The increasing popularity of patient-focused outcome measurement has 
accompanied a consequent rise in the production of numerous rating systems, 
though the number in use is unknown. When choosing the appropriate rating 
system for  clinical or research purposes, it is necessary to identify existing 
instruments that measure the outcome of interest in the target population [151]. 
An appropriate measure should be supported by published evidence 
demonstrating that it is acceptable to patients, reliable, valid and responsive 
(sensitive to change) [152]. Furthermore, these properties should have been 
tested on similar reference groups of patients to those being studied, thereby 
ensuring the validity of a tool from a language and cultural perspective [153]. 
Within the domain of musculoskeletal health, particular emphasis has been 
placed on the use of clinical rating systems for particular anatomical locations 
(predominantly joints) rather than generic health measures. More recently this 
has evolved to concentrate on condition specific tools, where, in certain groups 
or in certain conditions, generic or region specific tools miss important aspects 
of health status [147]. For the appropriate interpretation, it is, therefore, vital that 
the clinical rating system selected is validated for use in the population of 
interest and for the specific condition being investigated.  
Systematic reviews assessing elbow-specific clinical rating systems have 
concluded that a paucity of quality measures exist [149, 154-156]. The most recent 
review by The et al [149] included the assessment of 12 rating systems using the 
Consensus-Based Standards for the Selection of health Measurement 
Instruments (COSMIN) checklist, although pathology specific assessment was 
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not undertaken, the authors conclude that the Oxford Elbow Score (OES) is the 
only system that has been developed using high-quality methodology. What is 
not known from this, and other elbow specific outcome measure reviews, is 
whether these reviews are assessing all of the outcome instruments that are 
being reported within the contemporary literature. It is interesting to note that 
the extensive review of shoulder outcome measures conducted by Smidt et al 
[157] do not include scores identified by Booker et al [158] as commonly used in 
shoulder research.  
The use of elbow-specific rating systems across different elbow pathologies is 
not known. Riedel et al [148] reviewed 65 articles, which used elbow specific 
aggregate scores specifically in elbow arthroplasty published between 2004 - 
2011. They report the predominant use of the Mayo Elbow Performance score 
in 75% of the literature they identified. They criticise the use of this physician-
administered score that was not developed with a formal methodology and is 
frequently inconsistently applied. 
It is therefore recognised that evaluation of outcome measures in elbow 
pathology is very limited, this study forms the starting point for the assessment 
of the use of clinical rating systems in elbow-related, and specifically LET-
related interventional studies. It is this primary exploration that will assess the 
appropriation of rating systems to specific elbow pathologies and their use 
across populations and any change in trends of use over time. Only when 
armed with the knowledge of either the conformity or heterogeneity of rating 
systems, can compelling arguments be made for the need for standardisation. 
Furthermore, once it is extrapolated which instruments are favoured and used in 
LET research, can a full and comprehensive standardised evaluation be 
conducted.  This study will provide a rounded assessment of ratings system use 
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that can then be used to inform pathology-specific assessment in lateral elbow 
tendinopathy.      
2.4 Method 
A comprehensive systematic review of elbow-specific clinical rating systems in 
the elbow literature was conducted. This review aimed to identify all articles 
reporting the use of both physician and patient-reported rating systems. Both 
rating systems designed specifically for use in elbow pathology and generic 
upper limb rating systems with a history of validation and in elbow pathology 
were included. The report has been written following PRISMA guidelines [159] 
(appendix 1). 
A search strategy was constructed using MeSH and free text terms (appendix 
2). The strategy was modeled to each database through the modification of 
thesaurus terms, wildcards, and truncation. The search was run on 10th April 
and subsequently updated on 1st May 2017 in Medline (Ovid MEDLINE, 1948 to 
2016 & Ovid MEDLINE In-Process & Non-indexed Citations) accessed through 
OVIDSP, Embase (Embase 1974 to 2017) accessed through OVIDSP and 
CINHAL (CINHAL 1981 to 2017) accessed through EBSCO host. 
The search strategy development was guided by previously published search 
strategies for systematic reviews published within the Cochrane library. The first 
focused on  interventions in elbow pathology [40] and the second on the 
identification of outcome measures[160] The construction of the two strategies 
had undergone rigorous methodological evaluation in line with the expectation 
of Cochrane reviews. The identification of outcome measures has previously 
posed significant challenges owing the wide spectrum of technical language 
and evolving terminology. This has resulted in an extensive search strategy 
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including 57 stems including extensive psychometric text word searching to 
produce a highly sensitive filter. Along with these terms, known outcome 
measures were included in order to capture relevant instruments published in 
previous systematic reviews of elbow-specific rating scales [149, 154-156] and 
search of the online library of Patient-Reported Outcomes and Quality of Life 
Database (PROQOLID) [161] was conducted to identify outcomes not previously 
explored as part of previous reviews. The final composite search strategy was 
assessed independently by the University of Exeter’s evidence synthesis team 
for structure, redundancy and optimisation of its structure. The final strategy 
extended to 57 stems including 663 items of 303 were included in a block 
assesses psychometric mesh and text word items. The resultant strategy was 
made publically available 
(http://medicine.exeter.ac.uk/research/healthresearch/healthservicesandpolicy/p
rojects/proms/optimisinginterventionaltreatmentoftenniselbow/medlinesearchstr
ategyforelbowoutcomemeasures/#d.en.504281).     
Following the extraction of the search strategy outputs, the review was 
conducted in a step-wise manner, through title, abstract and full text screening 
prior to data extraction. At each stage, dual review was employed with the lead 
author and a further co-reviewer. In cases of disagreement between reviewers, 
the article proceeded to the next stage of review to ensure maximum sensitivity. 
The review process was used to exclude duplicates, non-elbow-based studies, 
case-reports, case-studies, surgical technique papers and conference 
abstracts. Abstract and full text screening utilised the above criteria and also 
excluded studies in a paediatric population, known non-elbow or non-upper limb 
rating systems, systematic reviews and papers reporting exclusively on 
development and or validation of a rating system. The resultant dataset 
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included all extracted articles reporting the use of clinical rating systems to 
assess patient outcome in elbow research.   
Data extraction was conducted by JE and NF. Publication date, geographical 
location of lead author or publishing institution, elbow pathology investigated 
and specific clinical rating systems reported were extracted.  
The elbow-specific pathology or intervention of interest was grouped into the 
following categories for ease of interpretation: arthritis interventions (non-
arthroplasty), arthroplasty (trauma and elective), arthroscopy, distal biceps 
intervention, neuropathy intervention, sports-specific population, tendinopathy 
(non-sports specific population) and trauma interventions (non-arthroplasty). 
Data are presented as proportional percentage of use of designated outcome 
measure within the predefined pathology, time period or geographic location of 
study.    
References were retrieved and imported into reference management software 
(Endnote X7, © 2017 Clarivate Analytics, PA, USA). Database management 
was conducted in Excel (Microsoft® Excel® 2013, Redmond, WA, USA). 
2.5 Results 
The review identified 980 articles reporting the use of elbow-specific clinical 
rating systems (Figure 2.2). Articles from 52 countries were included; 72 
separate instruments were identified (appendix 3).  
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Figure 2.2: PRISMA flowchart 
 
The 980 articles reported 1,383 separate outcomes; 322 (32%) of articles 
reported the use of two separate elbow-specific clinical rating systems, 77 (8%) 
reported the use of three, four (0.4%) reported the use of four separate elbow-
specific clinical rating systems.  
The number of articles reporting elbow-specific rating systems has increased 
over time (Figure 2.3) reaching 106 published articles in 2016.  
Overall, from database inception, the Mayo Elbow Performance (MEP) score 
was reported in 54% of articles, the Disabilities of Arm Shoulder and Hand 
(DASH) in 29%, the Morrey Score 12%, the abbreviated DASH (quickDASH) in 
8%, the Patient-Rated Tennis Elbow Evaluation (PRTEE) in 5%, the American 
Shoulder and Elbow Society-Elbow score (ASES-e) in 4%, the Oxford Elbow 
Score (OES) in 4%. All other scores were reported in less than 2% of articles.  
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Since 2000 and 2010 respectively, the proportionate use within the literature for 
the above rating systems are: MEPS 55% & 61%, DASH 30% & 34%, Morrey 
12% & 9%, quickDASH 9% & 13%, PRTEE 5% & 7%, ASES-e 4% & 3%, and 
OES 4% & 6% (Figure 2.4). 
 
Figure 2.3: Number of studies published per year that report use of elbow/region-specific clinical rating systems. 
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Figure 2.4: Proportional prevalence of the most common rating systems in articles since database inception, 2000 and 2010.  
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Figure 2.5: Top five clinical rating systems in each pathology group. 
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The top five clinical rating systems for the individual pathology or intervention 
group are outlined in Figure 2.5. 
For the three largest groups: arthroplasty, tendinopathy, and trauma, the most 
popular clinical rating systems are further grouped by time periods; database 
inception, since 2000 and since 2010 (Table 2-1) 
Geographic distribution is shown in Table 2-2, with data grouped into three 
broad localities; North America, Europe, and Rest of the World.
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Table 2-1: Change in use of clinical rating systems over time in the three largest indication subcategories 
  
  
Arthroplasty Tendinopathy Trauma  
Database 
Inception  
  Since 
2000 
  Since 
2010 
  Database 
Inception 
  Since 
2000 
  Since 
2010 
  Database 
Inception 
  Since 
2000 
  Since 
2010 
  
Articles (n) 151  %  133  % 74  % 198  % 190  % 128  % 405  % 365  % 128  % 
Total Outcomes 
(n) 
199 
 
180   109   244 
 
235   162   621 
 
580   162   
MEPS 124 82.1 116 87.2 66 89.2 26 13.1 25 13.2 22 17.2 270 66.7 270 74.0 200 74.6 
DASH 25 16.6 24 18.0 17 23.0 61 30.8 61 32.1 46 35.9 132 32.6 132 36.2 100 37.3 
MORREY 5 3.3 3 2.3 1 1.4             92 22.7 85 23.3 46 17.2 
QDASH 10 6.6 10 7.5 9 12.2 19 9.6 19 10.0 19 14.8 28 6.9 28 7.7 27 10.1 
ASES-e                         21 5.2 21 5.8 12 4.5 
PRTEE             46 23.2 46 24.2 39 30.5             
OES 6 4.0 6 4.5 6 8.1                         
Roles+Maudsley             14 7.1 13 6.8 2 1.6             
Nirschl              17 8.6 16 8.4 10 7.8             
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Table 2-2:Geographical use of clinical rating systems grouped by locality and major indication subcategories 
  North America Europe Rest of the World 
Total Arthroplasty Tendinopathy Trauma Total Arthroplasty Tendinopathy Trauma Total Arthroplasty Tendinopathy Trauma 
Articles (n) 264 % 50 % 47 % 86 % 370 % 76 % 66 % 151 % 319 % 26 % 77 % 155 % 
Total No. of 
Outcomes 
370 
 
58 
 
57 
 
140 
 
558 
 
109 
 
78 
 
254 
 
411 
 
32 
 
98 
 
204 
 
MEPS 117 44.3 37 74.0 8 17.0 47 54.7 198 53.5 63 82.9 6 9.1 101 66.9 195 61.1 25 96.2 13 16.9 114 73.5 
DASH 97 36.7 6 12.0 16 34.0 43 50.0 109 29.5 15 19.7 19 28.8 50 33.1 73 22.9 3 11.5 24 31.2 35 22.6 
MORREY 20 7.6 1 2.0 
  
16 18.6 59 15.9 3 3.9 
  
42 27.8 35 11.0 1 3.8 
  
31 20.0 
QDASH 15 5.7 
  
2 4.3 4 4.7 22 5.9 11 14.5 5 7.6 15 9.9 18 5.6 1 3.8 9 11.7 5 3.2 
ASES-e 23 8.7 2 4.0 
  
12 14.0 10 2.7 
      
5 1.6 
    
5 3.2 
PRTEE 9 3.4 
  
9 19.1 
  
10 2.7 
  
9 13.6 
  
26 8.2 
  
21 27.3 
  
OES 4 1.5 
      
29 7.8 6 7.9 
  
15 9.9 3 0.9 
      
HSS 2 0.8 1 2.0 
    
6 1.6 
      
6 1.9 
      
Roles+ 
Maudsley 
1 0.4 
      
11 3.0 
  
10 15.2 
  
3 0.9 
      
Nirschl  5 1.9 
  
6 12.8 
  
3 0.8 
  
3 4.5 
  
8 2.5 
  
8 10.4 
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2.6 Discussion 
The elbow has long been thought of as the forgotten joint, with pathologies that 
are difficult to treat and surgical procedures that carry higher complication rates 
than any other major joint [162]. However, modern diagnostic and treatment 
practices have shown great promise, and clinical effectiveness research has 
sought to accurately quantify the benefits patients are experiencing. In keeping 
with modern research reporting practice, the ultimate goal has been to 
demonstrate the ability of an intervention to restore or preserve functioning and 
well-being related to health [163]. This study has demonstrated that the use of 
elbow-related clinical rating systems that aim, in some form, to demonstrate 
patient-related benefit following an intervention has rapidly expanded year on 
year. Though previously published reviews have highlighted the deficits in many 
of the available instruments [73, 149, 154, 164], this study has failed to show large 
shifts in choice towards clinical rating systems produced with high quality 
methodology.  
Global data across pathologies and interventions of 980 articles identified the 
Mayo Elbow Performance Score (MEPS) as the predominant rating system. 
The MEPS was developed by Morrey and Adams in 1992 [165], for outcome 
assessment in total elbow arthroplasty. It consists of a physician assessment of 
pain, arc of motion and stability, with a patient rating of daily function. It has a 
history of validation in elective elbow surgery patients with mixed pathology [166, 
167], arthroplasty [165], trauma [168] and rheumatoid arthritis [156]. Assessment 
under the COSMIN checklist rated all its development and validation domains 
as fair to poor [149]. The Disabilities of Arm Shoulder and Hand (DASH) is also 
commonly employed. This patient-reported outcome measure (PROM) was 
introduced in 1996 [169]. It consists of a 31 core item questionnaire with eight 
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additional questions for sport and work assessment. It was designed to evaluate 
the entire upper limb but has a history of validation in elbow-specific pathology 
including: arthrolysis [170], arthroplasty [171, 172], lateral epicondylar tendinopathy 
[173-180], rheumatoid arthritis [181], neuropathy [182, 183], elective elbow surgery [166, 
167, 184, 185], biceps tendon repair and radial head surgery [186]. Interestingly, it has 
not been included in reviews that perform systematic evaluation and head-to-
head comparison with other elbow-specific rating systems using recognised 
techniques such as COSMIN [144] or EMPRO [187]. Of the other scores, large 
heterogenicity of application was demonstrated, astoundingly 72 separate 
instruments were identified across the literature, since 2010, 45 of these 
separate instruments are continuing to be used.   
Assessment of the use of rating systems in the predefined criteria groups 
showed some element of preference for specially designed scales. Neuropathy, 
sports-specific population, and tendinopathy groups showed the utilisation of 
scores specifically designed for population or pathology use. Examples include 
the Dellon score [188] in neuropathy, Andrews-Carson score [189] in sports 
population and the Patient-Rated Tennis Elbow Evaluation (PRTEE)[175] in the 
tendinopathy group. Of note, within all the above-mentioned groups and distal 
biceps group, the DASH score remains the first or second score of preference. 
The three largest condition subgroups were assessed for a change in use of 
rating scale over time. The recent emergence and promotion of patient-rated 
over physician-rated evaluation would lead most to the hypothesis of increased 
proportional representation within these groups over time. Within all groups, the 
use of DASH and quickDASH is rising, the tendinopathy group also 
demonstrated a particular emergence of the PRTEE. Yet, whilst the Morrey and 
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HSS are declining in use, of interest is the progressive rise of the MEPS across 
all groups.  
Trends in rating systems in differing geographical areas since 2010 was also 
assessed. Though the sub-division of areas is rather crude it yields groups of a 
size substantial enough to interpret broad distribution trends. The MEPS, 
though developed in the USA, has a higher total proportion of use in Europe 
and Rest of the World groups. The MEPS has only been formally assessed for 
cross-cultural validity in Turkish [190, 191], UK English [166, 167] and Dutch [192]. The 
DASH score is proportionally more popular in North America, though it has 
been cross-culturally adapted to multiple languages. Interestingly, the 
abbreviated quickDASH is twice as commonly employed in Europe when 
compared to the USA. Again the quickDASH is available in multiple languages, 
but it is important to note that in terms of elbow-specific cross-cultural 
adaptation and validation, this has only been conducted in Turkish, Italian and 
Dutch [174, 185, 193].  
The shift in focus from physician to patient-reported outcomes is well 
documented, with support both within the literature and from a 
governmental/health service level [194]. Within elbow-specific literature Dawson 
et al [166] stated that patient-reported results are more likely than clinically 
assessed outcome measures to reflect patient satisfaction with elbow surgery 
and that condition-specific measures are more likely than generic measures to 
be closely aligned with patient satisfaction. Yet, we have shown that within the 
literature there remains a persistent reticence to embrace PROMs more fully. 
As Snyder et al [195] comment, though PROMs have the potential to improve the 
quality of patient-centred medical care, there is a great deal of research to be 
done before they are fully embraced by all stakeholders. Within elbow-specific 
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literature, it may be the consensus that the literature is, as yet, uncompelling 
and lacking clear recommendations. Recent review evidence, that 
systematically assesses the development and psychometric properties of 
elbow-specific rating systems, has only emerged since 2013 [148, 149] and it may 
be that the trickle-down effect may simply not have been felt. Currently, no 
pathology-specific reviews utilising recognised outcome measure evaluations 
(COSMIN [144] and EMPRO [187]) exist. This information is clearly of great 
importance to assist practitioners in their choice of outcome measure. 
Furthermore, if rating systems do not possess clear validation information, it is 
the duty of the researcher to undertake this process prior to instigating clinical 
studies.    
It is vitally important to recognise that inappropriate rating system choice can 
have a great impact on the interpretation of results, particularly where they are 
used as the primary endpoint in clinical studies [149]. The choice of a rating 
system should be optimally aligned with a conceptual framework that defines 
the health condition and will meet the performance requirements of the clinical 
context and measurement needs [164]. Therein, a score developed for the elbow 
may not be valid across all populations and all pathologies. Quantification of 
health-related quality of life in an elderly rheumatoid arthritis patient undergoing 
total elbow arthroplasty may require an evaluation of very different domains to a 
middle-aged manual labourer with tennis elbow. This must also be the case for 
the geographical population of interest, where the cross-cultural validation of an 
outcome measure is a vital component in ensuring its interpretability [135]. 
Consequently, for example, an American-developed measure in the English 
language, does not have automatic validity in other English speaking 
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populations. This study has identified that currently pathological or geographical 
application of ratings system is not well aligned with their known validity.    
Though previous reviews have highlighted the psychometric aspects of clinical 
rating systems, this is the first comprehensive assessment of their use within 
the literature and underlines the need for standardisation, or at least general 
consensus, of outcome evaluation in the clinical and scientific community. Only 
then will we be able to compare results between different groups, hospitals, and 
protagonists [196]. As we look forward, initiatives to combat this include the Core 
Outcome Measures in Effectiveness Trials (COMET) and the International 
Consortium for Health Outcomes Measurement (ICHOM), who utilise expert 
panels to devise agreed ‘outcome sets’ that include validated PROMs and 
objective measures of function in an attempt to represent what really matters to 
patients. By producing these sets, they hope to unlock the potential of value-
based healthcare, where patients ask their doctors about meaningful outcomes, 
and doctors can respond with clear, validated, data-driven answers. As yet 
there are no published outcome sets for elbow pathology. National societies can 
also hold great influence in the ongoing selection of outcomes, the American 
Shoulder and Elbow Surgeons (ASES) Value Committee has recently produced 
a consensus document recommending a package of patient-centred outcomes 
that includes the QDASH, VR-12 generic quality-of-life score and the Single 
Assessment Numeric Evaluation (SANE); for research purposes they also 
recommend the MEPS, though they recognise the ongoing need for pathology 
specific-validation studies [197]. The U.S. National Institutes of Health (NIH) 
Patient Reported Outcomes Measurement Information System (PROMIS®) aim 
to bring standardisation to PROM selection using instruments that employ Item 
Response Theory (IRT) techniques. These instruments, that focus on health 
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domains rather than disease-attributed scales, produce universally relevant 
scores that can be compared across populations and pathologies, furthermore 
the IRT approach also allows ‘cross-walking’ between other PROMs to produce 
equivalent scores. This review has not identified any studies that have utilised 
this system for elbow pathology. Only by adopting common standards and 
metrics will clinical researchers be able to directly compare patients’ 
evaluations; once achieved this will have a huge impact on the ability to 
undertake international syntheses of evidence, such as meta-analyses [153]. 
Furthermore, the use of registries may force some level of conformity in data 
collection. In the UK the National PROMs programme has collected Oxford hip 
and knee scores since 2009. With the inclusion of elbow arthroplasty into the 
National Joint Registry in 2012, it remains likely that an outcome measure will 
be added to this dataset. The New Zealand joint registry started collecting the 
Oxford Elbow Score for all elbow arthroplasties in 2015.    
Limitations 
As with all systematic reviews, this study is limited by the search strategy used, 
however, considerable care was taken to produce a strategy that was as 
sensitive as possible. The subclassifications of data into pathology and 
population groups were derived to give the best impression possible of rating 
scale use. The use of arthroplasty, for example, was kept as a single group, 
though a case can be made that rheumatoid and trauma patients may respond 
differently and require different rating systems, under the recommendations 
outlined above.  Equally, the trauma group could easily be further sub-
classified. However, we feel that the strength of the data is the representation of 
the three large sub-classification groups.   
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2.7 Conclusion 
This study is the first to identify the true magnitude of choice of clinical rating 
systems for the elbow. From 980 manuscripts we identified 72 individual clinical 
rating systems. Although we are seeing a small advance in the use of validated 
condition-specific PROMs, such as the PRTEE, the overwhelming key players in 
outcome measurements remain the historic or generic measures, such as the MEPS 
and DASH score. The co-administration of multiple scores may be seen as a 
panacea, but there is little justification for ever increasing the patient burden. Though 
the rapid progression of outcomes research may provide computational models of 
comparison between measurements, in the immediate term, it is clear that a 
systematic evaluation of condition-specific elbow-related rating systems, using well-
recognised methods such as the COSMIN checklist [144] or EMPRO tool [187] is 
needed. Only then can clinicians and researchers make informed decisions on the 
appropriate tool for the elbow pathology and population of interest. In chapter 3, 
having defined this need and the clinical rating systems that are used, a systematic 
and standardised evaluation in lateral elbow tendinopathy (LET) will be undertaken.     
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3 Chapter 3 - Assessing patient-centred outcomes in lateral 
elbow tendinopathy: a systematic review and standardised 
comparison of clinical rating systems 
3.1 Abstract 
Background 
Lateral Elbow Tendinopathy (LET) is a common condition affecting adults. A lack of 
treatment consensus has resulted in numerous effectiveness studies, which 
commonly aim to quantify patient outcome. Our aim was to undertake a standardised 
evaluation of the available clinical rating systems that report patient-centred 
outcomes in LET. 
Methods 
A systematic review of studies reporting the development, assessment of metric 
properties, and/or use of instruments aiming to quantify LET-specific patient-centred 
outcome measures was conducted in MEDLINE, Embase and CINAHL (inception-
2017) adhering to PRISMA guidance. The evidence for each instrument was 
independently assessed by two reviewers using the standardised EMPRO method 
evaluating overall and attribute-specific instrument performance (metric properties 
and usability). EMPRO scores >50/100 were considered indicative of high 
performance.  
Results 
Out of 7,261 references, we identified 105 articles reporting on 15 instruments for 
EMPRO analysis. Median performance score was 41.6 (range: 21.6-72.5), with four 
instruments meeting high-performance criteria: QDASH (72.5), DASH (66.9), OES 
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(66.6) and PRTEE (57.0). 179 articles reported instrument use internationally with 
DASH the most frequent (29.7% articles) followed by PRTEE (25.6%), MEPS 
(15.1%) and QDASH (8.1%).  The correlation between frequency of use and 
performance was r=0.35. 
Conclusions 
This is the first study to provide standardised guidance on the choice of measures for 
LET. A large number of clinical rating systems are both available and being used for 
patients with LETs. Robust evidence is available for just a few of such measures, 
with QDASH obtaining the highest scores. The use of instruments in the literature is 
only in part explained by instrument performance.  
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3.2 Overview 
The previous review identified the great variety of clinical rating systems available 
and makes the case for unification of outcome measure choice. Though it identifies 
the measures in existence and quantifies their application, this information, in and of 
itself, does not provide information on the psychometric superiority of one measure 
over another. This chapter attempts to progress the information available to 
researchers and clinicians by focusing on the pathology-specific application of 
clinical rating systems in LET. It applies a standardised evaluation to all the available 
evidence that imparts information on their development and metric properties. 
3.3 Background 
The 2013 review by The et al [149] represents the only previous attempt at a 
standardised assessment of elbow-specific measures. They included 12 outcome 
measures using the Consensus-Based Standards for the Selection of health 
Measurement Instruments (COSMIN) checklist which concluded that the Oxford 
Elbow Score (OES) was developed using highest quality methodology. However, for 
certainty of use, the performance of clinical rating systems needs to be assessed 
specifically for the condition of interest. As The et al [149] comment, it is essential to 
be aware that established validity characteristics might not be applicable when using 
the rating system in a different population. Therein, a rating system originally 
designed for the assessment of elbow joint arthroplasty, may not be appropriate for 
use in LET, unless evidence of performance has been explicitly presented. 
Furthermore, a narrow focus on elbow-specific instruments neglects the possibility 
that region-specific (i.e. upper limb) instruments may have been robustly assessed 
for certain pathologies. Finally, reviews of measures with a region/anatomical 
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location perspective disregard the very different characteristic clinical presentations 
of different conditions, though they may advise on the use of measures that work 
best across conditions, but not necessarily the best option for any given condition.  
To our knowledge, no systematic review has previously identified the clinical rating 
systems for patients with LET and assessed both their use in the scientific literature 
and their performance against validated standards, both to establish what 
instruments offer the best performance and whether these are indeed the ones most 
widely used. This study aims to apply a standardised system to evaluate evidence 
available on the metric properties, development process and utility of clinical rating 
systems assessing patient-centred outcomes in LET.   
3.4 Methods 
Systematic Review 
The search strategy (appendix 1) and resultant systematic review database applied 
in chapter 2 was re-analysed from the title screening level down, to isolate published 
studies on the development and/or use of clinical rating systems in patients with 
LET. This systematic review was registered with the PROSPERO International 
prospective register of systematic reviews (PROSPERO 2016:CRD42016037317) 
(appendix 4) and the report has been written following PRISMA guidelines [159] 
(appendix 5).  
All articles reporting the development, psychometric evaluation, or use of clinical 
rating systems in Lateral Elbow Tendinopathy in English-speaking adults (>18yrs), 
were included. In instances where the study included multiple elbow pathologies, it 
had to specify that this comprised, at least in part, a population of LET patients. 
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Multi-item upper limb or elbow-specific instruments that were either clinician or 
patient-led were included.  
Study selection utilised a step-wise approach. Screening was conducted by two 
reviewers at all stages. To ensure highest levels of sensitivity, in cases of 
disagreement, the study proceeded to the next step for more in-depth assessment. 
Reviewer comprehension of the research aims was assessed using a 20-manuscript 
pilot, achieving an Inter-rater agreement (Kappa) of 0.85. Titles and abstracts were 
disseminated to reviewers using electronic sifting software (Rayyan) [198]. Full text 
assessment was undertaken using hard copy manuscripts. Studies were excluded if 
reporting case studies, case reports, surgical technique papers, conference 
abstracts and manuscripts not in the English language. Forward and backward 
searches were undertaken on full-text manuscripts using Scopus® (Elsevier B.V.). 
Instrument manuals or complementary support material, were available, where 
sourced via the instruments’ associated website or in direct contact with the 
developer.  
Due to the principles of cross-cultural adaptation, the metric properties of an 
instrument are not directly comparable across different versions. Hence, only full-
texts of instruments developed or tested in the English speaking populations were 
included in the standardised assessment [187].  By convention, the instruments were 
identified by their name and acronym, when one had been given, or by the name of 
the first author in the seminal paper, and the clinical rating systems were classified 
as either Patient Reported Outcome Measures (PROMs), Clinician Reported 
Outcome Measures (CROMs) (where the clinician makes a judgement on the health 
status of the patient [199]) or mixed PROMs/CROMs.  
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Evaluating Measures of Patient-Reported Outcomes (EMPRO) 
The EMPRO tool [187] was developed to measure the performance of patient-centred 
outcomes for informing the identification of the best candidates among measures 
competing for the same purpose.  Originally designed for PROMs, the content, 
structure and methodology are apt for the evaluation of all clinical rating systems. It 
has been utilised in a number of areas, including assessment of shoulder outcome 
instruments [157] and it has been found to be  valid and reliable [187]. Its particular 
strength includes the synthesis of the whole body of evidence surrounding an 
outcome instrument, and its ability to facilitate the selection of the most appropriate 
outcome instrument [187]. Unlike the COSMIN checklist, it does not evaluate the 
quality and design of the evaluation of the psychometric properties, but rather the 
performance of the instrument. 
EMPRO consists of eight scales measuring the following attributes each: Conceptual 
and measurement model (7 items); Reliability (8); Validity (6); Responsiveness (3); 
Interpretability (3); Administrative burden (7); Alternative modes of administration (2) 
and Cross-cultural adaptations into chosen reference language (3).  Each item 
consists of a short statement, together with suggested aspects to be considered. 
Reviewers then express their agreement on an ordinal Likert-type response scale of 
1-4. Where appropriate, ‘not applicable’ and ‘no information available’ response 
categories are available. At the end of the tool, reviewers are requested to provide 
an overall recommendation in reference to the relevant research question [187] (Table 
3-1). 
Each instrument was evaluated independently by two researchers using the EMPRO 
tool and based on the following information: 
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 The instrument to be assessed 
 The instrument’s user manual (where available) 
 Full-texts of all publications which provide information concerning the 
development process, the metric properties or administration of the instrument 
including a sample which, at least in part, contains participants with LET.   
 
The researchers were experts in outcomes research, they received additional 
training in the use of the EMPRO, and none of them had been involved in the 
development of the reviewed measures. EMPRO scores were consolidated and 
tabulated. Where discrepancy in scores exists, the two reviewers initially discussed 
the case to resolve through consensus, where necessary a third reviewer opinion 
was sought.  
 
Attribute Definition No. of 
items 
Higher scores represent… 
Conceptual and 
measurement 
model 
The rationale for and 
description of the concept and 
the populations that a measure 
is intended to assess and the 
relationship between these 
concepts 
7 The concept to be measured is 
clearly stated. The empirical basis 
and methods for obtaining the item 
and for combining them are more 
appropriate 
Reliability The degree to which an 
instrument is free from random 
error 
8 More clearly described and 
superior methods to collect internal 
consistency data. Better values of 
Cronbach’s alpha and/or KR-20 
coefficients 
Validity The degree to which the 
instrument measures what it 
purports to measure 
6 More evidence regarding content-
related validity of the instrument for 
its intended use 
Responsiveness An instrument’s ability to 
detect change over time 
3 More clearly described and more 
appropriate methods to assess 
sensitivity to change. The 
estimated magnitude of change is 
more clearly described, and the 
results are better 
Interpretability Possibility of assigning 
meaning to quantitative scores 
3 The strategies to facilitate 
interpretation are more clearly 
described and appropriate 
Burden The time, effort, and other 
demands placed on those to 
whom the instrument is 
7 The skills and time to complete the 
instrument are more clearly 
described and acceptable 
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administered (respondent 
burden) or on those who 
administer the instrument 
(administrative burden) 
Alternatives 
modes of 
administration 
Alternative modes of 
administration used for the 
administration of the 
instrument 
2 The metric characteristics and use 
of each alternative mode of 
administration are specifically 
described and are adequate. 
Table 3-1: EMPRO attributes definition, number of items, and scoring description (adapted from (Maratia et al., 
2016 [200]) & (Garin et al., 2014 [201])). 
 
Analytic Strategy 
Attribute-specific scores were calculated as the response mean of the applicable 
items. Items for which the response was ‘no information’ were assigned a score of 1 
(lowest possible). This raw mean was linearly transformed into a range of scores 
from 0 (worst possible) to 100 (best possible).  
From the attribute scores, an overall attribute mean score was calculated. The 
scores of the five attributes that relay the psychometric-related information 
(conceptual and measurement model, reliability, validity, sensitivity to change, and 
interpretability) were included. The overall attribute score was only calculated when 
at least three of the five attributes have a score. EMPRO overall attribute scores for 
each outcome instrument are considered adequate if they reach at least 50 out of 
the maximum score of 100 [187].  
Agreement between reviewers was assessed using a weighted Cohen’s Kappa 
Coefficient. All analysis was undertaken in STATA (2015. Release 14. College 
Station, TX: StataCorp LP). Databases of instruments’ distribution were managed in 
MS Excel (2013, Redmond, WA: Microsoft®). Kappa scores and resource numbers 
are displayed as (median) (Interquartile range (IQR) (Range). Spearmans correlation 
coefficiant was used to assess the relationship between EMPRO score and 
proportional use of the instrument within the literature.   
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3.5 Results 
The primary review search strategy identified 7,261 articles (Figure 3.1). Following 
duplicate removal 6,185 articles were reviewed at the title level. After evaluation of 
references screened as full-texts, 15 clinical rating scales were identified (Table 3-2).  
Assessment of the instruments’ reported use in LET studies found four instruments 
to be reported much more frequently than the remaining 11 (Figure 3.2). The 
Disabilities of the Arm Shoulder and Hand (DASH) score was the most frequently 
reported (29.7% of articles), followed by the Patient-Rated Tennis Elbow Evaluation 
(PRTEE) (25.6%), Mayo Elbow Performance Score (15.1%) and Quick Disabilities of 
Arm Shoulder and Hand (QDASH) (8.1%).  Over time this trend has shifted with the 
reporting of these scores increasing over time. Of note, of the 179 articles in the 
international literature, 40 (22.3%) reported two using two or more clinical rating 
systems to assess patient-centred outcomes.
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Figure 3.1: PRISMA flowchart of systematic literature review. Review of articles reporting development/metric 
properties or use of outcome instruments presented as separate streams. 
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Instrument Author (year) Development purpose  Assessor Dimensions (No. 
items) 
Scales No. documents 
reporting 
development and 
metric properties 
(appendix 6) 
No. documents 
reporting 
instrument use 
internationally 
(English speaking) 
 (appendix 6) 
A&C 
(Andrews and 
Carson) 
Andrews et al  
[189] (1985) 
To evaluate subjective and 
objective results of elbow 
arthroscopy 
Clinician  Symptoms (3) 
Activities (1) 
Function (3) 
4 point Likert scale 
Scored out of 200 
then interpreted as 
one of four groups 
(poor – excellent) 
1 2 (2) 
ASES-e 
(American 
Shoulder and 
Elbow Score-e) 
King et al [202] 
(1999) 
Elbow functional 
assessment  
Patient 
and 
Clinician 
Pain (5) 
Function (12) 
Satisfaction (1) 
+ Clinical 
assessment 
Mixture of visual 
analogue scale and 
four point Likert 
scales.  
3 5 (5) 
DASH 
(Disabilities of 
the Arm, 
Shoulder and 
Hand) 
Hudak et al 
[169]  
(1996) 
Region (arm) specific 
measure of disability and 
symptoms with any or 
multiple musculoskeletal 
disorders of the upper 
limb.  
Patient Physical function 
(21) 
Symptoms (5) 
Psychosocial (4) 
(Optional work and 
sport/music 
module) 
5 point Likert scale 
 
Raw score 
converted to 0-100 
scale 
18 60 (23) 
HSS 
(Hospital for 
Special Surgery) 
Inglis and 
Pellicci 
[203] 
(1980) 
Pre and post op 
assessment of elbow 
arthroplasty  
Clinician Pain (2) 
Function (2) 
+ Clinical 
assessment 
Categorical scoring 
of pain at rest (5 
options) and in 
bending (4). 
Function split into A 
(4) and B (5) 
+ Clinical 
assessment 
 
Scored 0-100 
3 1 (1) 
LES 
(Liverpool 
Elbow Score) 
Sathyamoorthy 
et al 
[204]  
(2004) 
Elbow specific measure of 
function and clinical state 
Patient 
and 
Clinician 
Physical Function 
(8) 
Pain (1) 
+ Clinical 
assessment 
 
5 point Likert scale  
 
Raw score 
converted to 0-10 
scale 
1 1 (0) 
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MEPS 
(Mayo Elbow 
Performance 
Score) 
Morrey and 
Adams 
[165]  
(1992) 
For the assessment of 
total elbow arthroplasty 
Clinician Pain (5) 
Function (15) 
+ Clinical 
assessment 
10 point Likert scale 
 
Scored out of 100 
then interpreted as 
one of four groups 
(poor – excellent) 
6 24 (9) 
Morrey Broberg and 
Morrey 
[205]  
(1986) 
For the assessment of 
radial head fractures 
excision 
Clinician Pain (1) 
+ Clinical 
assessment 
Categorical scoring 
of pain (4 options) 
  
Scored out of 100 
then interpreted as 
one of four groups 
(poor – excellent) 
2 4 (0) 
Nirschl Nirschl 
[27] 
(1979) 
Assessment of LET based 
on phases of pain  
Patient 
and 
Clinician 
Pain (1) 
+ addition of VAS 
and surgical 
findings 
Categorical scoring 
of pain (7 options) 
 
2 16 (7) 
OES 
(Oxford Elbow 
Score) 
Dawson et al 
[142]  
(2004) 
For the assessment of the 
outcome of elbow surgery 
Patient Pain (4) 
Function (4) 
Limitation to work 
and leisure 
activities (2) 
Psychosocial (2)  
Categorical scoring 
options  
Converted to 
numerical value (0-
4) 
 
Domains scored 
individually   
5 5 (2) 
PRTEE 
(Patient-Rated 
Tennis Elbow 
Evaluation) 
(formally PRFE) 
Overend et al 
[206]  
(1999) 
For measurement of 
forearm pain and disability 
in patients with LET 
Patient Pain (5) 
Function 
 Specific 
(6) 
 Usual (4) 
  
10 point Likert Scale 
 
Raw score 
converted to 0-100 
scale 
9 53 (21) 
QDASH 
(quick 
Disabilities of 
the Arm 
Shoulder and 
Hand) 
Beaton et al 
[207]  
(2005) 
Abbreviated DASH score Patient Physical Function 
(6)  
Pain (2) 
Psychosocial (3)  
5 point Likert scale 
 
Raw score 
converted to 0-100 
scale 
8 18 (5) 
R&M 
(Roles and 
Maudsley) 
Roles and 
Maudsley 
[208]  
(1972) 
To classify the outcome of 
surgery in Radial Tunnel 
Syndrome 
Clinician Pain  
Movement 
Activity  
Placed in 1 of 4 
groups (poor – 
excellent) 
dependent on 
composite of 
dimension finding 
2 16 (2) 
100 
 
TEFS 
(Tennis Elbow 
Functional 
Score) 
Lowe 
[209]  
(1999) 
For the assessment of 
disability in patients with 
LET 
Patient Pain (10) 5 point Likert scale  
 
Scores of 10 items 
added together 
1 3 (0) 
ULFI 
(Upper Limb 
Functional 
Index) 
Pransky et al 
[210]  
(1997) 
For the assessment of 
upper limb function  
Patient Function (8) 10 point Likert scale 
 
Scores of 8 items 
added together 
 
1 6 (3) 
Verhaar Verhaar et al 
[211] (1993) 
For the assessment of the 
outcome of surgery in LET  
Clinician Pain 
Satisfaction 
Movement 
Strength 
Placed in 1 of 4 
groups (poor – 
excellent) 
dependent on 
composite of 
dimension finding 
1 6 (1) 
Table 3-2: Summarised characteristics of the 15 identified outcome instruments. 
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Figure 3.2: The change in the percentage of use of outcome instruments over time. 
 
Clinical rating systems 
Of the 15 outcome clinical rating systems, six were Patient Reported Outcome 
Measures (PROMs), six were clinician-reported outcome measures (CROMs), and 
the remaining three included both clinician and patient-reported information (Table 
3-2).  
The instruments had been developed between 1979 and 2008. Four instruments had 
been designed specifically for the assessment of LET: Patient-Rated Tennis Elbow 
Evaluation (PRTEE), Nirschl score, Tennis Elbow Functional Scale (TEFS) and 
Verhaar score. Three more instruments had been designed as elbow-specific across 
different pathologies: American Society of Shoulder and Elbow Surgeons-Elbow 
(ASES-e), Liverpool Elbow Score (LES) and Oxford Elbow Score (OES). Three other 
instruments (DASH, QDASH, and ULFI) are region-specific (upper limb), and the 
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remaining five Instruments had been designed for the assessment of other 
pathologies (eg arthroplasty, radial head fracture), but have been used in the 
assessment of LET outcomes.    
Psychometric evaluation 
All instruments were assessed using the EMPRO methodology (appendix 7). The 
volume of resources informing each EMPRO assessment averaged four articles 
(IQR 8.5) (Range 1-41) (Table 3-2).  
Concordance between individual EMPRO evaluations was moderate to substantial in 
all cases, Kappa Median 0.72 (IQR 0.36) (range 0.47 – 0.94) [212]. Resolution of 
score differences was achieved by consensus in all cases. The overall summary 
scores ranged from 72.5 (QDASH) to 21.6 (ASES-e). Only four instruments met the 
threshold score of 50/100: one LET specific (PRTEE), one elbow specific (OES) and 
two upper-limb specific (QDASH, and DASH). It was not possible to calculate overall 
scores for the Morrey, Andrews and Carson, Roles and Maudsley, HSS, Nirschl and 
Verhaar instruments, because of lack of available evidence (Figure 3.3).   
Whereas no reviewer ‘strongly recommended’ any of the outcome instruments, 
QDASH, DASH, OES and PTREE were all ‘recommended (with provisos or 
alterations)’. Of those instruments, recommendations of use extended only to group 
comparison of a general adult population rather than individual monitoring, owing to 
lack of clear responsiveness data in LET patients.  
The Spearman correlation coefficient between overall performance and frequency of 
use in the literature was r = 0.35 (95%CI: -0.11; 0.83).  
1 
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Figure 3.3: Attribute specific and Overall EMPRO scores. 0 (worst) - 100 (best). 
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3.6 Discussion 
This study identified 15 clinical rating systems that, to varying degrees, attempt to 
assess patient outcomes in individuals suffering from Lateral Elbow Tendinopathy 
(LET). All 15 clinical rating systems were systematically evaluated in view of their 
development, metric properties and history of use within the LET literature. Of those 
instruments, only four met both the overall attribute benchmark score of 50 and 
overall recommendation of the reviewers, to suggest that their use can be justified in 
the evaluation of LET. This study has gone a step further than previous elbow-
specific outcome instrument evaluations [149, 154, 213-215] in attempting to systematically 
compare the instruments in a condition-specific context, furthermore it is the first to 
attempt to quantify both the properties of the instruments, and the instruments’ 
distribution of use within the literature, which both feature significantly in the 
researcher’s or clinician’s mind when choosing a tool. From this assessment, we 
would recommend authors of future studies of LET participants, where English 
language instruments will be used, consider the QDASH, DASH, OES or PRTEE. 
Furthermore, summary tables from the EMPRO evaluation can be used to guide 
instrument choice when the quantification of a particular attribute is desirable, for 
example, responsiveness in longitudinal studies or the inclusion of specific 
dimensions such as psychosocial effect. This presentation of condition-specific 
quality may also reduce the 22% of studies that utilise two or more clinical rating 
systems, with its consequent burden on the study participants. 
To the author’s knowledge, this is the first upper-limb specific study that has 
quantified the condition-specific quality of the instrument, and formally identified the 
instruments’ distribution of use. Previous EMPRO evaluations have found 
concordance between the quality of the instruments and their history of use [201]. 
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Though there is some agreement between quality and use of instruments in LET, 
instruments are being widely used although the evidence for their metric properties 
are significantly limited compared to alternatives. While the results of our 
standardised evaluation would support the common use of the DASH and PRTEE, 
the MEPS, which did not meet our minimum benchmark is used twice as often as the 
QDASH and seven times more often than the OES. Furthermore, this trend has not 
changed significantly over time. The QDASH is the abbreviated version of the DASH, 
scored more highly than the full version owing to a more compelling record of 
validation in LET populations. Its use is becoming increasingly popular, yet between 
2010 - 2017 it was only utilised in a minority (14.6%) of LET studies.  
High performing instruments 
The QDASH, DASH, OES and PTREE exceeded the minimum criteria for 
recommendation. Of note, both the QDASH and DASH scored >50 on every 
attribute-specific score. Of these four measures, particular strengths (identified as a 
particular metric attribute specific score >80/100), were the conceptual development 
of the OES and responsiveness of the QDASH. The OES developed its items with 
patient groups and expert panels, using a high-quality methodology, however, it is 
worth noting that due to the unidimensional nature of the three discrete constructs of 
pain, function and psychosocial impact, the resulting instrument should be presented 
as a profile of scores rather than a single composite score, a fact ignored in many 
subsequent studies using the instrument. The assessment of dimensionality 
assesses the fit of items in an instrument around a construct (e.g. pain or function). A 
unidimensional instrument can provide a single score once it can be proved that the 
items used measure similar things (that there is a level of interrelatedness between 
the items of the questionnaire). However, if it is revealed that the instrument is 
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multidimensional (assesses multiple discrete constructs), then the instrument should 
be divided into subscales. Further analysis of each subscale is then required to 
ensure that the items for each construct are in themselves unidimensional. The 
resultant score should be presented as multiple subscale scores. The 
responsiveness of the QDASH has been complemented by studies containing 
considerable proportions of LET patients [216, 217], however, it is worth noting that the 
DASH, OES and PRTEE all scored well in this attribute.  The condition-specific 
PRTEE, though reliable, valid and responsive, was developed without clear patient 
involvement. Factor analysis has not been reported and the justification of visual 
numeric scales is not clear. 
Areas where further data could enhance these scores include: assessment of metric 
properties in isolated LET groups for the QDASH, DASH and particularly the further 
assessment of condition-specific construct validity of the OES. Furthermore, future 
studies focusing on the interpretability through minimal change scores would 
strengthen this specific attribute considerably. 
Other instruments  
The TEFS, ULFI, LES, MEPS and ASES-e scored below the minimum criteria for 
recommendation. Though the TEFS is a condition-specific score, the reporting of its 
metric properties has only occurred in a University Masters thesis published in 1999 
[209]. However, it has a history of use in peer-reviewed publications as recently as 
2012. Though scoring well for reproducibility, the weight of evidence for the 
remaining metric properties currently precludes its recommendation. The ULFI is a 
generic upper limb score with a history of use in LET and although conceptually well 
designed and responsive, lack of information on its metric properties within a 
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condition-specific context preclude its recommendation.  The LES is a robustly 
designed instrument that has been employed in LET studies, however, a significant 
lack of data on the instrument’s responsiveness and interpretability hugely hamper 
the instrument’s utility to the researcher. The MEPS is a commonly used instrument; 
within the LET literature it is reported in 15% of studies. However, this tool was never 
designed for application in LET and consequently, its domain structure may not 
reflect the experience of LET patients. Lack of data across all metric aspects 
highlight that this is likely to be an unsuitable instrument, yet its use appears to be 
increasing over time. The particular lack of data on the instrument’s interpretability in 
the context of LET exemplifies that though this is historically popular, researchers 
may struggle to justify its use. A similar scenario is present for the ASES-e score, 
which again lacks metric details in LET populations.  
The remaining instruments scored below the required three out of five attribute 
scores for calculation of a composite score. They were all developed prior to 1986 
and are clinician rated. The lack of data on all of their metric properties implies that 
their use does not stand up to modern reporting requirements of outcome 
instruments [135, 218]. This is prescient information due to the continued reporting of 
these instruments in contemporary literature.     
Limitations 
This study should be interpreted with reference to limitations inherent to its 
methodology. Firstly, our results are dependent on the information retrieved from the 
search strategy. It is important to note that the strategy was developed with 
reference to extensive protocols, and the largest health science databases 
(MEDLINE, Embase and CINHAL), were utilised and complemented with the 
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addition of thesis searching and hand searching in recognised repositories. 
Furthermore, authors of the identified instruments were contacted and asked to 
confirm whether the list of manuscripts identified were as comprehensive as 
possible. Nevertheless, inherent in all search strategies is the possibility of missed or 
omitted evidence.  
Secondly, the choice of the EMPRO tool itself should be scrutinised.  Multiple 
attempts have been made to quantify the strength of evidence surrounding a set of 
instruments. The EMPRO tool was used owing to its emphasis on assessing the 
whole body of evidence relating to an instrument. We feel the validated output of a 
‘score’ and recommendation is very beneficial to the clinician and researcher. The 
authors recognise that this may be complemented with the addition of the commonly 
cited COSMIN (Consensus-based standards for the selection of health measurement 
instruments), which would scrutinise the methodological quality of the studies 
assessing the metric properties, rather than the instrument itself. This approach may 
be complementary, but to our knowledge this method has not yet been reported.  
Thirdly, it is recognised that our use of English language tools only, limits the 
generalisability of our findings. However, we feel that the use of both non-English 
language instruments and data derived from cross-culturally adapted instruments 
imparts variables that the EMPRO tool was not conceived to deal with. Where the 
EMPRO provides comparative scores across instruments, the addition of information 
derived from a different cultural context is unhelpful for the researcher/clinician. 
Where adaptation of a tool is undertaken, certain aspects of its metric properties 
cannot be compared and should not be collated to complement the body of evidence 
[219] [135]. Strictly speaking, though all English language in origin and application, the 
use of data from different English-speaking countries could be questioned. The 
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presented data should therefore be followed with the exploration of culturally-specific 
metric properties, that would allow a detailed country-specific analysis.      
Fourthly, beyond the assessment of LET-specific studies, this assessment derived 
some information from studies that contained a component of non-LET participants. 
Therefore, contamination of our findings is possible as, in many instances, it is not 
possible to quantitatively extract the LET information and assess it in isolation from 
other pathologies. Here a pragmatic and more subjective assessment was required 
to assess what are perceived as strengths and weaknesses of the tool in this specific 
cohort. The authors feel that at present, though pathology-specific advice is highly 
sought after, it is a significant challenge in musculoskeletal health owing to the 
traditional use of region or joint-specific instruments. We advise our methods as a 
best possible route, but would recommend that the reporting of pathology-specific 
details in all future development or assessment of musculoskeletal PROMs 
instruments, will greatly enhance this process.   
Future research 
We hope that the presentation of information on both quality and distribution of use 
will compel researchers to carefully consider their instrument choice. Though this 
study reports the current strengths and weaknesses of LET instruments, it is 
important to comment on the changing landscape of outcome measure assessment 
in upper limb pathology. New novel instruments have been developed that integrate 
both patient-reported PROMs assessment and patient-reported objective function, 
including the German language Elbow Self-Assessment Score (ESAS)[220]. There is 
also an emergence of computer-based systems that use predictive algorithms to 
administer streamlined PROMs, easing data collection, analysis and decreasing 
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participant burden. These systems offer great potential but are in the early stages of 
use in upper limb pathology [221]. Of note, the NIH PROMIS system, the largest 
computer adaptive testing system, has not yet reported specific properties for the 
elbow region or specific elbow pathologies [221].    
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3.7 Conclusion 
This study is the first to provide a systematic evaluation of LET-specific PROMS 
instruments. The available evidence would currently support the use of the 
QDASH, DASH, PRTEE or OES instruments. Though the QDASH scored 
highest, the choice of instrument should also depend upon the study’s particular 
requirements. The evidence presented for each metric attribute will facilitate in 
the selection process. Future instrument development and validation, 
particularly for those not meeting the recommended standards, can also be 
optimised using the presented evidence. It is now clearly recognised that the 
choice of outcome instrument must be justified from both a validity and burden 
standpoint. The information presented should therefore be used in conjunction 
with a culturally specific analysis, which should be used in combination with this 
EMPRO assessment to select a high performing instrument.  
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4 Chapter 4 - Patient-Centred Outcomes in Lateral Elbow 
Tendinopathy: A Systematic Review of Available 
Evidence in UK Populations 
4.1 Abstract 
Aim 
To systematically review the evidence for clinical rating systems in the 
assessment of outcomes of UK patients with Lateral Elbow Tendinopathy (LET).  
Methods 
A systematic search was performed in Ovid MEDLINE, Embase and CINAHL. 
Studies were included if they reported the administration of PROMs in UK 
populations with LET. PROMs characteristics and the populations in which they 
had been used were assessed using a structured classification system. PROMs 
reporting in randomised controlled trials was assessed against CONSORT 
standards (PRO extension). 
Results 
A total of 16 articles were included based on eligibility criteria. Out of seven 
different PROMs, there was evidence of partial validation for five of them. The 
assessment of validity, reliability and responsiveness of all PROMs in LET UK 
populations extended to just 20 individual patients. No articles conformed to the 
CONSORT PRO extension standards.   
Conclusion 
There exists a huge paucity of data on the psychometrics and usability of 
PROMs in UK LET populations.  Without these data, trial design and 
interpretation of health technology assessment are significantly hindered. The 
high prevalence of this condition allied with the significant volume of studies 
being conducted into novel treatments, highlight the need for this knowledge 
gap to be resolved.   
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4.2 Overview  
The standardised EMPRO evaluation, presented in the preceding chapter, has 
identified the English language PROMs that can be recommended for use in 
LET. Though this pathology related validity is of utility to the researcher, it is 
also vitally important that they are confident that the instrument is appropriate, 
valid and interpretable in the chosen population. In this chapter, the level of 
evidence available for clinical rating systems in UK populations is explored 
through systematic review. The evaluation of EMPRO evidence and this cross-
cultural assessment can then be used to inform the need for further culturally 
specific validation.       
4.3 Background 
Appropriate outcome measures must demonstrate that they are acceptable to 
patients, reliable, valid and responsive (sensitive to change) [152]. When the 
outcome measure has been developed in a different clinical or geographical 
population, there needs to be evidence of equivalence both in a disease-
specific and cross-cultural context [153, 222]. The validation of a PROMs in a new 
language is accepted as integral to its interpretability, what may be less 
appreciated is the requirement for cultural adaptation, for a PROM delivered in 
its original language but in a different geographical location and in a different 
population [219]. Though not previously investigated in elbow pathology, it is 
notable that a recent evaluation of population norms of English language 
shoulder outcome measures, the Association of Shoulder and Elbow Surgeons 
(ASES) shoulder score, University of California, Los Angeles (UCLA) shoulder 
rating scale and Shoulder Pain And Disability Index (SPADI), administered to 
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Canadian and Australian population samples reported statistically significant 
variability in the scores between the two countries [223]       
A structured assessment of outcome measurement in LET in UK populations 
has not been undertaken. This study aimed to address this gap by 
systematically assessing the outcome measures used for measuring PROMs in 
Lateral Elbow Tendinopathy in a UK population, and to assess the reporting of 
randomised controlled trials using PROMs in LET. Only when valid outcomes 
have been identified, can recommendations on choice of outcome measures for 
future research be made.   
4.4 Methods 
PRISMA guidelines on the reporting of systematic reviews were followed [159] 
(appendix 8). All articles reporting the development, psychometric evaluation, or 
use, of clinical rating systems in LET in UK adults (≥18yrs) were included. Any 
measures of symptoms and functioning in LET that involved a patient-centred 
outcome measurement (regardless of whether this also contained a physician-
reported outcome component) were included.  Studies in paediatric populations, 
case-reports, case-studies and conference abstracts were excluded.  
The search strategy and resultant systematic review database applied in 
chapter 2 was re-analysed. The specific inclusion/exclusion criteria above were 
applied to full-text articles identified from the chapter 3 EMPRO evaluation. Dual 
screening was utilised.  
At the full-text level, articles were also sub-categorised in two groups to: articles 
reporting primary research on the development and/or psychometric evaluation 
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of PROMs in LET in UK populations (development); and articles reporting the 
use of outcome measures in clinical studies in UK populations (use).   
Data synthesis 
Development articles were classified according to three guiding concepts, using 
the structured classification system proposed by Valderas and Alonso [143]: 
construct (the measurement object), population (based on age, gender, 
condition and culture) and measurement model (dimensionality, metric and 
adaptability) [143].  
The assessment of construct denotes, for the purpose of this study, the range of 
characteristics measured by the outcome measure, which are affected by LET. 
The construct analysis has, at its foundation, the conceptual strengths of the 
Wilson and Cleary model [224] in which psychological variables, symptom status, 
functional health, general health perceptions, and overall quality of life are 
considered in an attempt to unify biomedical and social science paradigms and 
build and overarching conceptual model of Health Related Quality of Life 
(HRQoL) [225].  The Valderas and Alonso integrate the Wilson and Cleary model 
with the  similar theoretical model that underpins the International Classification 
of Functioning, Disability and Health (ICF), this classification system proposed 
by the World Health Organisation is based on the sociological perspective of 
health and considers disability along the whole functioning continuum [143]. The 
integration of these models thereby produces a descriptive classification system 
for PROMs based around valid conceptual models of health. A strength of the 
model that is particularly pertinent in the assessment of LET outcome 
measures, is the systematic consideration of intended population of use. Within 
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the axis of population, consideration of culture is also made, where there is 
information pertaining to the dyad of language and country for which the 
outcome measures have been devised. 
It should be noted that this system is only descriptive and does not provide any 
fundamental evaluation of measurement properties [143]. But in this stage of 
outcome measure assessment, where the adequacy of information to conduct a 
full culturally specific standardised assessment (e.g. EMPRO of COSMIN), this 
approach provides the clearest method of identifying the candidate pool of 
measures. 
Articles reporting the use of clinical rating systems were all peer-reviewed, 
published articles with outcome measure evaluation in a population of LET 
patients. Date of publication, outcome measure(s) chosen and population of use 
were extracted. For randomised control trials, the CONSORT Patient-Reported 
Outcome (PRO) extension [218] was used to systematically assess the reporting 
of outcome measure choice and justification. The original CONSORT statement 
aims to encourage transparent and complete reporting of clinical trials and is 
associated with improved reporting practice [226].  
An a priori hypothesis was formulated with regard to informed choice of 
outcome measures in UK populations. We hypothesised that articles reporting 
the use of PROMs would more frequently use PROMs for which there would be 
evidence from studies of validation of such measures in specific UK 
populations.  
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4.5 Results 
From the original 7,261 records derived in chapter 2,236 articles reporting 
metric properties of elbow/upper limb instruments in LET derived in chapter 3 
were re-analysed, yielded 16 articles that met the UK specific inclusion criteria. 
This comprised five articles reporting the development and/or psychometric 
evaluation of outcome measures in LET-specific patients and 11 articles 
reporting their use in a UK population (Figure 4.1) (appendix 9).  
 
Figure 4.1: PRISMA Flowchart of the UK specific elements of the systematic literature review. 
 
Measures  
Five outcome measures were identified that were developed, or had undergone 
psychometric evaluation, on UK populations that at least, in part, contain 
patients with LET (Table 4-1). They were all fully standardised measures that 
had all been developed for measuring symptoms (mainly pain) and functioning 
in English speaking UK adults of either gender. However, only one of them, the 
Patient-Rated Tennis Elbow Evaluation (PRTEE) was LET-specific, the 
remaining instruments were developed as elbow-specific tools designed for 
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varying pathologies, but including in their validation a sub-sample of LET 
patients. Two outcome measures were originally developed for UK populations: 
the Oxford Elbow Score (OES) and the Liverpool Elbow Score (LES). The 
remaining three outcome measures were developed in the English language 
outside of the UK (US, Canada and Australia), but had undergone some level of 
psychometric evaluation in UK populations.  Of note, no modification was 
deemed necessary in the wording or description of the symptoms or activities 
measured for any of those instruments.  
Only the PRTEE has been assessed in a UK cohort that was exclusively 
diagnosed with LET in an assessment of its interpritability. This was conducted 
on 57 patients to quantify the Minimally Important Difference (MID) of the 
PRTEE. This study formed part of a larger prospective trial assessing 
microcurrent therapy in LET and analysed data from 57 individuals with 
clinically and sonographically diagnosed LET who all underwent microcurrent 
therapy. They report a weak correlation between the PRTEE and global change 
scale, but no assessment of construct validity or any other metric assessment 
was undertaken and hence, it cannot be used as formal evidence of cross-
cultural validity. For the four remaining outcome measures, the proportion of 
patients included within their study cohorts who were diagnosed with LET 
ranged from 11% to 12.7% (Table 4-1). None were evaluated in more than 12 
patients, and as multiple measures were reported on the same patient cohorts, 
when all individual patients from these studies were tallied, it reveals that this 
equates to 20 UK LET patients in total.   
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Eleven additional articles reported using PROMs to evaluate disease impact in 
UK populations with LET. These studies were published between 2003 and 
2014 (Table 4-2). Out of the five outcome measures for which there had been a 
previous psychometric evaluation, only three were subsequently applied to 
evaluate LET outcomes (DASH, OES and PRTEE). The outcome measures 
that were not utilised were the LES and the Mayo Elbow Performance Score 
(MEPS). Perhaps more surprisingly, two additional measures were used, the 
Nirschl score and the Patient-Rated Wrist Evaluation (PRWE), although no 
evidence on the psychometric properties or even their cross-cultural 
equivalence was available. Overall, the PRTEE (and precursor PRFEQ) was 
reported six times, the DASH four times, the Nirschl score twice, the OES once 
and the PRWE once. Seven of the 11 studies stated that the outcome measure 
was their study’s primary outcome. 
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Outcome measure Country 
of origin 
Exclusively 
Patient Reported 
(no. items) 
Construct  
(no. items) 
Population* Measurement 
model $ 
UK LET assessment 
Oxford Elbow Score 
(OES) [142] 
 
 
United 
Kingdom 
Yes (12) A1. Symptoms 
Pain (4) 
A2. Function 
Elbow function (4) 
Psychosocial (4) 
Assessment of 
outcome of 
surgery of the 
elbow [142] 
 
C1. Profile 
C2. 
Psychometric 
C3. 
Completely 
Standardised 
Surgically treated LET patients 
make up 11.2% (n= 12/107) of the 
total development and validation 
cohort [142, 167, 227] 
Liverpool Elbow 
Score (LES)[204] 
 
 
United 
Kingdom 
No, physician 
administered (15) 
A1. Symptoms 
Pain (1) 
A2. Function 
Range of motion (4) 
Strength (1) 
Ulnar nerve function (1) 
Activity (8) 
 
B1. Adults 
B2. All genders 
B3. Assessment 
of elbow 
pathology in 
tertiary care 
setting [204] 
B4. UK English  
C1. Index 
C2. 
Psychometric 
C3. 
Completely 
Standardised 
Tertiary care patients with LET 
make up 12.7% (n=8/63) of the 
total development and validation 
cohort [204] 
Patient-rated Tennis 
Elbow Evaluation 
(PRTEE)[206] 
 
 
Canada Yes (15) A1. Symptoms 
Pain (5) 
A2. Function 
Activity (10) 
B1. Adults 
B2. All genders 
B3. Lateral 
Epicondylar 
Tendinopathy 
patients [206] 
B4. UK English  
C1. Index 
C2. 
Psychometric 
C3. 
Completely 
Standardised 
57 LET patients (100% of cohort) 
[228] (MCID only) 
 
(PRTEE delivered in a modified 
form but not formally cross-
culturally validated) 
Disabilities of the 
Arm Shoulder and 
Hand (DASH)[169] 
 
2x Optional modules 
Work 
Sporting/performing 
arts 
 
US, 
Canada, 
Australia 
Yes (30) A1. Symptoms 
Pain (5) 
A2. Function  
Physical function (21) 
Psychosocial (4) 
B1. Adults 
B2. All genders 
B3. Applied to 
multiple elbow 
pathologies [229] 
B4. UK English 
C1. Index 
C2. 
Psychometric 
C3. 
Completely 
Standardised 
Surgically treated LET patients 
make up 11.2% (n= 12/107) of the 
total development and validation 
cohort [142, 167, 227].  
Tertiary care patients with LET 
make up 12.7% (n=8/63) of the 
total development and validation 
cohort [204] 
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(DASH delivered in original form, 
without any modifications) 
 
(UK English DASH translation 
available from 2015 [230])  
Mayo Elbow 
Performance Score 
(MEPS)[165] 
 
Physician 
administered 
 
8 Items: 
1x pain 
1x Range of motion 
1x Instability 
5x Function 
United 
States 
No, physician 
administered (15)o 
A1. Symptoms 
A2. Function 
B1. Adults 
B2. All genders 
B3. Applied to 
multiple elbow 
pathologies [231] 
B4. UK English 
C1. Index 
C2. 
Clinometric 
C3. 
Completely 
standardised 
Surgically treated LET patients 
make up 11.2% (n= 12/107) of the 
total development and validation 
cohort [142, 167, 227] 
 
(MEPS delivered in original form, 
without any modifications) 
* All measures were developed for English-speaking adults of either gender. $ All measures were fully standardised. 
 
Table 4-1: Outcome measures for the assessment in Lateral Elbow Tendinopathy (LET) with psychometric evaluation in UK population 
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Author Year Title Study Type and Population Outcome measure      
(* Primary outcome) 
Melikyan, E. Y., et 
al.  
2003 Extracorporeal shock-wave treatment for tennis elbow: a randomised double-
blind study 
RCT 
LET patients who failed 
conservative treatment  
DASH 
Dunkow, P. D., et al. 
 
2004 A comparison of open and percutaneous techniques in the surgical treatment 
of tennis elbow 
RCT  
LET patients who failed 
conservative treatment 
DASH* 
Connell, D. A., et al. 
 
2006 Ultrasound-guided autologous blood injection for tennis elbow Prospective Cohort  
LET patients who failed 
conservative treatment 
Nirschl* 
Alizadehkhaiyat, O., 
et al. 
 
2007 Pain, functional disability, and psychologic status in tennis elbow Cross-sectional  
LET with symptoms lasting >3 
months 
DASH 
PRWE 
PRFEQ 
Connell, D., et al. 
 
2009 Treatment of lateral epicondylitis using skin-derived tenocyte-like cells Prospective Pilot Study (Not 
Randomised)  
LET patients who failed 
conservative treatment 
PRTEE* 
Clarke, A. W., et al. 
 
2010 Lateral elbow tendinopathy: correlation of ultrasound findings with pain and 
functional disability 
Prospective Cohort of 
LET who had not undergone 
invasive treatment 
PRTEE* 
Creaney, L., et al. 
 
2011 Growth factor-based therapies provide additional benefit beyond physical 
therapy in resistant elbow tendinopathy: a prospective, single-blind, 
randomised trial of autologous blood injections versus platelet-rich plasma 
injections 
RCT 
LET patients who failed 
conservative treatment 
PRTEE* 
Nazar, M., et al. 
 
2012 Percutaneous Tennis Elbow Release Under Local Anaesthesia Prospective Cohort 
LET patients who failed 
conservative treatment 
DASH* 
OES 
Stenhouse, G., et al. 
 
2013 Do blood growth factors offer additional benefit in refractory lateral 
epicondylitis? A prospective randomized pilot trial of dry needling as a stand-
alone procedure versus dry needling and autologous conditioned plasma 
Prospective Pilot Study 
(Randomised ) 
LET patients who failed 
conservative treatment 
Nirschl 
Maffulli, G., et al. 
 
2014 Assessment of the Effectiveness of Extracorporeal Shock Wave Therapy 
(ESWT) For Soft Tissue Injuries (ASSERT): An Online Database Protocol 
Online Database Protocol of 
Clinically or Radiologically 
confirmed LET 
PRTEE* 
Tonks, J. H., et al. 
 
2007 Steroid injection therapy is the best conservative treatment for lateral 
epicondylitis: a prospective randomised controlled trial. 
RCT  
LET patients who had not had 
treatment for the preceding 6 
months.  
PRTEE 
Table 4-2: Studies reporting the use of PROMs in patients with Lateral Elbow Tendinopathy. 
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Reporting guideline adherence 
Four of these 11 studies were randomised controlled trials (RCTs). The level of 
adherence to CONSORT-PRO standards for reporting PROMs in RCTs for the 
four trials suggested substantial room for improvement (Table 4-3). No 
information was available for three CONSORT-PRO standards for any RCT and 
only partial information was available for the other two standards in a minority of 
studies.  
CONSORT 2010 statement PRO Extension Studies meeting the 
requirements 
Structured summary of trial 
design, methods, results, and 
conclusions 
The PRO should be identified in the 
abstract as a primary or secondary 
outcome 
1/4 
Specific objectives or 
hypotheses 
The PRO hypothesis should be stated and 
relevant domains identified, if applicable 
0/4 
Completely defined pre-
specified primary and 
secondary outcome measures, 
including how and when they 
were assessed 
Evidence of PRO Instrument validity and 
reliability should be provided or cited if 
available, including the person completing 
the PRO and methods of data collection 
(paper, telephone, electronic, other) 
0/4 (validity of PROM in 
UK population) vs 2/4 
(validity of PROM in 
another LET population) 
1/4 (data collection 
method) 
Statistical methods used to 
compare groups for primary 
and secondary outcomes 
Statistical approaches for dealing with 
missing data are explicitly stated 
0/4 
Trial limitations addressing 
sources of potential bias, 
imprecision, and, if relevant 
multiplicity of analyses 
PRO-specific limitations and implications 
for generalisability and clinical practice 
should be discussed 
0/4 
Table 4-3: Adherence to CONSORT reporting standards (PRO extension) of UK-based lateral elbow 
tendinopathy randomised controlled trials. 
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4.6 Discussion  
This study has identified a lack of evidence with which to inform outcome 
measure choice in Lateral Elbow Tendinopathy in the UK. Future validation of 
outcome measures in UK populations is required in order to be able to ground 
any recommendations on a firm evidence base. Furthermore, some outcome 
measures are currently being used as primary outcomes in UK-based studies in 
the absence of any evidence for their cross-cultural appropriateness and 
psychometric properties.  
We were able to retrieve at least some evidence of the evaluation of the 
psychometric properties of five outcome measures. The PRTEE is the only 
measure specifically designed for the evaluation of a LET population. All 
measures attempt to measure the domains of function and symptoms in adults. 
All but the DASH have been designed to assess these domains in reference to 
the elbow exclusively.   
The total reporting of validity, reliability or reproducibility of outcome measures 
in UK LET patients is limited to 20 patients [142, 204]. All of these patients have 
been embedded in larger cohorts containing a heterogeneous group of elbow 
pathology. Due to the limited size of this LET sample, it has been unfeasible to 
conduct a culturally specific standardised psychometric assessment of the 
outcome measures using methods such as COSMIN or EMPRO.  
The largest assessment outcome measure utility in UK LET patients was 
published by Poltawski et al [228] and included 57 patients. Although this is by far 
the largest sample of LET patients of any of the studies included here, outcome 
interpretability through derivation of MCID score was undertaken with no 
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evaluation of other relevant psychometric characteristics. The PRTEE was not 
originally designed for a UK population and no evidence of the assessment of 
cross-cultural appropriateness is presented. This would always be necessary 
when applying a new instrument to a different population, as the use of 
language across continents, though English in origin, confers both linguistic and 
cultural differences. Even more interesting is that in this case, the need was 
additionally increased by the fact that items in the PRTEE were altered by the 
authors prior to administration (the words coffee and milk were removed from 
the item “Lift a full coffee cup or glass of milk to your mouth’, “pants” were 
replaced by “trousers” and “washcloth or wet towel” by “wet cloth”). The authors 
acknowledge that the altering of the outcome measure wording may have 
altered its measurement properties [228].  
In many circumstances it will be completely appropriate and even highly 
advisable to alter the wording of outcome measures if this has been suggested 
as needed by patients. When required, it should be undertaken under the 
principles of cross-cultural adaptation [219, 222]. It is widely recognised that if a 
measure is to be used across cultures, the items must be both linguistically 
translated and culturally adapted to maintain the content validity of the outcome 
measure at a conceptual level [219]. Guillemin et al [232] have proposed scenarios 
that should alert authors to situations where translation or adaptation should be 
undertaken. In the situation of an outcome measure being used in another 
country, but in the same language, cultural adaptation is required. For LET in 
UK populations, this would be the case for the DASH, MEPS, PRTEE and 
Nirschl outcome measures. Of note, the DASH and quickDASH score have 
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been culturally adapted to UK English since 2015 [230]. To the best of our 
knowledge, this particular score was not used in any of the identified studies.  
This study has identified that the reporting of outcome measures in UK LET 
randomised controlled trials does not conform to the CONSORT-PRO guidance. 
Though two of the studies were published prior to the guidance publication in 
2010, the stark paucity of reporting of outcome measure detail is concerning. 
This lack of reporting is in line with the deficits in outcome measure validity 
highlighted through the Valderas [143] classification system. Though we 
hypothesised that there would be a preference for outcome measures with 
published validity in the target population, we have identified that with the 
current level of evidence this is not possible. Long et al (2015) [101] reported in 
their National Institute of Health Research Health Technology Assessment 
review of systematic reviews of conservative treatments in LET, that a lack of 
standardised application of outcome measures hindered interpretation and 
synthesis of results. They recommend that the inclusion of a valid patient-
reported measure of upper extremity function in interventional trials would ease 
results synthesis. However, though we have identified candidate English 
language PROMs valid for use in LET, we have identified the lack of a clear 
choice for specific UK populations. 
Limitations 
The inherent limitations of this study should be discussed. The search strategy 
may have failed to identify all outcome measures used, and the identification of 
the study populations’ nationality in interventional trials can be prone to error. 
However, attempts were made to ensure that the strategy was as robust as 
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possible. Outcomes in LET can be measured in numerous ways, including grip 
strength, pain provocation tests and visual analogue scales to mention a few, 
and this may be a highly legitimate method in UK populations, but was not 
assessed as part of this study. Although it should be noted that a background 
literature review (chapter 1) did find that validation studies on these methods 
had not been undertaken in UK populations. The authors feel that the approach 
to concentrate on patient-centred outcomes is justified owing to the 
recommendation by the NIHR in the UK that they are included in clinical 
effectiveness trials [133, 147]. Furthermore, the use of condition-specific PROMs is 
increasingly common in musculoskeletal medicine and are collected as part of 
the English NHS PROMs programme [233]. With the increasing use of PROMs 
used as primary outcomes in clinical trials, it is therefore highly relevant that 
their use is rigorously assessed.  
4.7 Conclusion  
This study has identified that, with current levels of evidence, it is not 
appropriate to recommend any PROMs for LET studies in UK populations. 
Though the OES, PRTEE and DASH show potential as patient-reported 
measures, with domains likely to be appropriate in LET, further assessment is 
required in UK populations to quantify their validity, reliability, responsiveness 
and patient acceptability.     
128 
 
 
5  Chapter 5 - A Comparative Assessment of Patient 
Reported Outcome Measures for Lateral Elbow 
Tendinopathy in a UK Population 
5.1  Abstract  
Background 
There is currently no guidance on the validity of Patient Reported Outcome 
Measures (PROMs) for the assessment of Lateral Elbow Tendinopathy (LET) in 
a UK population. This study aimed to evaluate the psychometric properties of 
four candidate instruments, identified as the best performing PROMs in a 
standardised evaluation of available measures.   
Methods 
A prospective validation study was conducted assessing the four candidate 
PROMs. Recruitment was conducted in primary care, secondary care and 
physiotherapy clinics. Repeat administration at baseline, 1 and 8 weeks allowed 
assessment of the psychometric properties (reliability, validity, responsiveness 
and interpretability) of the Oxford Elbow Score (OES), quick Disabilities of the 
Arm Shoulder and Hand (QDASH), Patient-Rated Tennis Elbow Evaluation 
(PRTEE) and Patient Reported Outcome Measures Information System 
(PROMIS). The EQ-5D-5L, Numeric Pain Scale and Global Change Criteria 
were also collected.  
Results  
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Invitations to 738 yielded 81 recruits, of which 50 completed all questionnaires. 
Psychometric evaluation suggested adequate internal consistency for all 
instruments (Cronbach’s alpha >0.87), adequate reliability (Intraclass 
Correlation Coefficient >0.85), construct validity was supported by agreement 
with hypothesised correlation strengths in all cases, effect sizes were found to 
be greatest in pain sub-scales (0.56-0.63).  
Conclusions 
This study’s low recruitment and retention constrains it from making clear 
recommendations on PROMs choice for a UK population of LET patients. The 
OES, QDASH, PRTEE and PROMIS all performed adequately in the 
assessment of LET. Generic upper limb measures (QDASH and PROMIS) were 
not found to be inferior to region-specific (OES) or condition-specific (PRTEE) 
measures. Measures that allow sub-scale assessment of pain (OES, PRTEE 
and PROMIS) demonstrated superior responsiveness to change. These 
findings support the use of the candidate PROMs in future LET research.   
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5.2 Overview 
The previous chapters have highlighted the need for standardisation of outcome 
measurement in elbow pathology and looked in detail at the English language 
clinical rating systems available for use in LET. An assessment of these 
instruments in UK populations has highlighted that use of the candidate PROMs 
identified in the EMPRO evaluation cannot be fully justified without their 
psychometric properties being tested in this target population. Therefore, the 
following study aims to undertake a validation study in a UK-based population of 
LET patients.  
5.3 Background  
The extensive systematic review conducted in chapter 3 was the first to assess 
the psychometric properties and trends in utilisation of patient-centred outcome 
measures in LET. The evidence for each instrument was independently 
assessed by two reviewers using the Evaluating Measures of Patient-Reported 
Outcomes (EMPRO) method evaluating overall and attribute-specific instrument 
performance [187]. EMPRO scores >50/100 were considered indicative of high 
performance. Of 7,261 references, 105 articles reporting on 15 instruments 
developed and/or validated in the English language were identified for EMPRO 
analysis. Median performance score was 41.6 (range: 21.6-72.5), with four 
instruments meeting high-performance criteria: the quick Disabilities of the Arm 
Shoulder and Hand (QDASH) (overall score 72.5/100), Disabilities of the Arm 
Shoulder and Hand (DASH) (66.9), Oxford Elbow Score (OES) (66.6) and 
Patient-Rated Tennis Elbow Evaluation (PRTEE) (57.0).  
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A total of 179 articles reported instrument use of these scores in research 
studies, with DASH the most frequently reported (29.7% articles) followed by 
PRTEE (25.6%), Mayo Elbow Performance Score (MEPS) (15.1%) and QDASH 
(8.1%).  Of these popular scores, the MEPS has no history of validation in LET, 
the DASH is a generic arm score, though robustly designed, its condition-
specific LET based validity is limited [173], and it has never been explored in a 
UK population, the PRTEE, though condition-specific and extensively used, has 
never been fully validated in a UK population. Within specific UK populations, 
there is also the use of the Oxford Elbow Score (OES), the only elbow-specific 
PROM designed and validated in a UK population. However, all validation work 
of the OES has been conducted on a heterogeneous population of patients with 
differing elbow-related diagnoses [142].  
Internationally, the most rapid increase in utilisation over the last five years has 
been with the abbreviated DASH score (QDASH). This score was developed 
with validated item-reduction approaches [207], and since 2010 is reported in 
13% of elbow tendinopathy publications, and performed the best in the EMPRO 
evaluation. It is familiar to clinicians and has a similar number of items to the 
OES and PRTEE. However, much like the DASH score, it has not been 
validated in a UK LET population. Owing to these outlined factors, the three 
PROMs most likely to demonstrate adequate development, validation and 
appropriate burden in a UK-based population are the PRTEE, OES, and 
QDASH.   
In addition to the above review, it is also important to realise that the PROMs 
landscape is changing rapidly. Though traditional PROMs of the type stated 
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above, where a standardised and fixed set of questions are administered, 
continue to be the predominant type, the use of large question banks and 
adaptive testing techniques are emerging. There are concerns that fixed length 
scales may not be adequately assessing the individual, therefore large question 
banks that utilise adaptive testing based on Item-Response Theory (IRT) 
modelling, using probability-based computer algorithms select only the 
minimum number of informative questions, will be more valid on an individual 
level whilst also reducing respondent burden [234].   
The Patient-Reported Outcomes Measurement Information System (PROMIS) 
developed by the National Institutes of Health (USA) is attempting to address 
the deficiencies in traditional fixed-length PROMs. Evaluation of several 
PROMIS computer-based adaptive tests (CATs) in a variety of orthopaedic 
patients has revealed high correlation with traditional PROMs but with reduced 
floor and ceiling effects, increased reliability and greatly reduced test length [234, 
235]. One of the main drawbacks of CAT testing in PROMs is the requirement for 
computer-based completion. Therefore there is a significant resource cost in 
computer infrastructure. To address this issue, PROMIS has also issued fixed-
length short forms. Though they are fixed in length and can be administered on 
paper, the score metric remains fixed to the principles of IRT. This family of 
statistical models links individual questions to a presumed underlying trait or 
concept of physical function or pain, represented by all items in the item bank. 
In upper limb pathology, PROMIS recommend the use of the Upper Extremity 
Item Bank (46 Items) or short form (7 Items) and Pain Interference Item Bank 
(40 Items) or short form (6 Items).  As yet, these tools have not been assessed 
in a UK population with elbow pathology. 
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Currently, evidence on the validity of PROMs in UK populations of LET is 
lacking to the extent that it is impossible to conform to contemporary PROM 
reporting standards. The creation of a new measure is not justified in the 
presence of PROMs that have been identified as processing adequate 
psychometric properties in their country of original development. This study is 
aiming to assess the culturally-specific and pathology-specific validity of the 
best performing candidate PROMS, the QDASH, PRTEE, OES and PROMIS 
instruments, in a UK population of LET patients.  
5.4 Methods 
This study was conducted as a cross-sectional validation of elbow-specific 
Patient Reported Outcome Measures (PROMs) in UK participants with LET.  
The properties of three PROMs, selected from the EMPRO evaluation 
identifying them as the best performing candidate instruments, plus one 
selected as an emerging instrument with a strong psychometric pedigree, were 
assessed in a UK population. The PROMs were assessed on their ability to 
perform as health status instruments by being internally consistent, valid, 
reproducible and interpretable.  
Sample size and recruitment strategy 
There is no unified method power calculation for validation of PROMs, rather 
consensus methodologies.  The recommended minimum sample size for 
validation studies (based on optimal numbers for correlations) ranges from 50 to 
100 [236-238].  
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The recruitment strategy targeted participants via three sources. These sources 
were set to assess a spectrum of tennis elbow symptoms. Participants were 
sourced in primary and secondary care and through physiotherapy clinics. 
Recruitment targets for these three sources were set at primary care (n=50), 
secondary care (n=20), physiotherapy (n=30). The recruitment target split was 
chosen to be representative of UK treatment practice and give a broad 
representation of the spectrum of symptoms, however, data assessing the true 
division of treatment practice in the UK have not been published.   
Inclusion and exclusion criteria 
Participants were eligible for inclusion if they were adults (>18yrs) with active 
LET symptoms within the month before the completion of the first questionnaire. 
To enhance the diagnostic categorisation of the participants, only those with 
LET diagnosed by a consultant orthopaedic surgeon, general practitioner or 
physiotherapist were included.  No active exclusion criteria will be set owing to 
the remit of including adult patients with a full spectrum of tennis elbow 
symptoms.   
Recruitment sources 
Primary care participants were identified through Read-code analysis at GP 
practices. Recruitment of practices was facilitated through collaboration with the 
National Institute of Health Research (NIHR) Clinical Research Network South 
West Peninsula. Following pilot testing, the Read codes ‘Tennis Elbow’ 
(N213211), "Lateral epicondylitis" (N2132), ‘Lateral epicondylitis of the elbow’ 
(N213200) and "Enthesopathy of elbow" (N313) were searched. Following 
identification, postal communication was used to request participation in the 
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study. On return of a signed consent form, questionnaires were sent out, 
completion used pre-paid envelopes for return. Using the NIHR Primary Care 
Resource Requirement Template, for a sample size of 100, we were 
recommended to invite 278 patients (50% response rate, 20% screen failure, 
10% dropout rate). Estimating a 1.5% prevalence [12] a patient population of 
18,519 was estimated to be required to yield 278 invitations. UK average 
general practice list size is 7,000, therefore initially three local practices were 
asked to participate.  
Secondary care participants were identified at upper limb specialty orthopaedic 
clinics at three hospital sites (Royal Devon and Exeter NHS Foundation Trust, 
Plymouth Hospitals NHS Trust, and Torbay and South Devon NHS Foundation 
Trust). Four orthopaedic consultants (CS, WT, RR and PG) who run weekly 
upper limb clinics recruited participants and provided questionnaires for 
participants to complete onsite initially, then postal returns of the one-week and 
eight-week repeat administrations.  
Physiotherapy clinics recruited participants at multiple sites. Recruitment and 
administration was led by musculoskeletal physiotherapists at each site. Patient 
information, consent, and questionnaire packs were provided to participants 
with pre-paid postal returns of the consent form and three questionnaires.    
Following the initial return of the consent form, email reminders were sent to all 
participants who provided addresses to remind them to complete the 
questionnaires at the three time-points.  
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Recruitment centres are documented in appendix 12. During the second round 
of recruitment, a £10 shopping voucher was provided to each participant who 
completed the 8 week questionnaire process.  
Instruments  
The Oxford Elbow Score (OES) is a 12-item patient-reported questionnaire. It 
was developed for the outcome assessment of surgery on the elbow [142]. It has 
three subscales: elbow pain, elbow function and socio-psychological effects 
[142]. Each item is scored from 0 (worst) to 4 (best).  Scores for each domain are 
calculated as the sum of each individual item score within that domain. This 
gives a score range of 0–16 for each domain. Dimensionality analysis isolated 
three separate domains, with each domain being unidimensional. Therefore 
composite ‘total’ scores are not recommended by the instrument developers 
[142]. Individual domain scores are scaled by converting to a metric score of 0–
100 (lower scores representing greater severity) [239].  
The Quick Disabilities of the Arm Shoulder and Hand (QDASH) is an 11-item 
patient-reported questionnaire. It has been designed as a region-specific 
measure of disability and symptoms in people with any or multiple 
musculoskeletal disorders of the upper limb [185], and is an abbreviated version 
of the DASH score. It has three subscales: function, symptoms, and 
psychosocial impact. Each item is scored from 1 (‘no difficulty’, ‘no symptoms’, 
‘no impact’) to 5 (‘unable to do’, ‘very severe’, ‘high impact’). The composite 
score has been deemed unidimensional and therefore the items are summed to 
form a raw score and then converted to a 0 to 100 scale where a higher score 
reflects greater disability [185].  
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The Patient-Rated Tennis Elbow Evaluation (PRTEE) is a 15-item patient-
reported questionnaire used to measure perceived pain and disability in people 
with tennis elbow [206]. It has three subscales: pain, usual activities, and specific 
activities covering two dimensions, pain, and function. Each item is scored on a 
scale of 0 (‘no pain’, ‘no difficulty’) to 10 (‘worst ever’, ‘unable to do’).  To 
calculate the total score, the items of the pain score are totalled out of 50, and 
the usual activities subscale and the specific activities subscale scores are 
added [240]. The total score ranges from 0 to 100, where high scores indicate 
greater pain and disability. 
The PROMIS Upper Extremity Short Form 7a is a seven-item patient-reported 
questionnaire. It has been designed using Item Response Theory to identify an 
underlying trait represented by a larger item bank of questions. Each item is 
scored on a scale of 5 (‘without any difficulty’) to 1 (‘unable to do’). It is 
recommended to administer this alongside the Pain Interference Short Form 6a. 
This has been produced using the same methodology. The items are scored 
from 1 (‘not at all’) to 5 (‘very much’). All PROMIS short forms are scored using 
item-level calibrations. Items are scored through the PROMIS Assessment 
Centre that looks at the responses to each item for each participant. This is 
referred to as ‘response pattern scoring’. The resultant score is termed the ‘T-
score’, this is a metric on a scale of 0-100, in which 50 is the mean of a 
reference population, which in this case is a USA-based general population 
sample (the UK population norms are yet to be assessed).  
Co-administration of EQ-5D-5L, numeric pain scale (NPS), and symptom Global 
Rating of Change (GROC) was undertaken. The EQ-5D-5L is a standardised 
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patient-reported questionnaire for the measurement of generic health status. It 
is one of the most commonly used generic health measures and can be 
converted to UK-specific value index scores using the EUROQOL Index value 
Calculator [241].  The numeric pain scale is commonly employed in the 
assessment of pain and measures the participant's attitude to pain 
characteristics across a continuum of values, a scale from 0 to 10 was utilised 
[242]. Symptom Global Rating of Change (GROC), also known as transition 
questions, assess perceived alterations in a condition from baseline and have a 
history of use in musculoskeletal validation studies [236]. Eleven response 
options were utilised on a scale from minus five (very much worse) through zero 
(unchanged) to plus five (completely recovered).  Key demographic information 
was also recorded, including age, weight, side of the affected arm, dominant 
hand, and profession. To facilitate thorough psychometric assessment, 
questionnaire responses were collected three times: day one, one week and 
eight weeks. Repeat administration allowed assessment of validity (baseline 
and 8 week administration), reliability (one week), responsiveness and 
interpretability (8 weeks). Present infrastructure does not allow widespread use 
of electronic PROM collection within NHS hospitals. The validity of the QDASH, 
OES and PRTEE have, thus far, only been confirmed using paper format [142, 175, 
243]. Therefore paper versions of these three PROMs and the short-form 
versions of the PROMIS PROMs were utilised for the formal analysis and a 
voluntary parallel electronic administration was offered to the participants.  
Examples of the PROMs and patient information pack can be found in 
appendices 10 and 11.  
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Funding, ethical approval and portfolio adoption 
This study attained a favourable ethical opinion from the East of Scotland 
Research Ethics Service (REC reference 17/ES/0017) and Health Research 
Authority (HRA) approval (appendix 13). As this study was conducted at 
multiple sites, individual site-specific approval was gained from the local NHS 
trust research and development teams. The study was adopted as part of the 
NIHR Clinical Research Network portfolio (CPMS ID 33853). The study was 
funded by grants from the British Elbow and Shoulder Society and Royal Devon 
and Exeter Hospital Foundation Trust following external scientific review.     
Statistical Methods  
Data were analysed in STATA (STATACorp, Texas, USA). Statistical 
significance was set at p<0.05. The following measurement properties of the 
PROMS were examined: 
 Reliability 
Reliability assesses the extent to which scores for objects of measurement that 
have not changed are the same for repeated measurement under several 
conditions: for example, using different sets of items from the same PROM 
(internal consistency) and over time (test-retest) [244]. The essence is the 
stability and consistency of the measure.  
Internal consistency was assessed using Cronbach’s Alpha. This measure can 
be defined as an estimate of the ratio of true variance (variance due to the 
underlying construct), to total variance (true variance plus error) for a measure 
[244]. When items are inter-correlated, the collection of items is assumed to 
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reflect the intended latent construct [244]. An alpha value of between 0.7 and 0.9 
is recommended [245]. Values above 0.95 can represent redundancy of items. 
Importantly, the Cronbach’s Alpha should be assessed only within the 
dimension of interest. For example, when assessing internal consistency of the 
OES, Cronbach’s Alpha should be calculated for each subscale of pain, function 
and psychosocial [149].      
Intraclass correlation coefficient (ICC) was used to assess the test-retest 
stability of PROMs scores over one-week repeat administrations where 
symptom scores were felt unlikely to have changed. It can be conceptualised as 
the ratio of between-group (i.e. repeated administration) variance to total 
variance [244]. Minimum ICC values of 0.7 are considered acceptable [245] 
however higher values are required if a score is being used on an individual 
level [236]. Scores from the baseline and one-week questionnaires, where the 
participant has graded their GROC as minus one , zero or plus one were 
utilised to calculate the ICC. Participants who demonstrated change greater 
than this were excluded from the reliability analysis as this was felt to represent 
real change beyond error and therefore not true stability of the PROM.     
 Validity  
Validity assesses the relative lack of systematic error, or rather, whether a 
measure actually measures what it is supposed to [244]. Where no gold-standard 
or ‘criterion’ exists, as is the case with LET measurement, quantification of 
construct validity can be employed. This assesses whether the scores of a 
measure are consistent with a hypothesis, based on the assumption that the 
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measure validly quantifies the construct of interest. The a priori hypotheses for 
the above measures were: 
 At least moderate correlations (Spearman’s rho in all cases) should exist 
between the PROMs and the generic health measure EQ-5D-5L index 
score (negative correlations for PRTEE, QDASH and PROMIS pain 
interference and positive correlations for OES and PROMIS upper 
extremity). 
 At least moderate correlations should exist between Numeric Pain Scale 
(NPS) and the PROMs pain subscales (positive correlations for PRTEE 
pain subscale and QDASH, PROMIS pain interference and negative 
correlations for OES pain subscale), and between the pain subscales 
themselves. At least moderate correlations should also exist between the 
functional subscales of the PROMs.  
 At least moderate correlations should exist between the PROMs used, as 
they purport to measure the similar constructs.  
Correlation (r) strength was classified as r=0.0-0.29 (none/weak), r=0.3-0.69 
(moderate) and r=>0.7 (strong).  
Floor and ceiling effects, where the score is the absolute maximum or minimum 
were evaluated. Assessment of floor effect (worst possible symptoms) was 
assessed at baseline. Assessment of ceiling effect (complete resolution of 
symptoms/no pain/normal function) was assessed at eight-week completion. 
Floor and ceiling effects are felt to be present for a health measure if more than 
15% of the study population score the minimum or maximum on any 
questionnaire (sub)scale [246]. 
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 Responsiveness 
The ability of the PROMs to detect symptomatic change was assessed using 
two methods: assessment of correlation between PROM change scores 
(baseline measurement minus eight week measurement) and Global Rating of 
Change/generic health measure, and quantification of effect size (mean change 
score / standard deviation of baseline score) as a method of calculating the 
extent of change measured by the instrument in a standardised way [247]. 
Clinical change in LET is known to occur over time as this is often a self-limiting 
condition. However, change can also occur following an intervention, be it 
conservative or surgical in nature. The eight-week interval in measurement was 
implemented to assess conservative change and, where interventions were 
utilised, improvement post-intervention.  
Responsiveness of the PROMs to change will be assessed using a priori 
hypotheses regarding correlation strength: 
 The change in PROM score should at least moderately correlate with 
EQ-5D change scores. 
 The change in PROM should at least moderately correlate with the 
relevant pain or function GROC score change or NPS scores. 
 Change scores should at least moderately correlate between PROMs. 
Again these should be stronger between the PRTEE and OES than 
between these PROMs and the QDASH and PROMIS scores. 
 
A paired t-test was performed between baseline and 8-week scores with 
significance set at p<0.05. Strength of effect size, in reference to Cohens 
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criteria [248] (0.2 = small, 0.5 = moderate, 0.8 = large) was compared between 
PROMs with the a priori hypothesis of greater effect size in the PRTEE and 
OES as elbow specific scores.    
 Interpretability  
This can be defined as the degree to which one can assign quantitative 
meaning to a quantitative score [144]. The assessment of interpretability was 
undertaken using both a distribution-based method and anchor-based method.   
The distribution-based method was used to define the Smallest Detectable 
Change (SDC). This represents the smallest intra-personal change score that 
denotes a difference above measurement error [249]. Initially, the standard error 
of the measurement (SEM) was calculated using the equation: 
 𝑆𝐷(𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒)√(1 × (𝑡𝑒𝑠𝑡 − 𝑟𝑒𝑡𝑒𝑠𝑡 𝑟𝑒𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑦)). The test-retest score utilised 
was already quantified as the Intraclass Correlation Coefficient (ICC). As we 
were taking multiple measures, this was then multiplied by the √2 and then 
confidence intervals (CI) applied using a chosen Z value, for rigour the 95% CI 
using the Z value 1.96 was applied using the method proposed by Terwee et al 
[236, 250]. 
Interpretability was also considered using the anchor-based approach, whereby 
the relationship between the PROM and the patient-reported Global Rating of 
Change (GROC) was assessed to achieve a Minimal Clinically Important 
Difference (MCID) score. This score is defined as the smallest measurable 
change that is perceived as significant by patients [251] which differentiates it 
from the statistical approach of the distribution-based method.  This process 
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assesses the change scores in the group of patients deemed to have 
experienced ‘minimal change’. For this cohort, we selected the patients who 
scored plus two (+2) to plus three (+3) on the GROC for pain or function. 
Thereby selecting patients likely to have changed beyond error (+1) but less 
that those experience a more than minimal difference (>+3). The MCID is 
defined as the mean change score of the PROM for this subgroup of 
participants. This MCID was related to the specific pain or function domain, 
dependent upon whether it was derived from the pain or function GROC. In 
composite scores (qDASH and PRTEE total) an average of the GROC for pain 
and function was taken.  
5.5 Results 
Between 12/4/2017 and 1/12/2017 invitations to participate were sent to 738 
primary care and physiotherapy patients. In secondary care, 30 potential 
participants were identified and invited to participate in the outpatient clinic. Of 
the 738 invitations, 81 individuals agreed to participate (10%) (n=23 primary 
care, n=34 physiotherapy care, and n=24 secondary care).  Of the 81 recruited 
participants, 50 (62% of recruited, 7% of invited) completed the eight-week 
questionnaire process (n=13 primary care (26% target), n=19 physiotherapy 
care (63% target), and n=18 secondary care (90% target). The average age of 
the participant was 54 yrs (range 31-78yrs), 34 were female and 16 male. The 
LET affected the dominant hand in 37 (74%). The average duration of 
symptoms was 2.43 years (mean), 1.5 years (median) (Range 1 month – 14 
years). Seven (14%) of participants were manual workers. Mean baseline 
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scores subcategorised by sex, recruitment source and symptom duration is 
seen in Table 5-1.   
 
No. OES 
pain 
OES 
function 
OES ΨS QDASH PRTEE 
total 
PROMIS 
UE 
PROMIS 
Pain 
Male 16 50.55 63.60 50.74 43.34 56.34 34.17 59.90 
Female 34 53.52 68.75 56.64 37.94 43.38 35.69 59.23 
Primary care 13 49.04 57.21 46.63 48.04 62.77 31.78 63.03 
Physiotherapy 19 56.91 74.67 64.14 31.76 47.19 36.85 57.74 
Secondary care 18 47.57 61.11 44.79 47.36 49.44 34.42 59.33 
Duration <6 months 11 52.27 69.89 55.68 37.27 39.55 35.33 58.95 
Duration >6months 39 51.28 63.94 51.76 42.83 55.74 34.47 59.89 
Table 5-1: Subcategories of mean baseline PROMS scores.  
N.B., OES ΨS denotes OES psychosocial subscale score.  
Results are presented for paper completion only as voluntary electronic data 
collection was not completed by any study participant.   
Reliability  
Cronbach’s alpha was assessed for the three subscales of the OES, the 
QDASH, PRTEE, PROMIS Upper extremity and PROMIS pain, with all 
exceeding the threshold value of 0.9 with the exception of OES pain (Table 
5-2).   
 OES pain OES function  OES ΨS QDASH PRTEE PROMIS UE PROMIS Pain 
Cronbach’s alpha  0.87 0.91 0.93 0.93 0.97 0.94 0.94 
Table 5-2: Cronbach's alpha values for all scales. 
 
There were 27 participants whose symptoms did not change between repeat 
administrations (GROC = -1 to +1). The results from these participants were 
used for test-retest reliability (ICC) (Table 5-3).  
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 OES pain OES function  OES ΨS QDASH PRTEE PROMIS UE PROMIS Pain 
ICC 
(95%CI) 
0.93 
(0.83 to 0.97) 
0.97 
(0.93 to 0.98) 
0.97 
(0.92 to 0.99) 
0.96 
(0.90 to 0.98) 
0.93 
(0.85 to 0.97) 
0.96 
(0.92 to 0..98) 
0.85 
(0.70 to 0.93) 
Table 5-3: Intraclass Correlation Coefficient (ICC) (95%CI) in participants with stable scores between 
collection points 1 and 2. 
 
Ceiling and floor effects, whereby absolute maximal (i.e. no pain or functional 
limitation) or minimal (worst possible pain or function) values as demonstrated 
by the PROMs was assessed. Floor effects were assessed at baseline, 
percentage of respondents demonstrating lowest possible scores; OES pain 
0%, OES function 0%, OES psychosocial 7.1%, QDASH 0%, PRTEE pain 0%, 
PRTEE function 0%, PRTEE total 0%, PROMIS UE 0%, PROMIS pain 0%. 
Ceiling effects were assessed at eight-week completion; OES pain 14.8%, OES 
function 18.5%, OES psychosocial 7.4%, QDASH 3.8%, PRTEE pain 3.7%, 
PRTEE function 7.4%, PRTEE total 3.7%, PROMIS UE 3.7%, PROMIS pain 
18.5%. 
Validity  
Correlation between instruments was found to be broadly consistent with a 
priori hypotheses of direction and strength. Spearman’s rho between baseline 
PROMs scores and generic health PROM EQ-5D-5L index scores are seen in 
Table 5-4 and are classified as strong correlations in all cases.  
 
OES pain OES function  OES ΨS QDASH PRTEE PROMIS UE PROMIS Pain 
EQ5D-5L 0.78 0.76 0.83 -0.79 -0.74 0.75 -0.80 
Table 5-4: Correlation between PROMs baseline scores and the EQ-5D-5L as a generic health measure 
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Correlations for the pain dimension were assessed between the relevant PROM 
or subscale and the Numeric Pain Scale (NPS). All correlations were graded as 
moderate both between the PROM and NPS and strong between the PROMs 
themselves (Table 5-5). 
 
 
OES pain QDASH PRTEE pain PROMIS pain NPS 
OES pain 1.00     
QDASH -0.84 1.00    
PRTEE pain -0.80 0.92 1.00   
PROMIS pain -0.79 0.86 0.80 1.00  
NPS 0.43 -0.45 -0.43 -0.45 1.00 
 
Table 5-5: Correlation matrix between PROMs baseline pain scores 
 
Functional correlations were assessed between PROMs subscales and again, 
were uniformly strong (Table 5-6). 
 
OES function  QDASH PRTEE function PROMIS UE 
OES function 1.00    
QDASH -0.92 1.00   
PRTEE function  -0.82 0.79 1.00  
PROMIS UE 0.92 -0.90 -0.86 1.00 
 
Table 5-6: Correlation matrix between PROMs baseline function scores 
 
Responsiveness 
Change score correlations were assessed initially between the PROMs and the 
EQ-5D-5L index score (Table 5-7). These were found to be directionally as 
expected from the a priori hypothesis but moderate rather than strong.  
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OES pain 
Change 
OES 
function 
Change 
OES  
ΨS 
Change 
QDASH 
Change 
PRTEE 
total 
Change 
PROMIS UE 
Change 
PROMIS 
Pain 
Change 
EQ5D-5L 
Change 
0.69 0.63 0.66 -0.75 -0.72 0.64 -0.81 
 
Table 5-7: Correlation between PROMs change score and EQ-5D-5L change 
This pattern was reflected in the correlations between the subscale responses 
and corresponding pain or functional Global Rating of Change (GROC) score or 
Numeric Pain Scale change score (Table 5-8). Of note is the only just moderate 
correlation between the change scores for OES function and Global Change 
Score (GCS) for function.   
 
OES pain 
Change 
QDASH 
Change 
PRTEE pain 
Change 
PROMIS Pain 
Change 
NPS Change -0.64 0.51 0.62 0.61 
GROC Pain  0.51 -0.55 -0.54 -0.69 
 
 
Table 5-8: Subscale correlations of PROMs change scores and NPS change or GROC score anchors 
The correlations between the PROMs change scores themselves were stronger 
than against the GCS anchor, with all at least moderate. Of note is no 
discernable pattern of the superiority of the elbow specific outcomes (OES and 
PRTEE) and the generic upper arm scores (QDASH and PROMIS) (Table 5-9). 
 
 
 
 
 
OES function 
Change 
QDASH 
Change 
PRTEE function 
Change 
PROMIS UE 
Change 
GROC Function 0.44 -0.62 -0.60 0.56 
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OES 
pain 
OES 
function 
OES  
ΨS 
QDASH PRTEE 
total 
PROMIS 
UE 
PROMIS 
Pain 
OES pain 1.00 
      
OES function 0.78 1.00 
     
OES Psychosocial 0.75 0.69 1.00 
    
QDASH -0.83 -0.85 -0.71 1.00 
   
PRTEE total -0.71 -0.65 -0.72 0.79 1.00 
  
PROMIS UE 0.62 0.53 0.65 -0.67 -0.65 1.00  
PROMIS Pain -0.70 -0.59 -0.60 0.75 0.76 -0.57 1.00 
 
Table 5-9: Correlations between PROMs change scores 
The effect size of the change calculated by the individual instruments was 
quantified between baseline and 8 week scores. The majority of instruments 
changed significantly (p<0.05) between baseline and eight-week measurements 
with the exceptions being the OES function and psychosocial, the PROMIS UE 
and the EQ5D-VAS. The effect size as a comparator between instruments 
reaches a moderate level (≥0.5) for the pain scores (OES pain, PRTEE pain, 
and PROMIS pain) and the QDASH (Table 5-10). 
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Baseline SD 8 Weeks SD Change SD p-value Effect size 
OES pain 52.92 21.96 66.81 25.52 13.89 17.97 0.00 0.63 
OES function 66.53 22.42 74.58 24.87 8.06 20.32 0.01 0.36 
OES ΨS 54.03 24.86 63.12 28.89 9.09 23.67 0.01 0.37 
QDASH 40.20 21.73 29.80 25.88 -11.06 18.56 0.00 -0.51 
PRTEE pain 23.96 12.08 17.24 12.94 -6.72 10.25 0.00 -0.56 
PRTEE function 27.53 19.62 19.17 19.42 -7.76 17.40 0.00 -0.40 
PRTEE total 51.22 29.91 36.41 30.97 -13.67 27.68 0.00 -0.46 
PROMIS UE 35.09 7.18 37.98 8.60 2.89 6.20 0.00 0.40 
PROMIS Pain 59.39 7.45 54.89 9.51 -4.50 8.12 0.00 -0.60 
EQ5D-5L Index 0.65 0.19 0.70 0.22 0.05 0.16 0.02 0.28 
EQ5D-VAS 75.67 14.32 75.43 20.81 -1.91 21.56 0.90 -0.13 
NPS 4.14 2.91 3.12 2.79 -1.02 2.62 0.03 -0.35 
Table 5-10: Mean and standard deviation PROM baseline, 8 week and change score. Paired t-test 
significance value (p-value) and effect size 
 
Interpretability  
The Smallest Detectable Change with 95% confidence intervals (SDC 95) was 
calculated for the PROMs using the baseline standard deviation and previously 
described ICC values (Table 5-11). 
 
OES 
pain 
OES 
function 
OES ΨS QDASH PRTEE 
pain 
PRTEE 
function 
PRTEE 
total 
PROMIS 
UE 
PROMIS 
Pain 
 SEM 5.90 3.89 4.38 4.41 2.42 6.63 7.97 1.48 3.25 
 SDC 95 16.35 10.80 12.14 12.23 6.71 18.36 22.09 4.11 9.00 
MCID 
 Pain 
12.83 
 
  8.85 
 
 
 
4.25 
MCID 
Function 
 
10.71   
 
8.14  3.91 
 
MCID 
Composite 
   8.85   17.82   
 
Table 5-11: PROMs standard error of measurement (SEM), smallest detectable change (SDC) and 
subscale minimal clinically important change (MCID) 
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The Minimally Clinically Important Change (MCID) was derived from 
participants reporting a Global Rating of Change (GROC) between the baseline 
and eight-week outcome measurements of +2 to +3 on the 11 point scale. This 
was separately assessed for the pain GROC (n= 19/50) and the function GROC 
(n= 14/50). The mean change scores for the individual PROMs for these groups 
are reported as the MCID for the relevant pain or functional subscale, or 
composite total score (Table 5-11). The MCID for the OES psychosocial (OES 
ΨS) could not be calculated owing to the GROC not being anchored to this 
domain. Of note is the SDC being higher than the MCID for all scores except 
PRTEE pain, against the a priori hypothesis.  
5.6 Discussion 
This study has aimed to address the gap in the assessment of psychometric 
properties in a UK population of Lateral Elbow Tendinopathy (LET) patients. 
Though this remains the largest study to date for the target population, more 
than doubling the currently available evidence base, it is unfortunate that due to 
very poor recruitment and retention of participants, we are only able to report 
preliminary results confirming the validity of the OES, PRTEE, QDASH and 
PROMIS instruments. 
The overall participant retention rate for this study was 7%. Throughout the 
course of the study, efforts were made to optimise the recruitment and 
retention, this included substantial ethical and protocol amendments to make 
the patient information documents as concise and clear as possible, instituting 
financial incentives (£10 shopping voucher) and telephone follow-up to discuss 
and encourage participation. Despite these measures, the recruitment rate 
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remained low. There may be multiple reasons behind this but they are likely to 
be broadly associated with two key factors, participant burden and the natural 
history of the LET. It is appreciated that the burden of completing multiple 
questionnaires, over an eight-week period, in a group where patients are not all 
being actively managed in a healthcare setting, is very challenging. The 
individual questionnaires used were intentionally short, but the total number still 
amounted to a seven-page booklet. Importantly, the questionnaires were not 
piloted in a patient or lay group prior to the study commencing which may have 
influenced an amendment in the structure of the data collection. The 
participants did not see the questionnaires until they were recruited and 
although 62% of those recruited did complete the questionnaires, this could 
have been imporved it the questionnaires were reduced. Though email 
reminders were sent, remembering to complete the questionnaires in a timely 
manner and then post the prepaid envelopes back to the research team may 
not be appropriate or feasible for the majority of people. Though the quantity of 
data required was significant, it is worth noting that it was the minimal amount 
required to attain the level of detail needed to meet the requirements of the 
psychometric calculations. A potential route to improving this situation, 
particularly in this study’s working age demographic, is the utilisation of remote 
electronic data collection via a web interface or mobile application. There are 
distinct challenges for this to be achieved, firstly a cross-validation of 
equivalence of the questionnaires in electronic format would be required. 
Following this, it is still the case that the creation of such an interface can be 
very costly, greatly exceeding that of paper communication. An electronic 
system for completion of a Computer Adaptive Test (PROMIS) was offered in 
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this study, though additional to the paper questionnaires and optional, it is 
relevant to note that no participants completed it. Though electronic data 
capture in the UK has been very successful in some instances [252, 253], it is 
interesting that within the UK the national PROMs programme continue to only 
offer paper-based completion of PROMs after hip and knee arthroplasty 
procedures [233], and that paper collection of PROMs in clinical scenarios 
remains the status quo.  
The natural history of this condition may have inhibited the ability to collect 
substantial data. As a largely self-limiting condition, many of the invited 
participants’ symptoms may have resolved. It is, therefore, noteworthy that the 
recruitment for primary care, who were sourced through recent Read code 
categorisation in GP records, was particularly poor, and that previous attempts 
at validating PROMs in LET have focused exclusively on surgical or secondary 
care participants who complete their questionnaires in a clinical setting [142, 206, 
217, 228]. This recruitment bias alters the generalisability of the results owing to 
the fact that the large majority of LET sufferers are treated with simple 
community care. It is also interesting that this is likely to be a difficulty that is 
common to the validation of PROMs in a variety of self-limiting musculoskeletal 
conditions. Finally, it is vital to note that the acquired population within this study 
may not be representative of a “normal” LET population. The average age of the 
participants (54yrs) is relatively high when compared to epidemiological studies 
of LET in populations which point to the greatest prevalence between 40 - 55 
yrs (sanders}. Furthermore, 68% of the study population were female, and only 
14% were manual workers which is in contrast to the large epidemiological 
studies that report broadly equal variance between sexes [12, 17, 18] and 
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occupational exposure [19]. This limitation in the data may relate to a sampling 
bias, whereby younger manual workers have been less likely to participate 
which may relate to the significant burden of questionnaire completion.   
The psychometric evaluation of the study should be interpreted in view of the 
low numbers. Though the recommended number of participants (50) for 
assessment of associations (correlations) [250] was reached, estimates of 
reliability and interpretability cannot be confirmed with the numbers presented, 
although true sample requirements for psychometric assessments of these 
aspects has not been defined. Though the presented figures should be viewed 
with caution, as a marker of potential accuracy the psychometric findings can 
also be compared against the best available standards of comparable patient 
groups.  
Initially, the reliability of the instruments was assessed, starting with their 
internal consistency. This measurement quantifies the interrelatedness of the 
items of a single domain [236]. The findings from this study are comparable to 
non-pathology specific studies for the OES [142, 193, 254] and the QDASH [255] with 
alpha values over 0.9. The pathology-specific PRTEE results were comparable 
to the non-UK population [175, 180]. The PROMIS scores have not been assessed 
specifically in elbow disorders, but this study would suggest that they are 
internally consistent. 
Test-retest reliability results were also strikingly similar between this study and 
previous non-UK studies of the PRTEE [175, 176, 206, 256] and a UK-based OES 
assessment of elbow surgery patients [142]. Test-retest for the QDASH has only 
been reported once in LET patients in a USA-based population [217]. In this 
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retrospective review of QDASH scores taken over an entire treatment period 
(Mean 39 days), using GROC of -2 to +2 (15 point scale) to denote stability 
between start and end visit, the authors report an ICC of 0.69, worse than that 
found in this study with GROC scores of -1 to +1 (11 point scale). The 
retrospective nature of this study, extended time between test-retest, and the 
addition of treatment during this period, is likely to have had an effect on the 
robustness of their findings and comparability to the findings presented in this 
study. The PROMIS scores have not been assessed in isolated elbow 
pathologies. Results from this study suggest that the OES, QDASH, PRTEE, 
and PROMIS scores are internally consistent at an item domain level, and 
reliable on repeat administration, however assessment in a larger sample would 
be recommended.  
There is no literature on the LET specific construct validity of OES or PROMIS 
scores, a single study has assessed the validity of an English language QDASH 
score, in an American LET population, against a GROC score and using a 
Pearson’s correlation (r=0.39)[217]. The Turkish version of the QDASH has been 
assessed against the Turkish PRTEE, where r=0.59 [174]. The construct validity 
of the PRTEE has been assessed against the non-abbreviated DASH score on 
numerous occasions, and in multiple languages (results ranging from r=0.67 [174] 
to r=0.88 [180]), but not in UK populations. None of the PROMs have been 
assessed against the standardised EQ-5D-5L in LET. Results from this study 
support convergent construct validity between the EQ-5D-5L UK index and all of 
the included PROMs (r>0.71 in all cases) and between the PROMs themselves 
both for total scores and subscales. The concordance in the validity of the 
PROMs in a homogeneous population of LET, when measuring similar 
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constructs, would be expected to be strong, however, the hypothesis that the 
region-specific OES and PRTEE would demonstrate superior concordant 
validity was not met, demonstrating that the QDASH and PROMIS instruments 
may possess similar levels of construct validity.        
The responsiveness of the PROMs was initially explored through assessment of 
the correlation of change scores with the EQ-5D-5L change score. Moderate to 
strong change scores correlations were seen for all PROMs implying LET has a 
significant impact on general health and quality of life. This was further explored 
through correlations between subscale correlations and NPS or GROC pain or 
function change scores, moderate correlations were found for all PROMs. In the 
only assessment of PROMs change scores in LET, Smith-Forbes et al [217] 
report a comparable correlation strength between the QDASH and GROC 
scores of r=0.39.  
Responsiveness was also judged through an assessment of statistical change 
between the baseline and eight-week completion, all PROMs were found to 
have changed (p<0.05). Effect size was calculated to allow comparison 
between scores. According to Cohen’s criteria [248], all of the effect strengths 
can be categorised in the mild to moderate range. Higher effect sizes have 
been calculated for the OES [227] and PRTEE [176] but these stand as reflections 
of the patients within the study, that were part of interventional trials or 
undergoing surgical treatment. As a group of LET sufferers primarily undergoing 
conservative therapy, the effect size in this study is likely to be muted and stand 
better as a comparison between the PROMs themselves. Of note, are the 
stronger effect sizes seen in the pain subscales (OES pain 0.63, PRTEE pain 
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0.56 and PROMIS pain 0.60), in comparison with the functional scores (OES 
function 0.36, PRTEE function 0.40 and PROMIS UE 0.40), highlighting that for 
the patient, LET is a pain predominant condition, and both treatments and 
outcome assessments should be directed at this. This may suggest that the 
isolated use of composite scoring of the QDASH (Effect size 0.51) and PRTEE 
total (0.46), where pain and functional domains are combined, in interventional 
trials may risk the underestimation of treatment effect.  
Finally, the interpretability of the scores should be discussed. Minimally 
important change scores are increasingly applied in the analysis of outcome 
measure results, under the knowledge that simple statistical differences mask 
difference that may be due to measurement error, or not clinically discernible at 
a patient level. Numerous methods have been ascribed to undertake this 
assessment, in this study two methods were employed, the assessment of 
Smallest Detectable Change (SDC) and application of the anchor-based 
methods to derive a Minimally Important Clinical Difference (MCID) using the 
mean change method. There are particular nuances to the use of these scores 
that need to be regarded. These values (SDC and MCID) are population and 
condition specific, and should not be applied to studies outside of this context 
[250, 257], and comparison of an MCID can only be justified if similar GROC and 
decision limits are applied [258]. Furthermore, the results should only be applied 
on an individual level, where the MCID can be used to dichotomise a group into 
those responding or not responding to an intervention [257] (as long as the 
individuals score is above the SDC that assesses measurement error). 
However, some ascribe to the raw SDC score being scaled to the particular 
study by being multiplied by the square root of the sample size being used [250]. 
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The scores derived in this sample remain broadly equivalent to those published 
for the OES [227] (pain SDC90 8.25, MCID 12.5, function SDC90 18.73, MCID 5.0, 
psychosocial SDC90 9.3) in elbow surgery patients, but are lower than those 
published for LET patients with the QDASH in American populations [217] SDC90 
22.49, MCID 15.3. In an Italian population of mixed upper limb patients 
(including LET) the findings of QDASH SDC90 12.85 are more in line with this 
study’s SDC findings, though we have reported the narrower confidence 
intervals of SDC95. The MCID of the PRTEE was assessed in a UK population, 
but using a modified questionnaire without confirmation of validation, limited 
GROC, and no subscale analysis, the MCID was 7 for the PTREE total [228], 
these findings are substantially lower than the MCID calculated in the current 
study. Values for PROMIS have not been published, and it is relevant that as 
their norm values are based on an American population, they would be difficult 
to interpret. Overall, it must be stated that the MCID values reported should not 
be applied without further assessment owing to the small number of participants 
used in this analysis.  
This study held the a priori hypothesis that the SDC (measurement error) 
should be lower than the MCID (patient relevant change). This hypothesis was 
violated for all instruments. Though this is a finding in PROMS interpretation 
that is not particularly uncommon [64] and has previously been demonstrated for 
the OES function [227], it can limit the PROMs utility as you cannot distinguish 
relevant change from measurement error. As with the other psychometric 
calculations, the inadequate sample size is of major relevance, however, the 
broad equivalence of the combined interpretability data with other populations, 
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namely the only other UK population with the OES [227], suggest that the 
instruments do have utility and justifies their continued exploration. 
Limitations  
This study’s assessment of the psychometric properties of the included PROMs 
is overwhelmingly limited by its small sample size. The reasons behind the low 
recruitment and retention numbers have been discussed. Working with the 
current recruitment rate, to reach a sample size of 100, one would have to invite 
2,635 individuals with a recent diagnosis of LET. This would require 
considerable resources and may not be feasible. However, the author would 
like to point out that the assessment of PROMs psychometrics in community 
populations of self-limiting conditions is very rarely undertaken, this study 
highlights the challenges in undertaking such research and therein such work 
may require different, or at least more flexible, methodologies. A discussion on 
such aspects is vital as these conditions are commonly researched and there is 
a rapidly increasing utilisation of PROMs as a study outcome, of which many 
may not be appropriately validated.   
Unfortunately, the routine collection of PROMs in primary or secondary care 
does not occur within the NHS for musculoskeletal conditions, therefore 
secondary data analysis is unlikely to be feasible. The analysis of psychometric 
properties of outcomes within clinical trials is also challenging as the data 
collection schedule does not often correspond to the optimal schedule for 
psychometrics and the use of GROC anchors is not often employed. The 
authors were unable to identify data from UK-based studies that could have 
supplemented this study.  
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Though preliminary results from this study suggest potentially adequate 
psychometric properties, there are two notable aspects that would need to be 
addressed even in the context of an adequate sample size. Though the 
convergent construct validity may be confirmed, as the OES, QDASH and 
PROMIS scores were not originally designed for use in LET, it would be 
necessary to assess the content validity in this context with supplemental 
qualitative interview data from patient groups [135, 259]. The minimal change data 
(SDC and MCID) should also be carefully regarded. Firstly, the MCID scores, 
though derived in this cohort require assessment in larger cohorts prior to any 
application in clinical study. Furthermore, owing to limited numbers, overall SDC 
and MCID scores were derived; however, the value of these scores is 
dependent upon the patient’s baseline status and their demographic details. 
Therefore secondary care patients, physiotherapy patients, and primary care 
patients may all derive different scores and sex, age, occupational status etc 
may also have a bearing that should be assessed. The methodological caveat 
to this being that even greater cohorts of patients are required.  
5.7 Conclusion  
This study aimed to evaluate the psychometric properties of four candidate 
PROMs, the OES, QDASH, PTREE, and PROMIS in the assessment of Lateral 
Elbow Tendinopathy. Poor recruitment and retention inhibit the recommendation 
of any particular PROM, or position on the superiority of particular instruments, 
but the results of this study suggest that all four instruments may possess 
adequate reliability, validity, responsiveness and interpretability for use in UK-
based LET patients. This study highlights the difficulty in collection of data in 
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musculoskeletal conditions of a self-limiting nature. Future studies may optimise 
data collection through the use of electronic PROMs or analysis of routinely 
collected data, if available within their healthcare system.  
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6 Chapter 6 - The Spread of Injectate after Ultrasound-
Guided Lateral Elbow Injection – A Cadaveric Study 
6.1 Abstract 
Background  
Injections into the tendinous portion of the common extensor origin are a 
common intervention in the treatment of Lateral Elbow Tendinopathy (LET). 
Clinical trials report a heterogeneous selection of injectate volumes and delivery 
techniques, with systematic reviews finding no clear consensus. The aim of this 
study is to assess the intratendinous distribution and surrounding tissue 
contamination of ultrasound-guided injections into the Common Extensor 
Tendon (CET) of the elbow. 
Methods 
20 cadaveric elbows were injected by a Consultant Radiologist under 
Ultrasound guidance. Elbows were randomised to equal groups of 1 or 3mls of 
methylene blue injection, delivered using single shot or fenestrated techniques. 
Following injection, each cadaver underwent a dry arthroscopy and dissection 
of superficial tissues. The CET was excised, set and divided into 1mm sections 
using microtome. Each slice was photographed and analysed to assess spread 
and pixel density of injectate in four colour graduations. The cross-sectional 
area of distribution was calculated and compared between groups.  
Results  
In all 20 cadaveric samples, contamination of the joint was noted on 
arthroscopy and dissection. Injectate spread through over 97% of the cross-
163 
 
 
sectional area. No differences were found in intratendinous spread of injectate 
between differing volumes or techniques.  
Conclusion 
This study found that commonly used injection volumes and techniques 
distribute widely throughout cadaveric CETs. There was no improvement when 
the volume was increased from 1 to 3mls or between single shot of fenestrated 
injection techniques. It should be noted that joint contamination using these 
techniques and volumes may be inevitable.   
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6.2 Overview 
The background literature review presented in chapter 1 reveals that though 
injection therapy remains a popular and heavily researched intervention in LET, 
the evaluation of the fundamental aspect of injection distribution has not been 
adequately addressed. This cadaveric study attempts to further our 
understanding of injection delivery mechanics and aims to assist in the future 
rationalisation of injection technique.  
6.3 Background 
Injection therapy for chronic lateral elbow tendinopathy (LET) remains a popular 
treatment choice [260]. Though corticosteroids were historically the most 
common preparation, recent evidence of its negative long-term sequelae [45] 
may see its usage decline. However, the emergence of novel therapies such as 
platelet-rich plasma (PRP), autologous blood (AB), botulinum toxin, 
glycosaminoglycan polysulphate, sodium hyaluronic or prolotherapy continue to 
promote interest in injection treatment. Systematic reviews of these therapeutic 
options remain inconclusive, with a recurring criticism of the heterogeneity of 
injection dosing and technique between studies [101, 106, 117-119].   
Pathological change in LET occurs within the proximal tendons of the common 
wrist extensor muscles, with particular reference to the extensor carpi radialis 
brevis (ECRB). Hence this is the intended site of injection therapy in LET. The 
ECRB tendon originates from the lateral epicondyle, lying deep to the remaining 
common extensor tendons and superficial to the thin articular capsule of the 
elbow [35]. Injection volumes delivered to this area commonly range from 0.5 – 
3.5mls [106] and employ either a single shot or fenestrated (pepper pot) 
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administration techniques [106, 117]. Cadaveric assessment has only been 
undertaken for anatomically guided injections [261]. The injections were delivered 
by experienced clinicians using their standard techniques, the study reported 
poor localisation of injectate, within only 33% (partially) localised to the ECRB 
tendon and 60% localised intra-articular.  
The location of the injectate in lateral elbow injections is of clear importance. 
Under the premise that many of these substances confer benefit due to their 
active constituents, it is of vital importance that the retention and distribution of 
injectate within the tendon is quantified, and furthermore that the commonly 
employed volumes and techniques are compared. Assessment of the 
contamination of joint space and surrounding tissues is also warranted owing to 
the potentially noxious or unwanted effects of botulinum toxin, or the potential 
chondrolytic effects of corticosteroid [262] and local anaesthetics [263]. This study 
aims to determine the intratendinous distribution and surrounding contamination 
of commonly utilised injection volumes and techniques, delivered under 
ultrasound guidance, in cadaveric specimens. It was hypothesised that 
ultrasound guidance would ensure accurate delivery to the common extensor 
tendons and that intratendinous distribution was dose-dependent and improved 
with fenestrated techniques.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
6.4 Methods  
In this cadaveric study, 20 fresh-frozen, unembalmed upper-limb specimens 
from 10 individuals were used. Age of the specimens ranged from 70 to 96yrs, 
four were female, and six were male. The specimens were sectioned at the 
upper 3rd of the humerus proximally and radio-carpal joint distally. Specimens 
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had not undergone previous upper limb surgery. Information regarding any 
history of tendinopathy or other pathological abnormalities was not known by 
the authors.  Ethical approval (REC 17/NW/0065) was obtained from the NHS 
North West - Preston Research Ethics Committee.  
Injections technique  
The specimens were block randomised (block size = four) stratified by side (left 
or right) to receive either a 1 or 3 millilitre (ml) injection, delivered using a single 
pass or fenestrated technique, yielding four groups of five specimens. Injection 
volume was derived from the 25% and 75% percentile of injection volumes from 
studies reported in a recent comprehensive systematic review [106]. The single 
pass technique delivered the injection into the mid portion of the anterior 
Common Extensor Tendon (CET) origin, corresponding to the position of the 
ECRB [264] and the most commonly injected position, the fenestrated technique 
used nine passes delivered in a 3x3 square pattern across the anterior CET 
origin. The injected material was 2.44% methylene blue; all injections were 
delivered using a 5 ml syringe and 21 gauge needle. Injections were delivered 
by a Consultant musculoskeletal radiologist, with six years’ experience, using a 
Siemens RS80A ultrasound machine (Seimens, Munich, Germany) using a16 
MHz transducer in both transverse and longitudinal planes (Figure 6.1). The 
prosections were positioned with the elbow flexed to 45-50°. Evidence and size 
of intrasubstance and footprint tendon tears before and after injection and 
calcification was quantified using ultrasound.  
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Figure 6.1: Longitudinal ultrasonogram of the Common Extensor Tendon (CET).  The hypodermic needle 
can be seen entering at the right side of the image. This particular specimen underwent a 1ml single shot 
injection. 
Anatomic dissection  
Following injection the elbows were positioned with the arm over a bar, 
mimicking the lateral decubitus position. The specimen was held with a single 
clamp on the skin overlying the triceps muscle. Dissection was preceded by a 
dry arthroscopy using a single high proximal anteromedial portal. The presence 
of joint contamination of injectate was recorded.  
Dissection was performed through a posterior midline incision, with subdermal 
excursion to the lateral side. Soft tissue contamination was recorded. The CET 
was identified. This was excised proximally subperiosteally to the lateral 
epicondyle, and distally at least 1cm distal to the musculotendinous interface. 
The excised CET was transferred to a dissection table where periosteal tissue 
was removed from the insertion, the musculotendinous junction was identified 
and tissue distal to it removed, leaving the isolated CET (Figure 6.2).  The 
macroscopic appearance of the CET was digitally photographed and recorded.   
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Figure 6.2: Dissected Common Extensor Tendon (CET). Showing non-articular side. Blue colouration from 
methylene blue dye injection. 
Image analysis 
The dissected CETs were placed in microtome template and surrounded with 
low melting point paraffin wax. Specimens were stored in the dissection room 
cold store at 6°C for 12 hours. The specimens were then mounted in a bench 
microtome (Brunel Microscopes Ltd, Chippenham, UK) and were sectioned in 
an axial plane at 1 millimetre intervals. Each section was digitally photographed 
using a static high-resolution 12-megapixel camera (Fujifilm, Tokyo, Japan).  
Each digital photograph underwent a two-stage image analysis process. Semi-
automated segmentation of the tendon border from the wax surround was 
undertaken and lighting normalised between sections using the median intensity 
of the region outside the tendon/wax specimen. Following this, algorithmic 
contour lines denoting intensity of the dye (i.e. the retention of the methylene 
blue from light blue (distributed dye) to dark blue (concentrated dye) in four 
increments representing quartiles of the blue colour spectrum) were overlaid 
using the red channel, following light smoothing with a Gaussian filter (Figure 
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6.3). The second stage quantified the total number of pixels denoting the tendon 
area, and subsequently, the number of pixels within the four increments of dye 
intensity was quantified. Pixel number was transformed to fractional area to 
allow comparison within and between the tendon samples. Finally, the slices 
were reformatted using the marching cubes algorithm to provide 3-dimensional 
representations which were visually assessed for patterns of injectate spread 
and pooling. 
 
Figure 6.3: Common Extensor Tendon (CET) held in wax surround of bench microtome. The four areas of 
algorithmically derived colour intensity are seen within each of the four contour lines. 
Statistical analysis 
The primary outcome, percentage of pixels, is reported descriptively using 
means and standard deviation.  Further analysis was performed using 
hierarchical linear regression modelling, with a fixed effect on injection 
technique, injection volume, and dye intensity, and a random effect on the 
cadaveric specimen, nested within patients. Each specimen was tested under 
each of the two conditions (technique and volume) with pixel percentage 
reported in four gradations (density of blue dye). Regression coefficients and 
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95% Confidence Intervals (CI) are reported and statistically significant 
differences in pixel percentage between injection technique and volume was 
defined as a global p<0.05 for catagorical variables. All statistical analysis was 
undertaken using Stata 14 (StataCorp. 2015. Stata Statistical Software: 
Release 14. College Station, TX: StataCorp LP). 
6.5 Results 
Pre-injection ultrasound identified that 60% of the 20 cadavers had CET tears, 
33% of those tears were located at the footprint and an average size on 
ultrasound measurement of 5.8mm (Range 6-8mm). Of the eight CETs without 
a pre-injection tear, the post-injection ultrasound identified a tear in five (62.5%). 
Intra-tendinous calcification was evident in seven (53.8%) of the CETs. 
Following injection, elbow joint contamination was evident in all 20 specimens 
on dry arthroscopy. Macroscopic assessment consequently found 
contamination in both the lateral and medial joint space and on the articular and 
non-articular sides of the CET.  
The appearance of the external surface of all 20 CETs demonstrated the focus 
of the dye at the tendon site with widespread surrounding soft tissue 
contamination that diminished in proportion to the distance from the injection 
position.  
The mean volume (mm3) of the CET specimens, derived from the total pixel 
density, was 1040mm3 (±371.91 Range 344.72mm3 to 1845.74mm3). When 
separated by group (injectate volume or technique), no statistical differences in 
tendon volume were found.  
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The mean percentage of intratendinous pixel density, at the most sensitive dye 
intensity (lightest blue), was  98.76% (±2.0) for 1 ml and 97.91% (±2.27) for 3 
ml, 98.63% (±1.96) for single shot injections and 98.05% (±2.35) for fenestrated 
injection.  Mean percentage of blue dye concentration, in the four colour 
intensities from lightest blue to darkest blue is shown in Table 6-1 and 
graphically in Figure 6.4 and Figure 6.5. Statistically significant differences were 
found between the groups of blue pixel distribution against the baseline of group 
1 (group 2 regression coefficient -0.06 (95% CI -0.10 to -0.02), group 3 -0.21 (-
0.25 to -0.17) and group 4 -0.60 (-0.61 to -0.54)) with a global p-value of 
<0.001. However, no statistically significant differences in blue pixel distribution 
were found between groups for the dependent variables of injection volume 
(p=0.255, 95% CI -0.10 to 0.03) or injection technique (p=0.514 95% CI -0.04 to 
0.08). Potential differential effects of brightness level for different injection types 
and volumes were investigated by addition of an interaction term between 
brightness and injection type/volume (only one interaction term was included 
per model). No differential effects of brightness across injection type/volume 
were observed.   
 
 
 
 
 
 
Injection type 
Blue pixel distribution group   
Lightest blue  Darkest blue 
 Group 1 Group 2 Group 3 Group 4 
Mean SD Mean SD Mean SD Mean SD 
1ml 98.76% 2.00% 94.00% 4.01% 79.55% 7.49% 44.04% 12.54% 
3ml 97.91% 2.27% 90.87% 7.92% 74.98% 12.59% 37.83% 15.30% 
Single shot 98.63% 1.96% 92.04% 7.26% 74.86% 11.25% 39.21% 10.29% 
Fenestrated 98.05% 2.35% 92.82% 5.59% 79.67% 9.32% 42.66% 17.33% 
Table 6-1: Mean percentage +/- Standard deviation (SD) of the Blue pixels distributed within the CET 
tendon from lightest blue to darkest blue in four groups of blue colour graduation (lightest blue = group 1, 
darkest blue = group 4) 
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Three-Dimensional (3D) reconstructions of the intratendinous injectate 
distributions visually confirmed broad tissue penetration centred in the 
midportion of the tendon with no discernable patterns of longitudinal or cross-
sectional spread or pooling, or a particular anatomical localisation (e.g. to the 
anterior or footprint component of the tendon in the position of the ECRB) 
(Figure 6.6). 
 
 
 
 
Figure 6.4: Bar chart showing the mean percentage of blue pixels in each of the four colour 
intensity groups for the 1ml and 3ml volume injections. Error Bars = 95% Confidence Intervals. 
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Figure 6.5: Bar chart showing the mean percentage of blue pixels in each of the four colour intensity 
groups for the single injection and fenestrated injection techniques. Error Bars = 95% Confidence 
Intervals. 
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Figure 6.6: Examples of 3D reformats of tendon segments for the four injection techniques. From left – tendon outer border, then working through four colour intensity contours. 
Note the absence of a pattern of pooling or longitudinal spread. 
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6.6 Discussion 
This study has identified that commonly used elbow injection volumes and 
techniques, distribute injectate throughout 97% of the common extensor tendon 
in cadaveric specimens. No differences were found between injection volumes 
or techniques. Dye contamination of the joint surface was noted in every 
specimen, and post-injection ultrasound revealed tears to the tendon in over 
60% of specimens that were previously uninjured.  
This is the first study to assess intratendinous injectate distribution of the elbow 
extensors in cadaveric tissue, although the use of human tissue has greater 
utility in its generalisability to a clinical context, the tissue morphology of 
cadaveric specimens should be taken into consideration in relevance to its 
generalisability to clinical use. The cadaveric tissue utilised in this study was of 
subjects with an average age much higher (range 70-96) than the peak age of 
onset of LET (45-60yrs), and though the specimens had no history of elbow 
surgery, their detailed medical history was not known.  Pre-injection tears were 
noted in 60% of specimens, and though the tear rate in asymptomatic 
individuals is felt to be very low [265, 266], the proportion of tears in this study 
population corresponds to the tear rate seen in tendinopathic individuals, which 
has been reported as 57% by Walton et al [83] and 58% by van Kollenburg et al 
[84]. Furthermore, calcification was noted in over half of specimens, and though 
the appearance of calcification is a common finding, known to increase with 
age, it may be of poor diagnostic value in LET [267]. Our finding of 53% is 
equable to asymptomatic 50yr olds and is, in fact, lower than normally reported 
in those >70yrs [265]. We, therefore, feel that the sample, though limited in 
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number, is morphologically representative of a LET population. It is currently 
unknown whether the fresh frozen cadaveric tissue of the elbow behaves as in 
vivo tissue would under injection. It is therefore prudent to highlight that 
although morphologically similar, there is an inherent limitation common to all 
cadaveric studies and some of the conclusions may not be generalizable to 
human tissue.   
Previous authors have commented upon the contamination of the joint and 
surrounding tissues in lateral elbow injections [261, 268]. However, the current 
literature has either assessed unguided injections in cadavers, or assessed the 
distribution on retrospective assessment of ultrasound images, without the 
known validity of such a method. Ultrasound injection is advocated in lateral 
elbow injections to improve accuracy and decrease contamination rate [261], but 
the present study reports that even with the application of ultrasound guidance, 
the joint contamination rate was 100%. The target site for elbow injection is the 
ECRB and though very challenging to isolate on USS from the CET, its position 
is deep and has a delicate and intimately associated connection to joint 
capsule, particularly at its anterior edge [35].  The presence of tears in this region 
and the propagation or creation of tears with guided injections may inevitably 
force the injection into the joint space. In five of the eight samples that did not 
have evidence of a pre-injection tear, a new tear was noted following injection. 
This finding, though only demonstrated on a very small sample, may have 
important clinical relevance. As discussed, joint contamination is an important 
consideration depending on the injectate substance, but furthermore the 
creation of a new tear may have an important part to play in and consequential 
effect of the injectate, be it therapeutic or detrimental.  
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The CET tapers from the musculotendinous junction to its origin at the lateral 
epicondyle. Its footprint has been defined as approximately 10mm in 
anteroposterior width [35], its true tendinous length is approximately 16mm [269], 
its thickness at the radiocapitelar joint is 4.4mm [270], the average width of the 
CET at the musculotendinous junction though not previously defined, was 
35mm in the current study. Calculating the volume of an oblique wedge [271] 
(𝑉 =
𝑏ℎ
6(2𝑎+𝑐)
 ), from these figures yields a volume of 938.66 mm3, which is 
similar to the mean total volume, derived from the pixel density, found in the 
current study (1040 mm3). The volume of 1 and 3ml injections clearly equates to 
a fluid volume of 1000 and 3000 mm3. Therefore, with localised injection of 
common injectate volumes, in an area of densely packed collagen, it is 
unsurprising that the tendon itself is both damaged and that the injectate is 
disseminated down a path of least resistance. With the delicate anterior 
capsular edge presenting as a likely route, joint contamination becomes 
inevitable. Dependent on the injection substance, this finding may be very 
relevant, particularly in the otherwise pathology free elbow joint.  
Cross-sectional analysis of the CET segments, including 3-dimensional 
reformatting, found widespread dissemination of the injectate dye regardless of 
volume or technique, with no apparent pattern or pooling. Previous cadaveric 
and animal studies have reported a preponderance toward longitudinal 
spreading of injectate [272-274], in line with collagen fibre orientation. However, 
these studies have predominantly utilised oval tendons including lamb distal 
forearm extensor and flexor tendons [272] and horse flexor tendons [274]. CET 
tendons were included by Loftus et al [273] but as 14% of a cohort of 
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predominantly hamstrings and patellar tendons, exclusively assessed with 
ultrasound.  This is the first study to report widespread cross-sectional spread in 
the broad flat tendon morphology of the CET, where tears were either present 
or induced. Indeed, collagen cross-linking is likely to have been disrupted as 
part of the injection process, allowing cross-sectional spread. The cross-
sectional distribution and high injection induced tear rate within this study 
demonstrate the notable effect on tendon structure that injections have which, 
regardless of injectate, should be considered as a potential driver of procedural 
pain, post procedural discomfort and as a component of any consequential 
healing response.  
The use of needle fenestration has been advocated as a method of distributing 
injectate more evenly [272], however systematic review of CET injections report 
conflicting findings of its superiority over single shot injections [106, 117]. This 
study did not demonstrate any statistical difference in the cross-sectional 
distribution of injectate between the two techniques using either 1ml or 3ml 
volumes. Further visual assessment of injectate distribution on 3D 
reconstruction did not isolate any noticeable difference in distribution patterns. It 
is important to note that significant escape of active injectate occured 
regardless of technique with the volumes used in this study, and the presented 
findings may be different if smaller volumes were employed. It is important to 
recognise that this study assessed fenestration as a method of distributing small 
aliquots of injectate around the CET. It is also recognised that fenestration is 
also utilised as a therapy in LET, where a needle is used to create 
micropunctures in the affected region and abraide the adjacent periosteum. The 
goal of this therapy is cause local bleeding promote tendon healing [275]. 
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Currently, no clinical evaluation on the effect of fenestration alone versus, 
fenestration and delivery of injectate in LET has been conducted.       
This study has identified that using commonly utilised injectate volumes and 
techniques with ultrasound guidance into a cadaveric common extensor tendon 
can create tendon tears and joint contamination may be inevitable. The 
structural disruption to the CET seen in this study raises questions about the 
potentially destructive, or indeed therapeutic, effect a large injection volume 
may have on the CET. The disruption could be thought of as analogous to a 
volumetric debridement, therein an injection of 1ml of saline may in itself have a 
treatment effect, and in this regard may not be an appropriate placebo 
intervention.  Though no clinical evidence of high volume injections efficacy has 
been presented in LET, a 2017 randomised controlled trial of Achilles 
tendinopathy treatment reported them as superior to PRP injection and 
physiotherapy treatment [27]. Further preclinical and subsequent clinical studies 
of high and low volume injections are therefore warranted and future placebo 
randomised controlled trials may require a placebo where no fluid is injected.  
Limitations 
The authors recognise several limitations present within this study. Although the 
number of cadaveric specimens used in the current study is greater than 
previously published tendon injection studies [261, 276], the volume and technique 
groups are of a small number. However, variability in injectate distribution was 
within acceptable limits, and the statistical methods were appropriate to the 
small group, repeated measures design. The use of fresh frozen cadaveric 
material, dry arthroscopy, careful dissection practice and avoidance of freezing 
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techniques for microtome slicing were all employed to reduce the risk of tissue 
destruction and degeneration not related to the injection. The choice of 
methylene blue was made to derive clear visualisation of contamination and to 
assess graduated tissue penetration. However, the dye used has a lower 
viscosity than some of the commonly used injectate preparations, with particular 
reference to PRP. Wilson et al [272] reported that there was no difference in the 
longitudinal spread of injectate in lamb tendons injected with pure methylene 
blue or methylene blue mixed with PRP. However, they do report cross-
sectional distribution was lower in the combined group, and it, therefore, 
remains a possibility that cross-sectional distribution observed in the current 
study may be reduced in higher viscosity injectates. The authors suggest that 
the volume effect, rather than viscosity, is likely to have a greater effect on 
collaged cross-link disruption. 
6.7 Conclusion 
Both 1ml and 3ml injections into cadaveric elbow common extensor tendons 
distribute injectate equally across 97% of the intratendinous area, with no 
difference demonstrated between single-shot or fenestrated injection 
techniques. The injection of these volumes into a small anatomical space may 
cause damage to the tendon structure, and due to the close association of this 
tissue to the joint capsule, elbow joint contamination may be inevitable and this 
should be taken into consideration when selecting the injection substance. 
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7 Chapter 7 - Platelet-Rich Plasma Injection in Lateral 
Elbow Tendinopathy: Exploring Expert Consensus with 
the Delphi Method 
7.1 Abstract 
Background 
Platelet-Rich Plasma (PRP) has become a popular treatment modality for 
Lateral Elbow Tendinopathy (LET) despite conflicting evidence on its 
effectiveness. With high levels of user experience, this study aimed to assess 
the levels of consensus amongst experts on the clinical application of this novel 
intervention.  
Methods 
An international Delphi study was conducted. The development of treatment 
statements and consensus measurement was developed over three rounds. 
Round one utilised a ten person primary working group who answered open 
questions on their clinical approach, and their answers were subsequently 
developed into 40 statements. Clinical users and researchers were invited 
through national society mailing lists and contact lists derived from a systematic 
search of PRP literature. In rounds two and three, an international group of PRP 
researchers and clinical users scored their levels of agreement with these 
statements on a five point scale. Consensus was defined as an interquartile 
range of ≤1.    
Results 
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Thirty-eight participants completed round two and 28 (74%) completed round 
three. Overall, consensus of agreement was reached for 17/40 (42.5%) 
statements. For statements on PRP formulation, consensus of agreement was 
reached in 2/6 statements (33%). No differences were observed between high 
volume (>20 per annum) or low volume (≤20 per annum) users.    
Conclusion 
Amongst experts, only limited consensus could be reached on the application of 
PRP in LET. High levels of user experience does not result in a convergence of 
opinion on the technical components of PRP formulation and delivery, echoing 
calls for further study and improved trial reporting.  
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7.2 Overview 
The previous chapter assessed injection technique using a cadaveric model, 
and reported that the perceived thinking on injection delivery may be flawed. 
The following study develops this theme by focusing on the clinical application 
of injection therapy. It explores the level of expert consensus on the process of 
delivering injections in LET with specific attention on Platelet-rich plasma.  
7.3 Background 
The use of Platelet-rich plasma (PRP) for the treatment of LET has rapidly 
increased in recent years [119]. Tendinopathy itself is multifaceted condition, with 
varied highly complex imflamatory system modulation dependent upon the 
patients,age, position of tendinopathy and chronicity of the condition. Biological 
therapies are currently being lorded as a potential treatment that seeks to meet 
these continuum of tendinopathy by boosting healing mechanisms  [277]. What 
this grand claim revolves around is the modulation of inflammatory pathways 
and the promotion of anabolic and proliferative effects on tendon cells. Initial 
animal studies emerged in the early 2000s with studies reporting increased 
TGFβ and PDGR in equine tendon which are involved in increasing the 
production of Type I collagen (the main collagen component of tendon), and the 
reduction of matrix metalloproteins (MMPs) involved in breaking down Type III 
collagen (the main collagen form in early tendon repair) [278, 279]. These findings 
have been replicated in in vitro human tissue where exposure to PRP has 
prompted increased concentrations of PDGF, VEGF, TGFβ, growth factors all 
involved in matrix production [280] and proliferation of human tenocytes [281]. 
However, clinical studies have been less positive, the latest Cochrane review 
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suggests no evidence to support the use of PRP for the management of 
musculoskeletal soft tissue injuries [116]. For Lateral Elbow Tendinopathy 
specifically, reviews have produced conflicting results on PRP efficacy [118, 119]. 
Much of the criticism directed towards PRP research relates to the 
heterogeneity of patient selection, PRP preparation, and administration 
techniques [105, 116, 118, 119, 277]. Furthermore, inconsistency of protocol reporting, 
outcome measurement, and adverse events reporting has hindered consistent 
interpretation of treatment effects or harm [101].   
PRP is prepared through concentration of the patient’s own blood. However, 
depending on the equipment, the protocol used and the patient’s own blood 
profile, highly variable concentrations of platelets, erythrocytes, and leukocytes 
are obtained [283]. Administration variability relates to patient selection, the 
frequency and interval of administration, the use of adjunct ultrasound guidance 
and post-operative protocols. Furthermore, the use of local anaesthetic, platelet 
pre-activation, anticoagulation and pH buffering are not standardised.  
The lack of treatment standardisation may, in part, be related to the regulation 
of biological therapies of this nature. Unlike medicinal products, PRP, as an 
autologous therapy, has not been subject to the standardised methodology of 
phased trials. Though the administrative device (e.g. centrifuge system) may 
have been subject to pre-market approval, the product to be administerd to the 
patients (i.e. PRP) has not been standardised. Therein the treatment 
constituents, dose, administration and adverse events have not been 
investigated according to the standards applied to medications. This has 
resulted in the evolution of the use of PRP being influenced by the reports of 
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trial data, which to date have yet to result in clear guidance. Nevertheless, the 
clinical use of PRP continues to increase.  
In 2013, it was estimated that 16% of UK orthopaedic surgeons used PRP [103]. 
Internationally, its use is more common. A 2015 review from Australia of 112 
sports physicians found 38% used PRP in their own practice and a further 49% 
referred patients for this treatment [108]. The experience from those sports 
physicians surveyed was that, of all conditions, PRP is most effective as a 
treatment option for LET. However, the patterns of technique and administration 
in LET were not explored.   
Though a large-scale trial of a methodology in accordance with a phase 2 
clinical drug trial may be able to elucidate the optimal PRP constituents, dose, 
and administration, this would require considerable resources and financial 
support. With the widespread use of PRP, both within the research and clinical 
community, an alternative approach may be to explore expert opinions in an 
attempt to gain consensus using a validated methodology.  
The Delphi method uses a series of sequential question sets (or rounds), 
interspersed with controlled feedback to gain the most reliable consensus of 
opinion of a group of experts [284]. It is a technique that is particularly useful 
where individual judgments need to be assessed and combined in order to 
address a lack of agreement or incomplete state of knowledge [285-287]. In 
addition to identifying a treatment consensus (or lack thereof), the technique 
can also inform research priorities where knowledge deficits exist [286]. It has an 
extensive history of use in healthcare settings, and has recently been employed 
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in expert consensus exploration of Achilles tendinopathy [288] and shoulder 
rotator cuff pathology [289].    
Originally developed by the Rand Corporation for technological forecasting, the 
classical Delphi achieves group opinion through multilevel group interaction 
over multiple rounds supervised by a facilitator [290]. Opinions are provided 
anonymously, thereby avoiding the problems arising from powerful 
personalities, group pressure, and status that can manifest in open discussion 
[291]. Recent iterations of the technique include the use of electronic data 
collection (e-Delphi) [292]. The iterative process uses controlled feedback and 
statistical group response that, as the rounds of questionnaires are completed, 
allow participants to reflect and modify their response [290].  
This study aimed to elicit opinion and assess levels of consensus on the use of 
platelet-rich plasma in lateral elbow tendinopathy. In the absence of phased trial 
data, exploration of expert consensus is justified. Patterns in treatment practice 
or indeed, lack thereof, may assist in the future formulation of study protocols 
and treatment guidelines. 
7.4 Methods 
Study design 
This study used a three-stage Delphi technique and was undertaken between 
January 2017 and October 2017. This methodology has been chosen to 
develop criteria that are based on consensus gained from an expert panel, 
where insufficient quality and grade of evidence exists to develop evidence-
based criteria [290].  
187 
 
 
Participant selection and recruitment 
A steering group was recruited to undertake round one through personal 
communication with the lead author (JE). This group of 10 individuals included 
UK-based upper-limb orthopaedic surgeons, musculoskeletal radiologists and 
PRP researchers who were invited directly. The steering group was utilised in 
round one and was asked to participate in the subsequent rounds.  
The subsequent rounds recruited the expert opinion of a larger cohort of 
participants. To increase the heterogeneity of the expert panel, including the 
desire to gain national and international opinion, two approaches were used to 
invite both research-based and clinical-based individuals with experience in 
PRP application. The research cohort was recruited through a database search 
of published articles on PRP followed by email communication with the lead 
author; the clinical cohort was recruited through national society mailing lists.   
Database searches were undertaken on 15/2/2017 in Medline, EMBASE and 
CINHAL databases from inception to the present, using modified British Medical 
Journal (BMJ) research filters for systematic reviews, randomised control trial, 
cohort and case-control studies (appendix 14). Following title and abstract 
review, 57 articles were identified. Where possible, contact email addresses 
were extracted from corresponding author details and invitations to participate 
in the Delphi process were distributed.  
To capture clinical users of PRP who may not be actively involved in research, 
the European Society for Surgery of the Shoulder and Elbow (SECEC), British 
Association of Sports and Exercise Medicine (BASEM) and British Society of 
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Musculoskeletal Radiologists were invited to participate via a mailout of society 
contact lists.  
Expert panel size 
The question of participant numbers is dependent on the minimally sufficient 
number to constitute a representative pooling of judgments [293]. Wide variations 
in expert numbers have been reported in Delphi studies [286], though nominally 
they tend to be within 20-60 [294].  
The study aimed to recruit a minimum of 25 experts. The primary group of 
experts in round one was 10. In round two, a minimum of 20 additional experts 
was required for study progression. Round three required retention of >60% of 
respondents. Though it has been reported that the reliability of composite 
judgments increases with respondent numbers, there is little empirical evidence 
on the effect of participant numbers on reliability or validity of the consensus 
process [287] if the panel composition is appropriate.  
Procedure  
 Round one 
The initial steering group was contacted through the Bristol Online Survey 
electronic portal (BOS, University of Bristol, Bristol, UK). This expert panel was 
presented with open questions based on the domains of PRP reporting 
identified by Murray et al [122]. These open questions asked for the participants’ 
opinions on the themes of patient selection, PRP preparation and delivery, post-
procedural care and outcome assessment (appendix 15). Consolidation of text 
answers was undertaken through content analysis. The answers were read by 
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two assessors (JE + CS), and, from the response themes, a list of 40 
statements was developed for agreement scoring in round two. In cases of 
disparity between participants, the predominant theme was utilised. The 
established statements were distributed amongst the study authors for the 
assessment of thematic structure and comprehension.  
 Round two   
The statements from round one were developed into an electronic questionnaire 
with each statement requiring an agreement score using a Likert scale from 1 
(Strongly disagree) to 5 (Strongly agree). The questionnaire was distributed to 
all those who responded to the invitation sent to PRP researchers, national 
society members and those from round one willing to be involved in subsequent 
rounds. Simple demographic information on the participant was collected to 
quantify participant PRP experience (Clinical User/PRP Researcher/Both), user 
occupation (Researcher/Surgeon/Radiologist/Sports Physician) and total 
number of PRP injections for LET administered annually. Participants were also 
able to suggest edits to the statements using a free text option. Statements 
were modified if suggestions by more than three participants were thematically 
similar and not in contrast to the predominant group response.   
 Round three   
Participants were sent an individualised feedback report including their round 
two scores and the groups’ scores for each statement, represented using a 
histogram (appendix 16). Participants were able to reflect on their scores and, if 
necessary, change their score whilst maintaining anonymity. The same Likert 
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scale was used for round 3. The benefit of continuing the iterative process was 
assessed following round 3 completion using standardised stopping criteria.    
Ethical considerations 
This study was granted ethical approval by the University of Exeter Medical 
School review panel (Nov16/B/105) (appendix 17). The iterative nature of the 
Delphi technique meant that the participants remained anonymous to each 
other, but not to the research team [294].  
Data analysis  
Quantitative analysis of Likert ratings was undertaken using Stata (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp 
LP). For measures of central tendency and level of dispersion, median and 
interquartile range (IQR) are strongly favoured when Likert scales are used [290, 
294]. The consensus criterion for this study was an interquartile range (IQR) of 
one or less. An IQR of less than one means that more than 50% of all opinions 
fall within one point on the scale [295]. For those with an IQR of ≤1, the median 
score was taken as the agreement level and statements grouped into one of 
three categories: consensus of agreement (median score 4 or 5), consensus of 
disagreement (median score 1 or 2) or consensus of ‘neither agree nor 
disagree’ (median score of 3). Percentage agreement (participants answering 
either four or five on the Likert scale) is also presented.  The stopping criteria at 
round 3 was assessed using the parametric method of Coefficient of Variation 
Difference (CVD) [296]. This was calculated by subtracting the individual item CV 
(Standard deviation/Mean) from round three, from the corresponding CV from 
round two. A value close to zero denotes stability of responses with a cut-off 
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value of >0.5 deemed a decision limit for a need for further rounds [295]. Post hoc 
analysis of response differences between different groups of PRP user 
experience (clinical user or clinical researcher/pure researcher), clinical 
occupation (radiologist/physician or surgeon) and injection number per annum 
(low volume ≤20 or high volume >20), was undertaken at the statement level 
using a non-parametric Mann-Whitney U test. Statistical significance was set at 
p<0.05.    
 
 
7.5 Results 
Participants 
The primary working group consisted of 10 participants, of whom nine were UK-
based Consultant orthopaedic surgeons and one a Consultant radiologist. Half 
of the group were actively involved in PRP research as well as clinical practice. 
The multimodal recruitment strategy resulted in a further 28 participants, with a 
total of 38 participants from 14 different countries, completing the round two 
questionnaires. Following the return of round two feedback and two email 
reminders, round three was completed by 28 participants (74% response rate). 
The group completing round three consisted of three radiologists, seven sports 
physicians, one researcher who did not undertake a clinical role and 17 
orthopaedic surgeons.  Of this group, 12 (43%) were actively involved in PRP 
research. As a marker of research impact demonstrated by the research active 
participants, their h-index was extracted from the Scopus® (Elsevier B.V.) 
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database yielding a median h-index of 13 (range 5 – 83). The annual use of 
PRP injection for LET was grouped into five categories, nine participants (25%) 
administered <5 injections per annum, two (7%) administered 5-10, eight (26%) 
administered 10-20, five (18%) administered 20-50 and six (21%) administered 
>50 per annum.   
Consensus development  
Between rounds two and three, two statements were modified following free text 
feedback from multiple participants. Statement 2 was changed from “PRP 
should only be considered following six-months of conservative therapy” to 
“PRP should only be considered following at least three months of conservative 
therapy”, and statement 24 was changed from “A 19g needle is the 
recommended minimum size used to administer PRP” to “A 19g needle is the 
recommended MAXIMUM size used to administer PRP”. 
Stability between rounds two and three was assessed and confirmed using the 
Coefficient of Variation Difference (mean CVD -0.03, SD±0.04, Range -0.11-
0.04). Further iterations of the questionnaire were therefore deemed unlikely to 
result in further change.  
Consensus of agreement (IQR≤1, median score 4 or 5) occurred for 17/40 
statements (42.5%) (Table 7-1). Consensus of disagreement (median score 1 
or 2) occurred for 2/40 statements (5%). Consensus of ‘neither agree nor 
disagree’ (median score 3) occurred for 4/40 statements (10%). Consensus was 
not reached for 16/40 statements (40%) (Table 7-2 and Table 7-3).    
Group analysis  
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Assessment of statistically different median scores between ‘PRP user 
experience’ groups revealed differences in opinion for statement 2 (“PRP 
should only be considered in patients who are experiencing considerable 
intrusion into their activities of daily life”) with clinical users scoring a median of 
3 and clinical researchers/pure researchers scoring a median of 4.5 (p=0.007). 
For occupation type, grouped into two categories of radiologist/physician or 
surgeon, statistically different median scores were found for statement 3 (“PRP 
should only be considered in patients who are experiencing considerable 
intrusion into their activities of daily life”) (3 vs 4 respectively (p=0.04)), 
statement 25 (“Ultrasound guidance should be utilised in all PRP injections for 
Lateral Elbow Tendinopathy”) (5 vs 4 (p=0.03)), statement 26 (“Needle 
fenestration is recommended over a single injection technique”) (4.5 vs 4 
(p=0.01)) and statement 30 (“Surgery is recommended for patients in whom 
PRP treatment is not effective”) (3 vs 4 (p=0.004)). No differences in statement 
scores were noted between low volume users (0-20 per annum) and high 
volume users (20->50 per annum).
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Table 7-1: Results of round 3. Statements in categories presented with Interquartile Range (IQR), median score and percentage agreement (a score of 4 or 5) and score histogram.   
Statement IQR Median % Agreement Response distribution histogram 
1.     PRP should only be considered in patients 
presenting with characteristic tennis elbow pain. 
1 4 89.29 
 
2.     PRP should only be considered following at 
least 3 months of conservative therapy. 
2.5 4 64.28 
 
3.     PRP should only be considered in patients who 
are experiencing considerable intrusion into their 
activities of daily life. 
1 4 64.29 
 
4.     PRP treatment can be considered in patients 
over the age of 18, with no upper age limit. 
1 5 96.43 
 
5.     PRP treatment can be considered in patients 
with manual or sedentary occupations. 
0.5 5 96.43 
 
6.     PRP treatment can be considered in both high 
demand (e.g. sports people) and low demand (e.g. 
office worker) patients. 
0.5 5 100 
 
7.     PRP is contraindicated in patients with a 
coagulopathy. 
1 2 21.43 
 
8.     PRP is contraindicated in patients with large 
wrist extensor tendon tears. 
2 2 28.57 
 
9.     PRP is contraindicated in patients taking 
anticoagulant medication. 
1 2 21.42 
 
10.  PRP is contraindicated in patients with a 
dependence on Non-Steroidal Anti-Inflammatory 
Drugs (NSAIDs). 
3 3 42.85 
 
                                                                                      Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree  
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Statement IQR Median % Agreement Response distribution histogram 
11.  PRP is contraindicated in patients with known 
thrombocytopenia (less than 150,000 platelets per 
microlitre of whole blood). 
1 4 51.85 
 
12.  PRP is contraindicated in patients who have 
received a steroid injection for LET, within 3 months 
of the intended PRP treatment date. 
2 3 42.85 
 
13.  The minimum recommended platelet 
concentration of injected PRP is 2x baseline. 1.5 3.5 50 
 
14.  The maximum recommended platelet 
concentration of injected PRP is 5x baseline. 1 3 39.29 
 
15.  The minimum recommended volume of PRP is 
1ml. 1.5 4 71.43 
 
16.  The maximum recommended volume of PRP is 
3mls. 1 3 46.43 
 
17.  Leukocyte deplete PRP is the recommended 
formulation. 1.5 3.5 50 
 
18.  A single spin cycle of 20 minutes or less is 
recommended. 1 4 64.29 
 
19.  The addition of an anticoagulant to the whole 
blood sample is recommended prior to PRP 
preparation. 
1 3 21.42 
 
20.  PRP activation, through the addition of additives 
prior to its administration, is not required. 1 4 82.14 
 
                                                                                      Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree  
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Statement IQR Median % Agreement Response distribution histogram 
21.  Once processed, PRP should be administered 
within 30mins. 1 4 82.14 
 
22.  Local anaesthetic should be administered to the 
skin and subcutaneous tissue. 2 4 60.72 
 
23.  Local anaesthesia should not be administered to 
the tendon. 2.5 4 60.71 
 
24. A 19g needle is the recommended MAXIMUM 
size used to administer PRP.  1 3 35.71 
 
25.  Ultrasound guidance should be utilised in all 
PRP injections for Lateral Epicondylar Tendinopathy. 2 4 67.86 
 
26.  Needle fenestration is recommended over a 
single injection technique. 0.5 4 82.14 
 
27.  Following the first administration of PRP, the 
patient should be reassessed to discern the need for 
repeated administration. 
1 5 85.72 
 
28.  A maximum of 3 administrations is 
recommended for each episode of Lateral 
Epicondylar Tendinopathy. 
2.5 3.5 50 
 
29.  If symptoms recur following a successful course 
of treatment, PRP injection can be reattempted. 1.5 4 75 
 
30.  Surgery is recommended for patients in whom 
PRP treatment is not effective. 1 4 71.43 
 
                                                                                      Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree  
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Statement IQR Median % Agreement Response distribution histogram 
31.  Immobilisation of the elbow following injection is 
not necessary. 1 5 89.29 
 
32.  Light loads should be avoided for the first 48 
hours following injection. 1 4 85.71 
 
33.  Heavy loads should be avoided for 6 weeks. 
2 4 64.28 
 
34.  Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) should be avoided for 1 week prior to PRP 
administration. 
2 4 67.86 
 
35.  Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) should be avoided for at least 2 weeks 
following injection. 
2 4 71.43 
 
36.  Acetaminophen (Paracetamol ) and weak 
opioid-based analgesia can be offered as required 
following PRP administration. 
1 5 96.43 
 
37.  Clinical assessment is recommended to assess 
the outcome of PRP administration. 0.5 5 96.43 
 
38.  A Visual Analogue Pain Score (VAS) should be 
collected in addition to clinical assessment. 2 5 71.42 
 
39.  A validated Patient-Reported Outcome Measure 
(PROM)) should be collected in addition to clinical 
assessment. 
1 4 82.14 
 
40.  Resolution of tendinosis on US or MRI can be 
utilised to assess outcome. 1.5 2 25 
 
                                                                                      Strongly disagree / Disagree / Neither agree nor disagree / Agree / Strongly agree 
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Table 7-2: List of statements categorised by consensus group – Consensus of: agreement and 
disagreement,  
Consensus of agreement (median score = 4 or 5) Statement Category 
PRP should only be considered in patients presenting with characteristic 
tennis elbow pain (lateral elbow pain exacerbated by wrist extension). 
Patient Selection  
PRP should only be considered in patients who are experiencing 
considerable intrusion into their activities of daily life. 
Patient Selection  
PRP treatment can be considered in patients over the age of 18, with no 
upper age limit. 
Patient Selection  
PRP treatment can be considered in patients with manual or sedentary 
occupations. 
Patient Selection  
PRP treatment can be considered in both high demand (e.g. sports people) 
and low demand (e.g. office worker) patients. 
Patient Selection  
PRP is contraindicated in patients with known thrombocytopenia (less than 
150,000 platelets per microlitre of whole blood). 
Contraindication 
A single spin cycle of 20 minutes or less is recommended. PRP formulation   
PRP activation, through the addition of additives prior to its administration, is 
not required. 
PRP Formulation  
Once processed, PRP should be administered within 30mins. Administration 
Technique 
Needle fenestration is recommended over a single injection technique. Administration 
Technique 
Following the first administration of PRP, the patient should be reassessed to 
discern the need for repeated administration. 
Administration 
Strategy  
Surgery is recommended for patients in whom PRP treatment is not effective. Administration 
Strategy  
Immobilisation of the elbow following injection is not necessary. Post Procedural Care  
Light loads should be avoided for the first 48 hours following injection. Post Procedural Care  
Acetaminophen (Paracetamol ) and weak opioid-based analgesia can be 
offered as required following PRP administration. 
Post Procedural Care   
Clinical assessment is recommended to assess the outcome of PRP 
administration. 
Outcome Assessment  
A validated Patient-Reported Outcome Measure (PROM) (e.g. PRTEE, 
DASH, OES) should be collected in addition to clinical assessment. 
Outcome Assessment  
Consensus of disagreement (median score = 1 or 2) Statement Category 
PRP is contraindicated in patients with a coagulopathy. Contraindications 
PRP is contraindicated in patients taking anticoagulant medication. Contraindications  
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Table 7-3: List of statements categorised by consensus group – Consensus of neither agree nor disagree 
or consensus not reached 
Consensus of  ‘neither agree nor disagree’ (median score = 3) Statement Category 
The maximum recommended platelet concentration of injected PRP is 5x 
baseline. 
PRP Formulation  
The maximum recommended volume of PRP is 3mls. PRP Formulation  
The addition of an anticoagulant to the whole blood sample is 
recommended prior to PRP preparation. 
PRP Formulation  
A 19g needle is the recommended MAXIMUM size used to administer 
PRP.   
Administration 
Technique  
Consensus not reached Statement Category 
PRP should only be considered following at least 3 months of 
conservative therapy 
Patient Selection  
PRP is contraindicated in patients with large wrist extensor tendon tears. Contraindication   
PRP is contraindicated in patients with a dependence on Non-Steroidal 
Anti-Inflammatory Drugs (NSAIDs). 
Contraindication  
PRP is contraindicated in patients who have received a steroid injection 
for treatment of their Lateral Epicondylar Tendinopathy, within 3 months of 
the intended PRP treatment date. 
Contraindication  
The minimum recommended platelet concentration of injected PRP is 2x 
baseline. 
PRP Formulation  
The minimum recommended volume of PRP is 1ml. PRP Formulation  
Leukocyte deplete PRP is the recommended formulation. PRP Formulation  
Local anaesthetic should be administered to the skin and subcutaneous 
tissue. 
Administration 
Technique  
Local anaesthesia should not be administered to the tendon. Administration 
Technique  
Ultrasound guidance should be utilised in all PRP injections for Lateral 
Epicondylar Tendinopathy. 
Administration 
Technique  
A maximum of 3 administrations is recommended for each episode of 
Lateral Epicondylar Tendinopathy. 
Administration 
Strategy  
If symptoms recur following a successful course of treatment, PRP 
injection can be reattempted. 
Administration 
Strategy  
Heavy loads should be avoided for 6 weeks. Post Procedural Care  
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should be avoided for 1 
week prior to PRP administration. 
Post Procedural Care  
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) should be avoided for at 
least 2 weeks following injection. 
Post Procedural Care  
A Visual Analogue Pain Score (VAS) should be collected in addition to 
clinical assessment. 
Outcome Assessment  
Resolution of tendinosis on US or MRI can be utilised to assess outcome. Outcome Assessment  
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7.6 Discussion  
This study has attempted to assess levels of expert consensus on the use of 
Platelet-rich plasma (PRP) in patients suffering from Lateral Elbow 
Tendinopathy (LET). The use of PRP is increasing despite inconclusive 
evidence of clinical efficacy [297]. It is likely that this expansion in its use arose 
both from the availability and inherent safety of this technology, and the desire 
to offer a treatment for a condition which is recognised as challenging to treat, 
with limited evidence of a gold standard treatment approach [101]. In a situation 
of lack of data regarding clinical efficacy, but widespread use, it was deemed 
both legitimate and practical to assess expert consensus. In doing so, an 
assessment of clinical experience can be made, in the scenario of a commonly 
administered treatment, one may presume that a convergence of opinion on 
patient selection, production, technique, and follow-up may be revealed that is 
not currently demonstrated in clinical trials. The current study has isolated some 
commonality in patient selection, administration techniques and post-procedural 
follow-up care, with 57.5% of all statements reaching consensus. However, this 
study has demonstrated wide variations in expert approach to PRP production 
and formulation, application of local anaesthesia, use of imaging adjuncts and 
the interplay with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and 
corticosteroids.  
Statements involving patient selection demonstrated adequate consensus, with 
agreement that participants can be selected if they have characteristic LET 
pain, are over the age of 18 yrs and are experiencing considerable intrusion into 
their lives. Furthermore, there was agreement that occupation or level of 
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demand on upper limb function should not be a factor in participant selection. 
The statement within this section which did not reach consensus related to the 
duration of symptoms, given the wide score dispersion apparent with an IQR of 
2.5. Furthermore, this statement was altered between rounds owing to feedback 
from multiple participants to lower the duration of conservative therapy from six 
to three months. Though this shifted the median from 3 (round two) to 4 (round 
three), significant dispersion remained. A significant majority of PRP studies 
have concentrated on chronic LET (>6 months of symptoms), and this lack of 
consensus may highlight an area of future research on the effect of PRP on 
early onset LET.  
There is limited evidence available on both the potential contraindications to 
PRP delivery and the potential post-procedural complications.  Miller et al [298], 
in a recent systematic review, comment that the potential for unreported 
complications remains a major limitation of the PRP literature. As a 
consequence of its autologous nature, there may realistically be few safety 
concerns, but the paucity of explicit information on adverse outcomes leaves 
the clinical user uninformed and simply guided by clinical experience. Though 
consensus was reached on PRP being contraindicated in patients with known 
thrombocytopaenia, consensus could not be reached on whether the presence 
of large wrist extensor tears, dependence on NSAIDs or a steroid injection 
within three months are contraindications, with experts providing very varied 
scores. Interestingly, consensus was reached on the statements regarding 
known coagulopathy and concurrent anticoagulation medication, with experts 
deeming that neither is a contraindication to PRP treatment in LET.  
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There have been recent calls to dramatically improve the reporting of the PRP 
formulation used in clinical effectiveness trials [122, 299-301]. Without this 
information, the ability to make decisions upon the plethora of PRP devices 
remains extremely challenging for the clinician. In this regard, it may not be 
surprising that limited consensus could be reached for the PRP formulation 
category. Consensus was gained on the use of a 20 minute or less, single spin 
cycle, and that the administration of additives for platelet activation was not 
deemed necessary. For the remaining statements, consensus of uncertainty (a 
median score of 3) or an inability to reach consensus was observed. Therein, 
the expert consensus group was unable to provide further information from their 
collective experience on the optimal volume, platelet concentration, addition of 
anticoagulant or leucocyte level. It is worth noting that though 71% of 
respondents did agree with the statement that 1ml of PRP was the minimum 
volume necessary, the overall score distribution resulted in an IQR above the a 
priori limit of one. The findings of limited consensus on PRP formulation, 
therefore, support the current call for improved reporting of PRP formulations, 
and studies undertaking formulation comparisons in an effort to greatly enhance 
the knowledge base in this area.  
Levels of consensus on the administration technique were equally lacking. 
Consensus could not be reached on the application of local anaesthetic, either 
to the skin/subcutaneous tissues, or deeper into the tendon itself, whether 
Ultrasound guidance for administration was preferable or a guide as to the 
optimal needle size. The needle size statement was altered between rounds 
two and three following the free text comments by several participants, but this 
did not reduce the overall dispersion of results. Consensus was reached on the 
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requirement to deliver the PRP within 30 minutes of preparation, which is in 
accordance with a recent synthesis of available evidence [297]. Interestingly, 
there was consensus on the use of a fenestrated needle administration 
technique over a single shot approach, an aspect that currently remains 
controversial in the research literature with conflicting results from large 
systematic reviews [106, 117].  
Administration strategy garnered two out of four statements reaching 
consensus. The participants reached agreement that patients should be 
followed up following the first administration to discern the need for a second 
injection. This opposes the studies employing standardised multiple 
administration methodologies [302, 303], and is in accordance with the only review 
of multiple administration strategies conducted through retrospective cohort 
analysis [304]. Currently, no prospective studies have compared PRP 
administration strategies. Consensus was reached in favour of offering surgery 
for treatment failures: subgroup analysis found that surgery was favoured by 
surgeons, but not by the group containing radiologists and sports physicians. 
Consensus was not reached concerning three injections being the maximum in 
one clinical episode, further research or expert consensus measurement could 
be considered to assess injection numbers either side of this value. Although 
75% of participants agreed that PRP could be reconsidered if symptoms were 
to reoccur, the spread of the responses was too great to provide a clear picture 
and the IQR exceeded one.     
Partial consensus of agreement was found for the post-procedural care 
statements. The participants did not deem immobilisation of the elbow to be 
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necessary following the procedure, but 48 hours of avoidance of light loads is 
recommended. However, the statement regarding avoidance of heavy loads for 
six weeks did not reach consensus and demonstrated a broad range of 
opinions. Further research would assist clinicians in refining this post-procedural 
element. Though Acetaminophen (paracetamol) and weak opioid based 
medications were deemed appropriate post-procedural analgesics, consensus 
could not be reached on whether NSAIDs should be avoided one week prior or 
for two weeks following PRP injection. Although the majority of respondents 
(68% and 71% respectively) agreed that NSAIDs should be avoided for these 
two periods, there was a considerable spread of results resulting in an IQR of 2 
for both statements. Although there are recommendations in the literature to 
avoid NSAIDs during this period [297], it is possible that limited prospective 
evidence, once again, appears to affect the ability to derive consensus on this 
important post-procedural element.  
Criticism from systematic reviews of PRP treatment often reference the 
heterogeneity or lack of validated Patient Reported Outcome Measures 
(PROMs) recorded as part of follow-up [101, 298]. Consensus was reached in the 
current study on the necessity to record validated PROMs in addition to the 
clinical examination. Furthermore, a strong consensus of agreement was 
recorded for the recommendation to conduct a clinical review of each patient 
undergoing PRP injection. However, consensus could not be reached on 
whether a Visual Analogue Scale (VAS) was beneficial, or whether adjunct 
imaging (MRI or USS) could be utilised as part of the outcome assessment.  
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Limitations 
The authors recognise that there are limitations to the current study. The 
sample size of 28 respondents represents a very small pool of international 
users of PRP injections in LET. Although this number would be insufficient for a 
simple survey, within the iterative methodology of a Delphi study this sample 
size is commensurate with published guidance on sample size to produce a 
representative pooling of judgments, particularly when stability between rounds 
can be demonstrated [290, 294]. Efforts were made to draw a varied international 
sample of research and clinical communities. However, a potential bias exists 
with a greater representative sample of surgeons over physicians and 
radiologists. Post hoc testing did not identify a disparity of agreement between 
these groups’ statement scores with the exception of the application of surgery 
as a second line treatment. This stability of response was also demonstrated 
between those categorised as high-volume and low-volume users, with no 
differences in statement scores.  
The method of statement production, through a semi-structured questionnaire to 
a smaller primary round of respondents, is in keeping with previously published 
Delphi studies [290]. However, the authors recognise that this strategy has the 
potential to miss certain domains of interest or produce an unrepresentative 
stance. Nevertheless, efforts were made to represent all domains identified in 
previous reviews of PRP [122] and at all stages participants were able to provide 
free text comments if they felt domains were not represented. Furthermore, in 
subsequent rounds, both agreement and disagreement with these statements 
were then assessed along with the spread of scores being utilised as the 
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consensus criterion, as recommended by Heiko (2012) [295]. Although 
percentage agreement levels are presented, and in some cases discussed 
above are >70% even though the IQR did not reach the consensus target, the 
authors feel that when assessing consensus on a novel therapeutic intervention 
the spread of scores, and therefore overall collective opinion, is the preferred 
consensus criterion, rather than a simple cut-off percentage. 
The use of PRP, regardless of the evidence base, appears to have advanced 
through the early stages of technology adoption outlined by Wilson (2006) [305]. 
Studies on the prevalence of use suggest that we have progressed through the 
innovators and early adopter of novel technology, and are now at a level of 
early majority adoption (between 18% and 45% using the technology) [103, 108], 
despite the clear lack of consensus on fundamental aspects of the treatment.  
Although no clear framework for the development of medical devices exists, if 
one were to extrapolate from the internationally recognised surgical IDEAL 
framework [306], levels of consensus from the present study would seem to 
suggest that PRP remains in the ‘Development’ or ‘Exploration’ phase, where 
there is a requirement for continued modification of techniques, indications, the 
reporting of adverse effects and development of parameters of quality. 
However, the majority of new publications and review articles are focused on 
Randomised Control Trial (RCT) data more befitting the Assessment stage [307], 
which should be utilised once stability of procedure, quality standards, and 
indications have been achieved.   
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7.7 Conclusion 
This study is the first to assess level of consensus in the applied use of Platelet-
Rich Plasma in Lateral Elbow Tendinopathy. Although the results should not be 
confused with evidence of effectiveness, the findings have utility in defining 
areas in which those with expert experience, acquired through a personal 
synthesis of published data and experiential practice, agree. In areas of 
agreement, this information can be used as clinical corroboration with reported 
evidence, and can guide those with more limited experience of the technique. 
Of course, what may be more relevant is where lack of consensus exists or 
where disagreement with manufacturers’ guidance is apparent. Though 
consensus existed on many of the aspects of patient selection, this study has 
identified a striking lack of consensus on optimal PRP formulation and many 
aspects of the delivery techniques, reinforcing calls for improved reporting in 
clinical trials and a more thorough dose-dependent exploration [122, 297]. Although 
avoidance of PRP treatment in those with coagulopathy, drug-induced or 
otherwise, was not deemed necessary, the peri-procedural use of NSAIDs, 
steroid injections, and local anaesthetics are not held with consensus by this 
expert group and require further study. The findings from this study support the 
requirement for a more structured approach to the fundamentals of PRP 
application and future research.  
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8 Chapter 8 - A Feasibility Randomised, Controlled Trial of 
Platelet-Rich Plasma injection vs Surgery for Chronic 
Lateral Elbow Tendinopathy 
8.1 Abstract 
Background 
Lateral Elbow Tendinopathy is a common condition of middle age. Though often 
self-limiting it can be associated with significant life-impairing disability. In 
chronic LET, surgery has traditionally been utilised following failed conservative 
therapy, recently there has also been an emergence of interest in Platelet-Rich 
Plasma therapy in this patient group. A prospective comparative study of these 
treatments has not been undertaken.   
Methods 
The feasibility of conducting a full-scale randomised prospective trial was 
assessed. Twelve participants were randomised to receive either open surgical 
release or two injections of leukocyte-rich PRP delivered under ultrasound 
guidance. Primary outcome was the measurement of recruitment and safety. 
Secondary outcomes were Patient Reported Outcome Measures (PROMs), 
qualitative analysis of patient interviews, analysis of a trial team debrief and 
patient and public involvement group (PPI) and adherence to reporting 
guidelines.     
Results 
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Target sample was achieved in 10 months. Recruitment rate was 86% (12/14). 
One participant dropped out of the surgical group prior to intervention and one 
participant from the PRP group crossed over following failed treatment at three 
months, there was no loss to follow-up. All PROMs scores improved over a six-
month follow-up period. Patient safety concerns were highlighted through 
qualitative interviews with significant injection-induced discomfort. Adherence 
with PROMs data collection was excellent and participants and PPI group 
preference this as a primary outcome.   
Conclusion 
This study confirmed the feasibility of conducting a full-scale randomised 
prospective trial comparing open surgical release to PRP with PROM-based 
primary outcomes. However, qualitative analysis, which has not previously been 
applied to PRP research, highlight significant injection pain that should be 
recognised as part of any future protocol and appropriately managed. 
Intervention-related pain assessment is also recommended.     
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8.2 Overview 
The following chapter assesses the feasibility of conducting an interventional 
trial in LET. It aims to discover whether it is possible to adhere to a best 
available evidence-based study protocol, whilst observing recognised trial 
reporting guidelines. In doing so it evaluates the feasibility of a patient-centred 
approach to LET research, with attention paid to adverse event evaluation and 
the ability and burden of using PROMs by applying both quantitative and 
qualitative data collection techniques    
8.3 Background  
Although LET is managed at a rate that is equivalent to hip and knee 
osteoarthritis in primary care [107], there is no consensus or standardised 
guidance on the optimal management of LET [99]. A vast quantity of options exist 
ranging from rest and analgesia to surgery, yet large systematic evaluations of 
treatments only reveal uncertainty as to their relative effectiveness [101, 118, 119]. 
Though non-operative management is successful in more than 90% of cases 
[308], for those patients with symptoms persisting for over six months, surgery 
may be offered. Debridement of the common extensor tendons has been 
reported to yield good to excellent results [70], with clinical remission of 
symptoms of up to 97% at 10 years [124]. However, it has also been reported 
that 24% of post-surgical patients remain in pain at one year [211] and the 
surgical procedure carries the associated risks of infection, haematoma, and 
nerve injury [308]. It is also prohibitive in terms of both healthcare costs and 
economic impact to the patient owing to a protracted recovery period and 
avoidance of exacerbating activity for up to three months [118] . In view of these 
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concerns, there has been a recent interest in alternative injection therapies, with 
the particular emergence of Platelet-rich Plasma.   
Platelet-rich Plasma (PRP) relies on the concept of delivery of humoral 
mediators that promote normal tendon healing [309]. PRP contains a concentrate 
of platelets, isolated from the patients’ whole blood using cell-separating 
systems [310]. Though clear guidance is not yet available, PRP is purported to be 
most effective in chronic cases where symptoms have been present for longer 
than three months  [118, 119], of the preparations of PRP, the leukocyte-rich 
variant has been recommended [117], ultrasound-guided injections have also 
been recommended over anatomically-guided techniques [261] and patient-
reported outcome measures (PROMs) have been recommended as the primary 
outcome measure [101]. On the question of control groups, corticosteroid 
injection, though commonly applied, are felt to be an inferior comparator due to 
the negative long-term effects [96], local anaesthetics have been shown to have 
a detrimental effect on the tendon itself [311, 312] and also interfere with platelet 
functionality by decreasing aggregation [313]. The use of saline injections as a 
placebo has also been questioned, where a high volume injection may in itself 
induce a healing response [117, 314]. The question of injection number has also 
been raised, with calls for trials to assess the therapeutic effect of two injections 
in previously treatment-resistant cases  where the efficacy of a single injection 
remains in question [119, 277].  
The clinical equipoise between surgery and PRP for LET has been recently 
reported in two retrospective cohort studies [315, 316]. Owing to this equipoise, the 
comparison of the current gold standard (open tennis elbow surgery), to the 
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novel intervention (PRP) of which the formulation and administration is guided 
by the best available evidence whilst also attempting to assess knowledge 
gaps, would seem both ethically acceptable to patients and clinically relevant.    
No full-scale randomised trial has been undertaken to compare these two 
interventions. Therefore the aim of this feasibility trial was to establish the 
projected patient eligibility, recruitment rate and adherence to interventions and 
outcome assessments to inform a future study design. It was also vital to 
ensure that the study was able to adhere to the reporting principles outlined in 
the CONSORT statement for reporting randomised trials [317] and recently 
published Minimum Information for Studies Evaluating Biologics in 
Orthopaedics (MIBO) guidelines [122].  Furthermore, no previous assessment of 
patient acceptability, of both the trial design and PRP intervention, has 
previously been undertaken. Though PRP use is increasing [103, 108] and is 
deemed safe and acceptable in principle, the paucity of any qualitative data on 
patient acceptability is surprising.  Previous trial reporting of adverse events has 
also been criticised [105], the single attempt at data extracted from injection trials 
in LET has highlighted pain as being the most commonly reported side-effect 
[105], but no elaboration on the details of this has been made.  
8.4 Methods 
Study design overview 
This trial was a parallel group, randomised, prospective feasibility trial. The trial 
protocol, conforming to SPIRIT guidelines [318], was registered with 
clinicaltrials.gov (NCT02755727). It was approved by the National Research 
Ethics Service (NRES) Devon and Torbay Research Ethics Committee (REC) 
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and South West REC (appendix 18). The study was funded through the 
attainment of a Royal Devon and Exeter Hospital Small Grant Award. No 
external industry sponsorship was gained. All study participants provided written 
informed consent. Reporting of the feasibility trial is in concordance with 
CONSORT guidance for parallel group pilot and feasibility randomised trials 
[319], and Patient-Reported Outcome use [320].   
Setting and participants 
This study was undertaken at the Royal Devon and Exeter NHS hospital, 
Exeter, UK. Recruitment was undertaken in the hospital orthopaedic outpatient 
department. All attendances were secondary care referrals from primary care 
physicians. Participants were screened by two Consultant upper limb surgeons 
(CS and WT) and provided with patient information sheets (appendix 19). 
Interventions were performed in the same hospital with surgery performed at 
the Princess Elizabeth Orthopaedic Centre and injections performed in the 
hospital's radiology department. Twelve participants were selected for this 
study. This number was selected as an achievable target within a 12-month 
single institution model, which would produce adequate qualitative and 
quantitative data for feasibility assessment and make the best use of a pump-
priming research grant. All participants were provided with an information leaflet 
outlining the study aims, the two interventions, and follow-up process.  
Inclusion and exclusion criteria 
Patients diagnosed clinically as experiencing LET with a symptom duration of 
more than six months were eligible for inclusion. Patients were also required to 
have failed conservative treatment (physiotherapy, oral analgesia, and activity 
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modification) and have a baseline elbow pain score of >3/10 on a visual 
analogue scale (VAS). All had undergone plain anteroposterior and lateral 
radiographs to exclude other sources of lateral elbow pain.   
Patients were excluded from inclusion if they were unfit for surgical intervention, 
had undergone previous elbow surgery, had previously undergone PRP 
injection, suffered from systemic autoimmune rheumatological disease, 
received immunosuppressive treatment, had undergone local steroid injection 
within three months of potential recruitment (at any site) or were unable to 
comply with follow-up or previously been treated with biological therapy for their 
LET.  
Randomisation and interventions 
Potential participants, once identified by the consulting surgeon, were referred 
to one of two project co-ordinators (JE and SG). Participants were screened on 
site and once eligibility was confirmed, were invited to participate through both a 
verbal discussion and after reading a patient information sheet. Consent and 
baseline outcome assessments were undertaken within the same appointment.  
Randomisation was undertaken using a 1:1 allocation to open surgery or PRP 
injection using sealed envelopes. Envelope randomisation and storage was 
undertaken by a third party not associated with the study. Owing to the 
difference in treatments, blinding of the patient or treating physicians was not 
deemed pragmatic within the context of a feasibility trial.   
Surgery 
A standardised Nirschl surgical technique [124] was used.  This involved the 
patient undergoing a general anesthetic.  An incision centred over the lateral 
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epicondyle was made and the plane opened between ECRL (Extensor Carpi 
Radialis Longus) and EDC (Extensor Digitorum Communis) to expose the 
damaged ECRB (Extensor Carpi Radialis Brevis) tendon.  The amount of 
abnormal tendon was documented. All abnormal tissue was excised.  EDC was 
also inspected and any abnormal tissue documented then excised.  The 
footprint of the excised ECRB +/- EDC was cleared of soft tissue and the bone 
scored with an osteotome to promote bleeding.  The interval was sutured closed 
and the skin wound closed with an absorbable subcuticular suture.   
Injection 
Participants received two injections spaced two weeks apart. They were asked 
to refrain from using any Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for 
two weeks prior to the injection. A leucocyte-rich PRP preparation was 
produced and the procedure was undertaken by a musculoskeletal radiologist 
using ultrasound control. 
For trial validity, the advanced Arthrex Angel™ system was chosen (Arthrex, 
Naples, Florida). This allows an automated, closed system, platelet capture that 
produced a leucocyte-rich PRP formulation in liquid form.  
In the outpatient setting a 40ml sample of venous whole blood was taken from 
the patient’s anticubital fossa using standard phlebotomy techniques. This was 
mixed with 6mls of Anticoagulant Citrate Dextrose-A (ACD-A) (7:1 ratio of whole 
blood to anticoagulant). Addition of an activating agent was not undertaken. The 
2% haematocrit double spin protocol was utilised as per the manufacturer’s 
recommendation for tendinopathy applications (Spin 1 @ 3500 rpm for 2 
minutes, Spin 2 @ 3000rpm for 9 minutes). Constituent separation was 
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automated using proprietary technology within the Angel system. Utilising the 
manufacturer’s dilution tables, a 40ml sample of whole blood will produce a 
platelet concentration of 6.58x baseline in a 2ml yield and 4.54x baseline in a 
3ml yield. White blood cell concentrations are 0.97x baseline in a 2ml yield and 
0.67x baseline in a 3ml yield.  
PRP was injected within five minutes of preparation. The sample temperature 
was not modified. Prior to injection, the skin was cleaned with 2% chlorhexidine 
spray. No local anaesthetic was administered. Injection was delivered under 
ultrasound control using a 5ml syringe and 23g needle. A fenestrated (pepper 
pot) technique was used. The tendon was fenestrated nine times and the PRP 
delivered in small aliquots during each fenestration. All injections were delivered 
by a single fellowship trained Consultant musculoskeletal radiologist with six 
years of consultant experience using a Siemens-Acuson Antares (SIEMENS 
medical solution, Mountain View, California, USA) with a 13 MHz linear array 
probe.  
Post-operative and post-injection protocol 
Following operative intervention, the participants were placed in a wool and 
crepe bandage and a broad arm sling. The bulky bandage was removed at 48 
hours and full active range of motion was initiated as pain allowed. A graduated 
resistance programme was undertaken at home from two weeks following 
advice from a physiotherapist, this included a graduated resistance programme 
starting with eccentric strengthening and progressing to concentric loading. 
Return to work for manual jobs or sport was advised at six weeks. Heavy 
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activities or heavy work before six weeks was to be avoided. Oral analgesia as 
per the patients’ preference was advised for pain control.  
Injection participants were placed in a broad arm sling which was advised for 
the first 48 hours. Full active range of movement was encouraged as soon as 
patient comfort allowed. The participants followed the same resistance 
programme but were not restricted in load at any point. Symptom-led 
progression to full loading was requested. Return to work for manual jobs or 
sport was advised at three weeks but was participant directed. Participants 
were asked to restrain from taking Non-Steroidal Anti-Inflammatory Drugs 
(NSAIDs) for the first six weeks. Following feedback from the first two 
participants, ice packs were suggested for the first 48 hours following injection if 
required for symptomatic pain relief.  
Outcomes and follow-up 
Primary outcome measure: feasibility of a full-scale randomised trial. 
Number of eligible participants, number recruited, adherence to intervention and 
loss to follow-up was recorded. The strengths and weaknesses of the research 
process and design were determined through a debriefing process with 
research team members and qualitative interviews with participants.  
Secondary outcome measures 
Participants were asked to attend follow-up appointments at six weeks, three 
months and six months following the intervention.  
Patients completed the quick Disabilities of Arm Shoulder and Hand 
(QDASH)[207], Oxford Elbow Score (OES)[142] and Patient-Rated Tennis Elbow 
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Evaluation (PRTEE)[206] at baseline and at all follow-up appointments. These 
three Patient Reported Outcome Measures (PROMs) meet minimum criteria for 
recommendation in LET in the previously documented EMPRO systematic 
review. The generic health measure EQ-5D-3L [321] was also recorded and 
participants were also provided with a pain diary for completion of a Visual 
Analogue Scale (VAS) at the time points,  day one, two, seven, week two, six 
and three months and six months.  
Qualitative participant assessment 
To address the lack of reporting on PRP injection acceptability, adverse events 
and patient experience during this feasibility trial, we undertook qualitative 
interviews of those participants who received the PRP intervention. Semi-
structured telephone interviews were conducted by a member of the research 
team (JE) using a topic guide designed to address the patient-focused aspects 
of feasibility trials suggested by O’Cathain et al (2015) [322] (appendix 20). 
Interviews were conducted at varied stages in the patient rehabilitation 
schedule. The interviews were transcribed verbatim (example in appendix 21) 
and analysed using stepwise thematic analysis. Thematic analysis is an 
approach based around the principle of grounded theory, whereby the 
interpretation of the data is ‘grounded’ in the perceptions and concerns of the 
participants, that is, that the hypothesis is developed from the data, rather data 
collection being used to test a predefined hypothesis. Applying this principle, 
thematic analysis is a method of identifying, analysing, organising, describing 
and reporting themes found within a dataset [323]. Analysis was undertaken by 
three researchers (JE)(AD)(IP) who have all received qualitative research 
219 
 
 
training. A six-phase thematic coding approach was used [323], whereby the 
researchers independently familiarised themselves with the data, then 
individually  produced initial codes (recognising important moments within the 
data),individual thematic coding (whereby notable themes and patterns emerge 
from the document and are recognised as implicit or explicit common ideas 
within the data), team review of trends in codes, amalgamation of codes and 
derivation of consensus within the codes (resulting in a coding matrix (appendix 
22 ) to summarise the thematic structure) and report production through 
synthesis of data. The qualitative data were interpreted in reference to the 
questions:  
1. What was the participant experience of the intervention (PRP)? 
2. What was the participant experience of the trial? 
3. Is PRP an acceptable and appropriate intervention for further study?    
Qualitative analysis was undertaken in NVivo qualitative data analysis software 
(QSR International Pty Ltd. Version 11, 2017) 
Patient and Public Involvement 
To inform the outcome measure assessment within this feasibility randomised 
trial, a patient and public involvement (PPI) group was set up to discuss the 
application of patient-reported outcome measures (PROMs) within LET 
research, with a focus on discussion of their utility and collection methods. 
Adverts were placed in local newspapers for participants previously diagnosed 
with LET to attend an open meeting. Open discussion, following introduction to 
paper-based and electronic PROMs collection methods was undertaken. 
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Discussion themes were recorded and discussed between three PPI co-
ordinators to reach a consensus on overall group opinions and themes.  
8.5 Results  
Recruitment 
The Consort flow diagram outlining recruitment, assignment and interventions is 
seen in Figure 8.1. The recruitment period ran from June 2016 to April 2017 in a 
single, two surgeon, orthopaedic outpatient clinic. All LET patients were 
approached during this period, which equated to 14 individuals. Baseline patient 
demographics can be seen in Table 8-1. No participants were taking antiplatelet 
medication, were diabetic or had known inflammatory conditions. Prior to 
delivery of the intervention, one patient withdrew from the study from the 
surgical arm. This patient had polio, and though eligible through our 
inclusion/exclusion criteria, stated that as it was their ‘good’ arm that was 
affected, she would have had the PRP intervention had she been randomised to 
it, but was not prepared to undertake the proportionally longer period of 
immobilisation related to the surgery. Within the PRP group, one patient 
crossed over to surgery following no clinical improvement at the three-month 
follow-up. This left five patients in each group who were followed up to the six-
month primary end-point. There was no loss to follow-up. The feasibility study 
was stopped at this point to complete qualitative interviews and research team 
debriefing.   
 Age Gender Hand 
dominance 
Occupation  Symptom 
duration  
PRP group 46.2  4 female 3 non-dominant  1 manual  13.5 months 
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(38-51) 2 male 3 dominant 5 sedentary (6-24) 
Surgery group 56  
(43-63) 
4 female 
2 male 
2 non-dominant 
4 dominant  
2 manual  
4 sedentary 
19 months 
(12-24) 
Total 51  
(38-63) 
8 female 
4 male 
5 non-dominant 
7 dominant  
3 manual 
9 sedentary  
16.3 months 
(6-24) 
Table 8-1: Participant demographic information - mean (range) 
 
 
 
 
 
 
 
 
Figure 8.1: CONSORT flow diagram 
 
 
Interventions 
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All participants were treated within the National Health Service, consequently 
following recruitment they were placed on standard waiting lists for surgical 
intervention (surgical group) or interventional radiology (PRP group). The 
median delay between recruitment and intervention for surgery was 54 days 
(range 47-71) and for PRP 64 days (range 34-76). No adverse events were 
reported in the surgical group, in the PRP group all patients reported significant 
but temporary procedural pain, this is discussed in detail as part of the 
qualitative analysis. Post-operative protocols were followed by all patients.   
The median volume of PRP injectate gained following processing was 1.55mls 
(Range 1ml – 4mls). Processing of the 40-47ml whole blood sample yielded a 
red blood cell concentrated fraction of 19mls (17 – 28mls) and a plasma fraction 
of 20mls (19-23mls). All injections were delivered within five minutes of 
processing. Pre-injection ultrasound evaluation within the PRP group of the 
common extensor origin revealed hyperaemia in all cases, three patients with 
central footprint tears of >5mm, two patients with small spurs <3mm in size, one 
patient with a 3mm central calcification lesion within the tendon. Of the surgical 
group, interoperative assessment reported a degenerative injected appearance 
of the ECRB in all cases, the presence of osterophytes at the ECRB insertion in 
one patient, a full thickness tear requiring suture anchor fixation in one patient, 
and a partial tear with a small plica and Grade IV rim arthritis to the radial head 
in one patient. 
Outcomes 
As a component of the feasibility trial participants completed three elbow 
specific outcome measures and a generic health assessment (Table 8-2 and 
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Figure 8.2). Within completed questionnaires, there were no missing item data. 
Compliance with the pain diary was 50%, all of whom were PRP trial arm 
participants. Although statistical analysis was not applied to the outcome 
measures, owing to the small sample size, trend data show improvement over 
time in both groups and throughout all outcomes. It is notable that from similar 
baseline scores (PRTEE worse in PRP group and QDASH worse in surgical 
group), the six-month outcome of the PRTEE and QDASH for the PRP group 
implies a return to pain-free function, however, the surgical group average is 
15%- 20% of total score. As an estimate of the magnitude of the difference 
between the groups, it is notable that the effect size in favour of PRP for the 
QDASH and PRTEE is 0.8 for both outcomes signifying a large effect in 
comparison to surgery [324]. These differences between PRP and Surgery are 
not reflected in the OES. The EQ-5D-3L, represented as UK index scores 
(using the Time Trade-Off (TTO) and Visual Analogue Scale (VAS) validation 
techniques) and EQ5D VAS again show a gradual trend to an improvement 
over the study period. Large differences in all outcomes between the three and 
six-month collections, with continued improvement and lack of a clear plateau in 
any outcome, shows the need to extend the outcome to at least the six-month 
point.  
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Table 8-2: Showing mean (SD)(Range) of Patient Reported Outcome Measures (PROM) separated by treatment group.  
  
Baseline 6 weeks 3 months 6 months 
PRP OES Pain 26 (10.8)(12.5-43.75) 56.3 (29.6)(6.3-81.3) 81.3 (14.0)(62.5-100) 90.6 (10.8)(75.0-100) 
 OES function 46.9 (18.9)(12.5-68.8) 67.5 (27.7)(18.8-87.5) 92.5 (6.8)(87.5-100) 98.4 (3.1)(93.8-100) 
 OES Psychosocial 12.7 (12.9)(0-31.3) 48.8 (27.7)(9.9-68.8) 86.3 (10.3)(68.8-93.8) 93.8 (5.1)(87.5-100) 
 PRTEE 97.3 (28.1)(67.0-143.0) 58.2 (47.6)(17.0-134.0) 13.4 (6.3)(3.0-20.0) 4.3 (0.5)(4.0-5.0) 
 QDASH 60.0 (16.0)(45.5-84.1) 39.1 (29.1)(15.9-88.6) 15.6 (11.8)(7.5-36.4) 4.0 (3.4)(2.3-9.1) 
 EQ-5D-3L Index (TTO) 0.64 (0.28)(0.07-0.76) 0.67 (0.23)(0.26-0.80) 0.88 (0.16)(0.69-1.00) 0.94 (0.12)(0.77-1.00) 
 EQ-5D-3L Index (VAS) 0.66 (0.18)(0.29-0.73) 0.66 (0.20)(0.31-0.76) 0.87 (0.18)(0.67-1.00) 0.94 (0.12)(0.76-1.00) 
 EQ-5D-3L VAS 69.2 (19.6)(50.0-95.0) 82.0 (9.1)(70.0-95.0) 92.8 (2.6)(90.0-95.0) 92.3 (8.3)(80.0-98.0) 
Surgery      
 OES Pain 28.1 (11.0)(12.5-43.8) 67.2 (29.0)(31.3-93.8) 72.4 (27.7)(43.8-100.0) 90.0 (13.0)(68.8-100.0) 
 OES function 58.3 (10.2)(43.8-68.8) 71.9 (31.3)(25.0-87.5) 82.8 (20.0)(62.5-100.0) 91.3 (13.0)(68.8-100.0) 
 
OES Psychosocial 24.0 (15.5)(6.3-50) 60.9 (20.7)(37.5-81.3) 71.9 (31.7)(31.3-100.0) 81.3 (19.8)(50.0-100.0) 
 
PRTEE 78.2 (29.1)(37.0-114.0) 52.0 (47.0)(17.0-119.0) 35.8 (40.2)(0.0-72.0) 21.6 (21.4)(0.0-51.0) 
 
QDASH 53.1 (12.4)(38.6-68.2) 33.5 (27.7)(18.2-75.0) 22.2 (23.1)(0.0-43.2) 15.0 (14.2)(0.0-36.4) 
 
EQ-5D-3L Index (TTO) 0.44 (0.36)(0.05-0.80) 0.69 (0.17)(0.43-0.80) 0.82 (0.12)(0.76-1.00) 0.85 (0.21)(0.56-1.00) 
 
EQ-5D-3L Index (VAS) 0.53 (0.23)(0.27-0.76) 0.67 (0.14)(0.73-1.00) 0.80 (0.14)(0.73-1.00) 0.84 (0.22)(0.55-1.00) 
 
EQ-5D VAS 60.0 (13.2)(40.0-75.0) 72.5 (20.2)(45.0-90.0) 86.3 (9.5)(80.0-100.0) 77.0 (9.7)(65.0-90.0) 
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Figure 8.2: Box plots showing Patient Reported Outcome Measure (PROMs) median score (Box = 
IQR) (Whiskers = Interquartile Range) (Dots = Outlier values). 
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A power calculation was conducted using data derived from the PROM outcome 
collection. PROM-based primary outcomes are increasingly employed and 
encouraged by funding bodies and publishers alike [133, 147, 197]. The previous 
systematic review has outlined that the QDASH demonstrates the greatest 
evidence for validity in this LET cohorts and hence it is utilised in this case as 
the potential primary outcome. The trial would be powered for non-inferiority, 
under the premise of significant cost saving and amelioration of operative risk in 
the PRP group. The smallest detectable change in the QDASH is utilised as the 
equivalence limit, as a measure of the error of the instrument and the smallest 
change that is detectable between two scores that is beyond error. This can be 
calculated from the standard deviation (SD) of the feasibility studies baseline 
sample (14.3), using a technique advocated by Terwee et al [250]. Initially, the 
standard error of the measurement (SEM) is calculated as SD(baseline) × √1 −
𝐼𝐶𝐶, where the Infraclass Correlation Coefficient (ICC) is a measure of test-
retest reliability. This has been derived in upper limb musculoskeletal disorders 
as 0.94 [216, 325]. To account for the repeated measures of the outcome and a 5% 
probability of Type 1 error, the smallest detectable change (SDC) is calculated 
as 1.96 ×  √2 × 𝑆𝐸𝑀.  
Therefore: 
SEM = 14.3 ×  √1 − 0.94  = 3.5  
SDC = 1.96 ×  √2  × 8.0  = 9.7 
Using this figure of 9.7 and the baseline QDASH SD of 14.3 and powering for 
non-inferiority [326], using the equation n = f(α, β/2) × 2 × σ2 / d2, (where σ = SD, 
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d = the equivalence limit (SDC)  and f(α, β) = [Φ-1(α) + Φ-1(β)]2, where Φ-1 is the 
cumulative distribution function of a standardised normal deviate [327], then 76 
patients (38 per group) are required to be 90% sure that the  lower limit of a 
one-sided 95% confidence interval (or equivalently a 90% two-sided confidence 
interval) will be above the non-inferiority limit of -9.7. Alternatively, were the 
PRTEE used in this calculation, with the ICC of 0.89 [206] and baseline SD of 
29.1, 42 patients (21 per group) are required to be 90% sure that the lower limit 
of a one-sided 95% confidence interval (or equivalently a 90% two-sided 
confidence interval) will be above the non-inferiority limit of -26.75 (SDC). 
Qualitative assessment  
Interviews were conducted at a median of 19 weeks post-injection (Range 8.8 – 
27.7 weeks). The key themes identified by all the three qualitative researchers 
were mapped to the study questions (appendix 23). The themes were 
discussed among researchers and assessed for the level of saturation within 
this small cohort. Illustrative quotes were grouped to the research questions 
(Table 8-3).  
The most prominent finding relating to the participants’ experience of 
undergoing the PRP intervention related to the level of pain. The consensus 
among participants was that the pain was very significant and worse on the 
second injection. Strikingly it was commented by all participants that it was one 
of the most painful experiences of their entire lives.  Though the injection pain 
was temporary and distinct from the latterly experienced post-procedural pain, it 
remained very significant to participants who were very clear about their 
experiences many weeks after their injection. Though the injection was very 
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painful, the overall process of the injection was felt to be safe and conducted in 
an appropriate and supportive environment. The post-procedural pain was 
experienced by participants for some weeks, many developed personal coping 
strategies not initially part of the post-injection protocol, including intermittent 
use of a sling and avoidance of the use of the arm for any lifting tasks for some 
weeks post procedure. It was also commented that though the injection was 
painful, the interference in their life was acceptable, and in reference to the 
post-surgery protocol, was deemed to be preferable.  
Participants were happy to be part of the trial and did not appear to perceive the 
extra appointments and outcome assessment a burden. Of interest, it was also 
identified that none of the participants were aware that a trial was being done, 
and that the expectations of intervention following a secondary care referral 
were very low. Only one participant was aware that surgical intervention might 
be offered. When the study was introduced with randomisation to PRP or 
surgery, all participants were happy that it was the PRP that was offered. 
Participants volunteered an opinion on potential improvements to the post-
procedural care, with all suggesting that a short period of immobilisation was 
helpful. At the time of injection, three of the five participants volunteered that 
anaesthetic or sedation would be preferable, though equally, they deemed the 
short outpatient style of intervention highly preferable compared to the longer 
day-case surgical procedure.  
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Research Question and Themes Participant quotes 
What was the participant 
experience of the intervention 
(PRP)? 
 
Themes 
 Procedural 
o Procedural pain 
o Experience of health 
professionals 
o Safety 
 Post Procedural  
o Post-procedural pain 
o Post-procedural treatments 
o Post-procedure 
interference with quality of 
life 
 
 
 
 Oh, God. Um… It was excruciating. 
 I just - I don’t think you can prepare anybody for quite how painful it’s gonna be. 
 It was just that thinking, well, I thought my arm was gonna explode. 
 It was uncomfortable when it was done the first place time cuz it was certainly far worse the second time.. 
 Ooh-hoo. Um, I- Well, as you know, it was the most- one of the most painful things I’ve ever, ever done, I think. 
 I mean the surroundings and the people and everything was brilliant. I mean, [the nurse] was absolutely wonderful. She was 
just holding my hand and you know, um, and being really good and everything, so from that point of view, but I do- I do th- 
definitely think that some, if it’s possible to give some sort of local anesthetic or something, because it- it was awful. 
 You know, um… Yeah. I mean, I- At no point did I ever feel unsafe or anything like that. I mean, it was all done, you know, it- 
in-in good, clean conditions an-and what have you and everythi- every step was explained to me 
 Um, the recovery was a good couple of hours post-injection. It was still incredibly painful — really, really sore — um, and I—
I—I don't think I'm a wimp, but it was really painful. 
 Um, with the second one, I would say probably about four—about a month or so 
 It was quite traumatic, and then coming home afterwards, um, you think about, you know, you sort of, um, at- You sort of sit 
and think about the pain that you were in, and it was quite- quite upsetting for a few days afterwards, actually. 
 It was, you know, by the time I’d sort of got back into the car and everything, um, it was, you know, th-the pain was sort of 
virtually, you know, gone from the- the extreme pain 
 So. Yeah. Yeah. I, um, I used the sling. I used the sling, um, fully for about two days. Um, and [10:00] I just took a paracetamol 
, um, and that seemed to just sort of help with any residual pain 
 Um, yeah. I definitely, definitely needed someone with me. Um, and I can’t remember if I’d actually to- I don’t think I’d taken 
any pain killers before I came that first time. 
What was the participant 
experience of the trial? 
 
Themes 
o Knowledge of trial 
o Reflection on being in a trial 
o Burden of being in a trial 
 Oh, it’s been absolutely brilliant, ‘cause it’s just sort of like, you know, if- You feel like you’re part of something that if you can 
then help a process along, which then helps, you know, other people  [13:47] to then, uh, avoid surgery or to, um, get back 
to, like, living life normally, ‘cause I mean this is something I’ve not been able to do for a long time is to sort of live life 
normally, but if it’s something that can help people to get back to work or to get back to living life normally, brilliant. I’m- I’ve 
been- I’ve been really pleased to be able to say I’ve been part of that. 
 Um, quite frankly, I was prepared to do anything to avoid that surgery. Um, yeah—no, I was—I was more than happy—
ecstatic, in fact, to be, um, even considered for it. 
 No, not really, um, I appreciate that, if you don't do the—the—the pain scoring stuff um… that wasn't, you know, very bad. 
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o Reflection on possibly being 
randomised to surgery 
o Improvements 
 
 No, not at all. No, not at all, because it worked. 
 No, it was all right. No, it was fine, actually 
 Well, I imagine it probably would have been more painful for a longer length of time, cuz any sort of surgery tends to be cuz 
you've got ripped tissues to repair. 
 You know, so I’d kind of gone in that. I really didn’t want to have the operation and be .. out of action for six weeks. 
 [If I’d had surgery] the six-week recovery period, which, to me, is an awful long time not be able to do normal duties at work. 
 So it just felt- It just felt to me like it was, um, an easier optio- uh, an easier version of the surgery, if that makes sense 
 It's like you're either losing it for six weeks cuz of surgery healing, or I have three days where y—where you're—I'm one-
handed for three days 
 Um, a shorter time span, and the only other thing I found was w-with- with it not being post-surgery, if you didn’t have to 
worry about, um, you know, b- getting it wet or worry about stitches or things like that. 
 It wasn’t, you know, um, uh, yeah. Maybe, I dunno, a little bit of pain relief might have been nice, um, even if it was just, you 
know, like, all pain relief. 
 Maybe, um, I think there's, like, mild sedation, like, when you go to the dentist and have stuff like that. 
 I do- I do th- definitely think that some, if it’s possible to give some sort of local anesthetic or something, because it- it was 
awful. 
Is PRP an acceptable and 
appropriate intervention for 
further study? 
 
Themes 
o Procedural pain 
o Safety 
o Repeat treatment  
o Recommendation or not of 
treatment 
 
 Procedural pain and safety quotes as above 
 I would- wouldn’t hesitate to… To say to people, “Oh, yes. You know, do it 
 Yeah, absolutely, uh, 100 percent I would recommend it, and all I would say to people if they were to go to through with it is, 
uh, get a that arm in a sling and take time off work, I think—I think you should really push for that. I—I think I could have 
done—I could have done more for myself on the first injection. 
 Yeah. Yeah. Yeah, I wouldn’t hesitate to, to be honest. 
 And, um, no, yeah, I, I would do it again. I would prefer this sort of thing to surgery, and I was, as I've said to that before, then 
if you get tennis elbow then, if you have to opportunity to try that, then I would try it. 
 But if it was offered to me again on something else, which I had only just started having a problem with, then I would say, 
“Yep. Fine. Go for it,” and even if it was as painful as it- as it was, um, I would say, “Yes. Do it.” 
 And actually, if, you know, I know that I would go for it again, so if it helped me, it can help other people 
Table 8-3: Qualitative data – Research Question with identified themes and key illustrative quotes. 
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Though all participants commented that the procedure was very painful, it is of great 
interest that when asked whether they would have PRP again or recommend the 
treatment to friends or family, without exception they all commented very positively. 
The overall impression of the process and procedure was that it was safe and 
appropriate. One of the participants had crossed over to surgical intervention due to 
treatment failure at three months, even with the treatment failure and pain 
experienced as part of the intervention, this participant would have the PRP 
intervention again and would recommend it. 
Study team debrief  
The study process was discussed between the study chief investigator, lead 
research nurse, lead surgeon (undertaking the surgical intervention) and the 
radiologist undertaking the PRP injection. The recruitment through the outpatient 
department was deemed feasible, however, baseline data collection was initially 
missed on two participants due to unavailability of the research packs. One post-
surgical patient was placed in the physiotherapy-led discharge route rather than the 
designated research clinic, resulting in loss of three-month outcome data. The 
process of data collection and PRP injection delivery was refined through the study, 
where the resultant strategy of participants attending 20 minutes early, allowing 
blood sample collection, then data collection of PROMs, ready for their designated 
appointment with the radiologist, resulting in a total outpatient time of one hour per 
participant.  
All members of the research team commented on the pain experienced by 
participants at the time of injection. The lack of local anaesthetic, in line with 
treatment recommendations, without substitute with pre-intervention analgesia was 
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deemed inappropriate. The use of conscious sedation techniques in the theatre 
setting was promoted as a potential approach whilst recognising the resource and 
cost increase associated with this strategy. 
Patient and Public Involvement 
A public meeting was held on the 18/4/2017. Nine participants, who suffer with, or 
have previously suffered from LET attended. One member of the group was a 
participant in the study. Reflections on the open discussion with the PPI group 
regarding outcome measurements and data collection methods were recorded and 
synthesised between two attending PPI co-ordinators and the study Principal 
Investigator. There was a positive response on the use of elbow specific 
questionnaires for the assessment of the impact of interventions in a trial. The 
participants assessed the OES, QDASH, and PRTEE and although all were deemed 
appropriate, the 10-point scale and particular questions on the PRTEE was liked the 
most. The general heath questionnaires (EQ-5D-3L and HowRU score were 
assessed) were not deemed relevant and an annoyance to complete. Overall there 
was a preference for paper-based questionnaire completion over online. There was 
also a desire to include a free text option to allow elaboration on the pain triggers 
and character.  There was a split in the group regarding the utility of knowing one’s 
own score or tracking the improvement individually. Some felt this would be useful to 
individuals within an interventional trial, others felt that they would not use this 
information at all. What they particularly liked about all the scoring methods, was the 
objectivity it imparted to the clinician about how significant this problem can be to 
their lives, in this regard it was deemed highly appropriate to have this as the primary 
outcome in a clinical trial.  
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Reporting standards  
This feasibility study has been reported in accordance with the CONSORT guidance 
for pilot or feasibility trials. The ability of a larger trial to comply with the reporting 
standards of the CONSORT PRO extension guidelines was also assessed. From 
details within this feasibility trial, we feel that 100% compliance with these guidelines 
is achievable. For intervention reporting, compliance with the Template for 
Intervention Description and Replication (TIDieR) and Minimum Information for 
Studies Evaluating Biologics in Orthopaedics (MIBO) was assessed. Full compliance 
with the TIDieR checklist was achieved, for the MIBO checklist, laboratory analysis 
of whole blood prior to processing for PRP production, and laboratory analysis of the 
PRP samples themselves was not undertaken within the feasibility study. This 
aspect will need to be addressed within a full scale randomised trial. Completed 
checklists can be found in appendix 24.  
8.6 Discussion 
This study has assessed the feasibility of running a full-scale randomised trial 
comparing Platelet-Rich Plasma (PRP) injections to Surgery for chronic Lateral 
Elbow Tendinopathy (LET). Current best available evidence has been used to design 
a standardised PRP production and delivery protocol that published laboratory-
based and comparative studies suggested as the most therapeutic. Recruitment 
rates and retention were acceptable and the feasibility trial has informed and 
highlighted the utility and importance of Patient-Reported Outcome Measurement 
(PROMs) in a study of this nature. This is also the first PRP study to confirm the 
ability to conform to the reporting standards of the CONSORT, CONSORT PRO, 
TIDieR and MIBO checklists in PRP research. However, qualitative analysis, which 
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has not previously been utilised in PRP research, has identified a significant source 
of patient morbidity not traditionally recorded or reported on the pain associated with 
injection delivery.    
The recruitment for this feasibility showed that, within a National Health Service 
District General Hospital serving 460,000 people, the secondary care referral rate for 
LET is low. The recruitment of 12 participants took 10 months. Therefore the 
recruitment for a full-scale randomised trial, in reference to the above power 
calculation, would take over five years. Therefore a multicentre approach is likely to 
be required to complete a trial of this nature within a reasonable period of time. The 
retention of patients in this feasibility study was 100%, however, it should be noted 
that there was one withdrawal from the surgical group and one cross-over from PRP 
to surgery. This 17% non-treatment allocation finding should be taken into account in 
the implementation of a full trial. In reference to the withdrawal, as the patient 
subsequently volunteered that they would have only continued in the trial had they 
been randomised to PRP, it is of vital importance that potential recruits are 
counselled correctly at the recruitment stage. Findings from this trial would suggest 
that a follow-up period for the primary end-point would need to be at least six months 
as gradual improvement was seen up to this point. Of note Merolla et al [328] who 
followed up PRP patients for nearly two years, demonstrated good treatment 
response within the first year, that then worsened when compared to patients treated 
with arthroscopic debridement of their LET, however Gaspar et al [329] reported 
sustained improvements up to three years. Though evidence is limited, it may be 
prudent, therefore, to consider longer follow-up periods. 
Some of the most informative and compelling information within this feasibility study 
was gained from the qualitative data. Although pain has previously been reported as 
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a potential adverse event [105], the level of pain experienced by the participants was 
striking. Local anaesthetic was not given prior to the administration of the PRP, in 
line with recommendations from laboratory studies [311, 312]. The use of local 
anaesthetic infiltration is advocated by 60% of experts questioned as part of the 
Delphi consensus study into PRP use in LET (chapter 7) which may be due to a 
practice that is informed through personal experience, or lack of knowledge of the 
background science. However, this leaves 40% of PRP users whose patients may 
be experiencing significant pain. To our knowledge, pain at the time of injection using 
a validated technique such as a Visual Analogue Pain Scale, has never been 
reported and is not commented on in any systematic review. At the very least, we 
believe the collection of these data should be mandated and compared to different 
techniques. Information on the clinical outcome of PRP, administered with or without 
local anaesthetic infiltration, is also required to compare to the laboratory-based 
findings.  
Although participants reported very significant pain at the time of injection, it is 
pertinent to note that when asked to reflect on the experience, all responded that 
they would have the treatment again, would recommend it to friends and family and 
would still prefer it as a treatment option over surgery. This poses an ethical 
challenge to the researcher and clinician, in that the principle of “Primum non 
nocere” is juxtaposed with a patient desire for treatment, regardless of the 
discomfort. Researchers of lateral elbow injections should be very mindful of this 
quandary and ensure that everything is done to ensure that analgesia is optimised. 
Though sedation was suggested by two participants, three participants felt strongly 
that the anaesthetic component of surgery was a principle reason for them 
preferencing injection treatment. It may, therefore, be necessary, within a trial to 
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openly discuss the level of expected pain prior to treatment and offer sedation where 
requested. Future reporting of PRP trials in LET must include injection induced pain 
and this should be reported in line with the CONSORT extension for reporting harms 
[330]. It is also apposite to consider the potential effect of placebo in the design of 
future trials of interventions in LET. Although beyond the aims of this current 
feasibility study, the effect of placebo cannot be explored in a standardised two arm 
interventional study such as this and it remains highly relevant that both injection and 
surgery may have significant placebo effects. Limited placebo injection and placebo 
surgery trials have been undertaken in LET [125]. Future investigators should explore 
placebo designs with patient involvement and carefully construct placebo protocols.    
The collection of Patient-Reported Outcomes as part of the follow-up process was 
logistically feasible and not seen as a burden by participants. Patient and public 
group involvement ratified the belief that the outcome measures collected data that 
was deemed important by LET sufferers. In line with the PPI recommendations, 
paper-based data collection should continue, this also is in line with the validity of the 
OES, QDASH, and PRTEE, which are yet to be validated for electronic collection [142, 
175, 243]. The previous systematic review (chapter 3) has identified the QDASH as 
demonstrating the highest levels of psychometric validity in LET populations and can 
be recommended within PRP vs Surgery trials. Of note is the PPI groups’ particular 
liking of the pathology-specific PRTEE from both a question item and scoring scale 
point of view. However, cross-cultural validity in a UK population and interpretability 
data (population norms and minimal clinically important difference data) though 
attempted, contain methodological flaws [228] that currently hinder its 
recommendation.    
Limitations 
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This feasibility trial is limited to the findings drawn from a small cohort of participants. 
However, the strength lies in the multimodal approach to assessing the feasibility of 
a larger trial, wherein the combination of secondary outcomes including PROMs, 
qualitative assessment, and PPI have provided valuable and unique insights. This 
feasibility study is attempting to address equipoise in the treatment of chronic LET in 
patients that have failed physiotherapy and conservative treatment approaches, 
consequently, the addition of a physiotherapy group as a control, though allowing 
better quantification of treatment effect, may not be justifiable in this patient group. 
Placebo injection or sham surgery, though highly relevant in the wider context of LET 
treatment, do not assist in the answering of the research question that a full-scale 
randomised trial based on this feasibility studies methodology is trying to answer. 
The current study did not blind the clinician and blinding of the participant is not 
possible, though this should be regarded as a limitation, the use of PROMs as the 
objective primary outcome reduces the potential assessor bias of more clinician-
focused outcomes.  
8.7 Conclusion 
This study has confirmed the feasibility of a randomised trial comparing PRP 
injection to open surgery in lateral elbow tendinopathy. Were it to be conducted in a 
similar healthcare setting, a full-scale trial is likely to require a multicentre approach. 
Patient-reported outcome measures are an appropriate and feasible primary 
outcome measure and dependent on population validity, the QDASH and PRTEE 
can be recommended. To enhance study validity it has also been demonstrated that 
within a stringent methodology, it is possible to conform to all necessary reporting 
guidelines. This is the first study to explore the patient experience of PRP injection 
with qualitative analysis and has identified significant pain at the time of injection as 
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a highly relevant factor that should be reflected on in the protocol design and 
reporting in all future PRP research. 
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9 Chapter 9 – Concluding discussion 
9.1 Overview 
The overarching aim of this research was to optimise the investigation of lateral 
elbow tendinopathy. Specifically, it applied a multiple methodology approach 
intending to address three key themes: to inform outcome instrument choice, to 
rationalise the delivery of injection-based interventions, and to assess if it is feasible 
and appropriate to apply these outcomes and interventional findings into a PRP trial? 
The body of this thesis is comprised of seven studies, the findings of which have 
been discussed within their relevant chapters. Each study addresses certain, or 
indeed multiple objectives related to the main themes; this chapter, therefore, 
attempts to synthesise the findings from these studies, discuss the study limitations, 
implications and the potential clinical and research applications.  
9.2 Summary of findings 
The work presented in this thesis contributes towards the evidence base for the 
investigation of interventional treatments in Lateral Elbow Tendinopathy by: 
 Identifying the patient-centred outcomes currently available in research on 
elbow tendinopathy and categorising their proportional use over time, within 
pathology types and geographical areas. (chapter 2) 
 Conducting a standardised evaluation of patient-centred outcomes in LET, the 
output of which provides evidence on the choice of outcome instrument for 
future research and clinical application (chapter 3)  
 Identifying psychometric attributes of patient-centred outcomes in LET that 
require further research evaluation to enhance their validity and utility in 
research and clinical applications (chapter 3) 
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 Assessing the ability of UK-based LET trials to conform to CONSORT-PRO 
guidance on the choice and reporting of patient-centred outcomes in LET and 
reporting that previously published research was not able to adhere to this 
modern standard (chapter 4) 
 Providing the best available evidence on the psychometric properties of 
patient-centred outcomes in a LET population within the UK (chapter 5) 
 Providing quantitative, qualitative and patient and public involvement evidence 
on the appropriateness and feasibility of using patient-centred outcomes in 
LET clinical effectiveness research (chapters 5 and 8)    
 Evaluating the anatomical basis for ultrasound guided lateral elbow injections 
using a cadaveric model and providing evidence that assists in rationalising 
injection volume and delivery techniques (chapter 6) 
 Assessing the level of expert user consensus in the patient selection, 
production, delivery and rehabilitation of LET patients undergoing PRP 
injection using an international sample and a validated iterative questionnaire 
methodology (chapter 7) 
 Identifying areas of clinical equipoise in the use and techniques of PRP 
injection that require further targeted research (chapter 7) 
 Evaluating the feasibility of conducting a randomised controlled trial of PRP 
injection versus current standard treatment that is in accordance with 
reporting guidelines (CONSORT, TiDIER and MIBO) (chapter 8)  
 Providing qualitative evidence on the impact and acceptability of PRP 
injection in the treatment of LET (chapter 8)  
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9.3 Outcome measure choice 
The synthesis of this theme was informed by the literature review (chapter 
1), the review of instruments (chapter 2), the standardised evaluation of 
instruments (chapter 3), the UK specific PROMs assessment (chapter 4), 
the PROMs validation study (chapter 5) and the feasibility RCT (chapter 8). 
 
The decision to concentrate on the utility and application of Patient Reported 
Outcome Measures (PROMs) was initially informed by the literature review. Though 
numerous approaches have been applied to quantify outcomes in LET, from 
biomechanical evaluation [77] and clinical tests [331], the current attention paid to 
PROMs is profound and has increased exponentially. The literature review 
highlighted the poor validity of clinical tests [76] and the consensus of opinion that 
outcomes should be patient-focused [147, 197], the review of instruments corroborated 
this by highlighting the increased application of PROMs as primary or secondary 
outcome measures, the qualitative interviews and patient and public involvement 
within the feasibility study supported this approach, with all parties commenting that 
these measures were appropriate and best supported their own perceptions. 
Although only a small aspect of the study, it is also worth noting that within the 
Delphi study, a statement that reached strong consensus was that validated PROMs 
should be collected as part of the treatment evaluation. 
The systematic review of instruments was the first to reveal the truly startling number 
of instruments available aiming to quantify patient-centred outcomes in elbow 
pathology. Even though many of the 72 instruments have only been applied a small 
number of times, the difficulties the research community may have in the 
interpretation and synthesis of information relating to this vast array of instruments 
was beginning to become apparent. The paucity of information on the pathology-
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specific use of patient-centred outcomes and the heterogeneity of use justified the 
requirement for the standardised EMPRO evaluation.  
The standardised evaluation (EMPRO) of patient-centred outcomes in LET initially 
assessed and collated the breadth of information available. This resulted in 15 
instruments for which information was available on their metric attributes. The result 
of this analysis was that only four of these instruments met the baseline quality 
criteria for use, the quickDASH, DASH, OES and PRTEE, all of which are classified 
as PROMs and hence the complete absence of clinician input for their scoring, thus 
corresponding with the multiple levels of support for the use of PROMs in onward 
research. It should be noted however that deficits in each of these outcome 
measures were recognised, and that improvements can be made that will optimise 
future score interpretation. The predominant factor being the lack of clear validation 
in pure LET populations. Interestingly, this factor may be an aspect of many 
musculoskeletal PROMs validations, and attempts at standardised evaluation, where 
multiple pathologies are used to validate scores targeting anatomical areas (eg 
shoulder/hip/knee). If one were to think of analogous examples, it would be very 
irregular to target a PROM at all respiratory pathologies, or expect the same metric 
properties of mental health instruments used to assess depression and bipolar 
disorder. This non-pathology based application of PROMs in elbow pathology has 
clear ramifications on the metric assessment and inhibits the best attempts at 
standardised evaluation.   
Following the EMPRO evaluation, a focused assessment of LET research outcomes 
in the UK was undertaken. This aimed to question whether, with the current levels of 
information, it is possible for UK-based LET research to comply with reporting 
standards for PROMs in trials. This identified both the misappropriation of outcome 
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measures and the need for formal evaluation of PROMs in UK LET populations. 
Validation of the PROMs was undertaken in a UK LET population sourced from 
primary, secondary and physiotherapy care. Owing to poor recruitment and retention 
this study is unable to make statements of the superiority of one PROM over the 
other, but it has trebled the current evidence base and offers the best available 
evidence that the high performing PROMs identified in the EMPRO paper do 
demonstrate appropriate psychometric properties in UK populations. The utility and 
burden of these PROMs in a UK population was also evaluated within a feasibility 
trial. Feedback from qualitative interviews was positive regarding the use and 
suitability of PROMs within a trial. The patient and public involvement group were 
equally positive about the use of PROMs in trials, and on reviewing the instruments, 
felt that the PRTEE contained items that most closely reflected their experience of 
LET. From the above studies, it can be recommended that within the UK, the use of 
the QDASH, OES or PTREE for the assessment of LET is valid and acceptable to 
patients, data from these studies can also ensure future compliance with the 
CONSORT PRO extension in UK based assessments.  
The feasibility of integrating PROMs into future LET trials was assessed. Within the 
feasibility trial, paper booklets containing the PROMs were used, which were 
deemed easy to complete within the outpatient department. Participants did not feel 
that this was overly burdensome, PPI feedback confirmed that this would be 
appropriate. It is vital however to recognise the potential bias within this population 
who were happy to be randomised into a trial or PPI group. It remains a possibility 
that this group may be particularly motivated and not representative of a wider 
population of LET sufferers. 
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Although explored only to a limited degree, the use of an electronic interface should 
also be discussed. For matters of data storage and processing, compliance with the 
PROMs structure and avoidance of missing data, there are strong arguments for the 
use of electronic interfaces. Interestingly, however, when discussed with the PPI 
group, it was commented by the majority that the paper form was easier, but this 
may relate to the particular interface that was demonstrated. Within the validation 
study, though an electronic version was available, there was very poor take-up of 
this option. Therefore, the application of an electronic data collection for PROMs in 
LET cannot be recommended, studies that aspire to use this technology should 
undertake further feasibility work to ensure that it is acceptable to patients and valid 
from a psychometric standpoint.  
This research is the first to quantify the utilisation of patient-centred outcomes in 
elbow pathology; it has identified the best-performing instruments in LET, and 
following the identification that they were not validated in a UK population, has 
expanded the knowledge base that can assist researchers and clinicians in their 
choice of PROM. Although it has also confirmed that it is appropriate and acceptable 
to patients, members of the public and experts to collect valid PROMs within a LET 
interventional trial, the low recruitment rate within the validation study may suggest 
that improved data collection techniques and/or instrument designs would optimise 
this further.    
9.4 Intervention and delivery technique 
The synthesis of this theme was informed by the literature review (chapter 
1), cadaveric assessment of injection technique (chapter 6), injection 
consensus study (chapter 7) and feasibility RCT (chapter 8). 
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The assessment of injection technique, with a particular focus on the application of 
Platelet-Rich Plasma (PRP), was guided by the background literature review. 
Although numerous interventions in LET continue to be assessed, it is the 
application of PRP that has particular attention in the research field [114] with an 
almost exponential rise in utilisation in clinical practice [297]. Interestingly, this 
increase in utilisation is not matched by systematic reviews asserting its efficacy [119]. 
The identification of this potential conflict motivated a further exploration into the 
fundamental basis for injection delivery, the surprising conclusion being that the 
question “where does the injection actually distribute?” had never been explored; this 
question would seem to be fundamental when one is delivering an injectate thought 
to be locally active. This element was studied while concurrently postulating that the 
increased utilisation of a technology could be exploited as a research commodity. 
Therein, an evaluation of expert consensus in the use of PRP for LET might reveal 
experiential trends that could hone future research or clinical application. An 
example of this is the postulation that systematic reviews have been unable to 
answer the question “how many injections of PRP should you administer in a single 
clinical episode?”, due to difficulty in both running randomised controlled trials 
assessing this, and the complexities of synthesising information from different 
studies. Therefore the question was asked, “Could a collective mass of experienced 
PRP users have found the optimal number of injections, due to individual trial and 
improvement?” This technique of assessing pertinent questions relating to PRP 
delivery was assessed using the iterative Delphi methodology. The final component 
of injection delivery assessment was integrated into a feasibility trial, where the best 
available evidence from a literature review informed the methodology.  
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The cadaveric assessment of injectate distribution found no difference between 1ml 
and 3ml injections or between single shot or fenestrated injection delivery. The 
distribution of the injectate through over 96% of the CET even with the 1ml single-
shot injections suggests that even this volume may be too high. This information is 
highly relevant for further studies investigating injection-based therapies. In the 
design of studies, researchers should, therefore, be able to answer two particular 
questions relating to their methodology. Firstly, if the efficacy of the injectates’ active 
constituents is being assessed, can a volume above 1ml be justified, particularly if it 
is known that it is likely to contaminate the joint? Secondly, if volumes of 1ml or 
higher are used, how can the potential therapeutic effect of volumetric tissue injury 
be controlled? Within the consensus study it should be noted that consensus of 
agreement for the optimal volume was not achieved. Furthermore, the literature 
review did not identify studies delivering PRP at a volume of less than 1ml (<1ml was 
reported for Corticosteroid only [332]). In the largest study of PRP injection 
(intervention) vs saline injection (placebo), Krogh et al [105] identified that all groups 
improved, but there were no statistically significant differences between the 
therapies. The conclusion of the authors being that PRP is no better than placebo, 
however the results from the cadaveric study suggest that injection of saline, though 
acting as a control, should not be referred to as a “placebo”. The potential 
therapeutic effect of high volume injection should be investigated for LET, and new 
designs of intervention for placebo are needed. A single pass of a needle without 
injection, or injection into subcutaneous tissue only, may both be options.  
Results from the cadaveric study do not support the use of needle fenestration as an 
adjunct to improve the distribution of injectate. This finding is in contrast to the Delphi 
study which found that the use of needle fenestration was one of the few aspects of 
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PRP delivery that reached a consensus of agreement. This perceived conflict should 
be cautiously interpreted, wherein the fenestration may, in itself, be a useful 
procedure, as it may itself have a therapeutic effect that should be assessed in 
isolation to the injection of substrate. A study assessing needle fenestration vs 
surgery in LET is currently underway (Clinicaltrials.org  NCT02710682); as yet no 
study has directly compared single shot or fenestrated delivery techniques (vs an 
appropriate placebo) of an injectate.  
The literature review identified the lack of guidelines on the optimal production and 
delivery of PRP. The Delphi consensus study attempted to assess if experiential 
reflection while using PRP resulted in clinicians reaching similar technical 
conclusions, and thus using PRP in a similar way.  Interestingly consensus of 
agreement or disagreement was only reached for 19 of the 40 statements. Hence 
this approach was unable to provide clear guidance on the application of PRP and 
highlighted the requirement for further trials to assess not only its efficacy, but the 
variability of its production and delivery techniques. The great benefit of an approach 
such as this, is that future research can now refine the research questions to 
correspond to particular areas of clinical equipoise.    
In regard to the technical aspects of PRP delivery in clinical trials, the feasibility 
study assessed the ability to deliver the intervention corresponding to best available 
evidence and contingent on the ability to comply with reporting guidelines. Although 
numerous PRP injection studies have been published, none have formally reported 
their compliance with the reporting guidelines for interventions for biologics (MIBO) 
[122]. It was identified that using a commercially available system, it was possible to 
deliver PRP injections in a radiology outpatient setting while complying with reporting 
standards. The patient experience of the injection is discussed in more detail below, 
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but from a purely technical standpoint, the investigation of the statements identified 
in the Delphi study as being in equipoise is entirely possible and indeed essential if 
the field of biologic treatments is to progress.   
This study set out to answer the question “can we rationalise the delivery of injection-
based treatments?”. The cadaveric study suggests that previous injection-based 
therapies have used volumes and techniques that cannot be rationalised as a way of 
assessing a dose response to a treatment, and questions the use of injection-based 
placebos within trials. A technical assessment of PRP, informed through the 
literature review as an area of current focus in LET therapy, can feasibly be 
undertaken as part of an RCT while complying with reporting guidance. What was 
maybe more surprising, for a therapy that is becoming increasingly common, is the 
multitude of questions on the technical aspects of its production and delivery that 
were identified in the literature review. The Delphi study was unable to resolve many 
of these questions but can act as a starting point in pinpointing areas of lacking 
consensus, which should act as primary aims for future research. Ultimately, well-
constructed, transparent trials are feasible and are desperately needed to justify or 
indeed to denounce injection therapies.            
9.5 Feasibility of an interventional trial  
The synthesis of this theme was informed by the literature review 
(chapter 1), the UK PROMs validation study (chapter 4), the Delphi 
study (chapter 7) and the feasibility Randomised Controlled Trial 
(chapter 8). 
 
Performing a trial in LET that is acceptable to patients, address therapies in 
equipoise, is methodologically transparent and repeatable, and in accordance with 
internationally recognised reporting standards should not be a research aspiration, 
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but rather the expectation. The construction of this thesis is embedded around the 
realisation that to fulfil this expectation additional knowledge was required. The 
synthesis of information discussed in the previous themes addresses the feasibility 
and validity of applying patient-centred outcome measures and the application of a 
justified injection technique. Additional information on the feasibility of a trial within 
this theme includes the choice of intervention for a parallel group design, which was 
informed through literature review and subsequently discussed in the qualitative 
interviews. The logistical aspects of running the trial were assessed within the 
quantitative assessment of the feasibility RCT and also informed through the PROMs 
validation study. The acceptability of the novel treatment application (in this case 
PRP injection) was explored through qualitative interviews and was reflected upon by 
the study investigators and investigated within the Delphi study. 
This thesis has focused its feasibility assessment on PRP interventions in LET. A 
major consideration in conducting this trial was the choice of a parallel group. 
Although systematic reviews have called for high-quality placebo-controlled trials [40, 
101], this is a challenging issue in LET injection therapy. Criticism of previously applied 
parallel groups in LET research was identified within the literature review, with the 
predominant concern being the use of corticosteroid injection that may impart a long-
term negative effect. The potential confounding of any injectate substance in a 
volume above 1ml as a placebo arm was identified as part of the cadaveric study. 
The use of physiotherapy as a control group was felt to be unethical in participants 
with chronic LET who within our care system had all tried, and failed, physiotherapy 
treatment. The option of no interventional treatment, through the use of oral 
analgesia and advice, was not felt to be appropriate for the same reason. As the 
participants receiving PRP injections were not anaesthetised, undertaking a sham 
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procedure that mimics the injection without creating a potential bias is exceptionally 
difficult, due to the sensation of injection delivery. There were also concerns 
regarding recruitment failure if ‘placebo’ or ‘non-active control’ group were part of the 
randomisation, particularly in the context of treatments being available outside of a 
trial at allied hospitals [333]. Hence, an active control group of standard practice was 
used, which, as it was currently offered by the trial hospital, was open surgical 
debridement. The author believes that as a consequence recruitment and retention 
levels were high, though it is conceded that the creation of a true placebo-controlled 
trial may be a superior situation. Further discussion of the optimal methodology is 
undertaken in the future research section. 
Although the target was very modest (n=12) The high recruitment and retention 
levels within the feasibility study contrast the poor figures within the validation study. 
Furthermore, the full completion of the outcome instruments within the follow-up 
outpatient clinic contrasts with the poor postal completion of the same questionnaires 
by the validation study group. Although the feasibility group were somewhat invested 
in the study, in that they had received a treatment, the difficulty in data collection in 
the validation study may be due to some of the same concerns voiced within the 
qualitative feedback and PPI group. The qualitative interviews and PPI feedback 
revealed that the items within the questionnaires were appropriate and relevant, and 
the participants could see the value of collecting data for the purposes of a study, yet 
when asked if they would wish to use the questionnaires to track their own 
symptoms, there was a strong feeling that this was unlikely to be helpful. When a 
demonstration of PROMs feedback graphs using an electronic interface was 
undertaken, the overall opinion of the PPI group was that data presented in this way 
were not particularly valuable. It could therefore be postulated that in musculoskeletal 
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conditions with a limited constellation of symptoms (predominantly pain with 
functional limitation), the utility and therefore compliance with PROMs for patient 
information may be limited. This may contrast with the more complex symptom 
patterns seen in chronic diseases and multimorbid states, where health-related 
quality of life is affected by a broader group of symptom domains. This information 
should be carefully regarded when designing larger LET trials, particularly if the 
treatments include non-interventional strategies. If PROMs are used as outcome 
measures, their delivery method should be carefully piloted to ensure participants feel 
they are feasible and appropriate, if electronic interfaces (to facilitate data collection) 
and participant facing feedback (as a motivator to improve compliance) are used, 
their benefit should be carefully explored.       
The background literature review of LET interventions was only able to identify a 
limited amount of information on patient experience and adverse event reporting in 
interventional studies, with a single systematic review reporting injection pain as an 
adverse event [105]. The Delphi study, with statements generated by a group of PRP 
users, did not isolate injection pain as a cause for concern or safety issue. It is 
interesting to note that two statements regarding the use of local anaesthetic did not 
reach consensus, and for injection-related analgesia only paracetamol  and weak 
opioid medication were advised. The feasibility study itself would not have identified 
procedural pain as a particular concern had the PROMs data been the only source of 
patient-centred feedback. The qualitative interview in contrast to all of the 
background literature, expert consensus and PROMs analysis, had one very 
common theme from all participants, that procedural pain was a significant issue. 
Although all participants would recommend the treatment to others, the pain reported 
at the time of injection was very significant. In the context of a feasibility trial that 
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aimed to comply with the laboratory-based conclusion that local anaesthesia 
compromises PRP effectiveness [311, 312], this finding was concerning. For clinicians 
delivering PRP injections (or if the findings from the cadaveric study are extrapolated, 
any injection of >1ml) into the common extensor tendon, should be aware that pain is 
a significant event and future trials should make efforts to ensure that it is quantified 
and reported.  
This research aimed to assess the feasibility of conducting a randomised controlled 
interventional study in chronic LET. Guided by the evolving trends present in the LET 
literature, Platelet-Rich Plasma injection was selected as the novel intervention, with 
the parallel control group being current standard therapy for chronic LET: open 
surgical debridement. We have shown that it is feasible to conduct a trial with parallel 
groups, with acceptable recruitment and retention. It is possible to incorporate 
validated patient-centred outcome measures and report their use in accordance with 
the CONSORT-PRO. The use of biologics can also be reported according to MIBO 
guidelines. Qualitative assessment of patient acceptability highlights the need for 
pain management and clear reporting of procedural discomfort in future trials. 
Though uncomfortable, PRP participants’ feedback uniformly agreed on a preference 
for injection therapies over surgery, therefore with the presented evidence of 
feasibility, it is vital that the research community conduct patient-centred, 
methodologically robust and transparently reported trials.     
9.6 Limitations  
This work is not without limitations, which need to be considered when 
interpreting results and forming conclusions. 
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The limitations of this work will be discussed in reference to the three overarching 
themes of this thesis, specific limitations relevant to the individual studies are 
discussed in their associated chapters. The first theme relates to the use of outcome 
instruments. This thesis attempts to inform the choice of outcome instrument through 
a sequential assessment of: identification of outcome measures, standardised 
evaluation and further validation. However, though this assessment was thorough in 
its approach, a decision was made early within the process to concentrate on 
patient-centred outcomes. There are numerous other outcomes that have been 
utilised in LET research, including strength measurements, pain provocation tests 
and imaging modalities including ultrasound scans and magnetic resonance imaging. 
Though these outcome modalities may have utility, the background literature review 
revealed that they have all been identified as not representative of prognosis [9, 76] or 
have their accuracy anchored to PROMs [86]. Therefore it would seem reasonable to 
concentrate exclusively on the PROMs themselves, which is in itself in concordance 
with international guidance on outcome evaluation in clinical effectiveness research 
[131, 133]. It could also be argued that the focus on outcomes was rather narrow, in that 
more generic tools such as a visual analogue pain scale (VAS) or generic health 
PROM such as the EQ5D or SF-36, could have been included in the assessment. 
Again, these tools may have utility, but generic health measures are recommended 
only as adjuncts in clinical effectiveness research [147], where a specific PROM is 
always recommended. Furthermore, it is likely that responsiveness of generic 
PROMs is poor in elbow pathology, though this has never been explicitly explored. A 
lack of comparative responsiveness of these generic measures was identified in the 
validation study (chapter 8) and has also been reported within the included PROMs 
development and validation studies [142, 243]. The use of simple numeric scales such 
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as a VAS is common within musculoskeletal research and has recently been 
advocated as part of an outcome set for elbow pathology [197]. However, the 
systematic review did not identify specific validation work using these instruments in 
elbow joint or pathology-specific contexts. Within the validation study the numeric 
pain scale was found to be poorly responsive to change.  
It is also recognised that the three steps of systematic evaluation (chapters 2,3 and 
4) used sequential data extraction for the same systematic search criteria. It is the 
author’s view that though the three studies aimed to address strategically different 
questions, the stepwise manner in which they were conducted, and the intentionally 
sensitive, rather than specific search strategy, limit the risk of missing data. In an 
effort to gain a comprehensive view on outcome measure choice, this strategy, 
though novel, results in a dataset that conceivably facilitates multiple analyses of 
pathology-specific and cross-culturally specific assessments. Though this is 
dependent on rigorous data extraction (which in this scenario was co-reviewed at all 
stages, with concordance between reviewers tracked throughout), it is a model of 
PROMs assessment that may be utilised more in the future. The data from this 
thesis have been made open source at figshare (https://figshare.com/) to facilitate 
future assessment and critique.  
It is recognised that the sequential methodology of the systematic review were not 
‘reviews within reviews’, rather shared data assessing different aspects of outcome 
measure use, which was then supplemented by the validation study to inform an 
overarching aim. In this regard it is accepted that the use of systematic review is only 
one tool of many when assessing outcome utility and does not entirely complete the 
process. Other potential methodologies would involve qualitative techniques 
including expert reviews, cognitive interviews and focus groups. A conclusive 
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appraisal of LET outcomes would include some aspect of this assessment but was 
beyond the scope of this thesis.    
The second theme undertook a synthesis of information regarding injection 
technique and used two particularly novel approaches, a cadaveric assessment and 
Delphi consensus methodology. The use of these methods provides new information 
that has previously proved difficult to obtain from clinical trials, but their findings do 
need to be interpreted with caution.  
Though every effort was taken to ensure that the cadaveric samples were treated in 
a way that the tissue remained as representative as possible (fresh-frozen rather 
than embalmed, no freezing post injection, dry arthroscopy), the behaviour of 
cadaveric tissue to injection may be different to human tissue. The Delphi consensus 
study used clinician experience as a proxy for technical refinement; yet it is perfectly 
conceivable that clinicians did not modify their techniques or methods of patient 
selection, PRP preparation and delivery. Consequently, the findings should be 
viewed simply as a current consensus, rather than a guideline. Though it has 
identified areas of particular disparity, which can hone research priorities, the areas 
of consensus should be viewed as accepted current clinician practice, not as a proxy 
marker of evidence of effectiveness. These questions still require rigorous evaluation 
as part of a well-designed trial.  
Theme three assessed the feasibility of conducting a PRP trial. Numerous trials have 
assessed PRP treatment, but systematic reviews have consistently criticised their 
methodological approach. It is recognised that the guidelines by which the reporting 
feasibility of the trial was assessed have only recently been published (MIBO 2017, 
CONSORT PRO 2013), therefore previous studies did not have such structures to 
 257 
 
comply with. This study concludes that it is feasible to comply with such guidelines 
and it is likely that their prominence in the current literature will ensure that in future 
studies compliance is improved.  
The qualitative interviews and PPI group discussions provided a wealth of important 
detail to the feasibility investigation. It is recognised that these investigations were 
limited in their scope and their representativeness may be very specific. The 
qualitative interviews were only conducted on the interventional (PRP) group of 
participants. Therefore the acceptability and treatment preference information was 
not balanced by those from the surgical group. Though the PRP group felt the 
intervention was acceptable, the authors concede that this is only one side of the 
discussion. The qualitative assessment utilised semi-structured interviews and a 
thematic approach to data analysis. Though the themes revealed reached saturation, 
it is recognised that alternate techniques such as focus groups and in-depth 
interviews may have garnered additional relevant information.       
The feasibility study used outcome measures and assessed their patient 
acceptability, burden and data collection feasibility. This trial was conducted in 
parallel to the outcome measure systematic review. The outcomes for the feasibility 
trial were selected as they had previously been used at the same institution for an 
elbow trial. It is fortuitous, rather than through judgment, that the measures used 
were subsequently identified through the EMPRO evaluation as high performing.  
Although it was found that a study of PRP vs surgery is technically feasible, two 
further questions must be asked that relate to the potential limitations of the findings. 
Firstly, is an RCT the most appropriate design for this intervention? Secondly, with 
information derived from the cadaveric and Delphi studies taken into account, should 
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more foundational research be conducted before further clinical trials?  These 
questions will be addressed in the forthcoming sections.   
9.7 Implications for clinical practice and research 
Following this synthesis of information from this conducted research, the next key 
question should be; “in what way can these findings be operationalised in future 
clinical and research practice?”   
The identification of four PROMs that show superior metric properties in LET can be 
applied to future evaluation of LET in clinical studies. This addresses the current void 
in information. The validity and responsiveness of these tools are adequate for their 
justified use in comparative research and the details on their properties mean that 
future studies, conducted in English language populations, can use this information 
to conform to CONSORT-PRO [320] reporting guidelines. However, details on the 
interpretability of these outcome measures, through derivation of minimal change 
scores, is still limited. This is of particular importance as these values are 
increasingly used to interpret the effect of an intervention in clinical trials [250]. 
Furthermore, misappropriation or extrapolation of minimal change scores from non-
representative populations can have a significant impact on study conclusions [257]. 
It should be noted that although four PROMs have been identified, superiority of one 
instrument over the rest had not been confirmed. Two explanations exist, firstly that 
the data available are not strong enough to clearly identify the best candidate 
instrument, or secondly that metric properties are indeed similar and superiority will 
not be confirmed. As the continued synthesis of information in systematic reviews 
and meta-analyses continues to be frustrated by the great variety of measures 
available, it is essential that national societies use data from standardised 
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evaluations to make informed decisions on instrument choice, thereby forcing the 
arm of future researchers. This is beginning to occur, Hawkins et al [197] have 
recently produced a consensus guideline from the American Society of Shoulder and 
Elbow Surgeons that has made clear recommendations on instrument choice. What 
is concerning and frustrating however, was that these instruments were chosen 
through a small group expert consensus, rather than through a validated 
standardised evaluation such as that performed within this thesis. Furthermore, 
poorly performing instruments, identified in this review for LET and previously by The 
et al [149], continue to be recommended. Though we are unable to suggest the 
number one choice of instrument for LET, what is maybe clearer is that the poorly 
performing instruments should not continue to be utilised in clinical trials without 
further evidence of their validity. There is still quite some way to go before the 
application of the ‘heritage instruments’ subsidies in preference to those measures 
shown objectively to outperform them.  
The presented assessment of injection delivery should be used to rationalise current 
practice. The cadaveric study suggests that in the assessment of the efficacy of 
injection substances, smaller volume, single shot injections should be delivered in 
preference to higher volume injections or fenestrated techniques. This proposition 
should now be tested in a clinical context. This study also concludes that the 
administration of “placebo” injection may be a misnomer, as the tissue destruction 
associated with a 1ml injection could be associated with a therapeutic benefit. 
Therefore, future studies should seek alternative injection methodologies, and the 
therapeutic effect of volumetric tissue damage should be assessed. 
The findings from the Delphi study could be used as a basis on which clinicians 
starting to use PRP base their practice. Though, as previously stated, this is not 
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evidence of efficacy, the statements that reached consensus provide more of a 
pragmatic framework for application of this therapy than has previously been 
available. As the Delphi method has identified aspects of practice that did not reach 
consensus, this should be scrutinised and considered carefully as areas of focus for 
future research.  
The feasibility study has identified that PROMs outcome measures are appropriate 
and acceptable to patients, the effect sizes observed within both the feasibility study 
and validation study suggest that they are sensitive to change at a magnitude that is 
greater than generic health measures and visual analogue scales. It is reasonable to 
assert therefore that they should be used as primary outcome measures in future 
research. The qualitative assessment has identified that patients believe PRP to be a 
treatment worthy of study. The quantification and reporting of procedural pain and 
refinement of technique and associated adjuncts aimed at reducing patient 
discomfort is vital for this treatment practice to continue.    
9.8 Future research 
The old models of research, where individuals with highly specialised expertise 
drove change through passionate engagement with small groups of researchers, is 
becoming rare. The scientific questions have now expanded to a point where they 
are too complex to be answered by the single expert [334], the expectation to deliver 
change has also shifted, with an ever-increasing focus on rapid transition of 
interventions from bench to clinical use [335]. The sustainability of this new approach 
is dependent upon one element above all others, teamwork. Collaborative research, 
that utilises multiple expertise, running multiple methodologies, at multiple sites, is 
the aspirational model of research for the 21st century. This thesis has approached 
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the investigation of LET treatments from a back to basics, foundational perspective, 
aiming to answer inherent problems that have acted as barriers to progress in the 
field. It was always the author’s intention that these findings should not exist as a 
standalone research portfolio, but rather that they assist in wider collaborative efforts 
to understand and treat this burdensome condition. Specifically in reference to the 
research aims, the presented research can support future programs of work that 
progress the fields of outcome measurement and delivery, assessment and delivery 
of new therapies and the investigation and application of novel trial designs.   
Within the first study of this portfolio of work, the exponential utilisation of patient-
centred outcome measures in elbow research was encountered. Though the short-
term goals include the identification of the best performing outcome instrument, the 
future of outcome assessment may look quite different. Groups such as the COMET 
initiative (Core Outcome Measures in Effectiveness Trials) and ICHOM (International 
Consortium of Health Outcome Measurement) recognise that the derivation of 
“Value” in healthcare will require standardised assessment of more than a pathology-
specific outcome measure. PROMs will sit within this framework with other measures 
that quantify health behaviour, satisfaction with care, medication burden and 
financial burden of care, amongst others.  
The way in which outcome measures are collected is also changing. This thesis 
acknowledges the limitations of fixed length questionnaires. The use of Item 
Response Theory (IRT) techniques, which utilise large question banks and statistical 
models to hone items on an individual basis, have the potential to hugely alter the 
utility of PROMs assessment. The PROMIS (Patient Reported Outcome 
Measurement Information System) was developed to improve outcome 
measurement by bringing universality to the system, allowing comparison within and 
 262 
 
across pathologies, across cultures and to allow cross-walking of scores to the 
currently applied fixed length questionnaires, which may be somewhat of a holy grail 
of psychometrics. Publications using these instruments in the field of upper limb 
pathology are emerging from the USA [336, 337], with a single publication in an 
undefined mixture of elbow pathology [338], the forthcoming years are likely to see an 
emergence of this system and testing of its validity in the UK and beyond.  
For the feasibility assessment of the efficacy of PRP a randomised control trial was 
undertaken. Though it confirmed that this was feasible, there are aspects of the trial 
that were encountered that suggest that it may not be the optimal design for study of 
this particular condition. The concern regarding an appropriate parallel group has 
been discussed within the literature review (chapter 1), the feasibility study (chapter 
8), and as a consequence of its findings, in the cadaveric study (chapter 6). Therein 
two distinct problems are encountered. Firstly, there is theoretically an inability to 
inject a substance into the tendons of the elbow that is entirely therapeutically 
benign, hence creating a potential confounder; furthermore the patient’s sensation of 
an injection (commented within the qualitative assessment) means that there will be 
an experiential difference between a sham injection (no injectate delivered) and a 
true injection, creating a bias. Secondly, the alternative use of a ‘standard treatment’ 
group carries with it the risk of bias (owing to the preference for a ‘novel’ minimally 
interventional therapy such as an injection) and a potentially high dropout rate as the 
‘novel’ treatment is available elsewhere without randomisation (as is increasingly the 
case with biologics such as PRP). It is difficult to escape these risks within the 
traditional RCT model and although there are numerous potential trial designs that 
may ameliorate the highlighted issues [339], two particular methodologies may offer a 
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solution, a step-wedge RCT design [340], or a cohort multiple randomised controlled 
design [342]. 
In the step-wedge RCT design all groups, or clusters, of participants eventually 
receive the intervention, but the implementation is staggered and randomised [340]. 
This trial design may assist in the thorough assessment of a novel intervention that is 
increasingly championed, due to its patient acceptability and relative cost saving. 
Therein, clusters (patients at particular hospitals, or whose care is under certain 
consultants in this case) could have their treatment changed from an accepted 
standard, identified in this thesis as surgery, to the novel intervention. This trial 
design offers patients a single treatment, be it whatever that particular cluster has 
been allocated at that time. Therefore, it does not rely on individual patient 
recruitment and its associated potential bias [340].   
It has been suggested that to address the problem encountered when comparing 
multiple treatments from different heterogeneous populations, application of a cohort 
multiple randomised controlled trial methodology may be beneficial [342]. In this 
design, a large observational cohort with the condition of interest is recruited, regular 
measurements of outcomes are undertaken, when appropriate there is identification 
of all eligible patients within that cohort, some of whom are randomly selected to 
receive the novel intervention, the outcomes are then compared between those 
randomly selected (novel treatment) and those not randomly selected (standard 
care). The consent process is designed to mirror real-world routine healthcare, in 
that the whole cohort are consented to collect observational data; however consent 
to “try” a particular intervention is sought only from those to whom it is offered [342]. 
This approach also has the benefit that at any time sequential or multiple 
randomised allocations to treatment can occur. It is vital to appreciate however, that 
 264 
 
this approach is only possible with a robust data collection system and the use of 
outcome measures that are known to be valid and that do not change throughout the 
trial. It would therefore be particularly appropriate to utilise this trial design with the 
use of dimension level PROMs assessment (pain, function, quality of life etc) using a 
flexible system such as PROMIS.  
9.9 Concluding remarks  
This research aimed to optimise the assessment of interventional treatment in 
Lateral Elbow Tendinopathy, with a focus on injectable therapies. It was identified 
that for the researchers to investigate LET treatments in a robust and transparent 
way, a unified approach to the choice of outcome measure was needed, an ability to 
rationalise the technical aspects of injection treatment was necessary, and the 
feasibility and patient-centred acceptability of randomised trial of PRP required 
exploration.  
A multiple-methodology approach was utilised, and the findings from individual 
studies were triangulated to address the overarching aim. This research can 
contribute to the literature by making the following recommendations: the DASH, 
QDASH, OES and PRTEE are the PROMs that are presently the best option for LET 
research, evidence of their validity in the UK has been improved and they can be 
recommended for use in this population; the use of high volume fenestrated 
injections is not required to optimise the distribution of an injectate around the 
common extensor tendon and this technique itself may be introducing a confounding 
treatment variable; there is an inconstant level of consensus on PRP preparation and 
delivery and further evaluation should prioritise the evaluation of dose-related effect, 
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and although trials of PRP injections are feasible and acceptable, patient safety and 
procedural pain must be recorded.   
LET is not a condition that one would deem high profile, it is not on the political 
agenda and has not been identified as a research priority by the NIHR, patients, 
clinicians or carer groups [343]. Yet, it is common, painful and costly to both the 
individual and society and for these reasons it is worthy of our attention and our 
research efforts. Perhaps it is because of difficulties attaining adequate funding, 
commercial bias or apathy and dissatisfaction associated with our continued failing 
to understand and treat this condition, that certain fundamental questions in the 
development and evaluation of treatments have not been thoroughly scrutinised. It 
may also be that this condition is more complex that we have previously appreciated, 
that the aetiology, pathology and required treatments are highly individualised and 
that our current focus on unified treatment algorithms is in vain. Many exciting 
research ventures, from basic science to clinical trials are being formulated and 
undertaken, there is no doubt that breakthroughs will be discovered and treatments 
improved, if one thing is certain it is that we should redouble our efforts to ensure 
that we only produce meaningful and appropriate research into this condition. This 
thesis represents an effort to explore ways in which we can optimise the future 
evaluation of LET, to ensure that the continuum of increasing evidence is 
fundamentally more robust, comparable and patient-focused. It is my hope that its 
findings are useful for researchers and ultimately beneficial for patients.         
 
-------- o ------- 
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PRISMA checklist for the study – Clinical Rating Systems in Elbow 
Research – A Systematic Review Exploring Trends and Distributions of 
Use 
 
Please see inserted document  
 
 292 
 
 Section/topic   #  Checklist item  
 Reported 
on page 
#  
 TITLE    
 Title   1  Identify the report as a systematic review, meta-analysis, or both.   65 
 ABSTRACT    
 Structured summary   2  Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
 65 
 INTRODUCTION    
 Rationale   3  Describe the rationale for the review in the context of what is already known.   68-70 
 Objectives   4  Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
 70 
 METHODS    
 Protocol and 
registration  
 5  Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, 
if available, provide registration information including registration number.  
 N/A 
 Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
 72 
 Information sources   7  Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
 71 
 Search   8  Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
 Appendix 
2 
 Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
 71-73 
 Data collection 
process  
 10  Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
 71 
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 Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
 72 
 Risk of bias in 
individual studies  
 12  Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be used 
in any data synthesis.  
 N/A 
 Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).   72 
 Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
 N/A 
 
 
  
 Section/topic   #  Checklist item  
 Reported 
on page 
#  
 Risk of bias across 
studies  
 15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
 N/A 
 Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
 72 
 RESULTS    
 Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
 73 
 Study 
characteristics  
 18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
 N/A 
 Risk of bias within 
studies  
 19  Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
 N/A 
 Results of individual 
studies  
 20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
 77 
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 Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
 N/A 
 Risk of bias across 
studies  
 22  Present results of any assessment of risk of bias across studies (see Item 15).   N/A 
 Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
 77-78 
 DISCUSSION    
 Summary of 
evidence  
 24  Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
 79 
 Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
 84 
 Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
 85 
 FUNDING    
 Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review.  
 N/A 
  
 From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
  
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Systematic review search strategy (Chapters 2, 3 & 4) 
 
Medline 
1. exp Elbow/ 
2. elbow.tw. 
3. exp Elbow joint/ 
4. exp Tennis Elbow/ 
5. epicondylitis.tw. 
6. common extensor origin.tw. 
7. epicondylalgia.tw. 
8. 1 or 2 or 3 or 4 or 5 or 6 or 7  
9. exp "Outcome Assessment (Health Care)"/ 
10. (Outcome? adj2 assessment).tw. 
11. patient reported outcome?.tw. 
12. outcome? measure?.tw. 
13. exp health status/ 
14. health status.tw. 
15. exp "quality of life"/ 
16. quality of life.tw. 
17. (QL or QoL or HRQL or HRQoL).tw. 
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18. (function* adj2 (status or psychological or mental or physical or social)).tw. 
19. disabilit*.tw. 
20. exp "Activities of Daily Living"/ 
21. activities of daily living.tw. 
22. (wellbeing or well being).tw. 
23. exp happiness/ 
24. (happi* or happy).tw. 
25. 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 
or 23 or 24  
26. assessment.tw. 
27. index.tw. 
28. indices.tw. 
29. instrument?.tw. 
30. measure?.tw. 
31. profile?.tw. 
32. rating?.tw. 
33. report*.tw. 
34. scale?.tw. 
35. schedul*.tw. 
36. scor*.tw. 
 297 
 
37. exp health surveys/ 
38. survey?.tw. 
39. 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38  
40. (symptom? adj2 (assessment or index or indices or instrument? or measure? 
or profile? or rating? or report* or scale? or schedule? or scor* or survey?)).tw. 
41. 25 or 40 
42. exp Self-Assessment/ 
43. self-assess*.tw. 
44. exp Questionnaires/ 
45. questionnaire?.tw. 
46. self report*.tw. 
47. 42 or 43 or 44 or 45 or 46  
48. (Validation Studies or Comparative Study).pt. or exp psychometrics/ or 
psychometr*.tw. or clinimetr*.tw. or clinometr*.tw. or exp observer variation/ or 
observer variation.tw. or exp Health Status Indicators/ or exp reproducibility of 
results/ or reproducib*.tw. or exp discriminant analysis/ or reliab*.tw. or unreliab*.tw. 
or valid*.tw. or coefficient.tw. or homogeneity.tw. or homogeneous.tw. or internal 
consistency.tw. or (cronbach* and (alpha or alphas)).tw. or (item and (correlation* or 
selection* or reduction*)).tw. or agreement.tw. or precision.tw. or imprecision.tw. or 
precise values.tw. or test-retest.tw. or (test and retest).tw. or (reliab* and (test or 
retest)).tw. or stability.tw. or interrater.tw. or inter-rater.tw. or intrarater.tw. or intra-
rater.tw. or intertester.tw. or inter-tester.tw. or intratester.tw. or intra-tester.tw. or 
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interobserver.tw. or inter-observer.tw. or intraobserver.tw. or intraobserver.tw. or 
intertechnician.tw. or inter-technician.tw. or intratechnician.tw. or intra-technician.tw. 
or interexaminer.tw. or inter-examiner.tw. or intraexaminer.tw. or intra-examiner.tw. 
or interassay.tw. or inter-assay.tw. or intraassay.tw. or intra-assay.tw. or 
interindividual.tw. or inter-individual.tw. or intraindividual.tw. or intra-individual.tw. or 
interparticipant.tw. or inter-participant.tw. or intraparticipant.tw. or intra-participant.tw. 
or kappa.tw. or kappa*.tw. or kappas.tw. or repeatab*.tw. or ((replicab* or repeated) 
and (measure or measures or findings or result or results or test or tests)).tw. or 
concordance.tw. or (intraclass and correlation*).tw. or discriminative.tw. or known 
group.tw. or factor analysis.tw. or factor analyses.tw. or dimension*.tw. or 
subscale*.tw. or (multitrait and scaling and (analysis or analyses)).tw. or item 
discriminant.tw. or interscale correlation*.tw. or error.tw. or errors.tw. or individual 
variability.tw. or (variability and (analysis or values)).tw. or (uncertainty and 
(measurement or measuring)).tw. or standard error of measurement.tw. or 
sensitiv*.tw. or responsive*.tw. or ((minimal or minimally or clinical or clinically) and 
(important or significant or detectable) and (change or difference)).tw. or (small* and 
(real or detectable) and (change or difference)).tw. or meaningful change.tw. or 
ceiling effect.tw. or floor effect.tw. or Item response model.tw. or IRT.tw. or Rasch.tw. 
or Differential item functioning.tw. or DIF.tw. or computer adaptive testing.tw. or item 
bank.tw. or cross-cultural equivalence.tw. 
49. 39 or 47 or 48 
50. 41 and 49 
51. (Oxford elbow score or Liverpool Elbow Score or Elbow Self-Assessment 
Score or Elbow Function Assessment or (American Shoulder and Elbow Surgeons-
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elbow) or (Modified American Shoulder and Elbow Surgeons) or Mayo Elbow 
Performance Score or Hospital for Special Surgery score or Hospital for Special 
Surgery short version or patient-rated elbow evaluation or Patient-Rated Tennis 
Elbow Evaluation or Elbow Functional Assessment or (Disabilities of the Arm, 
Shoulder and Hand questionnaire) or subjective elbow value or (Broberg and 
Morrey) or Ewald).mp. or Pritchard.tw. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, tn, dm, 
mf, dv, kw] 
52. (OES or LES or ESAS or ASES or ASES-e or MEP or PREE or PRTEE or 
EFA or DASH or quickDASH).mp. [mp=ti, ab, ot, nm, hw, kf, px, rx, ui, tn, dm, mf, dv, 
kw] 
53. 8 and 52 
54. 8 and 50 
55. 51 or 53 or 54 
56. exp ANIMALS/ not humans.sh. 
57. 55 not 56 
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Full list of outcome measures  
 
In order of prevalence of use 
1. MEPS (Mayo Elbow Performance Score) 
2. DASH (Disabilities of the Arm Shoulder and Hand) 
3. Morrey 
4. QDASH (Quick Disabilities of the Arm, Shoulder and Hand) 
5. PRTEE (Patient-Rated Tennis Elbow Evaluation) 
6. ASES-e ((American Shoulder and Elbow Surgeons Score - elbow) 
7. OES (Oxford Elbow Score) 
8. Roles and Maudsley 
9. Nirschl 
10. HSS (Hospital for Special Surgery) 
11. PREE (Patient Rated Elbow Evaluation) 
12. Andrews-Carson 
13. Japanese Orthopaedic Association 
14. ASES (American Shoulder and Elbow Surgeons Score) 
15. EFA (Elbow Functional Assessment) 
16. Ewald 
17. LES (Liverpool Elbow Score) 
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18. PREFQ (Patient-Rated Forearm Evaluation Questionnaire 
19. Upper extremity functional scale 
20. SECEC score 
21. Verhaar 
22. Bishop 
23. Conway-jobe 
24. Dellon 
25. Levine 
26. Radin and Riseborough 
27. Timmerman and Andrews 
28. Cassebaum 
29. Figgie 
30. Jupiter 
31. KJOC (Keralan-Jobe Orthopaedic Clinic) 
32. PRWE (Patient Rated Wrist Evaluation) 
33. Tennis elbow functional scale 
34. Wilson and Krout score 
35. Constant 
36. ESAS (Elbow Self Assessment Score) 
37. Flynn 
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38. Grundberg and Dobson 
39. McGowan 
40. Michigan hand questionairre 
41. PRUNE (Patient Rated Ulnar Nerve Evaluation) 
42. Smith and Cooney 
43. Tinvon's 
44. Total elbow scoring system 
45. Aitken-Rorabeck 
46. Amadio 
47. American Rheumatism Association 
48. Broberg and Morrey 
49. Cauchoix and Deburge 
50. Chinease medical society hand surgery standard evaluation  
51. Functional elbow score 
52. Gabel and Amadio 
53. Inglis and Pellicci 
54. Kellgren and Lawrence 
55. Khalfayan 
56. Larsen  
57. Leipzig 
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58. Modified Andrews elbow scoring system 
59. Modified elbow rating system 
60. Musculoskeletal Functional Assessment  
61. Nestor 
62. Novak 
63. Pain-free Functional Index 
64. Patient specific functional scale 
65. PEM (Patient Evaluation Measure) 
66. Pritchard 
67. Sane 
68. Single assessment numerical evaluation score 
69. Steinberg 
70. Svenlov and Adolfson 
71. Wesley 
72. Yasutake 
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PRISMA check list for the study - Assessing patient-centered 
outcomes in lateral elbow tendinopathy: a systematic review and 
standardized comparison of clinical rating systems 
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 Section/topic   #  Checklist item  
 Reported 
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 ABSTRACT    
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study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
 86-87 
 INTRODUCTION    
 Rationale   3  Describe the rationale for the review in the context of what is already known.   88-89 
 Objectives   4  Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
 89 
 METHODS    
 Protocol and 
registration  
 5  Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, 
if available, provide registration information including registration number.  
 89 
 Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
 89 
 Information sources   7  Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
 89+71 
 Search   8  Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
 Appendix 
2 
 Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
 89-90 
 Data collection 
process  
 10  Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
 90-93 
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 Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
 91-93 
 Risk of bias in 
individual studies  
 12  Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be used 
in any data synthesis.  
 N/A 
 Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).   91-93 
 Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
 93 
 
 
 
 
 
 
 
 
 
 Section/topic   #  Checklist item  
 Reported 
on page 
#  
 Risk of bias across 
studies  
 15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
 N/A 
 Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
 93 
 RESULTS    
 Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
 94-95 
 Study 
characteristics  
 18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
 96-98 
 Risk of bias within 
studies  
 19  Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
 N/A 
 Results of individual 
studies  
 20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
 96-98 
 314 
 
 Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
 N/A 
 Risk of bias across 
studies  
 22  Present results of any assessment of risk of bias across studies (see Item 15).   N/A 
 Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
 99-101 
 DISCUSSION    
 Summary of 
evidence  
 24  Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
 102 
 Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
 105 
 Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
 104-109 
 FUNDING    
 Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review.  
 N/A 
  
 From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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EMPRO Attribute and individual item scores for each outcome instrument.  
Item scores graded from 4 (strongly agree) to 1 (strongly disagree or no information).   
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CONCEPTUAL AND MEASUREMENT 
MODEL 
                              
Concept of measurement stated 3 4 4 2 3 4 3 4 4 4 4 1 3 3 2 
Obtaining and combining items 
described 
1 3 4 1 4 1 1 1 4 1 3 1 2 3 1 
Rationality for dimensionality and scales 1 2 3 1 1 1 1 1 3 2 4 1 1 2 1 
Involvement of the target population 1 2 3 1 4 1 1 1 4 2 2 1 2 3 1 
Scale variability described and adequate 1 1 3 2 2 2 2 2 3 3 3 1 3 3 1 
Level of measurement described 2 1 3 2 3 2 2 1 3 1 3 1 2 3 1 
Procedures for deriving scores 2 1 3 1 3 2 2 2 4 3 4 1 1 3 1 
ATTRIBUTE SCORE 19.
0 
33.3 76.2 14.
3 
61.9 28.6 23.8 23.8 85.7 42.9 76.2 0.0 33.3 61.9 4.8 
RELIABILITY: Internal consistency                               
Data collection methods described 1 1 3 1 3 1 1 1 4 3 3 1 1 3 1 
Cronbach's alpha adequate 1 1 4 1 4 1 1 1 4 4 4 1 2 3 1 
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IRT estimates provided 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Testing in different populations 1 1 2 1 3 1 1 1 2 4 3 1 1 2 1 
ATTRIBUTE SCORE 0.0 0.0 50.0 0.0 58.3 0.0 0.0 0.0 58.3 66.7 58.3 0.0 8.3 41.7 0.0 
RELIABILITY:  Reproducibility                               
Data collection methods described 1 3 4 1 2 2 1 1 3 4 3 1 4 1 1 
Test-retest and time interval adequate 1 1 4 1 2 2 1 1 2 3 3 1 4 1 1 
Reproducibility coefficients adequate 1 4 4 1 2 1 1 1 4 4 4 1 4 1 1 
IRT estimates provided 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
ATTRIBUTE SCORE 0.0 41.7 75.0 0.0 25.0 16.7 0.0 0.0 50.0 66.7 58.3 0.0 75.0 0.0 0.0 
VALIDITY                               
Content Validity adequate 1 2 4 1 4 1 1 2 2 1 3 1 1 3 1 
Construct/critereon validity adequate 2 3 3 3 3 4 3 1 4 3 4 2 4 3 1 
Sample composition described 1 1 1 3 3 1 3 1 2 4 2 2 2 2 1 
Prior hypothesis stated 1 4 3 1 1 4 1 1 4 4 3 1 2 2 1 
Rational for criterion validity 1 1 1 1 1 1 1 1 1 1 4 1 1 1 1 
Tested in different populations 1 1 3 1 3 1 1   1   3     2   
ATTRIBUTE SCORE 5.6 33.3 50.0 22.
2 
50.0 33.3 22.2 6.7 44.4 53.3 72.2 13.3 33.3 38.9 0.0 
RESPONSIVENESS                               
Adequacy of methods 2 1 4 1 2 4 1 1 4 4 4 2 4 4 1 
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Description of estimated magnitude of 
change 
2 1 4 1 1 4 1 1 4 3 4 3 2 3 1 
Comparison of stable and unstable 
groups 
1 1 1 1 1 1 1 1 2 3 3 1 1 1 1 
ATTRIBUTE SCORE 22.
2 
0.0 66.7 0.0 11.1 66.7 0.0 0.0 77.8 77.8 88.9 33.3 44.4 55.6 0.0 
INTERPRETABILITY                               
Rational of external criteria 1 1 4 1 1 2 2 1 3 3 4 1 2 1 1 
Description of interpretation strategies 1 1 3 1 1 1 1 1 3 3 4 1 2 1 1 
How data should be reported stated 1 1 2 1 1 2 1 1 3 1 1 1 1 1 1 
ATTRIBUTE SCORE 0.0 0.0 66.7 0.0 0.0 22.2 11.1 0.0 66.7 44.4 66.7 0.0 22.2 0.0 0.0 
BURDEN:  Respondent                                
Skills and time needed 1 1 3 2 3 1 2 1 2 2 2 1 1 2 1 
Impact on respondents  1 1 4 1 2 1 1 1 3 3 3 1 1 1 1 
Not suitable circumstances 1 1 4 1 1 1 1 1 2 3 3 1 1 1 1 
ATTRIBUTE SCORE 0.0 0.0 88.9 11.
1 
33.3 0.0 11.1 0.0 44.4 55.6 55.6 0.0 0.0 11.1 0.0 
BURDEN: Administrative                                
Resources Required 1 1 4 3 4 1 2 1 4 4 3 1 1 1 1 
Time required 1 1 1 1 4 1 1 1 4 1 1 1 1 1 1 
Training and expertise needed 1 1 1 1 1 1 1 1 4 1 2 1 1 1 1 
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Burden of score calculation 2 1 4 2 3 3 2 1 4 4 4 1 1 2 1 
ATTRIBUTE SCORE 8.3 0.0 50.0 25.
0 
66.7 16.7 16.7 0.0 100.
0 
50.0 50.0 0.0 0.0 8.3 0.0 
OVERALL SCORE N/A 21.67 66.90 N/A 36.2
7 
33.49 N/A N/A 66.5
9 
57.02 72.46 N/A 41.6
7 
39.6
0 
N/A 
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 Section/topic   #  Checklist item  
 Reported 
on page 
#  
 TITLE    
 Title   1  Identify the report as a systematic review, meta-analysis, or both.   109 
 ABSTRACT    
 Structured summary   2  Provide a structured summary including, as applicable: background; objectives; data sources; 
study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; 
results; limitations; conclusions and implications of key findings; systematic review registration 
number.  
 109 
 INTRODUCTION    
 Rationale   3  Describe the rationale for the review in the context of what is already known.   109-110 
 Objectives   4  Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS).  
 111 
 METHODS    
 Protocol and 
registration  
 5  Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, 
if available, provide registration information including registration number.  
 N/A 
 Eligibility criteria   6  Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., 
years considered, language, publication status) used as criteria for eligibility, giving rationale.  
 111 
 Information sources   7  Describe all information sources (e.g., databases with dates of coverage, contact with study 
authors to identify additional studies) in the search and date last searched.  
 111+71 
 Search   8  Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated.  
 Appendix 
2 
 Study selection   9  State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis).  
 112 
 Data collection 
process  
 10  Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
 112-113 
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 Data items   11  List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made.  
 112-113 
 Risk of bias in 
individual studies  
 12  Describe methods used for assessing risk of bias of individual studies (including specification 
of whether this was done at the study or outcome level), and how this information is to be used 
in any data synthesis.  
 N/A 
 Summary measures   13  State the principal summary measures (e.g., risk ratio, difference in means).   112 
 Synthesis of results   14  Describe the methods of handling data and combining results of studies, if done, including 
measures of consistency (e.g., I2) for each meta-analysis.  
 N/A 
 
 
 
 
 
 
  
 Section/topic   #  Checklist item  
 Reported 
on page 
#  
 Risk of bias across 
studies  
 15  Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
 N/A 
 Additional analyses   16  Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
 113 
 RESULTS    
 Study selection   17  Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram.  
 113 
 Study 
characteristics  
 18  For each study, present characteristics for which data were extracted (e.g., study size, PICOS, 
follow-up period) and provide the citations.  
 117-120 
 Risk of bias within 
studies  
 19  Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12).  
 N/A 
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 Results of individual 
studies  
 20  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary 
data for each intervention group (b) effect estimates and confidence intervals, ideally with a 
forest plot.  
 117-120 
 Synthesis of results   21  Present results of each meta-analysis done, including confidence intervals and measures of 
consistency.  
 N/A 
 Risk of bias across 
studies  
 22  Present results of any assessment of risk of bias across studies (see Item 15).   N/A 
 Additional analysis   23  Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
 120 
 DISCUSSION    
 Summary of 
evidence  
 24  Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).  
 121 
 Limitations   25  Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias).  
 123 
 Conclusions   26  Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
 124 
 FUNDING    
 Funding   27  Describe sources of funding for the systematic review and other support (e.g., supply of data); 
role of funders for the systematic review.  
 N/A 
  
 From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 
6(7): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
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Documents included in the UK-specific evaluation  
 
1. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, et al. The development and 
validation of a patient-reported questionnaire to assess outcomes of elbow surgery. J 
Bone Joint Surg Br. 2008;90(4):466-73. 
2. Sathyamoorthy P, Kemp G, Rawal A, Rayner V, Frostick S. Development and 
validation of an elbow score. Rheumatology. 2004;43(11):1434-40. 
3. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, et al. Comparative 
responsiveness and minimal change for the Oxford Elbow Score following surgery. 
Qual Life Res. 2008;17(10):1257-67. 
4. Dawson J, Doll H, Boller I, Fitzpatrick R, Little C, Rees J, et al. Specificity and 
responsiveness of patient-reported and clinician-rated outcome measures in the 
context of elbow surgery, Orthopaedics & Traumatology: Surgery & Research 98.6 
(2012): 652-658. 
5. Poltawski L, Watson T. Measuring clinically important change with the Patient-rated 
Tennis Elbow Evaluation. Hand Therapy. 2011;16(3):52-7. 
6. Melikyan EY, Shahin E, Miles J, Bainbridge LC. Extracorporeal shock-wave treatment 
for tennis elbow. Bone & Joint Journal. 2003;85(6):852-5. 
7. Dunkow PD, Jatti M, Muddu BN. A comparison of open and percutaneous techniques 
in the surgical treatment of tennis elbow. Bone & Joint Journal. 2004;86(5):701-4. 
8. Connell DA, Ali KE, Ahmad M, Lambert S, Corbett S, Curtis M. Ultrasound-guided 
autologous blood injection for tennis elbow. Skeletal radiology. 2006;35(6):371-7. 
9. Alizadehkhaiyat O, Fisher AC, Kemp GJ, Frostick SP. Pain, functional disability, and 
psychologic status in tennis elbow. The Clinical Journal of Pain. 2007;23(6):482-9. 
10. Connell D, Datir A, Alyas F, Curtis M. Treatment of lateral epicondylitis using skin-
derived tenocyte-like cells. British Journal of Sports Medicine. 2009;43(4):293-8. 
11. Clarke AW, Ahmad M, Curtis M, Connell DA. Lateral Elbow Tendinopathy Correlation 
of Ultrasound Findings With Pain and Functional Disability. The American Journal of 
Sports Medicine. 2010;38(6):1209-14. 
12. Creaney L, Wallace A, Curtis M, Connell D. Growth factor-based therapies provide 
additional benefit beyond physical therapy in resistant elbow tendinopathy: a 
prospective, double-blind, randomised trial of autologous blood injections versus 
platelet-rich plasma injections. British Journal of Sports Medicine. 2011;45(12):966-71. 
13. Nazar M, Lipscombe S, Morapudi S, Tuvo G, Kebrle R, Marlow W, et al. Percutaneous 
tennis elbow release under local anaesthesia. Open Orthop J. 2012;6:129-32. 
14. Stenhouse G, Sookur P, Watson M. Do blood growth factors offer additional benefit in 
refractory lateral epicondylitis? A prospective, randomized pilot trial of dry needling as 
a stand-alone procedure versus dry needling and autologous conditioned plasma. 
Skeletal Radiology. 2013;42(11):1515-20. 
15. Maffulli G, Hemmings S, Maffulli N. Assessment of the effectiveness of extracorporeal 
shock wave therapy (ESWT) for soft tissue injuries (assert): an online database 
protocol. Translational medicine@ UniSa. 2014;10:46. 
16. Tonks JH, Pai SK, Murali SR. Steroid injection therapy is the best conservative 
treatment for lateral epicondylitis: a prospective randomised controlled trial. 
International Journal of Clinical Practice. 2007;61(2):240-6. 
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Participant questionnaire evaluation booklet  
 
Please see the Inserted document   
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Participant patient information sheet and participant instructions   
 
Research 
supported by:          
 
 
 
 
Would you like to help researchers at 
the University of Exeter learn more 
about how Tennis Elbow affects 
people’s lives? 
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To thank you for your involvement, you will 
receive a £10 Love2Shop voucher which can 
be used at over 20,000 shops, restaurants and 
attractions.  
 
 
Research supported by:           
 
 
If your Tennis Elbow has bothered you at all within the last month,  
we would really like you to help us with our study. 
 
 
By completing a set of specialist questionnaires you will help us identify: 
1. Which questionnaire best reflects how Tennis Elbow affects you 
2. Which questionnaire changes when your condition changes 
3. What your score means compared to other people with Tennis Elbow  
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What is the purpose of this study? 
 Tennis Elbow is very common. It affects people of all ages and all occupations (from desk workers 
to bricklayers, and occasionally, tennis players). Even though it is common, and can cause significant 
patient distress and work-related sickness, we are still trying to find the best treatments. When we study 
Tennis Elbow, it is really important that we have a way of accurately measuring the pain and functional 
problems you experience.   
 
 This study is attempting to use a set of specialist questionnaires known as Patient-Reported 
Outcome Measures (PROMs). They have been designed to accurately measure how elbow problems affect 
patients’ lives.  They have not been tested on UK patients with Tennis Elbow. 
 
Why have I been approached? 
 You have been identified by your Physiotherapist or Consultant as suffering from Tennis Elbow.   
 
Who is organising the study? 
 This study has been organised by the University of Exeter Medical School. The study is being 
supported by the British Elbow and Shoulder Society (BESS) and the Royal Devon and Exeter Hospital 
Foundation Trust.   
 
What will happen if I participate? 
 If you are happy to participate in this study, we would like you to complete the attached Consent 
Form and post it back to us using the pre-paid envelope or return it to the researcher if they are with you 
in person.  
 Once we have received those we will send you 3 sets of questionnaires.  
 Each set of questionnaires takes an average of 20 minutes to complete.  
 The questionnaires ask some basic information about you (height, weight, profession and how 
long tennis elbow has bothered you) and then there are different questionnaires that ask you about 
your pain and symptoms. 
 We will ask you to complete the questionnaire as soon as you receive them, then in 1 week later, 
then 8 weeks after that.  
 Once the questionnaires are completed, we would like you to return them to us for analysis.  
 There is also the option of completing a short electronic questionnaire on the Internet. This new 
system uses a large set of questions, using your previous answer it predicts the most relevant next 
question. No participant details are required and it on average less than 2 minutes to complete. 
 
 
Do I have to take part? 
 You are under no obligation to take part. If you do not participate, your care or any future care 
you receive will not be affected in any way.  
 
What are the possible benefits of taking part? 
 We know that the best way to truly understand a medical condition is with the input of patients. 
Your participation will greatly help the way we measure the effect of treatments and design healthcare 
services for Tennis Elbow sufferers.  
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Will what is found out about me be kept confidential? 
 The results of the questionnaires are only being used for research and will be confidential. They 
will not become part of your medical record and will not be discussed with your General Practitioner, 
Physiotherapist or Consultant. 
 
Where will my personal information from this study be stored? 
 The information you provide, in the form of personal contact details and questionnaire answers, 
will be stored on an Encrypted University of Exeter computer. This will only be accessed by the research 
team. We will store your personal information for 6 months, to allow us to send you questionnaires during 
your participation in the study.  The research data will be anonymised and will be stored for 10 years.  
 
What will happen to the results of the study? 
 The results will be published in journals and publications which will help other researchers and 
healthcare professionals be informed about the work we have done. You will be able to obtain a copy of 
the research on request by contacting Jon Evans via email on j.evans3@exeter.ac.uk and a summary of the 
results will be published on the study website (available at http://bit.ly/2cPZDWl) 
Your name and any identifiable details will not be included in the published articles. 
 
How and when will I receive the shopping voucher? 
 The research team would like to offer you a £10 shopping voucher to thank you for completing 
the questionnaires. Once the research team receive the three questionnaires we have asked you to 
complete, we will post the voucher to you.   
 
Who has reviewed the study? 
 The East of Scotland Research Ethics Service REC 2, which has responsibility for scrutinising all 
proposals for research on humans, has examined the proposal and has raised no objections from the point 
of view of research ethics.  It is a requirement that your records in this research, together with any relevant 
medical records, be made available for scrutiny by monitors from the University of Exeter and Royal 
Devon and Exeter Foundation Trust, whose role is to check that research is properly conducted and the 
interests of those taking part are adequately protected. 
 
Who else is taking part? 
 We will be asking for participants from GP practices, physiotherapy clinics and specialist elbow 
surgery clinics. We are doing this to be able to assess the whole spectrum of Tennis Elbow symptoms.  
 
If you have a concern about any aspect of this study, you should ask the Patient Advice and Liaison 
Service (PALS team) who can be contacted on 01392 402093 or rde-tr.PALS@nhs.net.  They will do their 
best to answer your questions.  If you remain unhappy and wish to complain formally, you can do this 
through Patient Advice and Liaison Service at RD&E.  If your concerns are about the way in which the 
study is being conducted then please contact the R&D department at the RD&E on 
research@rdeft.nhs.uk. 
On behalf of the study team and the members of BESS thank you for taking the time to read this 
information sheet. 
 
 
What to get involved?  Here’s what to do:  
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Once we receive the questionnaires  
we will post you a £10 Love2Shop voucher  
to thank you for your support.  
 
 
Love2shop Vouchers are the UK's leading 
multi-retailer gift voucher. They can be 
redeemed in over 20,000 stores, restaurants 
and attractions.  
 
 
If you have any further questions or require clarification please feel free to contact  
 
Jon Evans 
University of Exeter Medical School    
Health Service Research Group                                                                                                                                                                   
Smeall Building, Room JS03 St Lukes Campus                     
Exeter  
EX1 2LU  
 
Email: j.evans3@exeter.ac.uk 
Tel: 01392 722750
Complete the 
attached Consent 
Form 
Post it back to us 
using the pre-paid 
envelope
The 3 sets of 
questionnaires 
will be sent to you 
in the post 
Complete the 
questionnaires 
and return them 
using the pre-paid 
envelope 
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Research supported 
by:           
 
Participant Instructions 
Thank you once again for participating in this study 
 Please follow the steps below 
 Please answer all the questions as honestly as 
possible  
 You may find some questions repetitive as some 
parts of the questionnaires are similar 
 If you feel that you are unable to answer a question, 
for whatever reason, please leave it blank 
1
• 1 week after completing the 1st questionnaire      
Complete questionnaire 2
2
• 8 weeks after completing the 1st questionnaire                                              
Complete questionnaire 3
3 
• Post them back to us using pre-paid envelope
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You also have to opportunity to complete a new Internet 
based questionnaire  
If you would like to do this, when you complete a paper 
questionnaire please also log on to: 
https://www.assessmentcenter.net/ac1/Assessments/TennisElbo
wUK  
When you are asked for your Participant Number, please 
use the one on the top of your paper questionnaire 
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Research Sites – PROMs validation study  
 
Primary Care  
 Honiton Surgery Group, Marlpits Ln, Honiton EX14 2NY 
 Claremont Medical Practice, Exmouth Health Centre, 
Claremont Grove, Exmouth EX8 2JF 
 St Leonards Medical Practice, Athelstan Rd, St Leonards, 
Exeter EX1 1SB 
 Whipton Branch Surgery, 10 Whipton Village Rd, Exeter 
EX4 8AR 
 Somerset Partnership NHS Foundation Trust (SOMPAR), 2nd Floor, 
Mallard Court, Express Park, Bristol Rd, Bridgwater TA6 4RN  
 
Secondary 
Care 
 
 Royal Devon and Exeter NHS foundation trust, Barrack Rd, 
Exeter EX2 5DW  
 Plymouth Hospitals NHS Trust, Derriford Rd, Crownhill, 
Plymouth PL6 8DH 
 Torbay and South Devon NHS foundation trust, Lowes 
Bridge, Torquay TQ2 7AA 
Physiotherapy   
 Exmouth Hospital, Claremont Grove, Exmouth, Devon, EX8 2JN 
 Honiton Hospital, Marlpitts Road, EX14 2DE 
 Axminster Hospital, Chard Road, Axminster. Devon.  Ex13 
5DU 
 Crediton Hospital,  Western Rd, Crediton EX17 3NH 
 Franklyn Community Hospital, Franklyn Dr, Exeter EX2 9HS 
 Torbay and South Devon NHS foundation trust, Lowes Bridge, 
Torquay TQ2 7AA 
 Somerset Partnership NHS Foundation Trust (SOMPAR), 2nd Floor, 
Mallard Court, Express Park, Bristol Rd, Bridgwater TA6 4RN  
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Ethical approval and Health Research Authority approval for the study  
- A Comparative Assessment of Patient Reported Outcome Measures 
for Lateral Elbow Tendinopathy in a UK Population 
 
Please see the inserted documents 
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Search strategy for Delphi study  
Medline 
1 Platelet-Rich Plasma/ 
2 Blood Transfusion, Autologous/ 
3 (platelet rich adj3 (plasma or therap* or fibrin)).tw 
4 (PRP or PRF).tw. 
5 ((platelet adj3 (gel or concentrate)) or buffy layer).tw. 
6 or/1-5 
7 tendinitis.sh. 
8 elbow.sh. 
9 elbow joint.sh. 
10 8 or 9 
11 7 and 10 
12 tennis elbow.sh. 
13 11 or 12 
14 epicondylitis.tw. 
15 elbow.tw. 
16 13 or 14 or 15 
17 6 and 16 
18 exp cohort studies/ 
19 cohort$.tw. 
20 controlled clinical trial.pt. 
21 epidemiologic methods/ 
22 limit 21 to yr=1966-1989 
23 exp case-control studies/ 
24 (case$ and control$).tw. 
25 or/18-20,22-24 
26 "randomized controlled trial".pt. 
27 (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab. 
28 (retraction of publication or retracted publication).pt. 
29 or/26-28 
30 (animals not humans).sh. 
31 ((comment or editorial or meta-analysis or practice-guideline or review or letter 
or journal correspondence) not "randomized controlled trial").pt. 
32 (random sampl$ or random digit$ or random effect$ or random survey or 
random regression).ti,ab. not "randomized controlled trial".pt. 
33 29 not (30 or 31 or 32) 
34 (review or review, tutorial or review, academic).pt. 
35 (medline or medlars or embase or pubmed or cochrane).tw,sh. 
36 (scisearch or psychinfo or psycinfo).tw,sh. 
37 (psychlit or psyclit).tw,sh. 
38 cinahl.tw,sh. 
39 ((hand adj2 search$) or (manual$ adj2 search$)).tw,sh. 
40 (electronic database$ or bibliographic database$ or computeri?ed database$ or 
online database$).tw,sh. 
41 (pooling or pooled or mantel haenszel).tw,sh. 
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42 (peto or dersimonian or der simonian or fixed effect).tw,sh. 
43 (retraction of publication or retracted publication).pt. 
44 or/35-43 
45 34 and 44 
46 meta-analysis.pt. 
47 meta-analysis.sh. 
48 (meta-analys$ or meta analys$ or metaanalys$).tw,sh. 
49 (systematic$ adj5 review$).tw,sh. 
50 (systematic$ adj5 overview$).tw,sh. 
51 (quantitativ$ adj5 review$).tw,sh. 
52 (quantitativ$ adj5 overview$).tw,sh. 
53 (quantitativ$ adj5 synthesis$).tw,sh. 
54 (methodologic$ adj5 review$).tw,sh. 
55 (methodologic$ adj5 overview$).tw,sh. 
56 (integrative research review$ or research integration).tw. 
57 or/46-56 
58 45 or 57 
59 25 or 33 or 58 
60 17 and 59 
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Delphi Primary Questions for Round 1 
 
1. Which patient factors affect your decision to offer PRP as a treatment option? 
(e.g. age, gender, co-morbidities, occupation, high/low demand activities) 
2. Which symptoms or signs would prompt you to consider PRP as a treatment 
option? (e.g. pain characteristics, symptom duration or examination findings) 
3. Do you think there are any contraindications to PRP treatment? (e.g. co-
morbidities, symptom or site specific pathology, previous conservative, 
pharmacological, injection or surgical interventions) 
4. What is your opinion on the minimum and maximum concentration of 
platelets? 
5. What is your opinion on the minimum and maximum volume of PRP? 
6. Do you have a preference over leucocyte concentration? 
7. Do you consider a preferred spin protocol (time, speed)? 
8. What is your opinion on the use of anticoagulants (including additives used) 
as part of PRP preparation? 
9. What is your opinion on PRP activation (including additives used) prior to 
administration? 
10. Are there further PRP constituents or processing techniques you feel 
contribute to your choice of PRP preparation? 
11. Do you consider an optimal, or cut-off time (in mins/hours) between 
processing and delivery of PRP? 
 389 
 
12. What is your opinion on the use of local anaesthetic prior to PRP delivery? 
13. Do you have a preferential needle size? 
14. What is your opinion on the use of adjunct imaging (e.g. Ultrasound) in the 
delivery of PRP? 
15. What is your opinion on injection technique (e.g. fenestration/peppering, 
single pass)? 
16. What is your opinion on the number and frequency of PRP injections that 
should be administered for a single clinical episode? 
17. What is your opinion on the use of immobilisation and/or activity modification? 
18. What is your opinion on the administration and/or avoidance of analgesics? 
19. How do you judge the outcome of PRP injections? 
20. What is your opinion on repeated PRP administration, if the primary treatment 
was unsuccessful? 
21. We would also like to invite you to provide any additional opinions on the 
use/preparation or delivery of PRP use in Lateral Epicondylar Tendinopathy 
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Delphi Secondary round feedback example 
 
Document inserted  
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Round 2 
Individual 
Summary 
Report 
Evans, Jonathan 
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Dear ……………………. 
Thank you so much for your participation in this study assessing the level of consensus in 
Platelet-Rich Plasma (PRP) use in Lateral Epicondylar Tendinopathy. We have had a fantastic 
International response from both researchers and clinical users.   
Please see your individual report for round 2 of the Delphi questionnaire process.  
We would ask you to carefully read your results, and compare your scores with the group 
scores summarised in the graphs.   
In keeping with the Delphi methodology, we would like to see if there is any convergence of 
opinion following this feedback. The validity of the consensus measurements will be greatly 
enhanced if you would be kind enough to complete the questionnaire a second time, giving 
you the opportunity to change your responses.    
Please place your new score in the column on the right.  
Please note that two statements have been altered following the synthesis of the groups free 
texts comments during the previous round. Please score the new statement.  
Once complete, please email this back to us using address j.evans3@exeter.ac.uk. 
We will, of course, update you on the group responses following this final round of 
questionnaires.   
 
Kindest Regards, 
Jon Evans 
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Orthopaedic Registrar and Post Graduate Researcher 
Health Service and Policy Research Group 
j.evans3@exeter.ac.uk Tel: +44(0)1392 722750 
University of Exeter Medical School, 
Room JS03, Smeall Building, St Luke’s Campus,  
Magdalen Road, Exeter, United Kingdom, EX1 2L 
 
 
 
 
 
 
 
 
 
 Statement 
Your 
Score 
Group Scores  
 
5 = Strongly agree  
4 = Agree 
3 = Neither agree or disagree 
2 = Disagree 
1 = Strongly disagree 
New Score  
P
a
ti
e
n
t 
S
e
le
c
ti
o
n
 1. PRP should only be 
considered in 
patients presenting 
with characteristic 
tennis elbow pain 
(lateral elbow pain 
exacerbated by 
wrist extension). 
5 
 
 
0 20 40 60
1
2
3
4
5
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2. PRP should only be 
considered 
following 6 months 
of conservative 
therapy. 
 
Question modified due 
to free text comments. 
See below: 
2 
 
/ 
PRP should only be 
considered 
following 3 months 
of conservative 
therapy 
  
New Score 
 
 
 
 
3. PRP should only be 
considered in 
patients who are 
experiencing 
considerable 
intrusion into their 
activities of daily 
life. 
4 
 
 
4. PRP treatment can 
be considered in 
patients over the 
age of 18, with no 
upper age limit. 
5 
 
 
5. PRP treatment can 
be considered in 
patients with 
manual or 
sedentary 
occupations. 
5 
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5
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6. PRP treatment can 
be considered in 
both high demand 
(e.g. sports people) 
and low demand 
(e.g. office worker) 
patients. 
5 
 
 
7. PRP is 
contraindicated in 
patients with a 
coagulopathy. 2 
 
 
C
o
n
tr
a
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d
ic
a
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o
n
s
 
8. PRP is 
contraindicated in 
patients with large 
wrist extensor 
tendon tears. 
1 
 
 
9. PRP is 
contraindicated in 
patients taking 
anticoagulant 
medication. 
1 
 
 
10. PRP is 
contraindicated in 
patients with a 
dependence on 
Non-Steroidal Anti-
Inflammatory Drugs 
(NSAIDs). 
1 
 
 
11. PRP is 
contraindicated in 
patients with known 
thrombocytopenia 
(less than 150,000 
platelets per 
microlitre of whole 
blood). 
1 
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12. PRP is 
contraindicated in 
patients who have 
received a steroid 
injection for 
treatment of their 
Lateral Epicondylar 
Tendinopathy, 
within 3 months of 
the intended PRP 
treatment date. 
4 
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13. The minimum 
recommended 
platelet 
concentration of 
injected PRP is 2x 
baseline. 
1 
 
 
14. The maximum 
recommended 
platelet 
concentration of 
injected PRP is 5x 
baseline. 
3 
 
 
15. The minimum 
recommended 
volume of PRP is 
1ml. 5 
 
 
16. The maximum 
recommended 
volume of PRP is 
3mls. 5 
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17. Leukocyte 
deplete PRP is the 
recommended 
formulation. 1 
 
 
18. A single spin 
cycle of 20 minutes 
or less is 
recommended. 5 
 
 
19. The addition of 
an anticoagulant to 
the whole blood 
sample is 
recommended prior 
to PRP preparation. 
1 
 
 
20. PRP activation, 
through the 
addition of 
additives prior to its 
administration, is 
not required. 
5 
 
 
21. Once 
processed, PRP 
should be 
administered within 
30mins. 
5 
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22. Local 
anaesthetic should 
be administered to 
the skin and 
subcutaneous 
tissue. 
4 
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23. Local 
anaesthesia should 
not be administered 
to the tendon. 1 
 
 
24. A 19g needle is 
the recommended 
minimum size used 
to administer PRP. 
 
Question modified due 
to free text comments. 
See below: 
1 
 
/ 
A 19g is the 
recommended 
MAXIMUM size 
used to administer 
PRP.   
  
New score 
25. Ultrasound 
guidance should be 
utilised in all PRP 
injections for 
Lateral Epicondylar 
Tendinopathy. 
3 
 
 
26. Needle 
fenestration is 
recommended over 
a single injection 
technique. 
5 
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27. Following the 
first administration 
of PRP, the patient 
should be 
reassessed to 
discern the need for 
repeated 
administration. 
5 
 
 
28. A maximum of 3 
administrations is 
recommended for 
each episode of 
Lateral Epicondylar 
Tendinopathy. 
5 
 
 
29. If symptoms 
recur following a 
successful course 
of treatment, PRP 
injection can be 
reattempted. 
5 
 
 
30. Surgery is 
recommended for 
patients in whom 
PRP treatment is 
not effective. 
2 
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31. Immobilisation 
of the elbow 
following injection 
is not necessary. 2 
 
 
32. Light loads 
should be avoided 
for the first 48 
hours following 
injection. 
4 
 
 
0 20 40 60
1
2
3
4
5
0 10 20 30
1
2
3
4
5
0 20 40 60
1
2
3
4
5
0 20 40 60
1
2
3
4
5
0 20 40 60
1
2
3
4
5
0 20 40 60
1
2
3
4
5
 400 
 
33. Heavy loads 
should be avoided 
for 6 weeks. 
4 
 
 
34. Non-Steroidal 
Anti-Inflammatory 
Drugs (NSAIDs) 
should be avoided 
for 1 week prior to 
PRP administration. 
3 
 
 
35. Non-Steroidal 
Anti-Inflammatory 
Drugs (NSAIDs) 
should be avoided 
for at least 2 weeks 
following injection. 
5 
 
 
36. Acetaminophen 
(Paracetamol) and 
weak opioid-based 
analgesia can be 
offered as required 
following PRP 
administration. 
5 
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37. Clinical 
assessment is 
recommended to 
assess the outcome 
of PRP 
administration. 
5 
 
 
38. A Visual 
Analogue Pain 
Score (VAS) should 
be collected in 
addition to clinical 
assessment. 
5 
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39. A validated 
Patient-Reported 
Outcome Measure 
(PROM) (e.g. 
PRTEE, DASH, 
OES) should be 
collected in 
addition to clinical 
assessment. 
5 
 
 
40. Resolution of 
tendinosis on US or 
MRI can be utilised 
to assess outcome. 4 
 
 
 
Please add any further comment below: 
 
 
 
 
 
 
Thank you so much for your continued participation. 
 
We will contact you in due course with the results of this final round of questions. 
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Ethics approval for the study - Platelet-Rich-Plasma Injection in Lateral 
Elbow Tendinopathy: Exploring Expert Consensus with the Delphi 
Method 
 
Document inserted 
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Ethical approval for the study - A Feasibility Randomised, Controlled 
Trial of Platelet-Rich Plasma injection vs Surgery for Chronic Lateral 
Elbow Tendinopathy 
 
Document inserted 
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Patient information sheet and consent form for the PRP vs Surgery 
feasibility RCT 
 
Document inserted 
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Patient 
Information Sheet 
 
A Randomised Controlled Trial of Interventions for Tennis Elbow 
 
You have been invited to take part in a research study.  Before you decide to 
participate, it is important for you to understand why the research is being done 
and what it will involve.  Please take the time to read the following information 
and discuss it with your friends and relatives if you wish.  Please ask us if there is 
anything that is not clear or if you would like more information and please take 
your time to decide whether or not you wish to take part. 
  
 
What is the purpose of this study? 
 
Tennis Elbow is a common condition. There are two treatments provided by 
hospitals when the symptoms are longstanding. These are injection of a 
concentrated form of your own blood called Platelet-Rich-Plasma (PRP) or a 
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surgical procedure called an Open Debridement. The first is conducted in the 
outpatient clinic and the second requires attendance for a day-case surgical 
procedure. No study has compared the two procedures to ascertain if one is better 
than the other.  
 
Why am I being chosen? 
 
You have been found to have chronic tennis elbow.  
We give you this diagnosis as you have had pain on the outside of the elbow for a 
long time. It is also likely that the treatments you have tried have not made you any 
better.  
 
Though tennis elbow often improves by itself, in a small number of people the 
symptoms persist and do not get better with pain killers or physiotherapy.  Patients 
tell us that the pain often interferes with their job and their ability to do things 
around the home. In this case surgery or injections are sometimes recommended 
by your surgeon.  
 
These treatments are designed to reduce your pain and increase the amount of 
activity you can do.  
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There is evidence that injection of Platelet-Rich-Plasma or Surgery can rapidly 
improve your pain. Both of these treatments are used both in the UK and the rest 
of the world.   
 
Platelet-rich-plasma is a form of your own blood that has been taken by injection. 
It is then concentrated and injected into the area of your arm that is painful. It is 
thought that this kick-starts healing in this area. Surgery involves removing the 
tissue around your elbow that is causing you the pain. 
 
Until now the normal treatment at the Royal Devon and Exeter Hospital has been 
surgery. Though common in other hospitals in the UK, this is the first time we will 
be using PRP injections at the Royal Devon and Exeter Hospital.     
 
Who is organising the study? 
 
The Chief Investigator is Mr Chris Smith, Consultant Shoulder Surgeon at the 
Royal Devon and Exeter Hospital.  Patients from all of the elbow surgeons are 
being invited to take part in this study. 
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Will anyone be paid? 
 
No patients are being paid to take part in this study. 
 
There is no commercial sponsorship of this study.  The staff involved are receiving 
their normal salary with no other benefits.   
 
We are receiving a small grant of £10,000 which covers the cost of running the 
study. 
 
What will happen if I participate? 
 
If you agree to participate you will be randomly assigned to either receive PRP 
injections or surgery.  
 
The only difference to your management will be that you will either attend hospital 
as a day patient for a surgical procedure that requires a general anaesthetic, or the 
outpatient department to have the injection procedure. The injection is given 
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twice. They will be given a week apart which will require 2 visits to the outpatient 
department..  
Both procedures take approximately 1 hour to complete.  
If any other condition is discovered during either procedure it will be discussed 
with you and then treated routinely. 
 
We will follow-up your progress following your treatment. We would like you to 
attend an outpatient appointment at 6 weeks, 3 months, 6 months and 1 year after 
your treatment. This is 2 or 3 extra appointments than we would normally do after 
Tennis Elbow treatment.  
 
At each follow-up appointment we will examine you and ask you to complete 4 
questionnaires that ask about your symptoms and allow us to track your progress. 
The questionnaires should take around 10 minutes to complete at each clinic visit. 
 
Do I have to take part? 
 
No.  Please remember that if you take part in this study it is entirely voluntary and 
that if you decide to take part you are free to leave the study at any time without 
having to give a reason as to why you wish to do so.  If you decide not to take part, 
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this will in no way affect your future medical care.  If you decide to take part you 
will have this information sheet to keep and you will be asked to sign a consent 
form that indicates that you have agreed to take part and that you understand that 
you can withdraw from this study at any time. 
 
What are the possible benefits of taking part? 
 
You will help us understand more about the most appropriate way to treat tennis 
elbow – a common condition in the general population.  
 
What are the risks of taking part? 
 
We do not think there are any increased risks associated with participation in this 
research project. Both treatments are common and safe.  
 
Will what is found out about me be kept confidential? 
 
All information collected about you during this study will be kept confidential in 
the same way that all of your medical notes are. Confidentiality, privacy and 
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anonymity will be ensured in the collection, storage and publication of any data 
that this trial generates in accordance with current regulations. 
 
What will happen to the results of the study? 
 
The results will be published in journals and publications which will help other 
surgeons become better informed about the work we have done.  This will help 
influence their practice so that they too can treat Tennis Elbow with a greater 
understanding.  You will be able to obtain a copy of the research on request by 
contacting 01392- 403560 and asking for Sian Gallacher.  You name and details 
will not be included in the published articles. 
 
Who has reviewed the study? 
 
All research in the NHS is looked at by independent group of people, called the 
NRES Committee South West -Exeter, to protect your interests.  This study has 
been reviewed and given favourable opinion by the NRES Committee South West 
– Plymouth and Cornwall. 
 
Who else is taking part? 
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12 people are being asked to take part. 6 randomised platelet-rich-plasma injection 
and 6 randomised for surgery. These are people who match the project’s selection 
criteria.  No-one, either the patients or the research team is being paid to take part.  
The study is a pilot study and will hopefully lead on to further work in this area.  
 
Contact for further information: 
 
If you have a concern about any aspect of this study, you should ask to the Patient 
Advice and Liaison Service (PALS team) who can be contacted on 01392 402093 
or rde-tr.PALS@nhs.net.  They will do their best to answer your questions.  If 
you remain unhappy and wish to complain formally, you can do this through 
Patient Advice and Liaison Service at RD&E.  If your concerns are about the way 
in which the study is being conducted then please contact the R&D department at 
the RD&E on research@rdeft.nhs.uk. 
 
Thank you: 
Thank you for taking the time to read this information sheet. You will receive a 
copy of what you have signed/read as well as the contact details of the research 
team. See below. 
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If you have any further questions or require clarification please feel free to contact: 
Mr Chris Smith, Chief Investigator, via the Hospital on 01392 411611. 
Mrs Sian Gallacher, Surgical care 
Practitioner. 07798-893517. 
 Certificate of Consent 
Title of study: 
 
Platlet Rich Plasma VS Open Surgery in the Treatment of 
Chronic Lateral Epicondylar Tendonopathy (Tennis 
Elbow) 
A Pilot Randomised Control Trial 
 
Name of Principal 
Investigator: 
Mr C D Smith 
Centre/Site number: Royal Devon & Exeter NHS Foundation Trust 
Study number: 1510155 
 
REC approval number: 
16/SW/0007 
Participant ID:  
 
PLEASE INITIAL THE BOXES IF YOU AGREE WITH EACH SECTION: 
1.  
 
I have read the information sheet dated………..……… for the above 
study and have been given a copy to keep. I have had the opportunity to 
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consider the information, ask questions and have had these answered 
satisfactorily. 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without my medical care 
or legal rights being affected. 
 
3.  I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
Research Team only, from regulatory authorities or from the NHS Trust, 
where it is relevant to my taking part in this research. I give permission 
for these individuals to have access to my records. I understand that the 
information will be kept confidential. 
 
4.  I understand that my Doctor will be informed of my participation and also 
if any of the results of tests done as part of the research are important 
for my health.  
 
5.  I understand that I will not benefit financially if this research leads to the 
development of a new treatment or test. 
 
6.  I know how to contact the research team if I need to. 
 
 
7.  I agree to participate in this study 
 
  
 ____________________ ____________________
 ____________________ 
 Name of Patient  Date  Signature  
  
  
 __________________________               __________________________         ___________________________ 
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 Name of Person  
 taking consent  Date  Signature  taking consent 
 
 
Topic guide for qualitative data 
 
PRP vs Surgery RCT feasibility trial: Interview topic guide – Intervention arm 
Introduction 
Thank you for agreeing to be interviewed today.  The interview is to find out about 
the care you received as part of the tennis elbow trial. Everything you say will be 
treated as strictly confidential.  The information you provide will be useful in helping 
us design new Tennis elbow trials including improvements on the one you have been 
involved in. Are you happy for me to turn on the recorder? 
 
Background 
 Tell me briefly how long and how bad your tennis elbow was prior to being 
referred to the hospital? 
o Prompt: Duration, activities, work interference, pain level 0-10 
 What treatments had you previously received? 
o Prompt: injections, physio, over the counter etc 
 If injections – type/number 
Expectations and decisions to seek referral to secondary care  
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 What made you decide to seek referral to secondary care (hospital 
consultant)? 
o Prompt: GP advice, personally sought, allied health care professional 
opinion, friends/family members opinion.  
 What were your expectations about what the consultant would offer you? 
o Prompt: Were you aware of surgery as a treatment for tennis elbow? 
Did you know a trial was taking place? Where you aware that injections 
were an option?  
Expectations and decisions to participate in the PRP trial 
 What did you think when it was mentioned that a trial was being run? 
o Prompt: Did it make you feel reassured/anxious?  
 How did it make you feel that the trial treatments were surgery or PRP 
injection? 
o Prompt: Do you think this is a fair comparison? Were the reasons for 
comparing these two treatments explained to you? Did you have a 
strong preference of treatment? 
 How do you feel about being randomised to the PRP treatment? 
o Prompt: What were your initial thoughts? Would you have rather been 
given the surgery at that stage?  
 Do you feel you have an understanding of how/why PRP works? 
o Was it explained to you? Have you read around the subject – what 
have you found out independently?  
Experience of care as part of the trial 
 How did you find the injection process? 
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o Prompt: Did you feel safe? Was the injection process explained to you? 
Did you feel prepared for the injection? 
  Can you tell me how the injection felt? 
o Prompt: Can you describe the discomfort? How bad was the pain out of 
10? What this more/less than expected?  
 How did you feel straight after the injection? 
o How comfortable were you? Did you feel safe to go home straight 
away? Did you have someone with you? Was this necessary?  
 How did you feel in the first 48 hours after the injection? 
o How was the pain level? Did you use the sling? Did you take pain 
killers? How much did you use the arm? 
 How did you feel in the first 5-7 day after the injection? 
o How was the pain level? Did you use the sling? Did you take pain 
killers? How much did you use the arm? 
 How do you feel these experiences differ from having surgery?  
o How do you feel about having an anaesthetic? How do you feel about 
the recommendation not to use the arm for 6 weeks and no driving?  
Experience of follow-up 
 Has the injection worked? Is so how long did it take to be effective? If not, 
have your symptoms changed? 
o How long till you were pain free? How long did you modify your 
activities? Did you follow the rehab protocol you were given? 
 
 Were you able to return to the work and social activities that you had hoped 
to? 
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 How did you find the experience of being part of a trial?  
o Did you mind the extra appointments? Did you mind the 
questionnaires? Could this process have been improved 
(postal/electronic/telephone communication or follow/up)? 
 Would you recommend this treatment? 
o Would you have the same treatment again? Would you rather have 
surgery?  
 
 What have you told your friends and family about the injection? 
 What would you say to someone undergoing this treatment? 
 
Further comments/ improvements that could be made 
Thank you   [Turn off recorder] 
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Example transcript from patient interview  
Interview 1 
Interviewer: [00:00] Fantastic, and so, if we just go right back to your experience of your 
tennis elbow, could you just tell me briefly how long you di—you'd had your tennis 
elbow prior to being referred to hospital? 
 
Participant: [00:10] Um, it started [00:12] april last year. 
 
Interviewer: [00:13] Okay, fine, fine, and in terms of how it was interfering with your life at that 
time, just tell me briefly what you were and weren't able to do and how bad the 
pain was. 
 
Participant: [00:24] Um, it was [00:25] the lack of sleep really. 
 
Interviewer: [00:26] Oh. 
 
Participant: [00:26] Um, I could sleep for about an hour and a half at the time, and then the 
pain would wake [00:30] me up, and then, I would probably get to sleep again, 
and that would happen all through the night for about [00:36] [crosstalk] 
 
Interviewer: [00:36] Really? Okay. 
 
Participant: [00:37] Um, so that was probably the worst part of it really. 
 
Interviewer: [00:39] Yeah, okay, fine, fine. 
 
Participant: [00:40] Um, yeah, it just interfered with everyday life because the job that I did. 
 
Interviewer: [00:43] Yeah. 
 
Participant: [00:43] It, everything was just painful and uncomfortable really. 
 
Interviewer: [00:46] Yeah, absolutely, okay. Um, what treatments did you try previously, 
before coming to hospital? 
 
Participant: [00:51] Um, I tried, um, [00:54] non steroidals but they didn't touch it 
 
Interviewer: [00:55] Mm hm. 
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Participant: [00:56] And, um, I had steroid injections, which didn't touch it either. 
 
Interviewer: [01:00] Did you just have the one steroid injection then? 
 
Participant: [01:02] Yeah, yeah, I wouldn't let her do it a second time [01:04]  
 
Interviewer: [01:04] [crosstalk] Really? [laughs] Okay, fine, but that didn't make any difference 
at all, not even [01:08] [crosstalk] 
 
Participant: [01:08] It, they di-, I just hurt, but if it made any difference, I would have done it 
again, but it made no difference [01:12] at all. 
 
Interviewer: [01:12] No difference at all, okay, fine, fine, and that was just done by the GP? 
They didn't use ultrasound or anything like that? 
 
Participant: [01:20] No, no, it was just done by my GP. 
 
Interviewer: [01:22] Just done by the GP, fine, fine. So, what was it that made you seek 
referral to hospital? Was it, was it your idea, or your GP's idea? How did it come 
about?  
 
Participant: [01:30] Um, I went—I had a week off, and the pain was just worse, and my friend 
kept on [01:36] at me all the time cuz I was in such pain. 
 
Interviewer: [01:38] Mm. 
 
Participant: [01:38] And the [01:38] [inaudible] came back and actually saw the [01:40] nurse 
at the medical center.  
 
Interviewer: [01:41] Okay. 
 
Participant: [01:42]He said, "I think you need to do something." He said, "I'd like you to have 
an X-ray, but I don't think they're gonna find anything." 
 
Interviewer: [01:47] Hm. 
 
Participant: [01:48] And, so, I had an X-ray for and went back to my gp to ask for some 
steroids 20 [01:49] and she said, "No, [01:53] this has gone on too long, we need 
to refer you know. 
 426 
 
 
Interviewer: [01:54] [crosstalk] too far, fine, fine, and what were your expectations about 
coming [02:00] to the hospital to see the consultant? Were you aware of any 
particular treatments that you would have been keep on trying or anything like 
that? 
 
Participant: [02:06] Uh, well, doing the job I do, I [02:08] had sort of been online [02:10] see 
what [02:10] sort of treatments there were. I had read about PRP [02:12]  
 
Interviewer: [02:11] Mm, [crosstalk] 
 
Participant: [02:13] Um, they were doing it in London a lot, but I think [02:15] somewhere like 
that that. 
 
Interviewer: [02:16] Mm. 
 
Participant: [02:16] Um, so, I'd read about that, but [02:17] it sounded quite good [02:18] 
because you don't have to have an anaesthetic [02:19]. 
 
Interviewer: [02:20] Yeah, fine. 
 
Participant: [02:21] I don’t really like anaesthetics but—and I saw [02:22] that there was the 
surgery that you could do [02:23] [inaudible] what was gonna be offered really. 
 
Interviewer: [02:27] Fine, fine, were you aware that we doing a trial at all or was that [02:30] 
[crosstalk]? 
 
Participant: [02:30] No. Not until I came the first time I saw whoever it was I saw [02:34] 
[phonetic] 
 
Interviewer: [02:35] Fine, fine, and what did you think when they mentioned that there was a 
trial being run? 
 
Participant: [02:39] Yeah, I was quite interested cuz, again, because of what I do, it, you 
know—people don't put themselves forward [02:44]your never going to know 
[02:45] [inaudible]  
 
Interviewer: [02:46] Mm. 
 
Participant: [02:46] And to be fair the pain was so bad I was up for trying anything. 
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Interviewer: [02:49] Mm, fair enough, and—and what did you think about the fact where you 
were comparing surgery and this PRP? Did you think it was a fair comparison? 
You thought it was an appropriate type of question that we were asking? 
 
Participant: [03:00] Yeah, apparently, [03:00] because I’d been on the internet recently 
[03:01] [crosstalk] 
 
Interviewer: [03:00] Mm, yeah. 
 
Participant: [03:02] They—they—they [03:02] and it was the comparison with the steroid 
injection that they were doing [03:03] wasn't it and the PRP [03:06] 
 
Interviewer: [03:06] Yeah, yeah. 
 
Participant: [03:07] Um, well, it seemed a bit different cuz we felt it—it cost we use steroid 
injections quite a lot [03:11] and it is quite short term. 
 
Interviewer: [03:12] Yeah. 
 
Participant: [03:13] Um, I know—I know that [03:16] tennis elbow is supposed to be self 
regulating [03:17] and that after [03:18] a certain length of time it sorts itself out 
anyway. 
 
Interviewer: [03:18] Mm, mm, you think so. Mm. 
 
Participant: [03:21] Um, but I was bit like, "If anything can make this go quicker, then I'll a 
have a go, and this PRP is the way to go, and [03:26] if that’s what I can have 
[03:28] and avoid having surgery, then that's what I want to do [03:30] [inaudible] 
 
Interviewer: [03:28] Mm. Sure, and, um, y—you're obviously a much more knowledgeable 
patient than most, [laughs] but how did you feel when you got randomized to the 
PRP? Were you reassured and happy that that was the treatment you were 
gonna be given? 
 
Participant: [03:43] Yeah, cuz that was the—the was, uh—during the reading and stuff, that 
[03:46] [crosstalk] my treatment of choice from—from my reading, and that was 
[03:48] [crosstalk] what I preferred. 
 
Interviewer: [03:46] Mm. Mm. 
 
Participant: [03:51] So, it was quite nice to see the [03:53] treatment was going to be PRP. 
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Interviewer: [03:54] Fair enough, good, good, and although this is—is in its infancy, what—do 
you manage to get any [04:00] information from the internet about how the PRP 
worked and why? 
 
Participant: [04:04] Yes, cuz there's—I can't think what hospital it was, but one of the 
hospitals came up with quite a lot of information, and it talked about how it 
worked, and— 
 
Interviewer: [04:10] Mm. 
 
Participant: [04:11] Um, cuz they use a lot of sports—other sports injuries that may [04:14] 
[phonetic] [04:15] [crosstalk] 
 
Interviewer: [04:15] Yeah, they do, mm hm. 
 
Participant: [04:16] Yeah, and, um, it just [04:19] sounded to me, if you can avoid messing 
around new joints, then it's gotta be a good thing, really. 
 
Interviewer: [04:24] Yeah, absolutely, good, and so, tell me about the injection itself. Uh, how 
did feel [04:30] about the injection process, in terms of the safety and how it was 
explained? Did you feel prepared for the injection? 
 
Participant: [04:35] Yes, yeah, well, I was prepared for how much it was gonna hurt. 
 
Interviewer: [04:38] Mm. 
 
Participant: [04:39] And—which probably is a good thing. 
 
Interviewer: [04:40] Mm. 
 
Participant: [04:41] And I thought that the recovery after the first one was much quicker 
[04:46] [crosstalk] [it was time to] [04:47] [phonetic] go home cuz I booked a 
couple days of work, thinking it was gonna be that sore, and actually, to be fair, it 
was fine. 
 
Interviewer: [04:47] Yup. 
 
Participant: [04:55] The first time was fine. I didn't have any issues with that at all. 
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Interviewer: [04:57] Okay. 
 
Participant: [04:58] And it was the second one [05:00] that was the bummer, really. 
 
Interviewer: [05:00] Really. 
 
Participant: [05:01] Yeah. 
 
Interviewer: [05:02] Okay, and tell me about the recovery from that one. 
 
Participant: [05:05] Um, the recovery was a good couple of hours post-injection. It was still 
incredibly painful — really, really sore — um, and I—I—I don't think I'm a wimp, 
but it was [05:17] really painful. 
 
Interviewer: [05:17] Mm. 
 
Participant: [05:19] Um, and it a couple of days before my arm felt comfortable to use 
normally. 
 
Interviewer: [05:23] Really? Yeah. 
 
Participant: [05:25] And—and it—it lasted about four to six weeks. It—it [05:28] started more 
comfortable. [05:30] It's not very comfortable at the moment. 
 
Interviewer: [05:32] No, okay, okay, cuz that—the pain, I think, that you experienced during 
the injection, as we discussed before, was this—this all bit—a bit of learning 
curve for all of us, and we're surprised at—that it is quite as painful, and in terms 
of the pain that you experienced, how bad was it out of ten, if you were to give it a 
score? Maybe [05:50] [crosstalk] 
 
Participant: [05:50] When you did it, it was [05:51] [crosstalk] 
 
Interviewer: [05:51] Yeah, mm. 
 
Participant: [05:52] Eleven. 
 
Interviewer: [05:53] Really? 
 
Participant: [05:54] Yeah. 
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Interviewer: [05:54] [crosstalk] 
 
Participant: [05:55] And I—I—I don't like to think that I, you know—I think I'm quite—I can 
cope [06:00] with that, but, yeah, I could have got up and walked away from that 
one. 
 
Interviewer: [06:02] Yeah, absolutely, no, and I think you [06:05] [crosstalk] 
 
Participant: [06:05] And I don't know if that was just me or whether other people have said the 
same. 
 
Interviewer: [06:07] The other people have said exactly the same. Yeah. 
 
Participant: [06:09] Yeah. 
 
Interviewer: [06:10] And that's it. It's been a bit of a surprise to us of how uncomfortable it's 
been, and I think, like I said to you, most people have said, with the benefit of 
hindsight and [06:19] You know they probably still would have had the injection, 
but it makes us a bit uncomfortable that it's caused you so much discomfort, you 
know. So— 
 
Participant: [06:27] Yeah, uh, I've think I said it to you before, but [is it definitely all right if] 
[06:30] it was the other way round, if I’d had that much pain the first time I’m not 
sure I would come back for the second one. 
 
Interviewer: [06:32] Yeah. I think that's absolutely—well, that's very [06:36] [crosstalk] 
 
Participant: [06:36] That’s human nature, isn't it? 
 
Interviewer: [06:39] Of course. 
 
Participant: [06:39] Um, and probably the fact that it didn't—it was uncomfortable when it was 
done the first place time [06:43] cuz it was [06:44] certainly far worse the second 
time.. 
 
Interviewer: [06:43] Mm. Sure, and what do you think about how all these experiences would 
differ [where you're] [06:50] were you having the operation? So you think you 
would have been more comfortable, or do you have any [06:58] [crosstalk] idea of 
how the surgery would have been? 
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Participant: [06:58] Well, I imagine it probably would have been [07:00] more painful for a 
longer length of time cuz any sort of surgery tends to be [07:04] [crosstalk] cuz 
you've got ripped tissues to repair. 
 
Interviewer: [07:04] Mm, yeah, yeah, it does. 
 
Participant: [07:07] And, and when you start making holes in anything, it's gonna take a while 
to recover. 
 
Interviewer: [07:11] Mm. 
 
Participant: [07:12] And—and at least I could go back to work and—and do relatively normal 
stuff. So— 
 
Interviewer: [07:18] Sure. 
 
Participant: [07:19] And you [07:19] [inaudible] for six-week recovery period, which, to me, is 
an awful long time not be able to do [07:23] [crosstalk] normal duties at work. 
 
Interviewer: [07:23] Yeah. Absolutely, all right. So, how long did you think it was until [07:30] 
you felt there was a difference from the injection in a positive way? 
 
Participant: [07:34] Um, with the second one, I would say probably about four—about a 
month or so. 
 
Interviewer: [07:38] Mm. 
 
Participant: [07:38] And it—it—it—because you suddenly realize that you can do stuff and it’s 
not hurting [07:41]. 
 
Interviewer: [07:42] Yeah, sure, okay. So, how quickly did you find that you returned to doing 
things that you—would have otherwise caused you [07:50] quite a lot of 
discomfort?  
 
Participant: [07:56] Uh, I wanna say about six weeks. I was [07:57] [crosstalk] experie—I was 
asking other people to do stuff [08:00] [crosstalk] at work. 
 
Interviewer: [07:57] About six weeks. Yeah, sure. Okay, good, good. 
 
Participant: [08:03] Because I could get away with asking other people to do it, I did. 
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Interviewer: [08:06] Yeah, of course. 
 
Participant: [08:07] I could do it, but I always knew I had done it, if that makes sense. 
 
Interviewer: [08:10] Mm, absolutely, and, um, to finish, really, how did you find the experience 
of being part of trial, in terms of the fact we'd done extra appointments for you, 
you filled loads of questionnaires, and—do you think anything about that process 
could have been improved or you would have done differently? 
 
Participant: [08:26] No, not really, um, I appreciate that, if you don't do the—the—the pain 
[08:30] scoring stuff um, again, when [you're used to] [08:30] [phonetic] doing 
pain scoring at work, [08:32] [crosstalk] that wasn't, you know, [very bad] [08:35] 
[phonetic] 
 
Interviewer: [08:32] Yeah. 
 
Participant: [08:37] Um, no, I think it was all very good [08:38] [inaudible] save [08:39] 
[phonetic] me. Everybody has been really helpful. Um— 
 
Interviewer: [08:43] good. 
 
Participant: [08:44] My only concern is my left elbow is very painful, [08:45] [crosstalk] you 
know? 
 
Interviewer: [08:45] Yes, [laughs] yes. 
 
Participant: [08:48] [laughs] [inaudible from laughter] that one really. 
 
Interviewer: [08:47] [laughs] I think—I think [08:49] [inaudible] mentioned in your—your recent 
appointment. Yeah, we'd sort of need to see how things go with that, but, um, 
there's, you know—if you do have problems with that, you should get in touch, 
you know, if it's getting worse and worse [09:00] and worse and we're—we're 
[09:01] [crosstalk] 
 
Participant: [09:01] Yeah, [09:01] [inaudible] that just because, as a rule, I don't carry 
shopping home because that's what I find—still find quite uncomfortable, [09:09] 
[crosstalk] carrying, you know, shopping. 
 
Interviewer: [09:09] Mm. 
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Participant: [09:11] Um, and today, actually, it would be easier to carry it in my right hand, 
which is my treated arm cuz my left arm, uh—my left arm is getting that painful 
there. 
 
Interviewer: [09:19] Mm, okay, well, yeah, I've—well, we'll see how we go. [laughs] See how 
we go. Um, I suppose, ultimately, in terms of this treatment, would you have the 
same thing again if you were offered [09:30] [crosstalk] it again? 
 
Participant: [09:30] Yeah. 
 
Interviewer: [09:31] You would? 
 
Participant: [09:32] Yes. 
 
Interviewer: [09:33] Good, and what have you told your friends and family about it? 
 
Participant: [09:36] Yeah, no, um, obviously, especially, my—my work colleagues at work are 
all really interested in it and somewhat [09:42] [crosstalk] 
 
Interviewer: [09:41] Mm. 
 
Participant: [09:43] And, um, no, yeah, I, I would do it again. I would prefer this sort of thing to 
surgery, and I was, as I've said [09:49] [crosstalk] to that before, [09:50] then if 
you get [09:51] tennis elbow then, if you have to [09:53] opportunity to try that, 
then I would try it. 
 
Interviewer: [09:49] Yeah. You would? Good, well, that's, that's positive to finish on. I think, 
that's—that's really helpful. 
 
Participant: [10:00] You might need to hit me over the head with a mallet to inject it [10:01] 
[crosstalk] 
 
Interviewer: [10:01] [laughs] Well, that is the question. So, were you to be offered it but we'd 
say, this time, we'd give you an anesthetic, would you go for that, or do you think 
that negates the positive side of it [10:13] [crosstalk] 
 
Participant: [10:13] Um, I think that will be, for me, personally, [10:15] [inaudible] the 
anesthetic [10:17] [crosstalk] that I wouldn’t really want to do. 
 
Interviewer: [10:17] Mm. 
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Participant: [10:19] Maybe, um, I think there's, like, mild sedation, like, when you go to the 
dentist [10:22] and have stuff like that. 
 
Interviewer: [10:22] Yup. 
 
Participant: [10:24] I'd probably do that. I wouldn't want local cuz, to me, if you put a local in, 
by the time [10:30] you've got the local in, you [10:31] might have well have done 
it. 
 
Interviewer: [10:31] Yeah, absolutely, yup. 
 
Participant: [10:33] So, to me, that's how I look at it. 
 
Interviewer: [10:34] Mm. 
 
Participant: [10:35] Um, I wouldn't really want the [10:36] GA to do it and if I had to man-up 
and do it again, I'd man-up and do it again, but [10:40] [inaudible from laughter] 
 
Interviewer: [10:40] [laughs] All right. 
 
Participant: [10:41] But, you know, there's different sorts of people, isn't there? 
 
Interviewer: [10:43] Yeah, exactly, that's absolutely right. Great, is there anything else you can 
think of, [10:46] [phonetic] that you'd like to mention? 
 
Participant: [10:50] No, I don't think so. Like, the—the only thing I find now is—is that I find 
that it's more painful, but it's not doing anything and [10:56] [crosstalk] less painful 
to—to use it, but it's [10:59] more when its at rest [inaudible] [crosstalk] and stuff, 
but it [11:00] [crosstalk] other than that, eh. 
 
Interviewer: [10:56] Yeah. And it stiffens up. Yeah, we'll see how you, see how you go, but, 
uh, look, I think I've said to you before that I think the surgical people tend to 
experience exactly the same at this stage, with this stiffness in their activity, and it 
still causes [11:15] [crosstalk] them a problem, and— 
 
Participant: [11:15] Yeah. And that's the thing with surgery, isn't it? [11:19] Then I assume 
they have to have physical therapy to get them up and working [11:21][inaudible] 
uh, after doing all that. 
 
Interviewer: [11:21] Absolutely, yeah. 
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Participant: [11:23] And then, that's just more time, isn't it, where it's actually—I've not really 
lost any time [11:28] out of my either working life [11:30] or my normal life really. 
 
Interviewer: [11:31] No. No, you were able to get working straight away [11:32] [crosstalk] 
 
Participant: [11:32] [crosstalk] normal. 
 
Interviewer: [11:34] Yeah, absolutely, great, lovely, well, thanks for talking, [11:37] [phonetic] 
That was really helpful. Well, [11:38] [crosstalk] 
 
Participant: [11:38] [crosstalk] 
 
Interviewer: [11:39] Uh, we'll document all that down and scratch our heads and have a think 
about it. 
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Coding Matrix 
Coding Matrix – Domains and Themes  
Symptoms Interference Knowledge 
Pre-procedural pain 
Procedural pain 
Post-procedural pain 
Stiffness 
Numbness/tingling 
Pre-procedure interference with work 
Pre-procedure interference with lifestyle 
Pre-procedure interference with sleep 
Post-procedure interference with work 
Post-procedure interference with lifestyle 
Post-procedure interference with sleep 
Knowledge of new treatments 
Instigation of referral 
Expectations of referral  
Knowledge of trial 
Sources of information  
Expectation of treatment 
 
 
Reflection  Managing symptoms  
Burden of being in a trial 
Being in a trial 
Recommendation or not of treatment 
Safety 
If randomised to surgery 
Improvements 
 
Pre treatment 
Post Treatment 
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Codes from qualitative analysis 
 
Qualitative Summary Document 
Research questions  
1. What was the participant experience of the intervention (PRP)? 
2. What was the participant experience of the trial? 
3. Is PRP an acceptable and appropriate intervention for further study? 
 
Themes directly associated with Question 1 
Procedural 
Procedural pain 
Experience of health professionals 
Safety 
Post Procedural  
Post-procedural pain 
Post-procedural treatments 
Post-procedure interference with quality of life 
Themes directly associated with Question 2 
  Knowledge of trial 
  Reflection on being in a trial 
  Burden of being in a trial 
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  Reflection on possibly being randomised to surgery 
  Improvements 
Themes directly associated with Question 3 
  Procedural pain 
  Safety 
  Repeat treatment  
  Recommendation or not of treatment 
 
Coding explanation 
Procedural pain 
Pain caused by the injection itself. 
Experience of health professionals 
The behaviours of health professionals and experience of the patient at the time of 
delivery of the injection. 
Safety     
The perceived safety of the environment and procedures surrounding the delivery of 
the injection and the direct post-injection time period. 
Post-procedural pain 
The pain experienced by the patients in the days and months following the injection 
and the interval between the first and second injection.  
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Post-procedural treatments 
The use and experience of analgesia, slings, ice packs etc by the patient, both 
advised by health professionals and self-administered. 
Post-procedure interference with quality of life 
The patient experience of the impact of the intervention on their quality of life.  
Reflection on being in a trial 
The patient’s own reflections on the process of being part of a trail. 
Burden of being in a trial 
The patients views on the burden of extra follow-up appointments and data collection 
through the use of questionnaires. 
Reflection on possibly being randomised to surgery 
The patient’s reflection on how they would have felt had they been randomised to the 
surgical arm of the trial. 
Improvements 
The patient’s opinion on any improvements that could be made in a further similar 
trial. This includes procedural improvements, patient information and post procedural 
care. 
Repeat treatment  
The patients views on being offered the treatment again in the future.  
Recommendation or not of treatment 
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The patient’s assessment of whether or not they would recommend the treatment to 
a friend or family member and what advise they would give this person.   
 
 
 
 
 
Feasibility Randomised Controlled Trial - checklists 
 
Please see inserted documents 
CONSORT – Pilot and Feasibility checklist 
CONSORT – PRO extension items checklist 
MIBO checklist 
TiDiER checklist  
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